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Abstract
Introduction: The coexistence of multiple chronic diseases within an individual, also known as
multimorbidity, is an ongoing challenge for patients, caregivers and primary health care (PHC)
providers. An enhanced understanding of the burden of multimorbidity in Canada is needed.

Objectives: This research had two main objectives. Objective One aimed to understand the
prevalence of multimorbidity among adult PHC patients, as well as the patterns of unordered and
ordered clusters of multiple chronic diseases. Objective Two aimed to determine the natural
progression of multimorbidity over time, as well as the patient-, provider- and practice-level
predictors of progressing into more complex clinical profiles.

Methods: Data were derived from the Canadian Primary Care Sentinel Surveillance Network
(CPCSSN) electronic medical record (EMR) database. For Objective One, descriptive and
computational analyses were conducted and for Objective Two, multilevel survival analyses
were conducted to account for clustering. Patients with at least one encounter recorded in their
EMR and who were at least 18 years of age at their first encounter were included in the analyses.
Chronic disease diagnoses were identified using the International Classification of Diseases, 9th
Revision (ICD-9) and a list of 20 chronic disease categories identified patients with
multimorbidity.

Results: Overall, 53.3% and 33.1% of adult PHC patients were living with at least two and at
least three chronic diseases, respectively. Patients with at least two chronic diseases had a mean
age of 59.0 years (SD: 17.0), while the majority were female (57.8%) and living in an urban
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setting (52.2%). Among female patients with multimorbidity, 6,095 unique combinations and
14,911 unique permutations were found. Among male patients with multimorbidity, 4,316
unique combinations and 9,736 unique permutations were detected. The multilevel survival
analysis indicated that several patient-level (patient age, patient sex and total number of chronic
diseases), provider-level (provider age) and practice-level (EMR type and practice location)
variables predicted time until subsequent chronic disease diagnosis.

Conclusion: This research explored the prevalence, characteristics, patterns and natural
progression of multimorbidity over time among a large cohort of adult PHC patients. When
carefully assessed, these findings will help to create a more nuanced understanding of the burden
of multimorbidity.

Keywords
Multimorbidity, primary health care, electronic medical records, chronic disease, prevalence,
multilevel survival analysis, epidemiology
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Chapter 1
1 Introduction
The coexistence of multiple chronic diseases within an individual, also known as
multimorbidity, has been deemed the “norm rather than the exception” in primary health care
(PHC) by both researchers and health care providers for many years. Beyond being recognized
as the “norm”, multimorbidity in fact represents one of the most complex issues in modern
medicine; an increasingly common issue that requires a more effective clinical approach to
respond to this complexity. To contribute towards the knowledge base in the area of
multimorbidity, as well as to address notable gaps in the existing multimorbidity literature, this
thesis aimed to achieve three main areas of understanding: 1) to identify the prevalence and
common characteristics of multimorbidity among adult PHC patients within a pan-Canadian
database; 2) to determine the patterns (both unordered clusters and ordered clusters) of multiple
chronic disease occurrence among adult PHC patients with multimorbidity; and 3) to understand
the natural progression of adult PHC patients as they moved to more complex clinical profiles
over time, as well as the patient-, provider- and practice-level variables that may predict the time
until an additional chronic disease diagnosis. The use of a national, longitudinal, de-identified
electronic medical record (EMR) database from the Canadian Primary Care Sentinel
Surveillance Network (CPCSSN) has allowed for this research to be possible. This exploration
of a complex issue in health care, using a complex set of electronic medical record data, has
provided insight that can contribute to the efforts of the international community that is working
to understand the burden of multimorbidity.
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Chapter 2
2 Literature Review
This chapter will introduce the three interrelated pillars of this doctoral research: primary
health care, electronic medical records and multimorbidity. While each pillar is presented
separately, the interrelatedness of these concepts creates the basis for this thesis.

2.1 Primary Health Care
2.1.1 Definition of Primary Health Care
According to Health Canada, the term “primary health care” refers to an approach to
health and a spectrum of services that go beyond the traditional health care system (Health
Canada, 2012). Primary health care serves a dual function in the broader health care system: 1)
to direct provision of first-contact services by health care providers such as family physicians
and nurse practitioners; and 2) to integrate and coordinate patients in need of more specialized
services such as those provided by specialists or through in-patient hospital care (Health Canada,
2012; Hutchison et al., 2011; Starfield et al., 2005). The range and configuration of PHC
services that are available varies from community to community, but often focusses on the
prevention and treatment of common diseases and injuries, basic emergency services, referrals
and coordination with other levels of care, mental health care, health promotion, maternity and
early-life care, as well as palliative and end-of-life care (Health Canada, 2012). The concept of
“primary care” is the element within PHC that focusses on the delivery of these health care
services to achieve health promotion, illness and injury prevention (both acute and chronic
illness prevention) and the diagnosis and treatment of illness and injury among populations
(Health Canada, 2012). In a similar sense, the World Health Organization (WHO) Alma Ata
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International Conference in 1978 and reports from the Institute of Medicine (IOM) defined
primary care as “the provision of integrated, accessible health care services by clinicians who are
accountable for addressing a large majority of personal health care needs, developing a sustained
partnership with patients and practicing in the context of family and community” (WHO, 1978;
IOM, 1978). As well, this definition of primary care has been used to measure four main
features of primary care services: 1) first-contact access for each new need; 2) long-term personfocussed care (not disease-focussed care); 3) comprehensive care for most health needs; and 4)
coordinated care when it must be sought elsewhere (Starfield et al., 2005; McWhinney and
Freeman, 2009). The term “primary health care” is used herein and refers to the definition of all
aspects of both “primary health care” and “primary care”, as defined above. Indeed, a strong
primary health care system is required to address the marked disparities or inequities in health
across populations and evidence of the substantial influence of a strong patient-centered PHC
system has been accumulating (Stewart et al., 2014; Kelley et al., 2014; Starfield et al., 2005).
In Canada, family physicians and nurse practitioners who see patients in a PHC setting
(e.g., in-office clinic, walk-in clinic or emergency department) provide the first point of contact
between a patient who is in need of health services and the health care system. This first-point
access is distinct from secondary health care services (e.g., medical specialist or in-patient
hospitalization) in which a referral or admission order is typically first required before receiving
these specialized services. The ways in which PHC services are organized and delivered have
been the focus of much debate. In fact, numerous studies have emphasized the importance of
PHC reform, including the Romanow Report published in 2002 (Hutchison et al., 2011;
Romanow, 2002). Explained further in the next section, the key feature of PHC reform was the
fundamental shift from singular PHC providers in their own in-office, unattached clinics to more
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robust teams of health care providers who work together to deliver multidisciplinary and
comprehensive services to their patients or clients (Hutchison et al., 2011; Health Council of
Canada, 2007; Starfield et al., 2005). This shift occurred based on the increasing evidence that a
team of professionals working as partners could achieve positive health outcomes, as well as
improved access to services, more efficient use of resources and higher satisfaction of both
patients and providers (Health Canada, 2012; Hutchison et al., 2011; Health Council of Canada,
2007). In fact, a team-based approach to PHC has become the focus in Canada and helps to
ensure that each health service is provided by the most appropriate professional, at the most
appropriate time and in the most appropriate location.

2.1.2 Primary Health Care in Canada
Canada has thirteen provincial and territorial health care systems that operate separately,
but are united under the legislative framework of the 1984 Canada Health Act. In 2010, 71% of
Canada’s health spending was publicly funded, but the delivery of care was largely private
(Hutchison et al., 2013). This means that most providers are independent contractors who are
then reimbursed by the provincial or territorial governments. In the early 2000s, despite the
country’s universal health care coverage, the Canadian PHC system experienced a period of
lagging behind other high-income countries on many PHC access and quality indicators
(Blendon et al., 2001; Hutchison et al., 2011). In an international survey examining PHC quality
among five high-income countries (Australia, Canada, New Zealand, United Kingdom and
United States), 61% of Canadian family physicians (the highest among all five participating
countries) were “very concerned” that their quality of care would decline in the future (Blendon
et al., 2001). These findings, combined with a number of federal and provincial reports, led to
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PHC reform in Canada. Although the goals and objectives of the provinces and territories for
PHC and its reform differ, common themes included focus on improved access to PHC services;
better coordination and integration of care; expansion of team-based approaches and
partnerships; improved quality of care, with an emphasis on patient engagement and selfmanagement; and the implementation and utilization of electronic records and other health
information management systems (Hutchison et al., 2011). Since this transition, several PHC
reform initiatives have been implemented broadly in one or more jurisdictions to advance the
quality of care received by PHC patients. For example, Family Health Teams and Community
Health Centres serve as the main interprofessional models in Ontario, while Family Medicine
Groups (Groupes de medicine de famille) are the main delivery models in Québec (Hutchison et
al., 2011).
A common criticism of PHC is the degree of “generalism” that this field of medicine
provides to their patients (McWhinney and Freeman, 2009; Stange and Ferrer, 2009). This
criticism is often referred to as the “paradox of primary health care”. This includes two
interrelated observations: 1) that PHC providers deliver poor quality of care for specific diseases,
as compared to specialists; and 2) that PHC is associated with higher value health care for the
whole person, resulting in better overall health, greater equity, lower health care costs and better
quality of care for the broader population (Stange and Ferrer, 2009). Quality of care is
commonly measured by the application of disease-specific, evidence-based process-of-care
guidelines, where PHC tends to require a more generalist approach to delivering services. To
date, family physicians and (increasingly) nurse practitioners are the principal sources of primary
medical care in Canada. As such, the term “primary health care provider” will be used herein
and refers to both family physicians and nurse practitioners. In their roles as primary health care
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providers, these professionals deliver ongoing, accessible care to their patient population and
build relationships with their patients to enhance the effectiveness of preventive and therapeutic
interventions over time (Martin et al., 2014; McWhinney and Freeman, 2009; van Weel, 2005).
Indeed, primary health care has been promoted as the building block of a high-value health care
system and should be supported to achieve its goals of providing quality care to its patients
(Stange and Ferrer, 2009; Chan, 2008; Rowan et al., 2007; Starfield et al., 2005).
A recent study conducted by Stewart and Ryan (2015) provided a Canadian synthesis of
health care use at the population level. This study examined health care needs and health care
use among provincial jurisdictions using the 2007 Canadian Community Health Survey (CCHS).
This database provided a large sample size of over 100,000 respondents from the ten Canadian
provinces (territories were excluded due to small sample sizes). The “ecology of health care”
was assessed by province, after age-sex standardization per 1,000 individuals for those who were
15 years of age and older (Stewart and Ryan, 2015). This study measured visits with family
physicians, visits with specialist physicians, visits with nurses and hospitalizations, as well as the
presence of chronic diseases. In Canada, a total of 243 contacts were reported to a family
physician per month per 1,000 people (Stewart and Ryan, 2015). This represented the most
frequent number of contacts per month, as there were only 70 contacts per month to a specialist
physician and 8 contacts per month that involved a hospitalization (both per 1,000 people).
Notable variation was observed from province-to-province. In fact, monthly contacts with
family physicians per 1,000 people ranged from as low as 158 contacts in Québec to as high as
295 contacts in British Columbia (Stewart and Ryan, 2015). Interestingly, the monthly rate of
having at least one chronic condition ranged from 524 per 1,000 people in Québec to 638 per
1,000 people in Nova Scotia, indicating differences in chronic disease occurrence based on
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geographic location (Stewart and Ryan, 2015). This study indicates the demand placed on the
primary health care system at the population-level in Canada. When these PHC services are
integrated, interdisciplinary and focused on the evolving health care needs of their patients, this
system is well positioned to provide the important facets of chronic disease prevention and
management to the populations they serve over time. Furthermore, these PHC providers can
deliver ongoing care to their patients, developing relationships that are beneficial to achieving
better health outcomes.

2.1.3 Chronic Disease Management in Primary Health Care
According to the 2014 WHO Global Status Report on Noncommunicable Diseases,
noncommunicable or chronic diseases are of a long duration and generally demonstrate slow
progression (WHO, 2014). These are health issues that require ongoing management over a
period of years or decades (WHO, 2014). The definition of “chronicity” proposed by O’Halloran
et al. (2004) is a disease lasting at least six months, having a documented pattern of recurrence or
deterioration, as well as an impact on an individual’s quality of life. Individuals living with
chronic diseases (and particularly those with multiple chronic diseases) often manage complex
treatment regimens that can include multiple appointments, multiple medications, regular
monitoring and adherence to different treatment and management protocols (Moffat and Mercer,
2015; Onder et al., 2015; Mercer et al., 2014; Smith et al., 2012; Sinnott et al., 2013; Fortin et al.,
2007; Boyd et al., 2005). For patients who are living with chronic diseases, access to regular and
effective PHC services can be highly desirable and associated with better health outcomes
(Smith et al., 2012; Soubhi et al., 2010; Noël et al., 2005; Starfield et al., 2003).
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In Ontario, almost two-thirds of respondents to the 2014 Commonwealth Fund
International Health Policy Survey of Older Adults who were living with chronic diseases
reported that they had easy access to a professional who could help with medical questions
between visits (Health Quality Ontario, 2015). Similarly, the 2011 Commonwealth Fund Survey
of Sicker Adults found that 96% of respondents with a chronic disease had access to a regular
medical doctor (Health Council of Canada, 2011). The vast majority (95.1%) of adults aged 40
years and older in the four western Canadian provinces (British Columbia, Alberta,
Saskatchewan and Manitoba) indicated they had access to a regular medical doctor (Weaver et
al., 2014). Generally, these results indicate that many Canadians with a disease that is of long
duration and generally slow progression are able to access their PHC provider. However, there
is a need to provide a complement of health care professionals in order to achieve the most
successful health outcomes for these patients (Rudland and Macey, 2013; Smith et al., 2007;
Hemmelgarn et al., 2007; Noël et al., 2007). This includes the involvement of health
professionals like dietitians, pharmacists, social workers, physiotherapists and occupational
therapists, many of which are now actively recruited into team-based settings. Even further,
these teams may involve specialist physicians, such as a psychiatrist or a geriatrician. This
increasingly diverse set of professionals will help to address the multidimensional needs of many
individuals who are living with chronic disease.
As stated by Barbara Starfield (2011), “Neither morbidity nor multimorbidity is randomly
distributed in populations. People and populations differ in their overall vulnerability to illness
and resistance to threats to their health; some have more than their share of illness and some have
less”. To date, a clear and comprehensive understanding of why “people and populations differ
in their overall vulnerability” and why some chronic diseases tend to cluster together within
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certain individuals. Indeed, this life course approach to understanding the occurrence of
individual chronic diseases, as well as multiple chronic diseases, is a large area of complex and
longitudinal research. More specifically, it is unclear how patients accumulate one disease after
another, as compared to other patients who remain unhindered by disease throughout their
lifetime (van den Akker et al., 2006). Extensive research has been conducted examining the
aetiology of individual chronic diseases (Ben-Shlomo et al., 2016; Non et al., 2014; Kamphuis et
al., 2013; Braveman and Barclay et al., 2009; Lynch and Smith, 2005; Barker 2004; Kuh et al.,
2004), however, a small subset of studies has examined the aetiology of multiple pathologies or
general disease susceptibility for multimorbidity, using a life course approach (Wister et al.,
2016; Vos et al., 2015; Pavela and Latham, 2015; Tomasdottir et al., 2015; Tucker-Seeley et al.,
2011). An article published more than twenty years ago by van den Akker et al. (1996)
identified the need for causal explanations or description of general susceptibility for disease in
observed patterns of chronic disease accumulation. Not only did this publication identify the
need for a differentiation between comorbidity and multimorbidity, but it signified the need to
understand the occurrence of multiple diseases in more detail.
Some patients may be more vulnerable to the co-occurrence of chronic diseases due to
genetic and immunological factors, the environment in which they live and work, lifestyle
behaviours and their level of adaptive or coping capacities (van den Akker et al., 1996).
Individual patient characteristics, such as stressful life events, vulnerability to stress,
(mal)adaptive approaches to illness and personal locus of control could be influential factors in
disease accumulation (van den Akker et al., 1996). Moreover, some chronic diseases may have a
common aetiology, common predisposing characteristics or a shared pathogenesis. For example,
although the aging process can vary from patient-to-patient, the biological ageing of organ
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systems can lead to increased general vulnerability for disease (van den Akker et al., 1996). As
well, some health care providers may be more aggressive in diagnosing, treating and managing
symptoms presented by their patients, due to personal or contextual influences on clinical care
behaviours (Vos et al., 2015). Finally, and particularly with the use of electronic records for
research, the potential influence of “detection bias” may result in increased chronic disease
burden. This detection bias refers to the fact that patients who have already been diagnosed with
one disease will contact the health care system more often than those who are relatively healthy.
As such, these patients will likely be examined more frequently and more extensively than their
healthy counterparts (van den Akker et al., 1996). Consequently, these patients are more likely
to be diagnosed with additional diseases, and may be more alert in recognizing or presenting
with symptoms for examination (van den Akker et al., 1996). The time elapsing between
diagnoses indicates an important period to either detect further pathophysiology or to avoid the
potential for overdiagnosis. While clinical judgement is intrinsic to family medicine, this
represents a point of intervention to avoid further disease progression. Therefore, the
management of chronic diseases over time and the assessment of variables that may influence the
accumulation of chronic diseases over time is an important, yet fairly unexamined, area of
research for those patients living with multiple chronic diseases.

2.2 Electronic Medical Records
2.2.1 Definition of Electronic Medical Records
Computer-based technology and the associated digital infrastructure, such as an
electronic medical record (EMR), can be particularly useful in facilitating the delivery and
organization of care to patients over time. An EMR is a computer-based repository of patient
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information, which is securely stored and readily accessible to authorized users. These
electronic records represent an important shift from traditional paper-based records and their
primary purpose is to support continuous, comprehensive, efficient and high quality health care
(Manca, 2015; Canada Health Infoway, 2013; Health Council of Canada, 2011; Schoen et al.,
2009; Hayrinen et al., 2008). Several elements can be documented within an electronic record
including patient demographics, lifestyle behaviours, presenting complaints or symptoms, past
medical history, family history, physical examination findings, clinical diagnoses, laboratory
tests and corresponding results, diagnostic imaging, medication administration, allergies,
immunizations, referrals, hospital admission and discharge notes (Canada Health Infoway, 2013;
Tu et al., 2015).
Health care systems are also increasingly offering patients the ability to access and
manage their health information through their own personal health record or through companion
applications such as health-related mobile applications or patient portals (Manca, 2015; Zulman
et al., 2015b; Goldzweig et al., 2013). Patient portals, in particular, are designed to give patients
secure access to health information (such as appointment and laboratory test results) and allow
secure methods for communication and information sharing between patients and their PHC
provider (Goldzweig et al., 2013). In comparison, an EMR is only accessible to an authorized
health professional or health organization (Canada Health Infoway, 2013). For example, within
a single PHC organization, those with access to the EMR system can be family physicians, nurse
practitioners, nurses, medical trainees (e.g., residents and medical students), administrative staff
and (in some cases) allied health professionals.
These EMR software programs can hold thousands of individual patient records, but
allow each health care provider to enter relevant patient-level data in unique ways (e.g., highly
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structured or “drop-down” data recording vs. highly unstructured or “free-text” data recording).
These EMR systems can also be integrated with other software that manages activities such as
billing and appointment scheduling. Canada Health Infoway is working towards the goal of one
electronic medical record system for all Canadians. However, since health care is organized at
the provincial and territorial level, each jurisdiction has its own EMR adoption program and
policies (Tu et al., 2015). This has had three important consequences: 1) there are multiple
vendors or companies that develop and sell EMR software programs to health care organizations,
such as PHC practices and hospitals; 2) there are no consistent or enforced guidelines for
recording clinical information within these electronic records; and 3) there is not a single
repository in Canada that automatically collects all of this clinical information. The United
Kingdom and its Clinical Practice Research Datalink is an excellent example of a country that
has recorded health-related data for every person registered with the National Health Service,
from birth to death, within a singular clinical database (Clinical Practice Research Datalink,
2016). The Canadian Primary Care Sentinel Surveillance Network (CPCSSN), which will be
described further in the next chapter, was established to address this notable gap in the Canadian
EMR landscape (Birtwhistle and Williamson, 2015; CPCSSN, 2016; Birtwhistle, 2011).

2.2.2 Adoption and Use of Electronic Medical Records in Canada
A systematic review conducted by Chang and Gupta (2015) indicated that the rates of
adoption of EMRs in Canada have increased from about 20% of physicians in 2006 to an
estimated 62% of physicians in 2013. This study found substantial regional variation in adoption
rates ranging from 40% of physicians in New Brunswick and Québec to more than 75% of
physicians in Alberta (Chang and Gupta, 2015; Schoen et al., 2012). As the use of EMR systems
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becomes increasingly common in PHC settings throughout Canada, it is important that these
EMR systems are used as effectively and efficiently as possible to maximize benefits and
improve quality of care (Terry et al., 2014; Canada Health Infoway, 2013). A recent study by
Paré et al. (2015) assessed the EMR use patterns of 331 family physicians in Québec and
determined that EMR systems “as-used” vary substantially from one family physician to another
in terms of the system capabilities that are actually mobilized in day-to-day clinical care. The
group of family physicians that were most impacted by their EMR system were those who had
the longest usage experience and consciously made the most use of their system’s capabilities
(Paré et al., 2015). However, many EMR adopters use only a fraction of their software’s
available functions and perceive the enhanced use of EMR systems as a substantial and
underused opportunity (Paré et al., 2015; Chang and Gupta, 2015). User-cited benefits of the
adoption of an EMR system into clinical care include time savings, improved record keeping,
heightened patient safety and confidence in the retrieved data when EMRs are used efficiently
(Chang and Gupta, 2015). In comparison, user-cited barriers to EMR adoption included
financial and time constraints (particularly for initial adoption of an EMR system), lack of
knowledgeable support personnel, lack of interoperability with hospital and pharmacy systems
and lack of integration with other allied health professionals (Chang and Gupta, 2015).
A recent study conducted by Zulman et al. (2015b) demonstrated that from the
perspective of patients living with multiple chronic diseases, the presence of an EMR can
markedly alleviate challenges and create opportunities for enhanced support. In a similar sense,
EMR use can support improved interactions and communications among members of the health
care team, as well as between providers and patients (Canada Health Infoway, 2013). The
patient-provider relationship may improve through additional opportunities for patient education
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(e.g., trending of test results over time), availability of information in real-time to facilitate
decision-making and options for patients and providers to communicate via secured messaging
(Manca, 2015; Canada Health Infoway, 2013). In contrast, the use of EMRs may introduce
challenges in building rapport between patients and providers, such as the distraction of entering
information electronically during the encounter or the unsuitable placement of the computer in
the examination room (Canada Health Infoway, 2013). To date, a balance between the benefits
and challenges of EMR use has not been consistently achieved.

2.2.3 Use of Electronic Medical Records in Epidemiological Research
Structured electronic records provide the potential to access point-of-care data to inform
clinical practice and to conduct academic research. With meaningful use, including standard and
consistent data entry in specific fields, EMR data can provide valuable practice-level information
(Manca, 2015). Epidemiological studies and public health assessments that measure population
morbidity often rely on the development and administration of surveys, which can capture selfreported morbidity among a sample of the target population of interest. An alternative approach
is to utilize information and diagnoses recorded during routine consultations in a clinical setting,
particularly in a PHC setting. An advantage of PHC consultation data is that encounter-level
information is collected longitudinally or at multiple time points. This information is recorded at
individual encounters between the patient and their PHC provider when the patient presents for a
clinical visit. This is distinct from typical population-level surveys, which are specifically
designed for a one-time or cyclic administration.
However, it is important to recognize that these PHC consultations and their
corresponding medical records do not necessarily reflect the “true” level of morbidity in a
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population, as many of the symptoms or morbidities (e.g., conditions or diseases) a patient may
be living with are not brought to the attention of the PHC provider. As well, a patient may be
living with a morbidity that remains undetected by the PHC provider. In a study completed by
Barber et al. (2010), the estimated population burden of multiple chronic diseases was actually
very similar between a population-level survey and an electronic medical record and was more
consistent for diseases with clear diagnostic features, such as diabetes mellitus. Electronic
medical records provide data that can reflect the entire care experience and can be analyzed for
entire populations receiving care (e.g., entire PHC practices and potentially in an ongoing and
real-time basis). This source of data can also improve the depth and breadth of information
available for research based on the longitudinal and patient-level data that are recorded.
Other sources of data, such as administrative data recorded for billing purposes, can be
used to capture real-world clinical information from a large population of patients (e.g., even
whole provinces such as Ontario or Alberta). These data, which can be held and analyzed by the
Canadian Institutes for Health Information, can be very valuable for clinical and policy purposes.
However, these data do not cover the breadth of clinical information from the PHC perspective
and are limited to patients who appear in the administrative database after receiving adjudicated
claims (e.g., prescriptions or hospital visits). In comparison, primary data collection, such as
surveys, allow researchers the ability to structure data collection to capture specific variables of
interest. This is particularly valuable for information that is not typically collected or contained
within a medical chart or an administrative database, such as patient socioeconomic
characteristics, experiences of disease or satisfaction with clinical care. The challenges of
primary data collection (e.g., surveys) include the time and resources that are required to recruit a
sufficient number of participants (Belletti et al., 2010).
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Electronic medical records offer great potential for research, enabling the rapid
identification of patients in the context of primary health care. EMRs use a combination of
structured data and unstructured (or free text) data (CIHI, 2013; Orueta et al., 2012; Terry et al.,
2010). The balance between these two components varies across different record systems with
some EMRs consisting primarily of coded data and others are a combination of coded and free
text fields. The accuracy of a diagnostic code within an electronic record depends on two steps:
whether the code accurately reflects the provider’s clinical opinion and whether that diagnosis
was correct (Coleman et al., 2015; Nicholson et al., 2011). A valid diagnostic code indicates that
a provider believes that: 1) a patient has a specific symptom, condition or disease; 2) this clinical
diagnosis is correct; and 3) this diagnosis code is accurately recorded within the patient’s EMR.
Occasionally, a code may be entered in error and not corrected (Greiver, 2015; Nicholson et al.,
2011). Alternatively, a provider may make a diagnosis, but not record it (Tu et al., 2015;
Weiskopf et al., 2013; Thiru et al., 2003). The practice of recording diagnostic codes is yet to be
fully understood and requires further research (Coleman et al., 2015; Orueta et al., 2012). At
present, the extent of accurately identified and non-missing cases in an electronic record database
can be estimated by comparison of prevalence rates obtained from within the database with those
from external sources, such as administrative datasets or population-based estimates.
Increasingly, the data contained within EMRs are being used for research purposes.
Although not collected for research purposes, these records contain rich, longitudinal and
individual-level data for each patient visiting their PHC provider. When the quality of these data
can be ensured, researchers using a PHC EMR database often have access to more robust clinical
data, when compared with self-reported surveys or administrative data. For example,
comprehensive and quality information can be derived from the diagnoses or referral data within
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an electronic record. Work is needed to enhance the coding practices of PHC providers, as well
as the technologies that are used by the PHC community, so that all data recorded in these EMRs
can be put to better use in clinical and epidemiological research, health services planning and
health care policy decisions (Terry et al., 2014; Hayrinen et al., 2008; Lobach and Detmer, 2007;
Thiru et al., 2003).

2.3 Multimorbidity
2.3.1 Concept of Multimorbidity
The issue of multimorbidity (that is, multiple chronic diseases occurring within the same
individual) is among the 21st century’s major emerging health issues and poses a myriad of
challenges for public health, primary health care and community care (Afshar et al., 2015;
Mercer et al., 2014; Parekh and Goodman, 2013). Moving beyond the health challenges and
economic burden of individual chronic diseases, the emerging prevalence of multimorbidity will
potentially lead to a substantial increase in demands on our society in the near future (Stewart et
al., 2013). The construct of “comorbidity” dates back to 1970, when Alvin Feinstein used the
term in addressing the functional effects of comorbid conditions on the patient, as well as the
combined effects of these comorbid conditions on the patient’s clinical profile (Feinstein, 1970).
Feinstein first defined the term “comorbidity” as “any distinct additional clinical entity that has
existed or that may occur during the clinical course of a patient who has the index disease under
study” (Feinstein, 1970). This definition implies that the index disease under study is of
principal importance and is the main focus for the health care provider. Although used
interchangeably in the past by many authors, there are important distinctions between the terms
“comorbidity” and “multimorbidity”. The concept of “multimorbidity” describes the
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“coexistence of two or more chronic diseases in the same individual”, in which no one disease is
designated the index disease or primary focus for the health care provider (van den Akker et al.,
1996; Boyd and Fortin, 2011). This conceptual difference between the terms comorbidity and
multimorbidity (Boyd and Fortin, 2011) has been adapted in this thesis and can be seen in
Figure 2.1. In this adapted figure, the patient becomes ancillary to the co-occurring chronic
diseases in the concept of comorbidity, as compared to the concept of multimorbidity, which
facilitates a more holistic and patient-centered approach.

2.3.2 Operationalization of Multimorbidity
To date, there is no internationally accepted list of chronic diseases that define or capture
patients with multimorbidity (Almirall and Fortin, 2013; Stewart et al., 2013; Diederichs et al.,
2011). Researchers must therefore create a list that is suitable for their research purposes and
corresponding data source. For this research, a list of twenty chronic disease categories and
corresponding diagnostic codes were used. Based on previous international literature that
examined the burden of multimorbidity among PHC patients using comprehensive national
electronic health records, this list of twenty chronic diseases was created (Mercer et al., 2014;
Barnett et al., 2012; Diederichs et al., 2011; George et al., 2006; Bayliss et al., 2005; Byles et al.,
2005; Crabtree et al., 2000; Greenfield et al., 1993; Charlson et al., 1987). This final list was
compared with more recently published definitions of multimorbidity (those studies that have
published the list of individual chronic diseases), to assess consistency in diseases and disease
categories that were captured. The comparison among lists is presented in Table 2.1.
Perhaps one of the reasons for the varying definitions and conceptualizations of
multimorbidity in the literature is the lack of a clear philosophical understanding of what it

18

means to examine the multidimensional concept of “multimorbidity”. For example, part of the
problem in choosing an appropriate measure of multimorbidity is due to the abstract nature of the
concept of multimorbidity and how it relates to other concepts, such as disease burden and
patient complexity (Huntley et al., 2012; Valderas et al., 2009). The methodology used to
measure multimorbidity is based on the underlying elements of multimorbidity that are important
for research work (e.g., count numbers of chronic diseases, burden on distinct body systems,
treatment burden, health system burden).
The definition of multimorbidity indicates the presence of multiple health issues within
an individual. The use of the terms disease, illness or condition are often used interchangeably
to describe these “health issues” of patients. The term disease refers to a defined pathological
process with a characteristic set of signs and symptoms, while the term illness is frequently used
as a synonym for disease, but in many cases it refers to the patients’ personal experience of their
disease (McWhinney and Freeman, 2009). In comparison, the term condition is a broader term
that includes the concept of disease, as well as other health issues that fall outside of the
traditional disease model (McWhinney and Freeman, 2009). For example, health issues like
obesity or hypertension may be seen as pre-existing conditions and a preceding risk factor to
subsequent diseases. Alternatively, they may be seen as their own chronic disease entity. In a
recent study examining the various terms that have been used in research to describe multiple
coexistent diseases, it was noted that the terms disease and condition were overwhelmingly used
in the definition of multimorbidity and seem to be more appropriate for describing the
coexistence of multiple health issues in a patient, particularly when no one disease has been
identified as the index disease (Almirall and Fortin, 2013). Therefore, the term disease was used
herein.
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Figure 2.1 Conceptual diagram of the terms comorbidity and multimorbidity (adapted
from Boyd and Fortin, 2010)

2.3.3 Measurement of Multimorbidity
Similar to its multiple definitions, multimorbidity can be measured in several different
ways. Measures of multimorbidity broadly fall into two types: simple counts of diseases in
individuals (with variation in the disease types included in this count) and indices to assess
morbidity burden that differentially weight disease to account for burden of illness or number of
body systems that are affected. Many commonly used indices were originally developed and
validated among elderly or specialized patient populations or hospital-based populations
(Brilleman and Salisbury, 2013; Huntley et al., 2012). To date, research has assessed the
prevalence of multimorbidity by comparing between multiple measures (Harrison et al., 2014;
Brilleman and Salisbury, 2013; Huntley et al., 2012; Diederichs et al., 2011; Valderas et al.,
2009; Fortin et al., 2005).
A study that examined the predictive validity of 17 different measures (including simple
disease counts, Adjusted Clinical Groups, Charlson Index of Comorbidity and Cumulative
Illness Rating Scale) of multimorbidity and their relationship with related outcomes (e.g., health
care utilization, health care costs, mortality and quality of life) found that simple counts of
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disease performed almost as well as complex measures in predicting important outcomes in
patients (Huntley et al., 2012). While the choice of measure of multimorbidity is primarily based
on the suitability of the measure for the data available, this systematic review indicated that the
most common approach to measuring multimorbidity is the use of simple disease counts
(Huntley et al., 2012). However, it remains challenging to compare findings between studies
examining the burden of multimorbidity, as different authors have utilized different lists of
diseases in their measure of multimorbidity. Also hindering the comparability between studies is
the fact that many publications do not include details about which diseases were included in the
multimorbidity list and the criteria for inclusion (Diederichs et al., 2011). Similarly, most studies
are based on counting of chronic diseases; however a definition of “chronicity” is rarely
explicitly stated. This can again lead to varying lists of multiple chronic diseases.
While the simple count of chronic diseases tends to be the most common approach to
examine the burden of multimorbidity, other commonly used indices to measure the burden of
multimorbidity have included the Charlson Index of Comorbidity (Charlson et al., 1987), the
Cumulative Illness Rating Scale (Miller et al., 1992), or indices that are applied to evaluate
quality of outcomes and resource utilization, such as the Johns Hopkins University Adjusted
Clinical Groups Case-Mix System (Salisbury et al., 2011). While these measures have been
applied in previous research examining multimorbidity burden, they are more complex and were
originally created for different purposes than estimating multimorbidity prevalence (e.g., risk of
mortality or health care cost). Therefore, the simple count of chronic diseases may indeed be the
useful approach to determining the prevalence of multimorbidity in a population. It may be
anticipated that more complex measures of multimorbidity (e.g., the Charlson Index of
Comorbidity, Cumulative Illness Rating Scale or Adjusted Clinical Group System) that
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differentially weight diseases, would be more effective at predicting outcomes related to
multimorbidity as compared to simple counts that weigh all diseases equally. However, some
studies have concluded that simple measures, such as counts of chronic diseases, are almost as
effective at predicting health care utilization and quality of life as more sophisticated
measurements (Huntley et al., 2012). In fact, these approaches to measuring multimorbidity are
more ideal as they are less costly (e.g., no registration or purchasing fee required) and can be
more easily applied to secondary data sources (e.g., electronic records or administrative data).
To date, clear and comprehensive criteria for the selection of individual chronic diseases,
which qualify for multimorbidity are still lacking. As a result, there is no clear agreement or
consensus on the number and type of diseases to be included in multimorbidity research. In fact,
existing definitions are characterized by their large degree of heterogeneity, considering as little
as four diagnoses (stroke, coronary heart disease, hypertension and diabetes) by McGee et al.
(1996) to as many as 185 diagnoses by Kadam et al. (2007). This often leads to incomparable
prevalence levels across studies and a lack of a “gold standard” measure for multimorbidity. In a
systematic review by Diederichs et al. (2011), researchers found that almost 60% of studies did
not specify the criteria for selecting the list of diseases included in the multimorbidity measure.
In these publications, a list of diseases was presented without any further explanation or
justification for the list selected (Diederichs et al., 2011). Overall, the mean number of diseases
that were considered in 39 multimorbidity indices was 18.5 diseases (median of 14 diseases).
Interestingly, the range of the number of diseases was in fact rather small, with 87.2% of the
indices including between 6 and 25 chronic diseases (Diederichs et al., 2011). When criteria
were given, the most frequently used selection criterion was found to be those diseases that were
“highly prevalent” in the population of interest (Diederichs et al., 2011). This systematic review
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concluded that future multimorbidity indices should include and measure at least 11 diagnoses,
particularly for studies that rely on ICD-10 diagnoses (Diederichs et al., 2011). It also
highlighted the heterogeneity of existing indices and the need for a new, established instrument
to assess multimorbidity.
Likewise, a systematic review conducted by Fortin et al. (2012) suggested that
investigators designing future studies to assess the prevalence of multimorbidity should include
at least 12 frequent chronic diseases and should attempt to report results for the two main
definitions of multimorbidity: at least two and at least three chronic diseases. This more uniform
operationalization and presentation of multimorbidity will assist in creating more comparable
estimates of multimorbidity prevalence in the literature. Indeed, the comparable estimation of
the burden of multimorbidity is important to fully characterizing this global health issue.
Valid comparisons of the prevalence rates of multimorbidity also require a rigorous
methodological approach, with specific criteria made explicit in academic publications (Stewart
et al., 2013; Schellevis, 2013; Fortin et al., 2012). According to Stewart et al. (2013), the criteria
for comparability of multimorbidity studies include commonality in: 1) the definition of
multimorbidity; 2) the definition of chronicity; 3) the level at which chronic diseases are defined
(e.g., transient ischemic heart attack or cerebrovascular disease; split or lumped); 4) the list of
chronic diseases that will be considered; and 5) the study population and data source being used
(e.g., administrative, clinical or survey data). Ultimately, there is a need to establish an approach
to measuring multimorbidity that balances both comprehensiveness (e.g., including all important
diseases) and efficiency (e.g., particularly for use in large secondary databases) when measuring
the burden of multimorbidity.
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2.3.4 Prevalence of Multimorbidity in Community Populations
Managing chronic disease is a daily reality for at least one third of Canadians, with this
proportion increasing as the Canadian population ages and risk factors continue to rise
(Broemeling et al., 2008). These chronic diseases impact the health and wellbeing of individuals
and represent a significant health system and economic burden. In their analyses of the 2005
Canadian Community Health Survey (CCHS Cycle 3.1), Broemeling et al. (2008) demonstrated
that multimorbidity was a common experience as more than one-half of adults over the age of 65
years reported having at least two of seven chronic diseases (arthritis, cancer, chronic obstructive
pulmonary disease, diabetes, heart disease, high blood pressure and mood disorders). This study
also found that among the almost 9 million Canadian respondents (over the age of 12 years),
approximately 33% had at least two of seven chronic diseases (Broemeling et al., 2008).
Individuals living with chronic disease also use health care services (e.g., visits to a PHC
provider) more often than individuals without chronic disease and the intensity of service use
increases as the number of chronic disease diagnoses increases (Broemeling et al., 2008).
A systematic review conducted by Fortin et al. (2012) examined previously published
prevalence estimates of multimorbidity in both general populations and primary health care
populations from more than ten different countries, including Canada, the United States, the
United Kingdom, the Netherlands and Australia. This review found that the prevalence of
multimorbidity, defined as at least two diseases, ranged between less than 10% to as high as 70%
in general population studies, stratified by age (Fortin et al., 2012), indicating wide variation.
In the United States, the National Health Interview Survey conducted in 2010 found that
among respondents who were over the age of 18 years, 26% had at least two of ten chronic
diseases and rates significantly increased among women and with advancing age (Ward and
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Schiller, 2013). A study conducted by Barber et al. (2010) in the United Kingdom found similar
rates of multimorbidity (defined as at least two of a possible seven chronic diseases) among more
than 5,000 respondents aged 50 years of age and older who replied to a self-reported postal
health survey (36.2%) and whose electronic medical record was also reviewed (32.3%). A study
conducted in Spain by Violán et al. (2013) also found comparable prevalence levels of
multimorbidity (defined as at least two of a possible 27 chronic diseases) among more than
15,000 respondents aged 15 years of age and older who responded to a self-reported national
survey (Health Survey for Catalonia) and whose electronic medical record was reviewed for
clinical chronic disease diagnoses (77.4% and 67.7%, respectively). Although conducted outside
of Canada, this work indicates that there is reasonable agreement between prevalence estimates
of multimorbidity derived from data sources that access general populations and primary health
care populations.

2.3.5 Prevalence of Multimorbidity in Clinical Populations
Among primary health care populations, the prevalence of multimorbidity (defined as at
least two diseases, ever diagnosed in the health record) has been calculated as high as 98.5%
among patients aged 65 years or older (Fortin et al., 2012). In studies that included patients of
all ages, an S-shaped curve was observed for the association between increasing patient age and
the prevalence of multimorbidity. More specifically, multimorbidity prevalence was
approximately 20% or lower before the age of 40 years, then increased dramatically between 40
and 70 years and finally plateaued around the age of 70 years (Fortin et al., 2012). Barnett et al.
(2012) utilized a national EMR dataset in Scotland, which holds records for almost two million
patients from 314 medical practices, representing about one-third of the entire Scottish

25

population. Among all patients, the prevalence of multimorbidity (defined as at least two of a
possible forty chronic diseases) was found to be 23.2%, and the association between increasing
patient age and prevalence showed the same S-shaped curve (Barnett et al., 2012). However,
there was a notable excess of multimorbidity among those living in economically deprived areas.
In fact, young and middle-aged adult patients living in economically deprived areas (measured
using a deprivation score) had the same prevalence of multimorbidity 10 to 15 years earlier, as
compared to adult patients living in the most affluent areas (Barnett et al., 2012). This echoed
previous work that found that the most deprived people spend twice as many years in poor health
before they die than those who live in affluent settings (Mercer et al., 2007).
A study conducted by Brett et al. (2013) estimated patterns and prevalence of
multimorbidity across the entire age spectrum of patients attending two large metropolitan
practices in Western Australia during a six-month period. Data were extracted from the medical
records of 7,247 patients at the two practices and the Cumulative Illness Rating Scale was used
to categorize 42 conditions into 14 domains. This study found that multimorbidity was present
among 52% of patients examined. The prevalence of multimorbidity was 20.6% among patients
younger than 25 years, 43.7% among patients aged 25 to 44 years, 75.5% among patients aged
45 to 64 years, 74.6% among patients aged 65 to 74 years and 92.0% among patients aged 75
years and older. These findings demonstrate the challenge and ultimate limitations of the singledisease framework by which most health care, medical research and medical education is
structured. In fact, research demonstrates that the clinical care to manage multiple individual
diseases can become duplicative, costly and inefficient. As well, this becomes burdensome and
unsafe for patients because of poor coordination and integration of care and management plans.
Better understanding of the epidemiology of multimorbidity, as well as a patient-centered
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perspective to delivering this care, is necessary to develop proactive interventions to prevent or
reduce the burden and to properly align health care services with patient need (Wang and Lo,
2016; Schattner et al., 2015; Green, 2013; Shippee et al., 2012; Soubhi et al., 2010). Until these
changes are achieved, a significant burden will be felt by many key stakeholders: the patients and
caregivers, the health care providers and the health care system.

2.3.6 Burden of Multimorbidity on Health Care System
Multimorbidity has been linked with adverse health outcomes including more frequent
and longer hospitalizations (Gruneir et al., 2014; Agborsangaya et al., 2013; Gijsen et al., 2001;
Librero et al., 1999), reduced functional status (Ryan et al., 2015; Vogeli et al., 2007; Bayliss et
al., 2004), polypharmacy, (Smith et al., 2007; Boyd et al., 2005; Tinetti et al., 2004),
compromised care and patient safety (Panagioti et al., 2015; Zulman et al., 2013; Vogeli et al.,
2007; Gijsen et al., 2001), reduced quality of life (Agborsangaya et al., 2013; Boyd and Fortin,
2010; Fortin et al., 2007; Fortin et al., 2006), higher health care costs (Salisbury et al., 2011;
Hartmann et al., 2011; Vogeli et al., 2007; Rapoport et al., 2004) and higher mortality (St. John
et al., 2014; Gijsen et al., 2001). Studies have projected that the number of Americans living
with chronic disease will increase from 125 million in 2000 to 164 million (or nearly 50% of the
population) in 2030 (Anderson and Horvath, 2004). An estimated 78% of the total health care
resources in the United States are devoted to individuals with chronic disease (Anderson and
Horvath, 2004).
In a study conducted by Charlson et al. (2008), electronic medical records were used to
construct a model that identified the demographic and clinical features (e.g., age, sex, multiple
morbidities and medications) that were predictive of total yearly costs to the healthcare system.
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Data were obtained for almost 6,000 patients over a one-year period and indicated a mean annual
per patient health system cost of $2,655 (Charlson et al., 2008). In this predictive model,
individuals with higher levels of morbidity (more disease diagnoses) incurred exponentially
higher annual costs, ranging from $4,317 among patients with two morbidities to $13,326 among
patients with seven or more morbidities (Charlson et al., 2008). More importantly, these
predictive models help to identify those patients who are at high risk of costly and ineffective
care. In fact, a study conducted by Alonso-Morán et al. (2015) found that predictive risk models
for negative health outcomes (e.g., hospitalization, readmission, cost) were most accurate when
measures of multimorbidity were included. This review indicated the impact of multimorbidity
on adverse and repeated health care utilization (Alonso-Morán et al., 2015).

2.3.7 Burden of Multimorbidity on Primary Health Care Providers
As identified by the United States Department of Health and Human Services Initiative
on Multiple Chronic Conditions, there is a need to catalyze change within the context of how
chronic diseases are addressed, from an approach focussed on individual diseases to one that
uses a multiple chronic disease approach. In fact, this report states that this process of evolution
and refocus will require a “culture change, or paradigm shift” for PHC providers (United States
Department of Health and Human Services, 2010). In a qualitative interview among 25 primary
health care providers (15 physicians and 10 nurses) in the United Kingdom, providers identified
tensions between delivering care to meet quality targets and fulfilling the patient’s needs and
these tensions were exacerbated with the presence of multimorbidity (Bower et al., 2011). Other
challenges included the need for patients to coordinate and navigate their own health care path
(through the health care system and with multiple appointments and providers); the difficulties of
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self-management support for multiple diseases; and understanding the relationship between
physical and mental health (Bower et al., 2011).
Clinical practice guidelines have been developed to guide clinical management decisions
for patients and improve quality of health care delivery. However, adherence to current single
morbidity-focused, single disciplinary guidelines may result in undesirable effects for those with
multimorbidity, such as adverse interactions from polypharmacy and conflicting management
strategies (Blozik et al., 2013; Boyd et al., 2005). Although clinical practice guidelines are not
intended to replace the diagnostic, therapeutic and patient-centered priorities of the patientprovider encounter, providing health care in compliance with the current practice guidelines
might in fact result in worse outcomes and increased cost for a growing population of complex
(and even vulnerable) patients.
Boyd and colleagues (2005) illustrated the limitations of clinical practice guidelines by
aggregating recommendations from relevant clinical guidelines for a hypothetical (yet typical)
case of a 79-year-old woman with five common chronic diseases: chronic obstructive pulmonary
disease, diabetes mellitus, osteoporosis, hypertension and osteoarthritis. This analysis found that
most clinical practice guidelines did not modify or discuss the applicability of their
recommendations for patients living with multimorbidity. If the relevant clinical practice
guidelines were followed, this hypothetical patient would be prescribed 12 medications, 19 doses
per day, which would cost her US$4,877 per year (assuming no prescription drug coverage).
This patient would also have a complicated and often conflicting, list of 14 non-pharmacological
activities, including weight bearing exercise and energy conservation (Boyd et al., 2005).
Furthermore, none of the five clinical practice guidelines were patient- or family-centered as they
did not discuss the burden of comprehensive treatment on the patients or caregivers. This review
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provides evidence that current clinical practice guidelines do not provide an appropriate,
evidence-based foundation for assessing quality of care in patients with multiple chronic
diseases. In the Canadian context, Fortin et al. (2011) appraised 16 Canadian guidelines and
assessed their relevance for patients with multimorbidity. This study found that although 56.2%
of individual chronic disease guidelines addressed treatment for patients with multiple chronic
diseases, three guidelines addressed specific recommendations for patients with two co-occurring
diseases and only one addressed more than two concurrent diseases (Fortin et al., 2011). Indeed,
it is widely recognized that current clinical practice guidelines provide little guidance for PHC
providers on how to appropriately care for patients with multimorbidity (Tinetti et al., 2014;
Blozik et al., 2013; Hughes et al., 2013; Guthrie et al., 2012; Tinetti et al., 2004). Furthermore,
there is a need for PHC providers to form an ongoing and collaborative partnership with patients
and their families to prioritize care efforts.

2.3.8 Burden of Multimorbidity on Patients and Caregivers
The full physical and psychological impact of multimorbidity can be highly dependent on
the specific disease combinations within a patient, the severity of the coexisting conditions, the
patient’s age and their ability to effectively cope with multiple chronic diseases (Duguay et al.,
2014; Smith and O’Dowd, 2007). Consequential impact is also felt by the family members and
informal caregivers of those affected by multimorbidity. Interestingly, while support may be
available in the community for single diseases (e.g., through the Heart and Stroke Foundation or
the Canadian Diabetes Association), it is less likely to be available for those with multimorbidity
(Smith and O’Dowd, 2007). There continues to be a lack of investigation into the longitudinality
of multimorbidity, in which patients experiencing multimorbidity are followed over time to
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understand their progression into more complex clinical profiles and how their associated needs
evolve (Noël et al., 2005). As a result, complex patients are forced to depend on a health care
system and societal resources that have been traditionally designed to serve only single diseases
(Guthrie et al., 2012; Tinetti et al., 2012; Upshur et al., 2008). Moreover, there is often a
mismatch between the needs and priorities as defined by patients and their caregivers and those
priorities of their health care providers (Gill et al., 2014). As such, patients with multimorbidity
are most in need of shared decision-making and enhanced communication with their providers.
Individuals living with multimorbidity face many challenges, including managing
polypharmacy (Hughes et al., 2013; Blozik et al., 2013; Taylor et al., 2010; Noël et al., 2005;
Boyd et al., 2005; Townsend et al., 2003; Bayliss et al., 2003), increased risk of drug interactions
(Moffat and Mercer, 2015; Cheraghi-Sohi et al., 2013; Boyd and Fortin, 2010; Boyd et al.,
2005), dealing with barriers to self-care and self-management (Kenning et al., 2015; Liddy et al.,
2014; Morris et al., 2011; Bayliss et al., 2007; Boyd et al., 2005; Bayliss et al., 2003) and
difficulties in coordinating health care services (Zulman et al., 2015; Gill et al., 2014; Gustafsson
et al., 2013; Hartmann et al., 2011; Noël et al., 2005). Because of these challenges, research has
confirmed that individuals living with multimorbidity place higher demands on the system and
have poorer health outcomes. Multimorbidity can also impact an individual’s overall quality of
life (Agborsangaya et al., 2013; Boyd and Fortin, 2010; Fortin et al., 2007; Fortin et al., 2006).
In a cross-sectional questionnaire (Health Related Quality Council of Alberta 2010 Patient
Experience Survey) of almost 5,000 adult respondents in the province of Alberta, multimorbidity
was associated with reduction in the health-related quality of life (HRQOL), which is a selfreported multi-attribute health utility instrument for describing and valuing health states
(Agborsangaya et al., 2013). Moreover, a study conducted by Fortin et al. (2007) has detected
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significant impacts on HRQOL among patients with multimorbidity, and even specific
synergistic negative effects of co-occurring diseases (e.g., cluster of respiratory and cardiac
morbidity). Overall, both quantitative and qualitative research demonstrates that those living
with multimorbidity experience considerable pressure from the management of their chronic
diseases and the maintenance of all other activities of daily life.

2.3.9 Natural History and Progression of Multimorbidity
Previous research has noted that examining how multimorbidity develops over time, as
well as understanding causal mechanisms, is an important area for progress in our understanding
(Boyd and Fortin, 2010; Valderas et al., 2009). The lack of prospective studies that examine the
changing burden of multimorbidity over time has been highlighted in the literature (Strauss et al.,
2014; France et al., 2012; Mercer et al., 2011). There is increasing recognition that clinicians
must move away from the single disease management approach for patients with multiple
chronic diseases and use an integrated treatment or management plan for these patients.
However, greater insight is required to provide the evidence for these treatment and management
plans. Research that identifies clusters of the most prevalent chronic diseases and investigates
the nuanced patterns or natural history of multimorbidity could indicate areas in which evidencebased information can integrate clinical practice guidelines for multimorbidity. The study of the
amount of time elapsing between chronic disease diagnoses may provide important points of
focus for prevention. More specifically, identifying those patients who are considered to be most
“at risk” of developing a subsequent chronic disease can allow both clinicians and researchers to
focus on this cohort of patients and to create resources to potentially avoid the next occurrence of
chronic disease. To date, this has not been achieved in the multimorbidity literature.
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2.3.10 Clusters and Patterns of Multimorbidity
When analyzing the impacts of multimorbidity, previous literature has focused on the
descriptive counting of individual diseases or the simple link between co-occurring pairs of
diseases. However, the analysis of cumulative interactions and non-random associations
between chronic disease diagnoses can lead to a deeper understanding of the multidimensional
burden and impacts of multimorbidity (Sinnige et al., 2015; Vos et al., 2014; Garin et al., 2014;
Prados-Torres et al., 2014; Prados-Torres et al., 2012). A retrospective study using an
exploratory factor analysis and EMR data from 275,682 adult patients in Spain and found that
five patterns of multimorbidity could be detected (Prados-Torres et al., 2012). These five
patterns were: cardio-metabolic (e.g., diabetes, hypertension and heart disease); psychiatricsubstance abuse (e.g., psychosis and neurosis); mechanical-obesity-thyroidal (e.g., low back
pain, varicose veins of lower extremities and osteoporosis); psychogeriatric (e.g., dementia and
Parkinson’s disease); and depressive (e.g., depression and insomnia). In the systematic review
conducted by Prados-Torres et al. (2014), 97 patterns composed of two or more diseases were
detected and the three most prevalent combinations of chronic diseases were classified as:
cardiovascular and metabolic diseases; mental health problems; and musculoskeletal disorders.
In comparison, a systematic review conducted by Sinnige et al. (2015) found that among older
adult populations, depression was the disease that was most commonly clustered with other
disease diagnoses and was specifically paired with eight other diseases (hypertension, arthritis,
diabetes mellitus, asthma or chronic obstructive pulmonary disease, stroke, cancer, heart failure
and heart disease). This work is beginning to uncover the previously unexplored complexities of
multiple chronic diseases within an individual. A comparable set of multimorbidity patterns,
identified in the Canadian primary health care context, has yet to be established. This research
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will work to address this gap in order to create a deeper understanding of the complexity of
multimorbidity in Canada.
As demonstrated, the epidemiology of multimorbidity has been examined in international
literature and a recent editorial concluded that although new descriptive epidemiological studies
will likely show similar trends as seen in past multimorbidity literature (despite variations in
methodology), future work should focus on statistical clustering of chronic diseases and the
development of prevalence rates of multimorbidity over time (Schellevis, 2013). Studies
examining the (statistical) clustering of diseases, showing higher prevalence rates of
combinations of chronic diseases than can be expected by chance (observed vs. expected rates),
may provide clues for further exploration of etiological factors. Moreover, the study of living
with multimorbidity must take a life course view, examining the development of multiple
chronic diseases over time. Such studies may provide clues for preventing or delaying the
occurrence of subsequent chronic diseases, as well as support health care planning and program
development to address patient needs (Schellevis, 2013; France et al., 2012; Mercer et al., 2011).

2.4 Summary
The current literature has indicated the importance of creating a more nuanced
understanding of multimorbidity, the critical role of primary health care and the emerging
benefits of using EMR data for epidemiological research. As such, this research will use a large
national EMR data source to determine the burden of multimorbidity among adult PHC patients
across Canada. The intent of this doctoral research is to add to the growing international
multimorbidity literature, as well as to contribute a perspective to improving the care and wellbeing for this increasing and complex patient population.
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Table 2.1 Comparison of multimorbidity chronic disease lists from publications in multimorbidity literature and the current list
of twenty chronic disease categories
Chronic Disease
Category

Pefoyo
et al.,
2015
++
++

Roberts
et al.,
2015
+

Tonelli
et al.,
2015
++
++

St. Sauver
et al.,
2015
++
++

Zulman
et al.,
2015
++
++

Fortin
et al.,
2014
++
++
++

Rocca
et al.,
2014
++
++

Strauss
et al.,
2014
++
++
++

Ornstein
et al.,
2013
++
++
++

Agborsangaya
et al., 2012

Hypertension
+
Obesity
+
Diabetes
+
Chronic Obstructive
Pulmonary Disease or
++
+
++
++
++
++
++
++
++
+
Asthma
Hyperlipidemia
+
++
++
++
++
+
Cancer
++
+
++
++
++
++
++
+
Cardiovascular Disease
++
+
++
++
++
++
++
++
++
+
Heart Failure
++
++
++
++
++
++
++
++
+
Anxiety or Depression
+
+
+
++
+
++
+
++
+
Osteoarthritis or
++
+
+
++
+
++
+
++
++
+
Rheumatoid Arthritis
Stroke or Transient
++
+
++
++
++
++
++
++
+
Ischemic Attack
Thyroid Problem
+
++
++
++
Kidney Disease or
++
++
++
++
++
++
++
++
+
Failure
Osteoporosis
++
++
++
++
++
++
++
Dementia
++
+
++
++
++
++
++
Musculoskeletal Problem
+
++
++
+
+
Stomach Problem
++
+
++
+
Colon Problem
++
+
Liver Disease
++
++
++
+
++
Urinary Problem
++
Note: ++ indicates that the definition, diagnosis codes and/or disease categories were the same or almost similar; + indicates that the definition, diagnosis codes
and/or disease categories were somewhat similar; - indicates that no comparable definition, diagnosis codes or disease categories were identified
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Table 2.1 Comparison of multimorbidity chronic disease lists from publications in multimorbidity literature and the current list
of twenty chronic disease categories, Continued
Chronic Disease Category

Barnett
et al.,
2012
++
++

Muggah
et al.,
2012
++
++

Prados-Torres
et al.,
2012
++
++
++

Rizza
et al.,
2012
++
++
++

van Oostrom
et al.,
2012
++

Diederichs
et al.,
2011
++
++

Broemeling
et al.,
2008
++
++

George
et al.,
2006
++

Bayliss
et al.,
2005
++
+
++

Byles
et al.,
2005
++
++

Hypertension
Obesity
Diabetes
Chronic Obstructive
Pulmonary Disease or
++
++
++
++
++
++
++
++
++
++
Asthma
Hyperlipidemia
++
++
Cancer
++
++
++
++
++
++
+
++
++
Cardiovascular Disease
++
++
++
++
++
++
++
++
++
+
Heart Failure
++
++
++
++
++
+
++
++
Anxiety or Depression
++
++
++
++
++
+
++
++
Osteoarthritis or
++
+
++
++
++
+
++
++
Rheumatoid Arthritis
Stroke or Transient
++
++
++
++
++
++
++
Ischemic Attack
Thyroid Problem
++
++
++
++
Kidney Disease or Failure
++
++
++
+
++
+
+
Osteoporosis
++
++
++
++
++
Dementia
++
++
++
++
++
++
Musculoskeletal Problem
+
++
++
++
+
+
Stomach Problem
++
++
++
+
++
Colon Problem
++
++
++
+
++
+
Liver Disease
++
++
++
++
Urinary Problem
+
++
+
Note: ++ indicates that the definition, diagnosis codes and/or disease categories were the same or almost similar; + indicates that the definition, diagnosis codes
and/or disease categories were somewhat similar; - indicates that no comparable definition, diagnosis codes or disease categories were identified
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Chapter 3
3 Research Objectives
The objectives of this doctoral research are two-fold. Objective One is to understand the
prevalence and characteristics of adult (at least 18 years of age) primary health care patients within
the CPCSSN database who are living with multimorbidity as of September 30, 2013. This
objective will also determine the clusters of multiple chronic diseases that tend to occur most
frequently together among patients with multimorbidity. Objective Two will build on this initial
understanding to provide more robust information on the natural history or progression of
multimorbidity among adult PHC patients over time. Both objectives will contribute to the
understanding of multimorbidity in PHC using the national and longitudinal electronic medical
record database from the Canadian Primary Care Sentinel Surveillance Network.

3.1 Objective One
The first objective has three key research questions (included below), which will measure
the point prevalence, characteristics and clusters of multimorbidity among adult PHC patients.
More specifically, this objective will determine the prevalence (and corresponding 95%
confidence intervals) of multimorbidity, defined as at least two chronic diseases and at least three
chronic diseases occurring in the same individual. The characteristics of patients living with
multimorbidity will also be reported.

These characteristics will be compared to those

characteristics found in the scientific literature. Previous research has indicated that many patients
living with multimorbidity are more likely to be older, female and live in a rural or low
socioeconomic setting (Barnett et al., 2012; Salisbury et al., 2011; Harrison et al., 2013; Britt et
al., 2008; Uijen et al., 2008; Fortin et al., 2005; van den Akker et al., 1998).

37

Objective One Research Questions:
1a)

What is the point prevalence of multimorbidity among adult PHC patients within
the CPCSSN database as of September 30, 2013?

1b)

How does this prevalence compare to those prevalence estimates reported in the
scientific literature?

2a)

What are the common characteristics of adult PHC patients with multimorbidity
within the CPCSSN database?

2b)

How do these characteristics compare to those reported in the scientific literature?

3a)

Among adult PHC patients with multimorbidity, what are the most frequent
combinations (that is, unordered clusters) of multiple chronic diseases?

3b)

Among adult PHC patients with multimorbidity, what are the most frequent
permutations (that is, ordered clusters) of multiple chronic diseases?

3.2 Objective Two
The second objective has three research questions (included below), which will examine
the natural history and changing burden of multimorbidity over time among adult PHC patients.
This objective will examine the time-to-event patterns of multiple chronic disease diagnoses,
among a cohort of adult patients. More specifically, the amount of time elapsing (in days) between
multiple chronic disease diagnoses will be determined using a multilevel recurrent event survival
analysis. In order to account for clustering of events at the patient-, provider- and practice-level,
the multilevel survival analysis will assess the variance contributed by each level. Research has
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suggested that chronic diseases involving related body systems will lead to a quicker accumulation
of related chronic disease diagnoses, beyond the effect of increasing age (Strauss et al., 2014).
However, previous research has not indicated the extent to which patient-, provider- and practicelevel factors will impact the subsequent rate of chronic disease accumulation.

Objective Two Research Questions:
1)

Among adult PHC patients with at least one chronic disease, what is the mean time
elapsing until next chronic disease diagnosis?

2)

Does the mean time until next chronic disease decrease as the number of chronic
disease diagnoses increase?

3)

What are the patient-, provider- and practice-level variables that predict the mean
time until next chronic disease diagnosis?

Chapter 4
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4 Methodology
This chapter will describe the key elements of this doctoral research: the main data
source, relevant database variables, database management techniques, study design and statistical
analyses for Objective One and Objective Two.

4.1 Canadian Primary Care Sentinel Surveillance Network Database
Data were derived from the Canadian Primary Care Sentinel Surveillance Network
(CPCSSN) database located in Kingston, Ontario (CPCSSN, 2016; Birtwhistle, 2011). This
network was initially funded in 2008 by the Public Health Agency of Canada (PHAC) to develop
a national repository of primary health care information derived from EMRs (Queenan et al.,
2016; Birtwhistle, 2011; Birtwhistle et al., 2009). This information was intended to be a
resource for monitoring chronic disease in Canada, as well as for PHC-oriented research.
CPCSSN’s vision is to collect these point-of-care data and facilitate clinical and epidemiological
research to understand the health of Canadians from the PHC perspective (CPCSSN, 2016).
CPCSSN also strives to build a stronger national knowledge base on chronic disease
management, in order to improve the quality of PHC delivery for millions of Canadians
(CPCSSN, 2016).
CPCSSN is a growing entity with ongoing recruitment of practice-based research
networks: PHC sites (nested within networks), PHC providers (nested within sites), PHC patients
(nested within providers) and health care encounters (nested within patients). This multilevel
structure of the CPCSSN data is presented in Appendix A. While this database does not include
all PHC patients across Canada, these data represent the largest source of patient-level PHC data
that are available in Canada. For CPCSSN, database recruitment begins at the network level
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(e.g., in a specific geographic area like London, Ontario or Halifax, Nova Scotia), followed by
the recruitment of PHC sites and providers in the network’s geographic area. CPCSSN has
attempted to achieve representativeness in their network locations (e.g., recruitment has recently
begun in the Northwest Territories), as well as representative patient and provider characteristics.
The participation of PHC sites and providers is not random, but instead relies on a number of
related factors: self-selection of sites and providers that utilize EMR systems and are interested
in participating in CPCSSN; providers who are willing to contribute their patients’ EMR data;
logistics of data extraction and geographic location of the sites (e.g., limiting potential
participation of rural and remote sites); and financial remuneration to participating providers,
which can impact initial recruitment and sustainability of participating networks. To date, the
CPCSSN database includes PHC sites from inner-city, urban, suburban, small town and rural
settings and is continuously looking to expand its coverage and representativeness (Queenan et
al., 2016; Godwin et al., 2015).
A recent study determined the level of representativeness of both patient and provider
characteristics in the CPCSSN database, as compared to the broader Canadian population.
Queenan et al. (2016) identified that CPCSSN patients were slightly older than the age reported
by the 2011 Canadian Census (mean age of CPCSSN patients was 3.5 years older than the mean
age calculated from the 2011 Canadian Census), but followed the same patterns of sex
distribution (slightly larger proportion of females in both populations) and residential location
(majority of patients and respondents were living in an urban setting). The provincial-level
comparison indicated a lack of representation from Québec and British Columbia within the
CPCSSN database (Queenan et al., 2016). This was likely due to the health legislative
requirements in Québec that has slowed recruitment and because the network located in British
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Columbia is relatively new and still recruiting providers and patients (Queenan et al., 2016).
Likewise, the PHC providers in the CPCSSN database had similar characteristics as those
reported in the 2013 National Physician Survey (NPS). Among both populations, similar
distributions were seen among provider age, provider sex and whether the providers practiced in
a rural or urban location (Queenan et al., 2016). However, this study identified a larger
proportion of academic primary health care centres participating in the CPCSSN database, as
compared to those reported in the 2013 NPS (Queenan et al., 2016). The representation of the
CPCSSN data will continue to improve as the number of sites, providers and patients increase.
Each participating CPCSSN site and provider was recruited after transitioning from
paper-based to electronic-based health records. As such, each site had a pre-adopted EMR
software type (e.g., Wolf or Nightingale). As well, each site varied in when the EMR was
adopted and implemented (e.g., when the transition took place) and the extent to which the EMR
system is used in daily clinical care. For example, some sites may rely heavily on their EMR
software for scheduling appointments and ordering referrals, but may not enter complete or
consistent diagnostic information during patient encounters (Coleman et al., 2015; Orueta et al.,
2012; Lau et al., 2012; Hayrinen et al., 2008). Other sites may achieve a higher level of
“meaningful use”, in which their EMR system is used regularly as an important tool for disease
prevention and ongoing disease management (Manca 2015; Terry et al., 2014; Blumenthal et al.,
2010; Thiru et al., 2003). In these sites, the providers actively engage with their EMR software
for each patient encounter. These patterns of meaningful use can vary from site to site and from
provider to provider. Throughout this thesis, the term “software” will refer to the EMR software
program (e.g., Nightingale or Wolf) used by a PHC provider, whereas the term “record” will
refer to the individual patient-level data.
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Every three months, de-identified data are extracted from the participating sites’ EMR
software by the regional CPCSSN data managers (individuals who are skilled in information
technology). These extracted data are then cleaned, coded and transformed into a common data
format that is compiled into the secure CPCSSN database. The exact details of these data
extraction processes vary slightly from network to network (e.g., some extractions are conducted
remotely, while others require in-person and manual extraction). However, each network's data
extraction process, specifically the de-identification, storage and utilization of these EMR data,
has been approved by their respective university research ethics boards and by the Health Canada
Research Ethics Board (CPCSSN, 2016).
One element of this ethics approval is that all participating CPCSSN sites must post
informational posters and distribute brochures about CPCSSN to their patients, in order to give
individual patients an opportunity to learn about this database and to opt-out (or opt-in, as is the
case in the network based in Québec) of contributing their personal health information to the
CPCSSN database. If a patient decides to opt-out, this decision is recorded in their EMR and
these patients do not have their health information extracted. At the CPCSSN central data
repository in Kingston, Ontario, a variety of organizational, physical and technological
safeguards are implemented to ensure that the privacy of patients is protected. These safeguards
are also important to ensure that all collection, retention and use or disclosure of data complies
with current privacy legislation and the 2010 Tri-Council Policy Statement, Ethical Conduct of
Research Involving Humans (CPCSSN, 2016). Personal information (of both patients and
providers) is removed from the data prior to being extracted from the EMR and further deidentification (e.g., removal of names from free text notes) is conducted by the data managers
after data collection and before compiling the data into the CPCSSN database.
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The longitudinal, clinical data held within the CPCSSN database are not only available
for academic research and policy purposes, but participating PHC providers can elect to receive
quarterly reports on their patient population and how their site characteristics (e.g., number of
patients who smoke or who have diabetes, performance of preventive measures for patients)
compare to other PHC sites in their region and across the country. This information can provide
valuable insight into the characteristics of a provider’s patient population, their clinical care
activities and their data input behaviours. The intent of this feedback is to improve both patient
care and the quality of data entered into EMRs.
As of June 2016, more than 1,500,000 de-identified electronic patient records have been
collected from more than 1,000 PHC providers (referred to as “sentinels” by CPCSSN) across
Canada (CPCSSN, 2016). During the data extraction period for this thesis work (known as the
Q3-2013 extract), a total of 600,565 de-identified electronic patient records were collected from
475 PHC providers in ten regional networks. These ten regional networks are located in seven
Canadian provinces: British Columbia, Alberta (two networks), Manitoba, Ontario (three
networks), Québec, Nova Scotia and Newfoundland and Labrador. The characteristics of these
ten participating networks (e.g., geographical location, number of sites, number providers,
number of patients, number of recorded encounters, type of EMR systems and time since EMR
adoption) at the time of data extraction are described in Table 4.1.
The CPCSSN data elements used for this research contain information on practice
characteristics (e.g., geographical location); provider characteristics (e.g., provider birth year and
provider sex); patient characteristics (e.g., patient birth year, patient sex and residential forward
sortation area); and in-office encounters (e.g., encounter date, billing diagnoses codes and
encounter diagnoses codes). The majority (approximately 95%) of the disease diagnosis codes
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within the CPCSSN database at the time of data extraction were recorded using the International
Classification of Disease, 9th Revision (ICD-9) system. As such, this coding system will be used
to detect chronic disease diagnoses for both Objective One and Objective Two.
These CPCSSN data contain patient-level, point-of-care information on disease
management and morbidity over time until the date of data extraction. While this information is
not principally collected for research purposes, the CPCSSN database represents the only known
pan-Canadian PHC EMR database. To obtain these secondary data, approval was obtained from
CPCSSN Research Committee in September 2013 (Project ID: 2013DEL04). The Letter of
Permission to access the CPCSSN database is provided in Appendix B. Ethical approval has
also been obtained from the Research Ethics Board at Western University and the Approval
Notice (File Number: 104705) is presented in Appendix C.
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Table 4.1 Characteristics of ten practice-based research networks participating in CPCSSN as of Q3-2013 data extract*
Start of

Number of

Number of

Number of

Providers

Patients

Encounters

Med Access, Wolf

60

55,053

1,204,548

2002

Med Access, Wolf

35

25,901

449,525

6

2005

Accuro, Healthscreen

21

19,029

516,523

Central Ontario

21

2006

81

140,791

1,610,614

5

Eastern Ontario

9

2010

Bell, Nightingale, Oscar

102

151,531

2,641,669

6

Québec

1

2012

DaVinci

25

8,942

212,694

9

2005

Nightingale, Wolf

53

47,860

896,053

Network ID

Province or Region

Number of Sites

1

Southern Alberta

7

2001

2

Northern Alberta

5

3

Southwestern Ontario

4

7

Newfoundland and
Labrador

EMR Software

EMR

Nightingale, Practice
Solutions, Xwave

8

Manitoba

3

2004

Jonoke

30

47,362

1,244,319

9

Nova Scotia

19

2006

Nightingale

53

86,359

1,093,733

10

British Columbia

2

2002

Wolf

15

17,737

343,087

475

600,565

10,212,765

Total

82

* All networks had the same data extraction date of September 30, 2013
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4.2 CPCSSN Data Procedures
After ethical approval and CPCSSN permission was received, a copy of the database (as
of the Q3-2013 extraction date) was transferred via an encrypted and password-protected
Microsoft Access database to a password-protected device at Western University. These
Microsoft Access files were then imported into the Stata SE 14.1 software to conduct
management, cleaning and statistical analyses of the data.

4.2.1 CPCSSN Database Management
The data dictionary of relevant CPCSSN variables is included in Appendix D. This
codebook outlines the variable names and the general process of entry into the EMR by the PHC
provider (e.g., family physician, nurse practitioner, nurse, medical resident or medical student).
New variables that were created for purposes of Objective One and Objective Two are also
included in the codebook and highlighted using italics. These new variables are described in a
similar manner to the original CPCSSN variables.

4.2.2 CPCSSN Data Cleaning
Once the data were received, all of the data tables and key variables of interest were
examined and explored. This “diagnostic exploration” uncovered the nuances of the data,
particularly the data entry patterns that were evident among networks, sites and providers. All
included variables (both original and new) were checked for range and consistency;
consequently, potential outliers and implausible values were identified. For continuous
variables, respective means, medians, range of values and standard deviations were calculated.
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For categorical variables, data distribution between categories was explored graphically and
statistically. The frequency and patterns of missingness were also assessed for each variable.

4.3 CPCSSN Data Elements
4.3.1 Primary Health Care Practice Characteristics
Each CPCSSN network has been assigned a unique Network ID, which is an autoincrementing value in which a unique number is generated when a new record is inserted into the
EMR table. The participating PHC practices (referred to as “sites” by CPCSSN, and these two
terms will be used interchangeably in this thesis) within each network were then assigned a
unique, auto-incrementing Site ID. While the network names and geographic locations (e.g.,
city, province or territory) are provided in the CPCSSN database and displayed on the CPCSSN
website (CPCSSN, 2016), specific Site ID information remains unavailable for researchers.
Instead, the geographic location of each site is recorded using the site’s forward sortation area
(first three characters of the site location’s postal code). Finally, details of each site’s EMR
software are recorded, including the name of the EMR software and the date the EMR software
was started within the practice. Therefore, the length of use and EMR software details for each
site can be explored. Each PHC provider (referred to as “sentinels” by CPCSSN, and these two
terms will be used interchangeably in this thesis) is nested within each Site ID and Network ID,
and their characteristics are described further in the next section.

4.3.2 Primary Health Care Provider Characteristics
Within the CPCSSN database, both family physicians and nurse practitioners have been
recruited as eligible PHC providers or sentinels. These are providers who: 1) are located at an
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academic or community site; 2) practice generalized or primary health care; and 3) utilize an
EMR system in their clinical work. After recruitment and consent to participate in the CPCSSN
database, each provider is then assigned a unique, auto-incrementing Provider ID. Similar to
Site ID, the majority of Provider ID information remains de-identified for researchers. Instead,
only the provider’s birth year and sex is recorded. Each patient and their health care encounters
are nested within each Provider ID, and these variables are described further in the next sections.

4.3.3 Primary Health Care Patient Characteristics
Patients who seek care from the participating CPCSSN providers (and who have not
refused to contribute their health data) are assigned a Patient ID, which is a unique, autoincrementing identifier for each patient in the database. Both patient birth year and patient sex
are recorded, as well as corresponding health information. As stated earlier, if a patient has
decided to opt-out of any data extraction period, the patient and their respective health
information are removed from subsequent data analyses. Unfortunately, details of the patient’s
socioeconomic characteristics, such as patient occupation, level of education, housing status,
language and ethnicity are incomplete and of poor quality in the CPCSSN database. This may be
because these fields within the EMR that are completed inconsistently, if at all, by the PHC
providers or more complete information is contained in another area of the EMR software not
extracted by the CPCSSN data managers (e.g., within clinical notes or patient profile). Examples
of data entries for these characteristics can be found in Appendix E. Due to missingness and
inconsistency, these socioeconomic variables were not a reliable source of information for use in
data analyses. However, the patient residential forward sortation area (FSA) has been recorded
for a larger proportion of patients and was used to identify whether a patient lived in a rural or
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urban setting and their median household income. This identification was done via a link with
Canada Post and Statistics Canada data and will be described further in the next two sections.

Residential Location and Forward Sortation Areas
The typical form of the Canadian postal code system is “ANA NAN”, where each “A”
represents an alphabetic character and each “N” represents a numeric character (Statistics
Canada, 2015). The first three characters of the postal code identify the FSA (Statistics Canada,
2015), which can be used to classify individuals into rural or urban residence. The first character
of the FSA (first alphabetic character) represents a province or territory, or a major region within
a province, as can be seen in Appendix F. The second character of the FSA (numeric character)
identifies whether the postal code is for a “rural” or “urban” area. For this character, a zero (0)
indicates a rural area, while any other digit between 1 through 9 represents a comparatively
urban area. As defined by Canada Post, “rural” residence refers to individuals living outside
centres with a population of 1,000 and outside areas with 400 persons per square kilometre
(Statistics Canada, 2015). In comparison, “urban” residence refers to individuals living within
population centres of 1,000 or more (Statistics Canada, 2015). The third character of the FSA
(second alphabetic character) narrows down the area of coverage and boundaries of each region.
The last three characters of the postal code (“NAN”) identify routes known as local delivery
units for mail delivery. For the purposes of this research, the CPCSSN database collects
residential FSA data for participating patients. The second character of each patient’s FSA was
used to categorize patients into rural (second character = 0) or urban (second character ≠ 0)
residence.
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Median Household Income and Forward Sortation Areas
In addition to linking with Canada Post data, the patient FSA data were linked with
household income data from the National Household Survey (2011) conducted by Statistics
Canada. Access to Statistics Canada data is covered through the Data Liberation Initiative
licence from Western University, which is a partnership between post-secondary institutions and
Statistics Canada for improving access to Canadian data resources (Western University, 2016).
Source data were derived from the Income Statistics Division of Statistics Canada (CANSIM
Table 202-0701), which collected information on market, total and after-tax income by economic
family type and income quintiles as of 2011. As such, annual household income was determined
before tax (total) and in Canadian dollars as of 2011 (Statistics Canada, 2016). More
specifically, household income was recorded for economic families (defined as two or more
persons who live in the same dwelling and are related to each other by blood, marriage, common
law or adoption), as well as unattached individuals (defined as a person living either alone or
with unrelated roommates), as of 2011 (Statistics Canada, 2016). The median annual household
income measure was used, instead of the mean annual household income, to account for a nonsymmetrical distribution. This median value helps to provide a better description of the central
tendency of the income data distribution.

4.3.4 Primary Health Care Encounter Characteristics
Each time a participating CPCSSN patient visits or seeks care from their CPCSSN PHC
provider, an encounter is recorded and assigned a unique, auto-incrementing Encounter ID. As
well, an associated Encounter Date (for Encounter Diagnosis information) or Service Date (for
Billing Diagnosis information) is recorded to indicate the date on which the encounter occurred.
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The details of the encounter are then documented in the EMR (again, the level of detail recorded
or documented within an EMR varies by site, provider and encounter). A number of
characteristics, specifically linked to the encounter, can be entered into the EMR by the provider.
For example, a provider has the ability to record relevant diagnostic codes, medication
information and specialist referrals that are made during the encounter. These data can also be
entered into various parts of a patient’s electronic record, as each EMR software has its own
individualized structure for clinical data input. This flexibility in data entry creates a need to
identify and extract from, all relevant areas of the EMR software program and the CPCSSN
database. Variability in EMR data entry requires adaptability from the researcher and the
approach used to identify the main source of diagnostic information is described in Section 4.6.

4.4 Identifying Sample of CPCSSN Patients
As of the Q3-2013 data extraction, the complete CPCSSN database consisted of 600,565
patients from 475 providers within ten regional networks. For both objectives, the inclusion
criteria required that eligible patients have at least one in-office encounter recorded in their EMR
and were at least 18 years of age as of their first encounter date (calculated using the patient’s
birth year and first recorded encounter date). Patients who had a missing or implausible (e.g.,
entry of “0”) Patient ID or birth year were excluded from the patient sample. A patient inclusion
flowchart is included in Figure 4.1. After applying the inclusion and exclusion criteria, the final
sample consisted of 367,743 eligible adult patients (at least 18 years of age at first encounter
date) who had at least one in-office encounter with their primary health care provider.
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4.5 Identifying Patients with Multimorbidity
As described in the Literature Review Chapter, there is currently no gold standard list for
measuring multimorbidity. Therefore, a list of twenty chronic disease categories and
corresponding ICD-9 diagnostic codes was created and used in this research to identify eligible
adult patients with multimorbidity. This list was created by a supervisory committee member
and an internationally recognized expert in multimorbidity research (Dr. Martin Fortin) as part of
a nationally funded research project. This project is co-led by Dr. Moira Stewart (Distinguished
University Professor, Western University, Ontario) and Dr. Martin Fortin (Professor, Université
de Sherbrooke, Québec) and is entitled “Patient-Centered Innovations for Persons with
Multimorbidity” or “PACE in MM” (PACE in MM, 2014). It is funded by the Canadian
Institutes of Health Research (CIHR) as a five-year signature initiative in community-based
primary health care (CBPHC), which supports innovative approaches to improve the delivery of
appropriate and high-quality primary health care to Canadians. The final list is composed of
chronic disease categories that are particularly relevant among clinical and general populations in
Canada. For example, the ICD-9 codes of 278 and 278.01, as well as a body mass index (BMI)
of thirty or greater, were used to capture patients with Obesity. The abbreviated list of chronic
disease categories and their corresponding ICD-9 codes is found in Table 4.2, while a more
detailed list is available in Appendix G.
To date, the performance of the list of chronic disease categories has been assessed using
a combination of criterion validity (through chart reviews), construct validity (through quality of
life), as well as through test-retest reliability and inter-rater reliability. This work has not yet
been published, but was conducted by Maude Richards who is a Master of Science student at the
Université de Sherbrooke in Québec. This study recruited 245 patients from the Family
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Medicine Group in Chicoutimi, Québec. After comparing the measurement of multimorbidity
with a chart review, this list of categories for multimorbidity had an overall sensitivity of 84.6%
(95% CI: 77.0 – 90.9) and specificity of 84.3% (95% CI: 76.4 – 90.4). Ms. Richard’s work also
found a moderate correlation between the measure of multimorbidity and quality of life (-0.5).
In terms of the reliability, there was fair agreement in the test-retest reliability (Cohen’s Kappa
coefficient of 0.64) and inter-rater reliability (Cohen’s Kappa coefficient of 0.79). Overall, this
research has demonstrated a fairly strong performance of this measure of multimorbidity, when
compared to the gold standard of chart review. For the research described herein, it was used as
a marker for multimorbidity among adult PHC patients within the CPCSSN database.
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Figure 4.1 Patient inclusion flowchart to create the final sample of adult patients with at least
one in-office encounter recorded during the data extraction period
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Table 4.2 List of twenty chronic disease categories and abbreviated ICD-9 disease codes*
Chronic Disease Category
Hypertension

ICD-9 Codes
401-405, 401, 401.1, 401.9, 405, 405.01, 405.09, 405.1, 405.11, 405.19, 405.9, 405.91,
405.99

Obesity

278, 278.01, BMI ≥ 30

Diabetes

250, 250.01, 250.02, 250.03, 250.1, 250.11, 250.12, 250.13, 250.2, 250.21, 250.22, 250.23,
250.3, 250.31, 250.32, 250.33, 250.4, 250.41, 250.42, 250.43, 250.5, 250.51, 250.52,
250.53, 250.6, 250.61, 250.62, 250.63, 250.7, 250.71, 250.72, 250.73, 250.8, 250.81,
250.82, 250.83, 250.9, 250.91, 250.92, 250.93

Chronic Obstructive

491, 491.1, 491.2, 491.21, 491.22, 491.8, 491.9, 492, 492.8, 493, 493.01, 493.02, 493.1,

Pulmonary Disease or

493.11, 493.12, 493.2, 493.21, 493.22, 493.8, 493.81, 493.82, 493.9, 493.91, 493.92, 496

Asthma
Hyperlipidemia

272, 272.1, 272.2, 272.3, 272.4

Cancer

140-239, 140-149, 150-159, 160-165, 170-176, 179-189, 190-199, 200-209

Cardiovascular Disease

412, 413, 413.1, 413.2, 440-449, 427, 427.3, 427.31, 417.32

Heart Failure

428, 394, 394.1, 394.2, 395, 395.1, 395.2, 395.9

Anxiety or Depression

296, 296.2, 296.21, 296.22, 296.23, 296.24, 296.25, 296.26, 296.3, 296.31, 296.32, 296.33,
296.34, 296.35, 296.36, 300, 300.01, 300.02, 300.09

Osteoarthritis or

714, 714.1, 714.2, 714.3, 715, 715.1, 715.2, 715.3, 715.8, 715.9

Rheumatoid Arthritis
Stroke or Transient

434, 434.01, 434.1, 434.11, 433.9, 434.9, 434.91, 435, 435.1, 435.2, 435.3, 435.8, 435.9

Ischemic Attack
Thyroid Problem

240-246, 240, 241, 242, 243, 244, 245, 246

Kidney Disease or Failure

585, 585.1, 585.2, 585.3, 585.4, 585.5, 585.6, 585.9

Osteoporosis

733, 733.01, 733.02, 733.03, 733.09

Dementia

290, 290.1, 290.11, 290.12, 290.13, 290.2, 290.21, 290.3, 290.4, 294, 294.1, 294.2

Musculoskeletal Problem

723, 723.1, 724, 724.1, 724.2, 724.3, 724.4, 724.5, 725, 726, 726.1, 726.2, 726.3, 726.31,
726.32, 726.33, 726.39, 726.4, 726.5, 726.6, 726.61, 726.62, 726.63, 726.64, 726.65,
726.69, 726.7, 726.71, 726.72, 726.73, 726.79, 726.9, 726.91, 727, 727.01, 727.03, 727.04,
727.05, 727.06, 727.09, 727.2, 727.3, 729, 729.1, 729.2, 729.4, 729.5

Stomach Problem

530, 530.81, 531, 531.4, 531.41, 531.5, 531.51, 531.6, 531.61, 531.7, 531.71, 531.9, 531.91

Colon Problem

555, 555.1, 555.2, 555.9, 556, 556.4, 556.5, 556.6, 556.8, 556.9, 564, 564.1

Liver Disease

571, 571.1, 571.2, 571.3, 571.4, 571.41, 571.42, 571.49, 571.5, 571.6, 571.8, 571.9

Urinary Problem

593, 593.3, 593.4, 593.5, 593.7, 593.71, 593.72, 593.73, 593.8, 593.82, 593.89, 593.9, 595,
595.1, 595.2, 595.9, 597, 597.8, 597.81, 597.82, 600, 601, 601.1, 601.3, 601.8, 601.9, 602,
602.1, 602.2, 602.3, 602.8, 602.9

* Reproduced with permission from co-Principal Investigator of PACE in MM CBPHC Team (Dr. Martin Fortin)
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4.6 Identifying Source of Chronic Disease Diagnoses
There are two areas of the CPCSSN database where diagnostic codes for each patient are
stored based on how the information was originally entered into the EMR. These are the Billing
Diagnosis and Encounter Diagnosis tables. After exploration of the raw data, it was clear that
the patterns of data entry for diagnostic information varied among sites and providers. There
was not a consistent source of diagnostic information for all patients between these two tables,
and diagnostic data had to be explored on a patient-by-patient basis. To overcome this
variability, the mean number of Billing Diagnosis codes and Encounter Diagnosis codes
(including both acute and chronic diagnoses) per encounter was calculated for each patient.
More specifically, the total number of Billing Diagnoses codes and the total number of
Encounter Diagnoses codes recorded for a patient in their EMR was divided by the total number
of encounters recorded for a patient. This produced the mean number of Billing Diagnosis codes
per encounter and the mean number of Encounter Diagnosis codes per encounter, respectively.
From this calculation, the higher mean number of diagnoses codes was identified as the main
source of chronic disease diagnoses for that individual patient. For patients with the same mean
number of Billing Diagnosis codes per encounter and Encounter Diagnosis codes per encounter,
the Encounter Diagnosis codes were selected as these codes were deemed more closely tied to
the encounter itself and were recorded beyond purposes of billing. The number of eligible adult
patients with a higher mean of Billing Diagnosis codes per encounter was 245,365 (66.7%),
while 110,608 (30.1%) patients had a higher mean of Encounter Diagnosis codes per encounter.
A total of 11,770 (3.2%) patients had the same mean number of Billing Diagnosis and Encounter
Diagnosis codes per encounter. Consequently, Encounter Diagnosis codes were used for
122,378 (33.3%) patients. This approach aimed to capture the maximum amount of clinical
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information available on a patient-by-patient basis. This produced a final prevalence estimate of
53.3%.
A three-part sensitivity analyses was conducted to detect potential differences in
prevalence of multimorbidity using either the Billing Diagnoses codes only, the Encounter
Diagnoses codes only or a combination of the two diagnostic sources. The results from these
three sensitivity analyses are presented in Table 4.3, as well as the results from the original
analysis. When all Billing Diagnosis codes were used to detect patients with multiple chronic
diseases, the prevalence of multimorbidity was found to be 56.7%. When all Encounter
Diagnosis codes were used to detect patients with multiple chronic diseases, the prevalence of
multimorbidity was found to be 54.1%. For the third part of the sensitivity analysis, Billing
Diagnosis codes were used for the 11,770 patients with an equal mean of Billing Diagnosis and
Encounter Diagnosis codes per encounter. Consequently, Billing Diagnosis codes were used for
257,135 (69.9%) and the resulting prevalence of multimorbidity was found to be 57.2%. After
conducting these analyses, the original analysis (reported in the Results Chapter) was deemed to
provide the most conservative estimate of multimorbidity among adult PHC patients in Canada.
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Table 4.3 Prevalence of multimorbidity (defined as patients with two or more chronic
diseases), stratified by source of diagnostic code information
Original Analysis

Prevalence of Multimorbidity

Highest Mean of Billing and Encounter Diagnosis Codes Selected and
Encounter Diagnosis Codes Selected for Patients with Equal Mean

53.3%
Prevalence of Multimorbidity

Sensitivity Analyses

(% Change from Original Analysis)

All Billing Diagnosis Codes Selected for All Patients

56.7% (+3.4)

All Encounter Diagnosis Codes Selected for All Patients

54.1% (+0.8)

Highest Mean of Billing and Encounter Diagnosis Codes Selected and
Billing Diagnosis Codes Selected for Patients with Equal Mean

57.2% (+3.9)

4.7 Objective One
4.7.1 Patient Sample
The first objective measured the point prevalence, characteristics and clusters of
multimorbidity among adult PHC patients in Canada. The patient sample, or population at-risk
of multimorbidity occurrence, was composed of participating CPCSSN patients with at least one
in-office encounter recorded in their EMR and who were at least 18 years of age as of their first
encounter date. As described in a previous section, this final sample consisted of 367,743 adult
patients. While the clinical data for these patients were recorded prospectively as the patients
consulted their PHC provider over time, the CPCSSN database created a retrospective or historic
cohort. The prevalence estimates of individual chronic diseases and multimorbidity were
calculated as of September 30, 2013.

4.7.2 Study Design
The first objective used a retrospective or historic observational cohort study design.
Prevalence estimates and corresponding 95% confidence intervals were calculated using the
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Stata SE 14.1 software (StataCorp., 2015). Prevalence estimates were stratified according to
relevant patient-, provider- and practice-level predictors: patient age, patient sex, residential
location, provider age, provider sex, EMR software type, practice location and CPCSSN
Network. Both crude and stratified prevalence estimates of multimorbidity were reported. To
identify the most frequently occurring clusters of chronic diseases accumulated by patients over
time, the frequency and type of unordered and ordered clusters (also known as combinations and
permutations, respectively) of chronic disease diagnoses were computed using customized Java
programming and the Stata SE 14.1 software (StataCorp., 2015), which are described in more
detail in Section 4.7.3.3.

4.7.3 Data Analyses
4.7.3.1 Research Question 1 – Prevalence of Multimorbidity
Prevalence estimates were calculated using two approaches, corresponding to the
prevalence estimates that are commonly reported within the multimorbidity literature. This
means that prevalence estimates of patients with at least two or at least three chronic diseases
were calculated, as well as the prevalence level of patients with zero, one, two, three, four and
five or more chronic diseases. Prevalence estimates and corresponding 95% confidence
intervals, were calculated using the proportion procedure in the Stata SE 14.1 software
(StataCorp., 2015). For all calculations, the denominator consisted of all adult patients (N =
367,743) in the final sample. These estimates were stratified by patient-level (age, sex,
residential location, median household income and total number of chronic diseases), providerlevel (age and sex) and practice-level (EMR software type, practice location and CPCSSN
Network) variables to investigate distinct patterns of multimorbidity.
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Patient age was calculated (in years) as of 2013, using the patient’s recorded birth year.
Age categories were then created to group patients into five categories: 18 – 34 years; 35 – 44
years; 45 – 64 years; 65 – 84 years; and 85 years or older. This calculation is separate from that
used in the inclusion criteria, which used the date of the patient’s first in-office encounter and the
patient’s birth year. Patient sex was recorded as a binary variable, female or male. As described
earlier, residential location and median household income were determined using each patient’s
residential FSA. The total number of chronic diseases was summed (ranging from zero to
twenty) for each patient as of September 30, 2013. Provider age was calculated (in years) as of
2013, using the provider’s recorded birth year and categorized into three groups: 25 – 44 years;
45 – 64 years; and 65 years or older. Provider sex was recorded as a binary variable, female or
male. Each practice’s EMR type was categorized based on the EMR software name (e.g.,
Nightingale or Oscar). Similar to patient residential location, practice location was defined by
the practice’s recorded FSA. Finally, practices were categorized according to their associated
CPCSSN Network (e.g., Network 1 or Network 2).
To compare prevalence estimates of multimorbidity with the existing international
literature on multimorbidity, a review of the literature was conducted and relevant articles that
reported prevalence of multimorbidity (defined as two or more chronic diseases and three or
more chronic diseases) were selected. For this review, both the Medline and Embase electronic
databases were searched for the reference period starting on January 1, 1990 and ending on April
25, 2016. As the term “multimorbidity” does not have an established Medical Subject Heading
(MeSH) Term, the term “multimorbidity” was searched as a keyword (in all fields) and the term
“comorbidity” was searched as a MeSH Term. The “epidemiology” and “prevalence” of
multimorbidity estimates were incorporated into the search as keywords and MeSH Terms.
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Similarly, the terms “characteristics”, “adult” and “humans” were all included to narrow the
literature search. Details of the main search terms used in this review are included in Table 4.4.
The final selection of published literature was identified from the titles derived from this search,
as well as through the review of references from included literature. The key methodological
elements (e.g., country of origin, study design, sample size, age range, sample recruitment, data
source, diagnostic coding system and number of diseases considered) and corresponding
prevalence estimates from relevant research articles were compiled into a summary table and
presented in the Results Chapter. Separate tables were created for those studies that defined
multimorbidity as at least two chronic diseases and those studies that defined multimorbidity as
at least three chronic diseases. The methodological elements and prevalence estimates from the
current study were also incorporated into these tables for qualitative comparison.

Table 4.4 Details of search terms to identify prevalence and characteristics of adults with
multimorbidity in the published literature
("comorbidity"[MeSH Terms] OR "comorbidity"[All Fields] OR "co-morbidity"[All Fields] OR
"multimorbidity"[All Fields] OR “multi-morbidity”[All Fields])
AND ("epidemiology"[Subheading] OR "epidemiology"[All Fields] OR "prevalence"[All Fields] OR
"prevalence"[MeSH Terms])
AND (“characteristics”[All Fields])
AND ("adult"[MeSH Terms] OR "adult"[All Fields])
AND ("1990/01/01"[PDAT] : "2016/04/25"[PDAT])
AND ("humans"[MeSH Terms])
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4.7.3.2 Research Question 2 – Characteristics of Adult PHC Patients with Multimorbidity
The characteristics of adult patients with multimorbidity were examined and compared
with the published multimorbidity literature. More specifically, the distribution of patient age,
patient sex, residential location, median household income and total number of chronic diseases
were explored for all adult patients with multimorbidity, defined as at least two chronic diseases
and at least three chronic diseases. The distribution of provider-level (provider age and provider
sex) and practice-level (EMR software type, practice location and CPCSSN Network) were also
explored for both definitions of multimorbidity.
In order to compare these patient characteristics with the existing multimorbidity
literature, a review of the literature was conducted and relevant articles that reported
characteristics of individuals with multimorbidity were selected. Similar to the previous search
for multimorbidity literature, this review included both Medline and Embase electronic databases
that were searched for the reference period of January 1, 1990 to April 25, 2016. Details of the
main search terms used in this review are included in Table 4.4. The final selection of published
literature was identified from the titles derived from this search, as well as through the review of
references from included literature. While it would be ideal to compare all patient-level
characteristics from the current research with those in the multimorbidity literature, there is a
lack of consistent reporting of characteristics of individuals living with multimorbidity (e.g.,
residential location or level of household income). Instead, the most consistently reported
characteristics in studies were in fact mean age and sex distribution. As such, these two
characteristics were used as a starting point in the qualitative comparison between the current
research and the published multimorbidity literature. These characteristics, as well as the key
methodological elements (e.g., country of origin, study design, sample size, age range, sample
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recruitment, data source, diagnostic coding system and number of diseases considered), from
relevant articles were compiled into a summary table and presented in the Results Chapter. Once
again, separate tables were created for those studies that defined multimorbidity as at least two
chronic diseases and those studies that defined multimorbidity as at least three chronic diseases.
The methodological elements and characteristics of patients with multimorbidity from the
current study were also incorporated into this table for comparison.

4.7.3.3 Research Question 3 – Most Frequent Clusters of Multiple Chronic Diseases
The prevalence estimates of individual chronic disease diagnoses among patients with
multimorbidity were calculated, stratified by patient age category and patient sex. Where
possible, the prevalence levels of individual chronic diseases were compared to the national
prevalence estimates from the 2013 Canadian Community Health Survey. Clusters of multiple
chronic diseases were then examined, accounting for both combinations (unordered clusters) and
permutations (ordered clusters). The frequency of unique clusters was determined in Objective
One, whereas the time elapsing between diagnoses was analyzed in Objective Two (to be
described in an upcoming section). A customized computational cluster analysis program was
created in Java in collaboration with Dr. Michael Bauer (Professor, Department of Computer
Science) at Western University. This computational program allowed for the identification and
sorting of the more than 18,000 unique combinations (unordered clusters) and 55,000 unique
permutations (ordered clusters) possible from our list of twenty chronic diseases. Further
information about this computational cluster analysis program (both its availability and
instruction for use) is provided within the Multimorbidity Cluster Analysis Toolkit, which is
included in Appendix H. This document is also provided when the computational program is
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accessed by external researchers who are interested in exploring unordered and ordered clusters
of diseases in their own data.
In order to run properly, this computational cluster analysis program requires a basic data
input file (in .txt format) that contains the unique Patient IDs, as well as the diagnostic codes
received by each patient by the end of the observation period. From there, the analysis program
detects and sorts all disease combinations and permutations into mutually exclusive groups. As
such, two sets of output are created from the raw data: 1) frequency and type of all unique
combinations (unordered clusters); and 2) frequency and type of all unique permutations
(ordered clusters). For this research, the data input files were stratified by patient age category
and patient sex to provide more specific output information. For example, the most frequently
occurring combinations were explored among all female patients with multimorbidity, as well as
those female patients in each of the five age categories. Likewise, the most frequently occurring
permutations were explored among all female patients with multimorbidity, as well as those
female patients in each of the five age categories. Similar output files were created for all male
patients with multimorbidity, as well as those male patients in each of the five age categories.
Finally, these results were further stratified by the total number of chronic disease diagnoses to
create mutually exclusive groups (e.g., female patients aged 18 to 34 years with exactly two
chronic diseases or male patients aged 45 to 64 years with exactly four chronic diseases).
To create the output files for the frequency and type of combinations, the computational
analysis program detected all patients (within the input data file) with the exact same number and
type of chronic disease diagnoses, regardless of the order in which these diagnoses occurred. For
example, all patients who were diagnosed with Hypertension, Obesity and Musculoskeletal
Problem at the end of the observation period were detected and categorized into the same
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combination cluster. To create the output data files for the frequency and type of permutations,
the computational analysis program detected all patients with the exact same number, type and
sequence of chronic disease diagnoses. For example, all patients who were diagnosed with
Obesity, then Hypertension and then Musculoskeletal Problem were detected and categorized
into one permutation cluster. However, all patients who were diagnosed with Musculoskeletal
Problem, then Hypertension and then Obesity were categorized into another permutation cluster.
In addition to reporting the frequency of the most frequently occurring cluster in each age-sex
multimorbidity subgroup (e.g., female patients aged 18 to 34 years or male patients aged 45 to 64
years), the proportion of patients living with this cluster from the subgroups was calculated.

4.8 Objective Two
4.8.1 Patient Sample
The second objective examined the natural history and the changing burden of
multimorbidity over time among adult PHC patients. The sample consisted of patients with at
least one in-office encounter recorded in their EMR and who were at least 18 years of age as of
their first encounter date. For this objective, patients with one or more chronic disease diagnoses
were included in order to assess both the onset and progression of multimorbidity over time.
This created a final sample of 286,998 adult patients. All patients were followed over time to
calculate the time elapsing (in days) between chronic disease diagnoses (regardless of disease
type). These patients were observed prospectively from one chronic disease diagnosis until a
subsequent chronic disease diagnosis or the end of the observation period, which was September
30, 2013. The beginning of the observation period occurred when a patient was diagnosed with
their first chronic disease, which is depicted in Figure 4.2.

66

4.8.2 Study Design
The second objective used a prospective cohort study design. To determine time elapsing
between chronic diseases, the corresponding encounter date for each chronic disease diagnosis
was determined, as described in a previous section and Appendix I. These dates were ordered
chronologically and the time difference (in days) between each diagnosis date was calculated.
Patients were stratified into subgroups to examine both “Time Until Multimorbidity” and “Time
Until Advancing Multimorbidity”. To examine “Time Until Multimorbidity”, the time elapsing
between a patient’s first chronic disease diagnosis and their second chronic disease diagnosis
was calculated. As such, this was calculated for the first patient subgroup shown in Figure 4.2.
The “Time Until Advancing Multimorbidity” was assessed for the remaining patient subgroups.
In these analyses, the observation period for the second patient subgroup began on the date of a
patient’s second chronic disease diagnosis; the observation for the third patient subgroup began
on the date of a patient’s third chronic disease diagnosis; the observation period for the fourth
patient subgroup began on the date of a patient’s fourth chronic disease diagnosis; and the
observation period for the fifth patient subgroup began on the date of a patient’s fifth chronic
disease diagnosis. As seen in Figure 4.2, the end of the observation period was when a patient
was diagnosed with a subsequent chronic disease diagnoses (referred to as the “event” in the
survival analysis) or as of September 30, 2013 if the patient did not receive another chronic
disease diagnosis (referred to as “right censoring” in the survival analysis).
If more than one chronic disease diagnosis was documented for a patient on the same
date (likely within the same encounter), the time elapsing between chronic disease diagnoses was
calculated to be zero days. For example, if a patient was diagnosed with Hypertension, Diabetes
and Depression or Anxiety at the same encounter, the time elapsing between all three diagnoses
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was equal to zero days. However, these data points did not necessarily depict a clear transition
from one chronic disease state to another. More specifically, there were three possible reasons of
the zero days elapsing between chronic disease diagnoses: 1) the patient was diagnosed with two
or more chronic diseases after a series of tests and clinical observations (therefore accurate
diagnoses of multiple chronic diseases occurred at the same encounter); 2) the patient was new to
the PHC practice and the provider was updating the patient’s EMR with their current health
status information (therefore inputting multiple chronic disease diagnoses at the same
encounter); or 3) data entry error into the patient’s EMR (that is, the second and third diagnoses
were entered by mistake at the same encounter). The second and third potential reason for zero
days elapsing between diagnoses would indicate an artefact in the EMR data, which cannot be
clearly differentiated from the first reason. Instead, the first reason is of interest for this research.
Exploration of the data was conducted to determine the proportion of patients with at
least one chronic disease who had at least one data point of zero days elapsing between
subsequent chronic disease diagnoses. While these data points (where time = 0) were maintained
in the complete dataset and contributed to the overall prevalence estimates of multimorbidity,
they were dropped from the computational cluster analysis previously described in Objective
One and the longitudinal analysis in Objective Two. This was done to ensure that the analysis
described a “true” transition from one chronic disease state to the next. The distribution of time
elapsing between incident chronic disease diagnoses are displayed in Figure 4.3 and Figure 4.4
and those patients with at least one data point of zero days were removed from the cluster and
time-to-event analyses. In total, 65,828 female patients had at least one data point of zero days
elapsing between chronic disease diagnoses, whereas 52,144 male patients had at least one data
point of zero days elapsing between chronic disease diagnoses. The approach of case-wise
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deletion of these patients was selected due to the large sample size, but more importantly,
because the sequence between the chronic disease diagnoses could not be reasonably assessed if
the pattern between two or more chronic disease diagnoses was not clear. However, sensitivity
analyses were conducted by including these excluded data points and similar patterns were seen
in both the cluster and longitudinal analyses (described further in the Results Chapter).
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Figure 4.2 Depiction of time elapsing (in days) between chronic disease diagnoses, as well as the corresponding start and end of
observation periods, among separate subgroups of patients with at least one chronic disease diagnosis

Legend:
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Figure 4.3 Distribution of time elapsing until subsequent chronic disease diagnoses among
female patients with multimorbidity

Figure 4.4 Distribution of time elapsing until subsequent chronic disease diagnoses among
male patients with multimorbidity
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4.8.3 Data Analyses
4.8.3.1 Research Question 1 – Time Until Multimorbidity
Descriptive statistics were used to examine the time (in days) that elapsed between
chronic disease diagnoses. The time elapsing between the first (or index) and second chronic
disease diagnosis was designated as the “Time Until Multimorbidity”, indicating the onset of
multimorbidity (defined as two or more chronic diseases). The time elapsing between the
subsequent chronic disease diagnoses was defined as the “Time Until Advancing
Multimorbidity”. As seen in Figure 4.5, the “Time Until Multimorbidity” observation period
began when a patient received their first chronic disease diagnosis (T1) and ended on the date the
patient received their second chronic disease diagnosis (T2). Likewise, the “Time Until
Advancing Multimorbidity” observation period began when a patient received their second
chronic disease diagnosis (T2) and ended on the date the patient received their third chronic
disease diagnosis (T3). The time elapsing was calculated using the summarize procedure in the
Stata SE 14.1 software (StataCorp., 2015) and was assessed by patient age category and between
females and males. As seen in Figure 4.6, “Time Until Multimorbidity” was stratified by index
chronic disease type in order to explore whether variations in time elapsing until subsequent
chronic disease diagnoses varied by a patient’s index chronic disease. For example, the “Time
Until Multimorbidity” was reported among patients who were first diagnosed with Hypertension,
as compared to those patients who were first diagnosed with Cancer or Cardiovascular Disease.
As described in Section 4.8.2, the data points where time elapsing between diagnoses was equal
to zero days were dropped from this analysis. This was done to ensure this described a “true”
transition from one chronic disease state to the next. A sensitivity analyses was conducted to
examine the impact of excluding these data points (described further in the Results Chapter).
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Figure 4.5 Time elapsing (in days) between first and second chronic disease diagnoses, as well as second and third chronic
disease diagnoses, among adult patients with at least one chronic disease diagnoses

Legend:

73

Figure 4.6 Time elapsing (in days) until subsequent chronic disease diagnoses, stratified by index chronic disease type among
adult patients with at least one chronic disease diagnoses

Legend:
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4.8.3.2 Research Question 2 – Time Until Advancing Multimorbidity
The approach described in the previous section was replicated for Research Question 2,
in which the mean time (in days) until subsequent chronic disease was explored among all
patients with at least two chronic disease diagnoses. As such, the “Time Until Advancing
Multimorbidity” was assessed in more detail. The mean time (in days) elapsing between the
penultimate and final chronic disease diagnosis was stratified among patients living with at least
two, at least three, at least four and at least five chronic diseases. These non-mutually exclusive
patient subgroups (except those patients with at least five chronic diseases) are presented in
Figure 4.2 and indicate the start and end of the observation period for each subgroup. This
analysis was conducted to determine whether the mean time until subsequent chronic disease
decreases when the number of chronic disease diagnoses increases. In each analyses, the time
elapsing was calculated using the summarize procedure in the Stata SE 14.1 software
(StataCorp., 2015) and was assessed among patient age categories and between females and
males. As described in Section 4.8.2, the data points where time elapsing between diagnoses
was equal to zero days were dropped from this analysis. This was done to ensure that this
analysis described a “true” transition from one chronic disease state to the next. A sensitivity
analyses was conducted to examine the impact of excluding these data points (described further
in the Results Chapter).

4.8.3.3 Research Question 3 – Predicting Time Until Subsequent Chronic Disease
The time elapsing between multiple chronic disease diagnoses was further examined in
Research Question 3. To observe patient progression into a more complex clinical profile, a
multilevel survival analysis was conducted using the Stata SE 14.1 software (StataCorp., 2015).
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Survival analysis, or time-to-event analysis, has historically been used in epidemiological
research to observe health-related events in patients. A multilevel survival analysis was used to
adjust for patient-, provider- and practice-level predictors and the data analyses plan followed the
recommended sequential process (Hosmer et al., 2008; Hosmer and Lemeshow, 2000). This
technique allowed for staggered entry dates of patients into the study period, as well as a nonnormal distribution in the time-to-event data. These non-normal data violate the normality
assumption of most commonly used statistical approaches, such as a multiple regression model.
A multilevel, mixed-effects parametric survival model was fit using the mestreg
command in the Stata SE 14.1 software (StataCorp., 2015), which can be used with single- or
multiple-record survival data. As patients were nested within PHC providers and providers were
nested within PHC practices, observations from the same cluster may have been correlated and
may have shared common cluster-level random effects. As such, a random effects model was
used to account for this intra-cluster correlation. An ordered, recurrent event (also known as
multivariate or multi-failure) analysis was conducted because two or more events (also referred
to as “failures”) may have occurred within one patient and the first chronic disease diagnosis
must have occurred before the second chronic disease diagnoses event could occur. As a result,
failure times were further correlated within PHC patients, which violated the independence of
failure times assumption required in traditional survival analysis and these dependencies between
failure times were accounted for using a variance-corrected model.
The event of interest was the point at which a patient received their subsequent chronic
disease diagnosis (regardless of the disease type). Once again, an ordered, recurrent event
analysis was conducted, in which patients were included more than once in the analysis if they
had more than two chronic disease diagnoses before the end of the observation period. For all
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analyses, the level of significance was set to 0.05. Consequently, this longitudinal analysis
utilized all relevant data (that is, including information for all patients diagnosed with more than
two chronic disease diagnoses). Right censoring occurred when a patient did not have another
event of interest during the observation period either because: 1) the observation period was not
long enough (that is, the patient would have received a subsequent chronic disease diagnosis
after September 30, 2013); or 2) the patient simply would never have the event of interest (that
is, the patient would not have been diagnosed with another chronic disease diagnosis after
September 30, 2013). The basic or reference structure of the survival analysis model is included
below:

h(t) = h0(t) exp(B1X1 + B2X2 + … BkXk)
where h(t) = hazard rate at time t
h0(t) = hazard for a patient with value of 0 for all independent variables (baseline
hazard function)
Bi = regression coefficient for independent variable Xi
Xi = independent variable

As previously described in Section 4.8.2, the data points where time elapsing between
diagnoses was equal to zero were dropped from this multilevel survival analysis. This was done
to ensure that the final results described the predictors that were relevant in the time elapsing
until a true transition from one chronic disease state to the next. A sensitivity analyses was
conducted to examine the impact of excluding these data points and a similar pattern of findings
were found between the two approaches (described further in the Results Chapter).
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4.8.3.4 Conceptual Model for Multilevel Variables
The multilevel predictors that were included in the multilevel survival analysis are
presented in Figure 4.7. This conceptual model was developed for the purposes of this research
and has not been published previously. Instead, the identification of these relevant independent
variables was informed by the existing multimorbidity literature, as well as those variables that
were available within the CPCSSN EMR database. For example, the patient-level variables
listed in Figure 4.7 have been reported previously to be associated with the occurrence of
multimorbidity (Barnett et al., 2012; Salisbury et al., 2011; Harrison et al., 2013; Britt et al.,
2008; Uijen et al., 2008; Fortin et al., 2005; van den Akker et al., 1998). Beyond the field of
multimorbidity, however, research has demonstrated patient-, provider- and practice-level nonclinical influences on clinical decision-making and diagnostic behaviour (Hajjaj et al., 2010).
While most clinical decisions are based on “traditional” clinical criteria, they are also
influenced by a wide range of non-clinical factors. At the patient-level, these influences can
include a patient’s personal characteristics, such as age (Bond et al., 2003; Little et al., 1999;
Haug and Ory, 1987), sex (Bertakis, 2009; Verbruggei and Steiner, 1981; Bernstein and Kane,
1981), culture (Waldman et al., 2009) and faith (Silvestri et al., 2003); socioeconomic status
(Bernheim et al., 2008; Dunlop et al., 2000); attitudes and behaviours (Steinmetz and Tabenkin,
2001; Jackson and Kroenke, 1999); concerns and worries about their health (Petursson, 2005;
Escher et al., 2004); and influences of a patient’s family members or friends (Franz et al., 2007).
At the provider-level, these influences can include a physician’s personal characteristics, such as
age (McKinlay et al., 2002), sex (Bertakis, 2009; Tracy et al., 2005; Franks and Bertakis, 2003;
Bertakis et al., 2003; Bensing et al., 1993), culture (Modi et al., 2007) and faith (Modi et al.,
2007); time constraints and workload (Hajjaj et al., 2010); demands from the patients or their
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caregivers (Franz et al., 2007; Petursson, 2005; Escher et al., 2004); and whether the physician
prefers to use an “interventionist” or “wait and see” approach (Hajjaj et al., 2010; Forrest et al.,
2006). Finally, practice-level influences can include characteristics of the practice organization,
such as practice size and type (McKinlay et al., 1996); management policies or culture within the
practice (Schumock et al., 2004; Prosser and Walley, 2003); geographic location of the practice
and availability of health resources (Iverson et al., 2005; McKinlay et al., 1996). Consequently,
the patient-, provider- and practice-level domains were considered to be relevant layers to
capture and explore in this time-to-event analysis.
The variables that comprise the conceptual model for this thesis are those variables that
were deemed to be relevant in predicting the time until subsequent chronic disease diagnoses.
More specifically, these variables were informed by the existing multimorbidity literature and
the variables that were available within the CPCSSN EMR database were highlighted and
selected for use in the multivariable analysis. The final patient-level variables included: Age
(continuous), Sex (binary), Residential Location (binary), Median Household Income
(continuous) and Total Number of Chronic Diseases (discrete). The final provider-level
variables included: Age (continuous) and Sex (binary). The final practice-level variables
included: Practice Location (binary) and EMR Type (categorical). These independent variables
were first explored in the univariate and bivariate analyses (described further in the next
sections) and were used to predict the dependent variable of interest, which was the time until
subsequent chronic disease diagnosis.
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Figure 4.7 Conceptual model depicting the patient-, provider- and practice-level variables
used to predict mean time until subsequent chronic disease diagnosis

* Variable available within CPCSSN EMR database

4.8.3.5 Univariate Analyses
All independent variables were explored using individual univariate analyses that
summarized the patterns and distribution for both continuous and categorical variables. For the
continuous variables (patient age, median household income, total number of chronic diseases
and provider age), the mean, median, range of values and standard deviations were reported. For
the binary and categorical variables (patient sex, residential location, provider sex, EMR type
and practice location), the distribution among categories were calculated. The continuous
dependent variable (time until subsequent chronic disease) was also explored. The
characteristics of all independent variables, as well as the main dependent variable, are presented
in Table 4.5.
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Table 4.5 Characteristics of all variables included in Objective Two analyses
Independent Variable

Variable Characteristics

Patient-Level
Age

Continuous, Measured in Years

Sex

Binary, Female or Male

Residential Location

Binary, Rural or Urban

Median Household Income
Total Number of Chronic Diseases

Continuous, Measured in Canadian Dollars
Count, Range from 0 to 20

Provider-Level
Age

Continuous, Measured in Years

Sex

Binary, Female or Male

Practice-Level
EMR Type

Categorical, Based on EMR Software Name

Practice Location

Binary, Rural or Urban

Dependent Variable
Time Until Subsequent Chronic Disease

Continuous, Measured in Days

4.8.3.6 Bivariate Analyses
All independent variables were explored using bivariate analyses to determine the joint
distribution between each independent variable and the continuous dependent variable. The
dependent variable was non-normally distributed. As a result, non-parametric tests were
conducted to explore relationships between variables. A Spearman correlation was conducted
for all continuous independent variables using the spearman command in the Stata SE 14.1
software (StataCorp., 2015), whereas a Wilcoxon-Mann-Whitney test was conducted using the
ranksum command for all binary independent variables. For the remaining categorical
independent variables, a Kruskal Wallis test was conducted using the kwallis command in the
Stata SE 14.1 software (StataCorp., 2015).
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4.8.3.7 Creation and Interpretation of Final Survival Analysis Model
Due to sufficient sample size (ratio of 9 independent variables to 286,998 patients), all
independent variables remained in the final survival analysis. To date, published multimorbidity
literature has not explored potential interaction among variables that may predict the occurrence
of multimorbidity. While included interaction terms can also be theory-driven, the eventual
interpretation of these interaction terms must be carefully considered. Among the independent
variables included in the final analysis, the potential interaction between patient age and patient
sex and the joint influence on the mean time until subsequent chronic disease diagnoses was
considered to be the only interpretable interaction. Consequently, this interaction term was
included in the final analysis. The final survival analysis model demonstrated the time elapsing
among recurrent events (that is, multiple chronic disease diagnoses) and all predictor variables at
the patient-, provider- and practice-level were included in the final model. Both crude and
adjusted hazard rates were calculated. The hazard rate described the probability that a patient
would experience the event of interest during time, t, at-risk.

4.9 Summary
In summary, this research utilized a national, longitudinal EMR database to examine the
prevalence, patterns and progression of multimorbidity among adult PHC patients within the
CPCSSN database. The point prevalence, patient characteristics and most frequently occurring
unordered and ordered clusters of multimorbidity were assessed in Objective One. The
progressing burden of multimorbidity was assessed in Objective Two, which analyzed the
amount of time elapsing between chronic disease diagnoses and potential patient-, provider- and
practice-level predictors of this progression were explored. A summary of the similarities and
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differences between the methodological approaches used for these two distinct, yet interrelated,
objectives is presented in Table 4.6.

Table 4.6 Summary of methodological elements for Objective One and Objective Two
Methodological
Element
Final Patient Sample
Chronic Disease
Diagnoses

Study Design

Eligible Patients

Objective One

Patients with at least one in-office encounter recorded in their EMR and who are at
least 18 years of age as of their first encounter date
All twenty chronic disease categories presented in Table 4.2
Retrospective or historic observational

Multilevel mixed-effects recurrent event

cohort

survival analysis

(retrospectively analyzed data)

(prospectively analyzed data)

All patients from final sample
(N = 367,743)
Mutually exclusive groups (patients with

Patient Groups

only two, only three, only four and five or
more chronic diseases)

Start of Observation
Period
End of Observation
Period

Objective Two

All patients from final sample with at
least one chronic disease diagnosis
(n = 286,998)
Non-mutually exclusive group (patients
with one or more chronic diseases)

Date of “first occurrence” chronic disease diagnosis

September 30, 2013

Next chronic disease diagnosis or
September 30, 2013 (if no event)
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Chapter 5
5 Results
5.1 Objective One
The results for Objective One present the overall patient sample characteristics, as well as
the prevalence patterns, patient characteristics, individual chronic disease distribution and the
most frequently occurring clusters among patients with multimorbidity.

5.1.1 Overall Patient Sample Characteristics
Following the inclusion and exclusion criteria, a total of 367,743 patients had at least one
in-office encounter recorded in their electronic record and were at least 18 years of age as of
their first encounter date. The characteristics of this final sample of adult PHC patients are
presented in Table 5.1. The mean number of chronic diseases and the prevalence of
multimorbidity (defined as two or more chronic diseases) for all adult PHC patients are also
presented in Table 5.1. The mean age of these patients was 52.3 years (SD: 18.3 years), with a
range between 18 and 114 years. Approximately 73.7% of the patients included in this sample
were under the age of 65 years and 36.6% of patients were between the ages of 45 and 64 years.
The majority (58.0%) of patients were female and were living in an urban setting (56.3%),
according to the first three letters of their residential postal code. While only thirty patients in
the sample were missing data on whether they were female or male, 27.4% of patients did not
have a suitable FSA recorded in their electronic record; therefore, whether they lived in a rural or
urban setting could not be determined. After linking with the Statistics Canada data, the adult
patient sample had a median household income of $60,310 per year, ranging from as low as
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$22,457 to $181,454 per year. Once again, 27.4% of patients could not be linked with the
income data as they did not have a suitable FSA recorded within their EMR.

Table 5.1 Patient-level variables for all eligible adult PHC patients (N = 367,743)
Patient Characteristics
Patient-Level Variable

n (%)

Mean Number of

Prevalence (95% CI) of

of Patients

Chronic Diseases (SD)

Multimorbidity**

Age (Years)
Mean (SD)

52.3 Years (18.3 Years)

Range (Minimum – Maximum)

18 Years – 114 Years

18 – 34

74,539 (20.3%)

0.9 (1.1)

23.4% (23.1% – 23.7%)

35 – 44

61,783 (16.8%)

1.4 (1.3)

38.6% (38.2% – 39.0%)

45 – 64

134,550 (36.6%)

2.1 (1.7)

59.1% (58.9% – 59.4%)

65 – 84

77,816 (21.2%)

3.2 (2.0)

78.0% (77.7% – 78.3%)

≥ 85

19,055 (5.2%)

3.2 (2.2)

74.8% (74.2% – 75.4%)

Female

213,402 (58.0%)

2.0 (1.8)

53.0% (52.8% – 53.3%)

Male

154,311 (42.0%)

2.0 (1.8)

53.5% (53.3% – 53.8%)

30 (0.0%)

1.1 (1.5)

23.3% (11.4% – 41.8%)

Rural

59,740 (16.3%)

2.1 (2.0)

54.6% (54.2% – 55.0%)

Urban

207,192 (56.3%)

1.9 (1.9)

49.3% (49.1% – 49.5%)

Missing

100,811 (27.4%)

2.2 (1.6)

60.6% (60.3% – 60.9%)

2.2 (1.6)

60.4% (60.1% – 60.7%)

Sex

Missing
Residential Location

Median Household Income (Canadian Dollars)
Median (IQR)

$60,130 ($12,497)

Range (Minimum – Maximum)

$22,457 – $181,454

Missing

100,811 (27.4%)

* SD = Standard deviation, CI = Confidence interval, IQR = Interquartile range
** Multimorbidity defined as patients with two or more chronic diseases

The demographic characteristics of the PHC providers for the final sample of adult
patients are presented in Table 5.2. The mean number of chronic diseases and the prevalence of
multimorbidity, stratified by provider-level variables, for all adult patients are also presented in
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Table 5.2. As demographic data for providers are not commonly recorded in the EMR, missing
data existed for both provider variables. The PHC providers for these patients had a mean age of
50.5 years (SD: 10.4 years) as of September 30, 2013 and a large proportion of these providers
were between the ages of 45 and 64 years. For patients with a mean of 2.0 chronic diseases, their
PHC providers were over the age of 65 years. In comparison, those patients with a mean of 1.7
chronic diseases had a PHC provider who was between the ages of 25 and 44 years. For patients
with a mean of 1.9 chronic diseases, their PHC providers were female. For those patients with
the highest mean number of chronic diseases, their PHC providers were missing information on
their age (these patients had a mean of 2.2 chronic diseases) or whether they were female or male
(these patients had a mean of 2.3 chronic diseases).

Table 5.2 Provider-level variables for all eligible adult PHC patients (N = 367,743)
Provider-Level Variable

n (%) of Patients

Mean Number of

Prevalence (95% CI) of

Chronic Diseases (SD)

Multimorbidity**

Age (Years)
Mean (SD)

50.5 Years (10.4 Years)

Range (Minimum – Maximum)

27 Years – 72 Years

25 – 44

52,383 (14.2%)

1.7 (1.8)

42.7% (42.3% – 43.2%)

45 – 64

101,864 (27.7%)

1.8 (1.8)

49.0% (48.7% – 49.3%)

≥ 65

15,077 (4.1%)

2.0 (1.9)

51.3% (50.5% – 52.1%)

Missing

198,419 (54.0%)

2.2 (1.8)

58.4% (58.2% – 58.6%)

Sex
Female

116,039 (31.6%)

1.9 (1.9)

42.8% (42.5% – 43.1%)

Male

92,319 (25.1%)

1.6 (1.7)

50.3% (50.0% – 50.6%)

Missing

159,385 (43.3%)

2.3 (1.7)

61.5% (61.2% – 61.7%)

* SD = Standard deviation, CI = Confidence interval
** Multimorbidity defined as patients with two or more chronic diseases
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The characteristics of the PHC practices for the final sample of adult patients are
presented in Table 5.3. The mean number of chronic diseases and the prevalence of
multimorbidity among all adult PHC patients, stratified by practice-level variables, can also be
seen in Table 5.3. For 28.0% of adult patients, their PHC practices were using the Nightingale
EMR software. The majority of patients received care from urban PHC practices, according to
the first three letters of the practices’ postal code. The largest proportion of patients belonged to
Network 4 (21.7%) and Network 5 (23.3%), which were located in Central Ontario and Eastern
Ontario, respectively. While all adult PHC patients were allocated to one of the ten CPCSSN
Networks, missing data were present for both the EMR software type and PHC practice location
variables. For patients with a mean of 2.5 chronic diseases, their PHC practice was using the
Jonoke EMR software, while those patients with a mean of 0.9 chronic diseases were based at a
PHC practice that was using the DaVinci EMR software. Those patients who received care at a
rural PHC practice had an average of 2.2 chronic diseases, while those patients who received
care at an urban PHC practice had an average of 1.9 chronic diseases. For those patients with a
higher mean number of chronic diseases, their PHC practices were missing information on their
EMR software (these patients had a mean of 2.4 chronic diseases) or whether the practices were
rural or urban (these patients had a mean of 2.3 chronic diseases). The range of the mean
number of chronic diseases and the prevalence of multimorbidity were also explored among
CPCSSN Network locations. The crude prevalence of multimorbidity, defined as two or more
chronic diseases, is presented geographically among all ten regional networks and can be seen in
Figure 5.1.
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Table 5.3 Practice-level variables for all eligible adult PHC patients (N = 367,743)
Practice-Level Variable

n (%) of Patients

Mean Number of

Prevalence (95% CI) of

Chronic Diseases (SD)

Multimorbidity**

EMR Type
Accuro

36,480 (9.9%)

1.7 (1.8)

43.9% (43.4% – 44.4%)

Bell

27,178 (7.4%)

2.2 (1.9)

57.4% (56.8% – 58.0%)

DaVinci

1,431 (0.4%)

0.9 (1.0)

26.3% (24.1% – 28.6%)

Jonoke

20,862 (5.7%)

2.5 (2.1)

62.1% (61.4% – 62.7%)

Med Access

12,548 (3.4%)

2.1 (2.2)

51.3% (50.4% – 52.2%)

Nightingale

103,031 (28.0%)

1.9 (1.8)

49.5% (49.2% – 49.8%)

Oscar

16,537 (4.5%)

1.4 (1.5)

37.5% (36.8% – 38.3%)

Practice Solutions

20,095 (5.5%)

1.6 (1.5)

43.4% (42.7% – 44.1%)

Wolf

38,056 (10.4%)

2.0 (2.1)

49.2% (48.7% – 49.7%)

Xwave

821 (0.2%)

2.4 (1.8)

64.3% (61.0% – 67.5%)

Missing

90,704 (24.7%)

2.4 (1.5)

65.4% (65.0% – 65.7%)

Rural

35,390 (9.6%)

2.2 (2.0)

55.0% (54.5% – 55.5%)

Urban

233,744 (63.6%)

1.9 (1.9)

48.4% (48.2% – 48.6%)

Missing

98,609 (26.8%)

2.3 (1.5)

64.1% (63.8% – 64.4%)

1

38,031 (10.3%)

2.2 (1.9)

55.4% (54.9% – 55.9%)

2

19,253 (5.2%)

2.3 (2.1)

57.6% (56.9% – 58.3%)

3

6,954 (1.9%)

2.8 (2.1)

69.0% (67.9% – 70.1%)

4

79,941 (21.7%)

1.8 (1.6)

48.5% (48.2% – 48.9%)

5

85,834 (23.3%)

2.0 (1.7)

55.9% (55.6% – 56.2%)

6

2,507 (0.7%)

1.2 (0.9)

32.5% (30.7% – 34.3%)

7

36,391 (9.9%)

1.9 (1.9)

47.3% (46.8% – 47.8%)

8

31,741 (8.6%)

2.5 (1.9)

64.2% (63.7% – 64.7%)

9

53,624 (14.6%)

1.9 (1.7)

51.6% (51.2% – 52.0%)

10

13,467 (3.7%)

1.8 (2.0)

44.9% (44.1% – 45.8%)

Practice Location

CPCSSN Network

* SD = Standard deviation, CI = Confidence interval
** Multimorbidity defined as patients with two or more chronic diseases
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Figure 5.1 Crude prevalence estimates of multimorbidity (defined as two or more chronic
diseases) among all ten regional networks of the CPCSSN database

5.1.2 Objective One, Research Question 1 – Prevalence of Multimorbidity
The patient-level variables, stratified by the total number of chronic diseases, among all
adult patients are presented in Table 5.4. While the largest proportion (24.8%, 95% CI: 24.6 –
24.9) of adult patients were living with one chronic disease diagnosis, 22.0% (95% CI: 21.8 –
22.1) of adult patients had no chronic disease diagnoses and 20.1% (95% CI: 20.0 – 20.2) of
adult patients had been diagnosed with two chronic diseases as of September 30, 2013. A total
of 14.0% (95% CI: 13.9 – 14.1) of these patients were living with three chronic disease
diagnoses; 8.9% (95% CI: 8.8 – 9.0) were living with four chronic diseases; and 10.2% (95% CI:
10.1 – 10.3) had been diagnosed with five or more chronic disease diagnoses. Among our final
adult patient sample, the prevalence of multimorbidity defined as patients with two or more
89

chronic diseases was 53.3% (95% CI: 53.1% – 53.4%), whereas the prevalence of
multimorbidity defined as patients with three or more chronic diseases was 33.1% (95% CI: 33.0
– 33.3). These results can be found in Table 5.5.
As seen in Table 5.4, an increasing mean age of patients was observed as the total
number of chronic disease diagnoses increased. For example, the mean age of patients with no
chronic disease diagnoses was 41.8 years (SD: 16.1 years) and the mean of age of patients with
five or more chronic diseases diagnoses was 68.4 years (SD: 14.1 years), indicating an increase
of 26.6 years on average between these two groups of patients. The proportion of female and
male patients did not change notably as the number of chronic diseases increased, in that the
majority of patients in all six categories were female (representing from 56.6% to 60.7% of the
patient sample). The largest proportion of patients living in a rural setting was seen in the five or
more chronic disease category (21.2% of those living with five or more chronic diseases), while
the largest proportion of patients living in an urban setting was seen in the category of patients
with no chronic disease diagnoses (73.9% of those living without any chronic disease diagnoses).
The median household income was fairly consistent among the six categories of patients, and did
not produce a clear trend between the categories.
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Table 5.4 Patient-level variables, stratified by total number of chronic diseases, among final adult patient sample (N = 367,743)
Total Number of Chronic Diseases
Patient-Level Variable

Zero

One

Two

Three

Four

Five or More

80,745

91,160

73,974

51,608

32,866

37,390

22.0 (21.8 – 22.1)

24.8 (24.6 – 24.9)

20.1 (20.0 – 20.2)

14.0 (13.9 – 14.1)

8.9 (8.8 – 9.0)

10.2 (10.1 – 10.3)

41.8 (16.1)

47.3 (17.0)

53.1 (16.9)

58.4 (16.3)

62.9 (15.3)

68.4 (14.1)

18 – 114

18 – 111

18 – 114

18 – 108

20 – 114

20 – 114

Female

59.8

56.9

56.6

57.4

57.9

60.7

Male

40.2

43.1

43.4

42.6

42.1

39.3

Rural

18.6

13.3

14.0

16.3

18.1

21.2

Urban

73.9

49.8

50.2

52.0

53.8

54.9

Missing

7.5

36.9

35.8

31.7

28.1

23.9

Number of Patients
Prevalence (95% CI)
Age (Years)
Mean (SD)
Range (Minimum – Maximum)
Sex (% of Patients)

Residential Location (% of Patients)

Median Household Income (Canadian Dollars)
Median (IQR)

59,980 (13,867)

60,310 (12,497)

60,952 (12,497)

61,130 (12,497)

60,480 (12,497)

61,221 (12,953)

Range (Minimum – Maximum)

22,457 – 181,454

23,370 – 181,454

22,457 – 181,454

23,972 – 181,454

23,972 – 181,454

22,457 – 181,454

7.8

37.1

36.0

31.8

28.3

24.0

Missing (% of Patients)

* SD = Standard deviation, CI = Confidence interval, IQR = Interquartile range
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The proportion of patients living with multimorbidity, stratified by patient-level variables
and the two definitions of multimorbidity, are presented in Table 5.5. For patients with two or
more chronic diseases, 40.6% of patients were between the age of 45 and 64 years and 57.8%
were female. The majority of these patients were living in an urban setting (52.2%) and the
median of the median household income was $60,952 per year (Canadian dollars). In fact, these
patients were living with a mean of 3.3 chronic diseases, ranging from two to fourteen chronic
disease diagnoses. For patients with three or more chronic disease, 39.6% of patients were
between the age of 45 and 64 years and 58.5% were female. The majority of these patients were
living in an urban setting (53.4%) and the median of the median household income was $61,175
per year (Canadian dollars). Similar to the group of patients with two or more chronic diseases,
the group of patients with three or more chronic diseases were living with a mean of 4.2 chronic
diseases, ranging from three to fourteen chronic disease diagnoses. These results will be
discussed further in the next section, which will compare the characteristics of patients with
multimorbidity in this research with those that have been reported in the published
multimorbidity literature.
The demographic characteristics of the PHC providers for patients stratified by the two
definitions of multimorbidity are seen in Table 5.6. Once again, as demographic data for
providers are not commonly recorded in the EMR, missing data existed for both provider
variables. However, for both definitions of multimorbidity, the PHC providers of these patients
were a mean age of about 51.0 years and tended to be between 45 and 64 years. However,
contrast was observed based on whether the PHC provider was female or male: about 30.0% of
patients with two or more chronic diseases were being cared for by a male provider, while about
31.0% of patients with three or more chronic diseases were being cared for by a female provider.
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Table 5.5 Prevalence of multimorbidity, defined as two or more and three or more chronic
diseases, and corresponding patient-level characteristics for Objective One
Two or More Chronic Diseases

Three or More Chronic Diseases

(n = 195,838)

(n = 121,864)

53.3% (53.1% – 53.4%)

33.1% (33.0% – 33.3%)

59.0 Years (17.0 Years)

62.7 Years (15.9 Years)

18 Years – 114 Years

18 Years – 114 Years

18 – 34

17,466 (8.9%)

6,119 (5.0%)

35 – 44

23,855 (12.2%)

10,719 (8.8%)

45 – 64

79,571 (40.6%)

48,254 (39.6%)

65 – 84

60,696 (31.0%)

45,961 (37.7%)

≥ 85

14,250 (7.3%)

10,811 (8.9%)

Female

113,209 (57.8%)

71,319 (58.5%)

Male

82,629 (42.2%)

50,545 (41.5%)

Rural

32,607 (16.7%)

22,274 (18.3%)

Urban

102,151 (52.2%)

65,026 (53.4%)

Missing

61,080 (31.2%)

34,564 (28.4%)

Median (IQR)

$60,952 ($12,497)

$61,175 ($12,497)

Range (Minimum – Maximum)

$22,457 – $181,454

$22,457 – $181,454

61,263 (31.3%)

34,662 (28.4%)

3.3 (1.5)

4.2 (1.4)

2 – 14

3 – 14

Patient-Level Variable
Prevalence (95% CI)
Age (Years)
Mean (SD)
Range (Minimum – Maximum)
Age Category, n (%) of Patients

Sex, n (%) of Patients

Residential Location, n (%) of Patients

Median Household Income (Canadian Dollars)

Missing, n (%) of Patients
Total Number of Chronic Diseases
Mean (SD)
Range (Minimum – Maximum)

* SD = Standard deviation, CI = Confidence interval, IQR = Interquartile range
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Table 5.6 Prevalence of multimorbidity, defined as two or more and three or more chronic
diseases, and corresponding provider-level characteristics for Objective One
Two or More Chronic Diseases

Three or More Chronic Diseases

(n = 195,838)

(n = 121,864)

51.2 Years (10.2 Years)

51.5 Years (10.1 Years)

27 Years – 72 Years

27 Years – 72 Years

25 – 44

22,402 (11.4%)

13,589 (11.2%)

45 – 64

49,871 (25.5%)

31,158 (25.6%)

7,730 (4.0%)

5,152 (4.2%)

115,835 (59.2%)

71,965 (59.1%)

Female

39,517 (20.2%)

23,738 (31.1%)

Male

58,364 (29.8%)

37,931 (19.5%)

Missing

97,957 (50.0%)

60,195 (49.4%)

Provider-Level Variable
Age (Years)
Mean (SD)
Range (Minimum – Maximum)
Age Category, n (%) of Patients

≥ 65
Missing
Sex, n (%) of Patients

* SD = Standard deviation, CI = Confidence interval

The characteristics of the PHC practices for patients stratified by the two definitions of
multimorbidity are seen in Table 5.7. For both definitions of multimorbidity, the PHC practices
of these patients tended to use the Nightingale EMR software (26.0% and 26.5%, respectively)
and the majority were based in an urban setting (57.8% and 59.2%, respectively). Almost one
quarter of those patients with two or more chronic diseases and three or more chronic diseases
were from Network 5 (24.5% and 23.5%, respectively).
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Table 5.7 Prevalence of multimorbidity, defined as two or more and three or more chronic
diseases, and corresponding practice-level characteristics for Objective One
Two or More Chronic Diseases

Three or More Chronic Diseases

(n = 195,838)

(n = 121,864)

Accuro

16,001 (8.2%)

10,115 (8.3%)

Bell

15,601 (8.0%)

10,467 (8.6%)

DaVinci

376 (0.2%)

109 (0.1%)

Jonoke

12,953 (6.6%)

9,407 (7.7%)

Med Access

6,437 (3.3%)

4,553 (3.7%)

Nightingale

50,998 (26.0%)

32,287 (26.5%)

Oscar

6,208 (3.2%)

3,192 (2.6%)

Practice Solutions

8,723 (4.5%)

4,738 (3.9%)

Wolf

18,732 (9.6%)

12,949 (10.6%)

Xwave

528 (0.3%)

355 (0.3%)

Missing

59,281 (30.3%)

33,692 (27.7%)

Rural

19,471 (9.9%)

13,744 (11.3%)

Urban

113,120 (57.8%)

72,085 (59.2%)

Missing

63,247 (32.3%)

36,035 (29.6%)

1

21,060 (10.8%)

13,743 (11.3%)

2

11,081 (5.7%)

7,507 (6.2%)

3

4,801 (2.5%)

3,430 (2.8%)

4

38,797 (19.8%)

21,946 (18.0%)

5

47,986 (24.5%)

28,612 (23.5%)

6

814 (0.4%)

181 (0.2%)

7

17,218 (8.8%)

11,136 (9.1%)

8

20,374 (10.4%)

13,831 (11.4%)

9

27,656 (14.1%)

17,555 (14.4%)

10

6,051 (3.1%)

3,923 (3.2%)

Practice- Level Variable
EMR Type, n (%) of Patients

Practice Location, n (%) of Patients

CPCSSN Network, n (%) of Patients

* SD = Standard deviation, CI = Confidence interval
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To place the prevalence of multimorbidity found in this research within the context of the
prevalence estimates reported in the existing multimorbidity literature, a review of the literature
was conducted. A summary of the methodological characteristics, as well as the reported
prevalence of multimorbidity, are presented in Table 5.8 (for the definition of two or more
chronic diseases) and Table 5.9 (for the definition of three or more chronic diseases). The
methodological characteristics and prevalence estimates from this research were also included
and separated between the two definitions of multimorbidity. A total of 23 studies that defined
multimorbidity as two or more chronic diseases, as well as 15 studies that defined
multimorbidity as three or more chronic diseases, were included in the prevalence comparison.
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Table 5.8 Key methodological elements and prevalence estimates from multimorbidity literature (defined as two or more
chronic diseases), as compared to elements and prevalence from current research
Citation

Country of
Origin

Study Design

Sample
Size

Age
Range

Sample
Recruitment

Data Source

Nicholson et
al., 2016
Pefoyo et al.,
2015
Roberts et al.,
2015

Canada

Retrospective
cohort
Retrospective
cohort
Crosssectional

367,743

≥ 18

10,336,297

≥ 18

105,416

≥ 20

Adult PHC
patients
All residents of
Ontario
General adult
population in
Canada

Stewart et al.,
2013

Canada

Retrospective
cohort

2,998

≥ 18

Adult PHC
patients

Agborsangaya
et al., 2012

Canada

Crosssectional

5,010

≥ 18

Muggah et al.,
2012

Canada

Crosssectional

28,450,000

≥ 20

General adult
population in
Alberta
All residents of
Ontario

CPCSSN EMR
database
Administrative
claims data
2011/2012
Canadian
Community Health
Survey
Deliver Primary
Health Care
Information EMR
database
2010 Patient
Experience Survey

Fortin et al.,
2005

Canada

Crosssectional

980

≥ 18

Canada
Canada

Adult PHC
patients from
consecutive
encounters

Diagnostic
Coding
System
ICD-9

Number of
Diseases
Considered
20

MM
Prevalence

ICD-9;
ICD-10
Self-report

16

30.2%**

9

12.9%

ICPC-2-R

98

34.0%

Self-report

14

18.8%**

Administrative
claims data

ICD-9

9

15.9%**

Health charts
review

Count;
CIRS

14

89.3%**

53.3%**

* CIRS = Cumulative Illness Rating Scale; CPCSSN = Canadian Primary Care Sentinel Surveillance Network; EMR = Electronic medical record; ICD-9 =
International Classification of Disease, 9th Revision; ICD-10 = International Classification of Disease, 10th Revision; ICPC-2-R = International Classification of
Primary Care, 2nd Edition, Revised; MM = Multimorbidity; PHC = Primary health care
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** Prevalence estimate extracted and calculated by author

Table 5.8 Key methodological elements and prevalence estimates from multimorbidity literature (defined as two or more
chronic diseases), as compared to elements and prevalence from current research, Continued
Citation

Country of
Origin

Study Design

Sample
Size

Age
Range

Sample
Recruitment

Data Source

Harrison et al.,
2014

Australia

Prospective
cohort

8,707

≥ 20

Health charts
review

Taylor et al.,
2010

Australia

Crosssectional

6,411

≥ 20

Randomly
selected PHC
patients
Randomly
selected adults

Wang et al.,
2015

China

Crosssectional

21,435

18 – 79

Communitydwelling adults

Chung et al.,
2015

Hong Kong

Crosssectional

25,780

≥ 15

General adult
population

Pati et al.,
2015

India

Crosssectional

1,649

≥ 18

van Oostrom
et al., 2012

The
Netherlands

Retrospective
cohort

173,958

≥ 15

Adult patients
from PHC
facilities
PHC patients

Northwest
Adelaide Health
Study
Questionnaire and
interview
Hong Kong
Thematic
Household Survey
Multimorbidity
Assessment
Protocol Survey
Network of
General Practice
EMR database

Diagnostic
Coding
System
ICD-10

Number of
Diseases
Considered
20

MM
Prevalence

Self-report

7

17.1%

Selfreport;
ICD-10
Selfreport;
ICD-10
Self-report

18

24.7%

46

12.5%

22

28.3%

ICPC

29

12.9%

43.7%

* CIRS = Cumulative Illness Rating Scale; EMR = Electronic medical record; ICD-10 = International Classification of Disease, 10th Revision; ICPC =
International Classification of Primary Care; ICPC-2 = International Classification of Primary Care, 2nd Edition; MM = Multimorbidity; PHC = Primary health
care
** Prevalence estimate extracted and calculated by author
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Table 5.8 Key methodological elements and prevalence estimates from multimorbidity literature (defined as two or more
chronic diseases), as compared to elements and prevalence from current research, Continued
Citation

Country of
Origin

Study Design

Sample
Size

Age
Range

Sample
Recruitment

Data Source

van den
Akker et al.,
1998
Prazeres et
al., 2015
Jovic et al.,
2016

The
Netherlands

Crosssectional

47,140

≥ 20

Adult PHC
patients

Portugal

Crosssectional
Crosssectional

1,993

≥ 18

13,103

≥ 20

Adult PHC
patients
Communitydwelling adults

RegistratieNet
Huisartspraktijken
EMR database
Questionnaire

Orueta et al.,
2014

Spain

Crosssectional

1,923,156

≥ 18

Adult PHC
patients

Prados-Torres
et al., 2012

Spain

Retrospective
cohort

275,682

≥ 15

PHC patients

Rizza et al.,
2012

Switzerland

Retrospective
cohort

66,212

≥ 20

Adult PHC
patients

Serbia

Diagnostic
Coding
System
ICPC

Number of
Diseases
Considered
335

MM
Prevalence

ICPC-2

147

72.7%

2013 National
Health Survey

Self-report

12

26.8%

Population
Stratification
Programme EMR
database
Spanish National
Health System EMR
database

ICD-9-CM;
ACG

40

23.6%

ICPC; ICD-9CM; ACG

114

36.8%**

ICPC-2

147

14.5%

Swiss Family
Medicine ICPC
Research using
EMR database

35.4%**

* ACG = Adjusted Clinical Groups Case-Mix System; EMR = Electronic medical record; ICD-9-CM = International Classification of Disease, 9th Revision,
Clinical Modification; ICPC= International Classification of Primary Care; ICPC-2 = International Classification of Primary Care, 2nd Edition; MM =
Multimorbidity; PHC = Primary health care
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** Prevalence estimate extracted and calculated by author

Table 5.8 Key methodological elements and prevalence estimates from multimorbidity literature (defined as two or more
chronic diseases), as compared to elements and prevalence from current research, Continued
Citation

Country
of Origin

Study Design

Sample
Size

Age
Range

Sample
Recruitment

Data Source

Diagnostic
Coding
System
Read
codes

Number of
Diseases
Considered
40

MM
Prevalence

Barnett et
al., 2012

United
Kingdom

Crosssectional

1,751,841

All ages

All PHC patients

National EMR
database

Salisbury et
al., 2011

United
Kingdom

Retrospective
cohort

99,997

≥ 18

Randomly selected
adult PHC patients

General Practice
Research Datalink

ACG

114

58.0%

Rocca et al.,
2014

United
States

Crosssectional

100,833

≥ 20

Adult PHC patients

Rochester
Epidemiology
Project EMR
database

ICD-9

20

22.6%**

Ornstein et
al., 2013

United
States

Crosssectional

667,379

≥ 18

Adult PHC patients

Practice-Based
Research Network
EMR database

ICD-9-CM

24

45.3%

Ward et al.,
2013

United
States

Crosssectional

27,157

≥ 18

Randomly selected
communitydwelling adults

2010 National
Health Survey

Self-report

10

26.0%

23.2%

* ACG = Adjusted Clinical Groups Case-Mix System; EMR = Electronic medical record; ICD-9 = International Classification of Disease, 9th Revision; ICD-9CM = International Classification of Disease, 9th Revision, Clinical Modification; MM = Multimorbidity; PHC = Primary health care
** Prevalence estimate extracted and calculated by author
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Table 5.9 Key methodological elements and prevalence estimates from multimorbidity literature (defined as three or more
chronic diseases), as compared to elements and prevalence from current research
Citation

Country of
Origin

Study Design

Sample
Size

Age
Range

Sample
Recruitment

Data Source

Nicholson et
al., 2016
Pefoyo et al.,
2015
Roberts et al.,
2015

Canada

367,743

≥ 18

10,336,297

≥ 18

Canada

Retrospective
cohort
Retrospective
cohort
Cross-sectional

105,416

≥ 20

Adult PHC
patients
All residents of
Ontario
General adult
population in
Canada

Agborsangaya
et al., 2012

Canada

Cross-sectional

5,010

≥ 18

CPCSSN EMR
database
Administrative
claims data
2011/2012
Canadian
Community Health
Survey
2010 Patient
Experience Survey

Muggah et al.,
2012

Canada

Cross-sectional

28,450,000

≥ 20

Fortin et al.,
2005

Canada

Cross-sectional

980

≥ 18

Harrison et al.,
2014

Australia

Prospective
cohort

8,707

≥ 20

Canada

General adult
population in
Alberta
All residents of
Ontario
Adult PHC patients
from consecutive
encounters
Randomly selected
PHC patients

Diagnostic
Coding
System
ICD-9

Number of
Diseases
Considered
20

MM
Prevalence

ICD-9;
ICD-10
Self-report

16

13.6%**

9

3.9%

Self-report

14

11.1%**

Administrative
claims data

ICD-9

9

5.6%

Health charts
review

Count;
CIRS

14

75.6%**

Health charts
review

ICD-10

20

27.4%

33.1%**

* CIRS = Cumulative Illness Rating Scale; CPCSSN = Canadian Primary Care Sentinel Surveillance Network; EMR = Electronic medical record; ICD-9 =
International Classification of Disease, 9th Revision; ICD-10 = International Classification of Disease, 10th Revision; ICPC-2 = International Classification of
Primary Care, 2nd Edition; MM = Multimorbidity; PHC = Primary health care
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** Prevalence estimate extracted and calculated by author

Table 5.9 Key methodological elements and prevalence estimates from multimorbidity literature (defined as three or more
chronic diseases), as compared to elements and prevalence from current research, Continued
Citation

Country of
Origin

Study Design

Sample
Size

Age
Range

Sample
Recruitment

Data Source

Taylor et al.,
2010

Australia

Crosssectional

6,411

≥ 20

Wang et al.,
2015
Chung et al.,
2015

China

Crosssectional
Crosssectional

21,435

18 – 79

25,780

≥ 15

Randomly selected
communitydwelling adults
Communitydwelling adults
General adult
population

Northwest
Adelaide Health
Study
Questionnaire and
interview
Hong Kong
Thematic
Household Survey

Hong Kong

Diagnostic
Coding
System
Self-report

Number of
Diseases
Considered
7

MM
Prevalence

Self-report;
ICD-10
Self-report;
ICD-10

18

12.0%

46

5.4%**

5.3%**

Prazeres et al.,
2015

Portugal

Crosssectional

1,993

≥ 18

Adult PHC
patients

Questionnaire of
PHC patients

ICPC-2

147

57.2%

Jovic et al.,
2016

Serbia

Crosssectional

13,103

≥ 20

Communitydwelling adults

2013 National
Health Survey

Self-report

12

14.3%**

Prados-Torres
et al., 2012

Spain

Retrospective
cohort

275,682

≥ 15

PHC patients

Spanish National
Health System
EMR database

ICPC; ICD9-CM; ACG

114

20.2%**

* ACG = Adjusted Clinical Groups Case-Mix System; EMR = Electronic medical record; ICD-9-CM = International Classification of Disease, 9th Revision,
Clinical Modification; ICD-10 = International Classification of Disease, 10th Revision; ICPC= International Classification of Primary Care; MM =
Multimorbidity; PHC = Primary health care
** Prevalence estimate extracted and calculated by author
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Table 5.9 Key methodological elements and prevalence estimates from multimorbidity literature (defined as three or more
chronic diseases), as compared to elements and prevalence from current research, Continued
Citation

Country of
Origin

Study Design

Sample
Size

Age
Range

Sample
Recruitment

Data Source

Rizza et al.,
2012

Switzerland

Retrospective
cohort

66,212

≥ 20

Adult PHC
patients

Zulman et al.,
2015

United
States

Retrospective
cohort

5,233,994

All
ages

United States
military veterans

Swiss Family
Medicine ICPC
Research using
EMR database
Veterans Affairs
health care system
database

Ornstein et al.,
2013

United
States

Crosssectional

667,379

≥ 18

Adult PHC
patients

Practice-Based
Research Network
EMR database

Diagnostic
Coding
System
ICPC-2

Number of
Diseases
Considered
147

MM
Prevalence

AHRQ
Chronic
Condition
Indicator

33

28.5%

ICD-9-CM

24

30.4%

7.3%

* AHRQ = Agency for Health Care Research and Quality; EMR = Electronic medical record; ICD-9-CM = International Classification of Disease, 9th Revision,
Clinical Modification; ICPC-2 = International Classification of Primary Care, 2nd Edition; MM = Multimorbidity; PHC = Primary health care
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5.1.3 Objective One, Research Question 2 – Characteristics of Adult PHC Patients with
Multimorbidity
The proportion of patients living with multimorbidity, stratified by patient-level variables
and the two definitions of multimorbidity, are presented in Table 5.5. Among patients with two
or more chronic diseases, 40.6% were between the ages of 45 and 64 years. When age categories
were grouped together, almost two-thirds (61.7%) of patients living with two or more chronic
diseases were under the age of 65 years. The majority of these patients were female (57.8%) and
lived in an urban setting (52.2%), while the median of the median household income was
approximately $60,950 per year (Canadian dollars). While all patients were living with at least
two chronic diseases, these patients in fact had a mean of 3.3 chronic disease diagnoses (SD: 1.5)
and the total number of diagnosed chronic diseases ranged from 2 to as many as 14 diagnoses.
Similar characteristics were seen among patients with three or more chronic diseases.
For example, the mean age of these patients was 62.7 years (SD: 15.9 years) and the largest
proportion (39.6%) of patients were between the ages of 45 and 64 years. Once again, the
majority of patients were female (58.5%) and living in an urban setting (53.4%), while the
median of the median household income was approximately $61,175 per year (Canadian dollars).
Similar to those patients living with two or more chronic diseases, while all patients within this
definition of multimorbidity were living with three or more chronic diseases, these patients in
fact had a mean of 4.2 chronic disease diagnoses (SD: 1.4), indicating a slightly higher burden of
chronic diseases than required within the definition itself.
To place the characteristics of those with multimorbidity found in this research within the
context of the characteristics reported in the existing multimorbidity literature, a review of the
literature was conducted. A summary of the methodological characteristics, as well as the
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characteristic category with the highest prevalence of multimorbidity, are presented in Table
5.10 (for the definition of two or more chronic diseases) and Table 5.11 (for the definition of
three or more chronic diseases). Due to the heterogeneity of methodology and reporting in the
multimorbidity literature, the main patient characteristics that were possible to consistently
compare with the existing literature were the prevalence estimates stratified by age and sex
category. A total of 21 studies that defined multimorbidity as two or more chronic diseases, as
well as 8 studies that defined multimorbidity as three or more chronic diseases, were included in
the characteristic comparison.
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Table 5.10 Key methodological elements and sample characteristics from multimorbidity literature (defined as two or more
chronic diseases), as compared to elements and prevalence from current research
Citation

Country
of Origin

Age
Range

Sample
Recruitment

Data Source

Nicholson et
al., 2016

Canada

≥ 18

Adult PHC
patients

CPCSSN
EMR
database

Pefoyo et al.,
2015

Canada

≥ 18

All residents
of Ontario

Administrative
claims data

Roberts et al.,
2015

Canada

≥ 20

General adult
population in
Canada

Diagnostic
Coding
System*
ICD-9

Number of
Diseases
Considered
20

MM
Prevalence

ICD-9;
ICD-10

16

30.2%**

53.3%**

Age Group (Years)
with Highest
Prevalence
18 – 34
35 – 44
45 – 64: 40.6%**
65 – 84
≥ 85
18 – 44
45 – 64
65 – 74
75 – 89
≥ 90: 83.2%
20 – 34
35 – 49
50 – 64
≥ 65: 31.3%
18 – 34
45 – 64
≥ 65: 55.8%**

Sex Category
with Highest
Prevalence
Female:
57.8%**

Not Reported

2011/2012
Self-report
9
12.9%
Female:
Canadian
15.1%
Community
Health Survey
Stewart et al.,
Canada
≥ 18
Adult PHC
Deliver
ICPC-2-R
98
34.0%
Male: 40.4%**
2013
patients
Primary Health
Care
Information
EMR database
* CPCSSN = Canadian Primary Care Sentinel Surveillance Network; EMR = Electronic medical record; ICD-9 = International Classification of Disease, 9th
Revision; ICD-10 = International Classification of Disease, 10th Revision; ICPC-2-R = International Classification of Primary Care, 2nd Edition Revised; MM =
Multimorbidity; PHC = Primary health care
** Prevalence estimate extracted and calculated by author
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Table 5.10 Key methodological elements and sample characteristics from multimorbidity literature (defined as two or more
chronic diseases), as compared to elements and prevalence from current research, Continued
Citation

Country
of Origin

Age
Range

Sample
Recruitment

Data Source

Diagnostic
Coding
System*

Number of
Diseases
Considered

MM
Prevalence

Age Group (Years)
with Highest
Prevalence

Agborsangaya
et al., 2012

Canada

≥ 18

General adult
population in
Alberta

2010 Patient
Experience
Survey

Self-report

14

18.8%**

Fortin et al.,
2005

Canada

≥ 18

Adult patients
from
consecutive
encounters
Randomly
selected PHC
patients

Health charts
review

Count;
CIRS

14

89.3%**

18 – 24
25 – 44
45 – 64
≥ 65: 35.8%
18 – 44
45 – 64
≥ 65: 98.6%**

Male:
89.4%**

20 – 29
Not Reported
30 – 39
40 – 49
50 – 59
60 – 69
70 – 79
80 – 89
≥ 90: 93.2%
Taylor et al.,
Australia
≥ 20
Randomly
Northwest
Self-report
7
17.1%
20 – 39
Not Reported
2010
selected adults
Adelaide
40 – 59
Health Study
≥ 60: 57.9%
* CIRS = Cumulative Illness Rating Scale; ICD-10 = International Classification of Disease, 10th Revision; MM = Multimorbidity; PHC = Primary health care
Harrison et al.,
2014

Australia

≥ 20

Sex
Category
with Highest
Prevalence
Female:
20.6%

Health charts
review

ICD-10

20

43.7%

** Prevalence estimate extracted and calculated by author
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Table 5.10 Key methodological elements and sample characteristics from multimorbidity literature (defined as two or more
chronic diseases), as compared to elements and prevalence from current research, Continued
Citation

Country
of Origin

Age
Range

Sample
Recruitment

Data Source

Diagnostic
Coding
System*
Selfreport;
ICD-10
Self-report

Number of
Diseases
Considered
18

MM
Prevalence

Age Group (Years) Sex Category
with Highest
with Highest
Prevalence
Prevalence
Wang et al.,
China
18 –
Community- Questionnaire and
24.7%
18 – 44
Female:
2015
79
dwelling
interview
45 – 59
29.6%
adults
60 – 79: 51.2%
Pati et al.,
India
≥ 18
Adult
Multimorbidity
22
28.3%
18 – 29
Female:
2015
patients from
Assessment
30 – 39
32.5%
PHC
Protocol Survey
40 – 49
facilities
50 – 59
60 – 69
≥ 70: 44.4%
van
The
≥ 15
PHC patients
Network of
ICPC
29
12.9%
15 – 24
Female:
Oostrom et Netherlands
General Practice
25 – 54
15.0%
al., 2012
EMR database
55 – 64
65 – 74
≥ 75: 59.2%
van den
The
≥ 20
Adult PHC
RegistratieNet
ICPC
335
35.4%**
20 – 39
Female:
Akker et
Netherlands
patients
Huisartspraktijken
40 – 59
37.9%**
al., 1998
EMR database
60 – 79
≥ 80: 78.2%**
* EMR = Electronic medical record; ICD-10 = International Classification of Disease, 10th Revision; ICPC = International Classification of Primary Care; MM =
Multimorbidity; PHC = Primary health care
** Prevalence estimate extracted and calculated by author
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Table 5.10 Key methodological elements and sample characteristics from multimorbidity literature (defined as two or more
chronic diseases), as compared to elements and prevalence from current research, Continued
Citation

Country
of
Origin
Portugal

Age
Range

Sample
Recruitment

Data Source

≥ 18

Adult PHC
patients

Questionnaire

Jovic et
al., 2016

Serbia

≥ 20

Orueta et
al., 2014

Spain

≥ 18

Communitydwelling
adults
Adult PHC
patients

Prazeres
et al.,
2015

≥ 15

Diagnostic
Coding
System*
ICPC-2

Number of
Diseases
Considered
147

MM
Prevalence

2013 National
Health Survey

Self-report

12

26.8%

Population
Stratification
Programme
EMR database

ICD-9-CM;
ACG

40

23.6%**

72.7%

Age Group (Years)
with Highest
Prevalence
18 – 34
35 – 49
50 – 64
≥ 65: 92.6%
20 – 44
45 – 64
≥ 65: 57.4%**
18 – 34
35 – 44
45 – 54
55 – 64
65 – 69
70 – 74
75 – 79
80 – 84: 76.4%
≥ 85
15 – 44
45 – 64
≥ 65: 67.5%**

Sex Category
with Highest
Prevalence
Male: 75.9%

Not Reported

Female: 25.9%

Spanish
ICPC; ICD114
36.8%**
Female: 40.1%
National Health
9-CM; ACG
System EMR
database
* ACG = Adjusted Clinical Groups Case-Mix System; EMR = Electronic medical record; ICD-9-CM = International Classification of Disease, 9th Revision,
PradosTorres et
al., 2012

Spain

PHC patients

Clinical Modification; ICPC = International Classification of Primary Care; ICPC-2 = International Classification of Primary Care, 2nd Edition; MM =
Multimorbidity; PHC = Primary health care
** Prevalence estimate extracted and calculated by author
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Table 5.10 Key methodological elements and sample characteristics from multimorbidity literature (defined as two or more
chronic diseases), as compared to elements and prevalence from current research, Continued
Citation

Country
of Origin

Age
Range

Sample
Recruitment

Data Source

Diagnostic
Coding
System*
ICPC-2

Number of
Diseases
Considered
147

MM
Prevalence

Age Group (Years) Sex Category
with Highest
with Highest
Prevalence
Prevalence
Rizza et al., Switzerland
≥ 20
Adult PHC
Swiss Family
14.5%
20 – 29
Male: 14.8%
2012
patients
Medicine ICPC
30 – 39
Research using
40 – 49
EMR database
50 – 59
60 – 69
70 – 79
≥ 80: 37.7%
Barnett et
United
All
All PHC patients
National EMR
Read
40
23.2%
0 – 24
Female:
al., 2012
Kingdom
ages
database
codes
25 – 44
26.2%
45 – 64
65 – 84
≥ 85: 81.5%
Salisbury et
United
≥ 18
Randomly
General Practice
ACG
114
58.0%
18 – 24
Not Reported
al., 2011
Kingdom
selected adult
Research
25 – 34
PHC patients
Datalink
35 – 44
45 – 54
55 – 64
65 – 74
≥ 75: 64.0%**
* ACG = Adjusted Clinical Groups Case-Mix System; EMR = Electronic medical record; ICPC = International Classification of Primary Care; ICPC-2 =
International Classification of Primary Care, 2nd Edition; MM = Multimorbidity; PHC = Primary health care
** Prevalence estimate extracted and calculated by author
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Table 5.10 Key methodological elements and sample characteristics from multimorbidity literature (defined as two or more
chronic diseases), as compared to elements and prevalence from current research, Continued
Citation

Country
of Origin

Age
Range

Sample
Recruitment

Data Source

Diagnostic
Coding
System*
ICD-9

Number of
Diseases
Considered
20

MM
Prevalence

Age Group (Years)
Sex Category
with Highest
with Highest
Prevalence
Prevalence
**
Rocca et al.,
United
≥ 20
Adult PHC
Rochester
22.6%
20 – 39
Female:
2014
States
patients
Epidemiology
40 – 49
23.4%
Project EMR
50 – 59
database
60 – 69
70 – 79
≥ 80: 87.9%
Ornstein et
United
≥ 18
Adult PHC
Practice-Based ICD-9-CM
24
45.3%
18 – 34
Not Reported
al., 2013
States
patients
Research
35 – 44
Network EMR
45 – 54
database
55 – 64
65 – 74
75 – 85: 81.0%
≥ 85
Ward et al.,
United
≥ 18
Randomly
2010 National Self-report
10
26.0%
18 – 44
Female, ≥ 65
2013
States
selected
Health Survey
45 – 64
Years:
community≥ 65, Female:
61.9%**
dwelling adults
61.9%**
th
* EMR = Electronic medical record; ICD-9 = International Classification of Disease, 9 Revision; ICD-9-CM = International Classification of Disease, 9th
Revision, Clinical Modification; MM = Multimorbidity; PHC = Primary health care
** Prevalence estimate extracted and calculated by author

111

Table 5.11 Key methodological elements and sample characteristics from multimorbidity literature (defined as three or more
chronic diseases), as compared to elements and prevalence from current research
Citation

Country
of Origin

Age
Range

Sample
Recruitment

Data Source

Nicholson et
al., 2016

Canada

≥ 18

Adult PHC
patients

CPCSSN EMR
database

Pefoyo et al.,
2015

Canada

≥ 18

All residents
of Ontario

Roberts et
al., 2015

Canada

≥ 20

General adult
population in
Canada

≥ 18

Diagnostic
Coding
System*
ICD-9

Number of
Diseases
Considered
20

MM
Prevalence

Administrative
claims data

ICD-9;
ICD-10

16

13.6%**

2011/2012
Canadian
Community
Health Survey
Health charts
review

Self-report

9

3.9%

33.1%**

Age Group (Years)
with Highest
Prevalence
18 – 34
35 – 44
45 – 64: 39.6%**
65 – 84
≥ 85
18 – 44
45 – 64
65 – 74
75 – 89
≥ 90: 66.0%**
20 – 34
35 – 49
50 – 64
≥ 65: 11.3%
18 – 44
45 – 64
≥ 65: 95.4%**

Sex Category
with Highest
Prevalence
Female:
58.5%**

Not Reported

Female:
4.5%

Adult PHC
Count;
14
75.6%**
Female:
patients from
CIRS
77.4%**
consecutive
encounters
* CIRS = Cumulative Illness Rating Scale; CPCSSN = Canadian Primary Care Sentinel Surveillance Network; EMR = Electronic medical record; ICD-9 =
Fortin et al.,
2005

Canada

International Classification of Disease, 9th Revision; ICD-10 = International Classification of Disease, 10th Revision; MM = Multimorbidity; PHC = Primary
health care
** Prevalence estimate extracted and calculated by author
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Table 5.11 Key methodological elements and sample characteristics from multimorbidity literature (defined as three or more
chronic diseases), as compared to elements and prevalence from current research, Continued
Citation

Country
of Origin

Age
Range

Sample
Recruitment

Data
Source

Diagnostic
Coding
System*

Number of
Diseases
Considered

MM
Prevalence

Harrison et
al., 2014

Australia

≥ 20

Randomly
selected PHC
patients

Health
charts
review

ICD-10

20

27.4%

Taylor et al.,
2010

Australia

≥ 20

Randomly
selected adults

Self-report

7

5.3%**

≥ 18

Adult PHC
patients

Northwest
Adelaide
Health
Study
Questionnair
e of PHC
patients

Age Group
(Years) with
Highest
Prevalence
20 – 29
30 – 39
40 – 49
50 – 59
60 – 69
70 – 79
80 – 89: 81.8%
≥ 90
20 – 39
40 – 59
≥ 60: 14.5%

Sex
Category
with Highest
Prevalence
Not Reported

Not Reported

18 – 34
Male: 61.6%
35 – 49
50 – 64
≥ 65: 82.7%
Rizza et al.,
Switzerland
≥ 20
Adult PHC
Swiss
ICPC-2
147
7.3%
20 – 29
Male: 7.6%
2012
patients
Family
30 – 39
Medicine
40 – 49
ICPC
50 – 59
Research
60 – 69
using EMR
70 – 79
database
≥ 80: 22.7%
* ICD-10 = International Classification of Disease, 10th Revision; ICPC = International Classification of Primary Care; ICPC-2 = International Classification of
Prazeres et
al., 2015

Portugal

ICPC-2

147

57.2%

Primary Care, 2nd Edition; MM = Multimorbidity; PHC = Primary health care
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Table 5.11 Key methodological elements and sample characteristics from multimorbidity literature (defined as three or more
chronic diseases), as compared to elements and prevalence from current research, Continued
Citation

Country
of Origin

Age
Range

Sample
Recruitment

Data Source

Diagnostic
Coding
System*
ICD-9-CM

Number of
Diseases
Considered
24

MM
Prevalence

Age Group
Sex Category
with Highest with Highest
Prevalence
Prevalence
Ornstein et
United
≥ 18
Adult PHC
Practice-Based
30.4%
18 – 34
Not Reported
al., 2013
States
patients
Research Network
35 – 44
EMR database
45 – 54
55 – 64
65 – 74
75 – 85
≥ 85: 69.0%
* EMR = Electronic medical record; ICD-9-CM = International Classification of Disease, 9th Revision, Clinical Modification; MM = Multimorbidity; PHC =
Primary health care
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5.1.4 Objective One, Research Question 3 – Most Frequent Clusters of Multiple Chronic
Diseases
In addition to presenting the most frequently occurring combinations (that is, unordered
clusters) and permutations (that is, ordered clusters) among all adult patients with multimorbidity
(stratified by both patient age and patient sex), the prevalence of the twenty individual chronic
disease diagnoses (included within the measure of multimorbidity) will first be presented.

Prevalence of Individual Chronic Diseases
The prevalence of individual chronic disease diagnoses among all adult patients, as well
as patients with multimorbidity, is displayed in Table 5.12 and includes the prevalence of all
twenty chronic disease diagnoses. Among all three patient groups (that is: 1) all adult patients;
2) patients with two or more chronic diseases; and 3) patients with three or more chronic
diseases), the most prevalent chronic disease diagnosis was Obesity, ranging from a prevalence
of 24.6% (95% CI: 24.5 – 24.8) among all adult patients to a prevalence of 30.2% (95% CI: 30.0
– 30.4) among patients with two or more chronic diseases. Once again for all three patient
groups, the second most prevalent chronic disease diagnosis was Hypertension, ranging from a
prevalence of 10.5% (95% CI: 10.4 – 10.6) among all adult patients to a prevalence of 18.9%
(95% CI: 18.6 – 19.1) among patients with three or more chronic diseases. The third most
prevalent chronic disease among all three patient groups was the diagnosis for Musculoskeletal
Problem, which ranged from a prevalence of 8.9% (95% CI: 8.8 – 9.0) among all adult patients
to a prevalence of 10.2% (95% CI: 10.1 – 10.4) among patients with two or more chronic
diseases. The least prevalent chronic disease diagnoses among all three patient groups were
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Stroke or Transient Ischemic Attack, Kidney Disease or Failure and Liver Disease. Each of
these chronic diseases had a prevalence of about 0.1% within each patient group.
The prevalence of individual chronic disease diagnoses among all patients with
multimorbidity, defined as two or more chronic diseases and stratified by patient age and patient
sex, are presented in Figure 5.2 to Figure 5.7. When compared, these six Figures indicate a
changing distribution of prevalent chronic disease diagnoses as patients age, regardless of patient
sex. Among all female patients with multimorbidity (n = 113,209), the most prevalent chronic
disease diagnoses were Obesity (28.4%, 95% CI: 28.1 – 28.7); Hypertension (16.0%, 95% CI:
15.7 – 16.2); Anxiety or Depression (10.5%, 95% CI: 10.4 – 10.7); Musculoskeletal Problem
(10.3%, 95% CI: 10.2 – 10.5); and Cancer (5.8%, 95% CI: 5.6 – 5.9). Among all male patients
with multimorbidity (n = 82,622), the most prevalent chronic disease diagnoses were Obesity
(32.7%, 95% CI: 32.4 – 33.0); Hypertension (16.7%, 95% CI: 16.5 – 17.0); Musculoskeletal
Problem (10.1, 95% CI: 9.9 – 10.3); Diabetes (7.4%, 95% CI: 7.2 – 7.6); and Anxiety or
Depression (6.4%, 95% CI: 6.3 – 6.6).
Among both female and male patients aged 18 to 34 years, the most prevalent chronic
diseases were Obesity, Anxiety or Depression and Musculoskeletal Problem. For young female
patients, the prevalence of Obesity was 32.7% (95% CI: 31.8 – 33.5); of Anxiety or Depression
was 19.8% (95% CI: 19.1 – 20.6); and of Musculoskeletal Problem was 12.6% (95% CI: 12.0 –
13.2). For young male patients, the prevalence of Obesity was 33.1% (95% CI: 32.5 – 34.9); of
Anxiety or Depression was 16.8% (95% CI: 15.9 – 17.8); and of Musculoskeletal Problem was
16.7% (95% CI: 15.8 – 17.7). Interestingly, these three chronic disease diagnoses remained the
most prevalent among both female and male patients aged 35 to 44 years. However, in this age
group, the overall prevalence of these diseases decreased as the frequency of other chronic
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diseases increased (except for Obesity, which had a rise in prevalence). The prevalence of
Obesity was 34.1% (95% CI: 33.3 – 34.9) and 36.4% (95% CI: 35.4 – 37.4) for female and male
patients aged 35 to 44 years, respectively. Among female patients, the prevalence of Anxiety or
Depression was 17.1% (95% CI: 16.5 – 17.7) and the prevalence of Musculoskeletal Problem
was 13.3% (95% CI: 12.8 – 13.9). For male patients of the same age, the prevalence of Anxiety
or Depression was 12.4% (95% CI: 11.7 – 13.1) and the prevalence of Musculoskeletal Problem
was 16.3% (95% CI: 15.6 – 17.1). Among female patients aged 45 to 64 years, the most
prevalent chronic diseases were Obesity (31.3%, 95% CI: 30.9 – 31.7); Hypertension (12.8%,
95% CI: 12.5 – 13.1); and Musculoskeletal Problem (12.4%, 95% CI: 12.0 – 12.7). This was
followed closely by Anxiety or Depression, which had a prevalence of 11.3% (95% CI: 11.0 –
11.6). Among male patients aged 45 to 64 years, the most prevalent chronic diseases were also
Obesity (36.3%, 95% CI: 35.8 – 36.8); Hypertension (15.4%, 95% CI: 15.1 – 15.8); and
Musculoskeletal Problem (11.6%, 95% CI: 11.3 – 12.0).
Female and male patients who were between the ages of 65 and 84 years were most likely
to be living with Obesity, Hypertension and Diabetes. For female patients, the prevalence of
Obesity was 24.6% (95% CI: 24.1 – 25.1); of Hypertension was 24.9% (95% CI: 24.4 – 25.3);
and of Diabetes was 7.4% (95% CI: 7.2 – 7.7). For male patients, the prevalence of Obesity was
29.5% (95% CI: 29.0 – 30.1); of Hypertension was 22.2% (95% CI: 21.7 – 22.7); and of
Diabetes was 10.9% (95% CI: 10.5 – 11.2). With the exception of the prominent diagnoses of
Obesity and Hypertension, prevalence estimates were more evenly distributed among a number
of other chronic diseases, such as Musculoskeletal Problem, Hyperlipidemia, Cancer and
Cardiovascular Disease. Likewise, those patients who were 85 years of age and older were most
likely to be living with Obesity and Hypertension. However, the most prevalent chronic disease
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in this age group was Hypertension with a prevalence of 33.9% (95% CI: 32.9 – 34.9) and 26.9%
(95% CI: 25.8 – 28.2) among female and male patients, respectively. While the next prevalent
chronic disease diagnosis was Obesity, the prevalence estimates were again more evenly
distributed among a number of other chronic diseases, such as Cardiovascular Disease, Diabetes,
Cancer and Osteoarthritis or Rheumatoid Arthritis.
Prevalence estimates of individual chronic diseases within the CPCSSN EMR database
were also compared with the 2013 Canadian Community Health Survey (CCHS), which can be
seen in Appendix J. These prevalence estimates were stratified by patient age and patient sex.
Before comparison, it was important to consider the marked differences in the methodology
between these prevalence estimates. For example, the 2013 CCHS data were derived from a
cross-sectional survey of community-dwelling respondents and data were collected directly from
survey respondents via self-report. In comparison, the CPCSSN EMR data were derived from
longitudinal clinical patient records that were recorded prospectively by PHC providers. Despite
these key methodological differences, the national estimates of relevant chronic diseases were
compared. Overall, Diabetes and Hypertension were the most comparable categories of diseases
between the CCHS and CPCSSN EMR data. This was because of the most concise overlap
between the definitions of both diseases. For example, the term “High Blood Pressure”, which
was used in the CCHS survey is commonly interchanged with the more clinical term of
“Hypertension”. However, there may have been considerable disparities between a respondent’s
interpretation of “Heart Disease” in the CCHS survey and whether their definition corresponded
to the diagnoses for “Cardiovascular Disease” in the CPCSSN EMR data. This is supported by a
study conducted by Muggah et al. (2013), which examined the accuracy of self-reported diseases
from the 2005 CCHS and confirmed that the highest agreement between the self-reported
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chronic diseases and administrative data (specifically within the province of Ontario) were for
Diabetes and Hypertension (Kappa range: 0.66 – 0.80). This was followed by a moderate level
of agreement for Myocardial Infarction and Asthma, while the remaining self-reported chronic
diseases (Stroke, Congestive Heart Failure and Chronic Obstructive Pulmonary Disease) showed
a poor level of agreement (Muggah et al., 2013).
The prevalence estimates of Diabetes between the CCHS and the CPCSSN EMR data
were within 10% throughout the age categories. The prevalence of Hypertension was
comparable for individuals aged 18 to 34 years and 35 to 44 years in the two datasets, however,
this prevalence was drastically lower in the CPCSSN EMR data (approximately 20% difference
in prevalence) among individuals who were 45 years and older. For both categories, the
CPCSSN EMR data reported a lower prevalence level as compared to the 2013 CCHS data.
While these differences in prevalence estimates are notable, it is not clear whether these
prevalence estimates were artefacts of the methodological differences between the survey and
EMR data, or whether these differences demonstrate the true prevalence of chronic disease
within these two study populations.
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Table 5.12 Prevalence of individual chronic disease diagnoses among all adult patients and
those with multimorbidity, defined as two or more and three or more chronic diseases
Prevalence (95% CI)
Chronic Disease

All Adult Patients

Category

(N = 367,743)

Among Patients with Two or

Among Patients with Three

More Chronic Diseases

or More Chronic Diseases

(n = 195,838)

(n = 121,864)

Obesity

24.6 (24.5 – 24.8)

30.2 (30.0 – 30.4)

27.5 (27.3 – 27.8)

Hypertension

10.5 (10.4 – 10.6)

16.3 (16.1 – 16.5)

18.9 (18.6 – 19.1)

Musculoskeletal Problem

8.9 (8.8 – 9.0)

10.2 (10.1 – 10.4)

9.5 (9.4 – 9.7)

Anxiety or Depression

8.1 (8.0 – 8.2)

8.8 (8.7 – 8.9)

7.5 (7.4 – 7.7)

Cancer

4.8 (4.7 – 4.9)

5.1 (5.0 – 5.2)

4.6 (4.5 – 4.7)

Diabetes

3.7 (3.6 – 3.8)

5.9 (5.8 – 6.0)

7.0 (6.8 – 7.1)

3.1 (3.0 – 3.2)

3.9 (3.8 – 4.0)

3.7 (3.6 – 3.8)

3.1 (3.0 – 3.1)

4.4 (4.4 – 4.5)

4.9 (4.8 – 5.0)

2.3 (2.3 – 2.4)

3.3 (3.3 – 3.4)

3.9 (3.8 – 4.0)

Thyroid Problem

2.1 (2.1 – 2.2)

2.9 (2.8 – 3.0)

3.0 (2.9 – 3.1)

Cardiovascular Disease

1.9 (1.8 – 1.9)

2.8 (2.7 – 2.8)

3.2 (3.1 – 3.3)

Urinary Problem

1.6 (1.6 – 1.6)

2.0 (1.9 – 2.1)

2.0 (1.9 – 2.1)

Colon Problem

1.0 (1.0 – 1.1)

1.2 (1.2 – 1.3)

1.2 (1.1 – 1.2)

Stomach Problem

0.9 (0.8 – 0.9)

1.1 (1.1 – 1.2)

1.2 (1.1 – 1.2)

Osteoporosis

0.5 (0.4 – 0.5)

0.7 (0.6 – 0.7)

0.8 (0.7 – 0.8)

Dementia

0.5 (0.4 – 0.5)

0.5 (0.4 – 0.5)

0.4 (0.4 – 0.4)

Heart Failure

0.2 (0.2 – 0.2)

0.3 (0.3 – 0.3)

0.3 (0.3 – 0.4)

Kidney Disease or Failure

0.1 (0.1 – 0.1)

0.1 (0.1 – 0.1)

0.1 (0.1 – 0.2)

Liver Disease

0.1 (0.1 – 0.1)

0.1 (0.1 – 0.1)

0.1 (0.1 – 0.1)

0.1 (0.1 – 0.1)

0.1 (0.1 – 0.2)

0.2 (0.1 – 0.2)

Chronic Obstructive
Pulmonary Disease or Asthma
Hyperlipidemia
Osteoarthritis or Rheumatoid
Arthritis

Stroke or Transient Ischemic
Attack
* CI = Confidence interval
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Figure 5.2 Type of chronic disease diagnoses among patients with multimorbidity, stratified by patient sex, all ages
All Ages
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Figure 5.3 Type of chronic disease diagnoses among patients with multimorbidity, stratified by patient sex, aged 18 – 34 years
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Figure 5.4 Type of chronic disease diagnoses among patients with multimorbidity, stratified by patient sex, aged 35 – 44 years
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Figure 5.5 Type of chronic disease diagnoses among patients with multimorbidity, stratified by patient sex, aged 45 – 64 years
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Figure 5.6 Type of chronic disease diagnoses among patients with multimorbidity, stratified by patient sex, aged 65 – 84 years
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Figure 5.7 Type of chronic disease diagnoses among patients with multimorbidity, stratified by patient sex, aged ≥ 85 years
≥ 85 Years
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Most Frequent Combinations of Multimorbidity
Total Number of Combinations
Following the computational cluster analysis, the total number of combinations among
patients with multimorbidity are presented in Table 5.13. After stratifying the results by patient
age, patient sex and total number of chronic diseases, a large number of combinations were
detected in each group. As described in Section 4.8.2, only those patients with at least one
chronic disease and with at least one day elapsing between chronic disease diagnoses were
included in this analysis. A combination is an unordered cluster of multiple chronic diseases
where the sequence in which the chronic disease diagnoses occurred is not assessed. Essentially,
these are co-occurring chronic diseases. The specific sequence in which the chronic disease
diagnoses occurred is explored in the Total Number of Permutations section. Overall, a total of
6,095 combinations were found among female patients of all ages with multimorbidity (n =
47,381) and a total of 4,316 combinations were found among male patients of all ages with
multimorbidity (n = 30,478). While these results may indicate a mean of 7.8 female patients and
7.1 male patients who had the same combination of multiple chronic diseases, the spread of
patients across combination type was not normally distributed.
Among patients aged 18 to 34 years (n = 8,189 patients), there were 645 combinations
found among females and 379 combinations among males. For those patients aged 35 to 44
years (n = 10,330 patients), 964 and 589 combinations were detected among females and males,
respectively. Among patients aged 45 to 64 years (n = 30,798 patients), the number of patients
and number of combinations approximately tripled as compared to the previous age group. For
female and male patients, 2,769 combinations and 1,863 combinations were detected,
respectively. Among both females and males, the largest numbers of combinations were
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detected among patients aged 65 to 84 years (n = 22,471 patients). For female patients aged 65
to 84 years, there were 3,765 combinations detected and among males, there were 2,780
combinations detected. For female patients aged 85 years and older, a total of 1,804
combinations were identified and among male patients aged 85 years and older, a total of 1,241
combinations were identified. While the total number of combinations decreased among patients
aged 85 years and older (n = 6,071 patients), these combinations represented increasingly unique
clusters.
As seen in Table 5.13, for both female and male patients, the total number of
combinations stratified by age category does not add up to the total number of combinations
among all ages. For example, male patients of all ages could be grouped into the same
combination, which would reduce the amount of potential combinations occurring among males
of all patients. In contrast, more combinations were observed when stratified by patient age
category due to the categorization by patient age and combination type. Therefore, there were a
total of only 6,095 combinations and 4,316 combinations detected among female and male
patients, respectively. Finally, to assess the differences that occurred when excluding cases in
which the time elapsing between diagnoses was zero days, the same computational analysis was
conducted for all patients and for all data points (that is, even when time elapsing between
chronic disease diagnoses was equal to zero). These results are included in Appendix K to
Appendix V. While there were differences in the total number of combinations found among
the stratified groups, a large number of combinations (as well as similar patterns of combination
types among females and males, stratified by patient age category) were detected among all
patients with multimorbidity.
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Table 5.13 Total number of combinations, stratified by patient age category and patient
sex, among patients with multimorbidity
Patient Sex

Patient Age Category

n

Total Number of Combinations*

Females

All Ages

47,381

6,095

18 – 34 Years

5,565

645

35 – 44 Years

6,747

964

45 – 64 Years

18,426

2,769

65 – 84 Years

12,819

3,765

≥ 85 Years

3,824

1,804

All Ages

30,478

4,316

18 – 34 Years

2,624

379

35 – 44 Years

3,583

589

45 – 64 Years

12,372

1,863

65 – 84 Years

9,652

2,780

≥ 85 Years

2,247

1,241

Males

* The total number of combinations, stratified by age category among female and male patients, will not add to the
total number of combinations among female and male patients of all ages

Most Frequently Occurring Combinations Among Female Patients
The most frequently occurring combinations were explored according to patient age and
total number of chronic diseases among female patients. These results include only those
chronic diseases that had at least one-day elapsing between the associated dates of diagnoses.
Among adult female patients of all ages (n = 47,381 patients), the most common combination of
chronic diseases was Anxiety or Depression and Musculoskeletal Problem (1,694 patients). This
meant that 1,694 female patients were either diagnosed first with Anxiety or Depression and then
Musculoskeletal Problem, or first Musculoskeletal Problem and then Anxiety or Depression.
This was followed by a combination of Anxiety or Depression and Obesity (1,179 patients) and
Musculoskeletal Problem and Obesity (1,132 patients). Among patients with three chronic
diseases, the most common combination was Anxiety or Depression, Musculoskeletal Problem
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and Obesity (675 patients). For patients with four chronic disease diagnoses, the most frequently
occurring combination was Anxiety or Depression, Cancer, Musculoskeletal Problem and
Obesity (180 patients). Lastly, for female patients living with five or more chronic diseases, the
most frequently occurring combination was present in 58 patients and was a cluster of Anxiety or
Depression, Hypertension, Musculoskeletal Problem, Obesity and Osteoarthritis or Rheumatoid
Arthritis. These results are presented in Table 5.14.
Among the youngest group of female patients aged 18 to 34 years (n = 5,565 patients),
the most commonly occurring combination was again Anxiety or Depression and
Musculoskeletal Problem (443 patients). Likewise, this was followed by a combination of
Anxiety or Depression and Obesity (397 patients) and Musculoskeletal Problem and Obesity
(253 patients). Among those patients with three chronic diseases, the most frequently occurring
combination was Anxiety or Depression, Musculoskeletal Problem and Obesity among 157
patients. For female patients with four chronic disease diagnoses, the most common
combinations were Anxiety or Depression, Cancer, Musculoskeletal Problem and Obesity (36
patients) and Anxiety or Depression, Chronic Obstructive Pulmonary Disease or Asthma,
Musculoskeletal Problem and Obesity (28 patients). For female patients aged 18 to 34 years who
were living with five or more chronic diseases, the most common combination was a diagnosis
of Anxiety or Depression, Cancer, Chronic Obstructive Pulmonary Disease or Asthma,
Musculoskeletal Problem and Obesity (8 patients). These results are presented in Table 5.15.
Among female patients aged 35 to 44 years (n = 6,747 patients), the most commonly
occurring combination was again Anxiety or Depression and Musculoskeletal Problem (497
patients). This was followed by a combination of Anxiety or Depression and Obesity (333
patients) and Musculoskeletal Problem and Obesity (330 patients). Among those female patients
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with three chronic diseases, the most frequently occurring combinations were Anxiety or
Depression, Musculoskeletal Problem and Obesity (203 patients) and Anxiety or Depression,
Cancer and Musculoskeletal Problem (115 patients). For patients with four chronic disease
diagnoses, the most common combination was Anxiety or Depression, Cancer, Musculoskeletal
Problem and Obesity among 50 patients. Lastly, for female patients aged 35 to 44 years who
were living with five or more chronic diseases, the most common combination was a diagnosis
of Anxiety or Depression, Cancer, Musculoskeletal Problem, Obesity and Thyroid Problem,
which was present among 13 female patients. These results are presented in Table 5.16.
For female patients aged 45 to 64 years (n = 18,426 patients), the most commonly
occurring combination was Anxiety or Depression and Musculoskeletal Problem (674 patients).
This was followed by a combination of Musculoskeletal Problem and Obesity (472 patients) and
Cancer and Musculoskeletal Problem (404 patients). Among those female patients with three
chronic diseases, the most frequently occurring combinations were Anxiety or Depression,
Musculoskeletal Problem and Obesity (291 patients) and Hypertension, Musculoskeletal
Problem and Obesity (205 patients). For patients with four chronic disease diagnoses, the most
common combination was Anxiety or Depression, Hypertension, Musculoskeletal Problem and
Obesity, which was present among 88 patients. For female patients aged 45 to 64 years who
were living with five or more chronic diseases, the most common combination was a diagnosis
of Anxiety or Depression, Cancer, Hypertension, Musculoskeletal Problem and Obesity (28
patients). These results are presented in Table 5.17.
Among female patients aged 65 to 84 years (n = 12,819 patients), the most commonly
occurring combination was Hypertension and Obesity (323 patients). This was followed by the
combinations of Hyperlipidemia and Hypertension (158 patients) and Cancer and Hypertension
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(147 patients). Among those female patients with three chronic diseases, the most frequently
occurring combinations were Diabetes, Hypertension and Obesity (129 patients) and
Hypertension, Musculoskeletal Problem and Obesity (100 patients). For patients with four
chronic disease diagnoses, the most common combination was Hypertension, Musculoskeletal
Problem, Obesity and Osteoarthritis or Rheumatoid Arthritis (73 patients). For female patients
aged 65 to 84 years who were living with five or more chronic diseases, the most common
combination was a diagnosis of Hyperlipidemia, Hypertension, Musculoskeletal Problem,
Obesity and Osteoarthritis or Rheumatoid Arthritis, which was present among 32 patients. These
results are presented in Table 5.18.
Finally, among female patients aged 85 years and older (n = 3,824 patients), the most
commonly occurring combination was Dementia and Hypertension (76 patients). This was
followed by the combinations of Cardiovascular Disease and Hypertension (69 patients) and
Hypertension and Obesity (63 patients). Among those older female patients with three chronic
diseases, the most frequently occurring combinations were Hypertension, Obesity and
Osteoarthritis or Rheumatoid Arthritis (31 patients) and Hypertension, Musculoskeletal Problem
and Obesity (26 patients). For female patients with four chronic disease diagnoses, the most
common combination was Hypertension, Musculoskeletal Problem, Obesity and Osteoarthritis or
Rheumatoid Arthritis (17 patients). For female patients aged 85 years and older who were living
with five or more chronic diseases, the most common combination was a diagnosis of
Cardiovascular Disease, Hypertension, Musculoskeletal Problem, Obesity and Osteoarthritis or
Rheumatoid Arthritis, which was present among only 8 patients. These results are presented in
Table 5.19.
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It is important to note that all unique combinations found among female patients
constituted mutually exclusive groups. This was because the results were stratified by the total
number of chronic diseases. For example, among all female patients, the 675 patients with
Anxiety or Depression, Musculoskeletal Problem and Obesity (three chronic diseases) or the 180
female patients with Anxiety or Depression, Cancer, Musculoskeletal Problem and Obesity (four
chronic diseases) are not subsets of the 1,694 female patients with only Anxiety or Depression
and Musculoskeletal Problem or the 1,179 female patients with Anxiety or Depression and
Obesity (two chronic diseases). This ensured that all clusters represented unique, unordered
clinical profiles among female patients with multimorbidity.
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Table 5.14 Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among
all eligible female patients with multimorbidity (n = 47,381)
Total Number of
Chronic Diseases
2
(n = 19,168)

Combinations*

Anxiety or Depression & Musculoskeletal Problem
Anxiety or Depression & Obesity
Musculoskeletal Problem & Obesity
Hypertension & Obesity
Anxiety or Depression & Cancer
3
Anxiety or Depression & Musculoskeletal Problem & Obesity
(n = 12,631)
Hypertension & Musculoskeletal Problem & Obesity
Anxiety or Depression & Cancer & Musculoskeletal Problem
Anxiety or Depression & Musculoskeletal Problem & Obesity
Anxiety or Depression & Hypertension & Obesity
4
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity
(n = 7,494)
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity
Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid Arthritis
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal
Problem & Obesity
Anxiety or Depression & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid
Arthritis
≥5
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or
(n = 8,088)
Rheumatoid Arthritis
Anxiety or Depression & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or
Rheumatoid Arthritis
Anxiety or Depression & Cancer & Hypertension & Musculoskeletal Problem & Obesity
Cancer & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid
Arthritis
* Combinations listed in alphabetical order

Total Number
of Patients
1,694
1,179
1,132
850
834
675
374
365
286
264
180
176
140
111

% of Female
Patients, All Ages
3.6
2.5
2.4
1.8
1.8
1.4
0.8
0.8
0.6
0.6
0.4
0.4
0.3
0.2

106

0.2

58

0.1

52
49

0.1
0.1

49
44

0.1
0.1
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Table 5.15 Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among
eligible female patients aged 18 – 34 years with multimorbidity (n = 5,565)
Total Number of
Chronic Diseases
2
(n = 3,478)

Combinations*

Anxiety or Depression & Musculoskeletal Problem
Anxiety or Depression & Obesity
Musculoskeletal Problem & Obesity
Anxiety or Depression & Cancer
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma
3
Anxiety or Depression & Musculoskeletal Problem & Obesity
(n = 1,387)
Anxiety or Depression & Cancer & Obesity
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal
Problem
Anxiety or Depression & Cancer & Musculoskeletal Problem
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Obesity
4
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity
(n = 501)
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal
Problem & Obesity
Anxiety or Depression & Colon Problem & Musculoskeletal Problem & Obesity
Anxiety or Depression & Musculoskeletal Problem & Obesity & Thyroid Problem
Anxiety or Depression & Musculoskeletal Problem & Obesity & Urinary Problem
≥5
Anxiety or Depression & Cancer & Chronic Obstructive Pulmonary Disease or Asthma &
(n = 199)
Musculoskeletal Problem & Obesity
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal
Problem & Obesity & Urinary Problem
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity & Thyroid Problem
Anxiety or Depression & Cancer & Colon Problem & Musculoskeletal Problem & Obesity
Results Supressed (<5 Patients)
* Combinations listed in alphabetical order

Total Number
of Patients
443
397
253
243
166
157
67
61

% of Female Patients,
18 – 34 Years
8.0
7.1
4.5
4.4
3.0
2.8
1.2
1.1

59
55
36
28

1.1
1.0
0.6
0.5

18
15
15
8

0.3
0.3
0.3
0.1

6

0.1

5
5

0.1
0.1
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Table 5.16 Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among
eligible female patients aged 35 – 44 years with multimorbidity (n = 6,747)
Total Number of
Chronic Diseases
2
(n = 3,624)

Combinations*

Anxiety or Depression & Musculoskeletal Problem
Anxiety or Depression & Obesity
Musculoskeletal Problem & Obesity
Anxiety or Depression & Cancer
Cancer & Musculoskeletal Problem
3
Anxiety or Depression & Musculoskeletal Problem & Obesity
(n = 1,859)
Anxiety or Depression & Cancer & Musculoskeletal Problem
Cancer & Musculoskeletal Problem & Obesity
Anxiety or Depression & Cancer & Obesity
Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal Problem & Obesity
4
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity
(n = 792)
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal
Problem & Obesity
Anxiety or Depression & Musculoskeletal Problem & Obesity & Thyroid Problem
Anxiety or Depression & Musculoskeletal Problem & Obesity & Urinary Problem
≥5
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity & Thyroid Problem
(n = 472)
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Hypertension &
Musculoskeletal Problem & Obesity
Anxiety or Depression & Cancer & Colon Problem & Musculoskeletal Problem & Obesity
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal
Problem & Obesity & Thyroid Problem
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity & Stomach Problem
* Combinations listed in alphabetical order

Total Number of
Patients
497
333
330
206
180
203
115
76
70
51
50
38
31

% of Female Patients,
35 – 44 Years
7.4
4.9
4.9
3.1
2.7
3.0
1.7
1.1
1.0
0.8
0.7
0.6
0.5

30
22
13
11

0.4
0.3
0.2
0.2

9
8

0.1
0.1

8

0.1
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Table 5.17 Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among
eligible female patients aged 45 – 64 years with multimorbidity (n = 18,426)
Total Number of
Chronic Diseases
2
(n = 7,516)

Combinations*

Anxiety or Depression & Musculoskeletal Problem
Musculoskeletal Problem & Obesity
Cancer & Musculoskeletal Problem
Anxiety or Depression & Obesity
Hypertension & Obesity
3
Anxiety or Depression & Musculoskeletal Problem & Obesity
(n = 5,171)
Hypertension & Musculoskeletal Problem & Obesity
Anxiety or Depression & Cancer & Musculoskeletal Problem
Cancer & Musculoskeletal Problem & Obesity
Anxiety or Depression & Hypertension & Obesity
4
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity
(n = 2,981)
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity
Anxiety or Depression & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid
Arthritis
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
Anxiety or Depression & Hyperlipidemia & Musculoskeletal Problem & Obesity
≥5
Anxiety or Depression & Cancer & Hypertension & Musculoskeletal Problem & Obesity
(n = 2,758)
Anxiety or Depression & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or
Rheumatoid Arthritis
Anxiety or Depression & Diabetes & Hypertension & Musculoskeletal Problem & Obesity
Cancer & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid
Arthritis
* Combinations listed in alphabetical order

Total Number
of Patients
674
472
404
404
345
291
205
162
132
131
88
84
68

% of Female Patients,
45 – 64 Years
3.7
2.6
2.2
2.2
1.9
1.6
1.1
0.9
0.7
0.7
0.5
0.5
0.4

66
54
28
27
24

0.4
0.3
0.2
0.1
0.1

22
20

0.1
0.1

137

Table 5.18 Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among
eligible female patients aged 65 – 84 years with multimorbidity (n = 12,819)
Total Number of
Chronic Diseases
2
(n = 3,467)

Combinations*

Hypertension & Obesity
Hyperlipidemia & Hypertension
Cancer & Hypertension
Hypertension & Musculoskeletal Problem
Hypertension & Osteoarthritis or Rheumatoid Arthritis
3
Diabetes & Hypertension & Obesity
(n = 3,257)
Hypertension & Musculoskeletal Problem & Obesity
Hypertension & Obesity & Osteoarthritis or Rheumatoid Arthritis
Hyperlipidemia & Hypertension & Obesity
Cancer & Hypertension & Obesity
4
Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid Arthritis
(n = 2,527)
Diabetes & Hypertension & Obesity & Osteoarthritis or Rheumatoid Arthritis
Diabetes & Hypertension & Musculoskeletal Problem & Obesity
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity
Anxiety or Depression & Hypertension & Obesity & Osteoarthritis or Rheumatoid Arthritis
≥5
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or
(n = 3,568)
Rheumatoid Arthritis
Diabetes & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid
Arthritis
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or
Rheumatoid Arthritis
Cancer & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid
Arthritis
Anxiety or Depression & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
* Combinations listed in alphabetical order

Total Number
of Patients
323
158
147
141
123
129
100
97
95
81
73
39
39
35
33
32

% of Female Patients,
65 – 84 Years
2.5
1.2
1.1
1.1
1.0
1.0
0.8
0.8
0.7
0.6
0.6
0.3
0.3
0.3
0.3
0.2

28

0.2

24

0.2

21

0.2

20

0.2
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Table 5.19 Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among
eligible female patients aged 85 years and older with multimorbidity (n = 3,824)
Total Number of
Chronic Diseases
2
(n = 1,083)

Combinations*

Dementia & Hypertension
Cardiovascular Disease & Hypertension
Hypertension & Obesity
Hypertension & Osteoarthritis or Rheumatoid Arthritis
Hypertension & Musculoskeletal Problem
3
Hypertension & Obesity & Osteoarthritis or Rheumatoid Arthritis
(n = 957)
Hypertension & Musculoskeletal Problem & Obesity
Cardiovascular Disease & Hypertension & Musculoskeletal Problem
Hypertension & Musculoskeletal Problem & Osteoarthritis or Rheumatoid Arthritis
Cancer & Hypertension & Obesity
4
Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid Arthritis
(n = 693)
Anxiety or Depression & Hypertension & Obesity & Osteoarthritis or Rheumatoid Arthritis
Cardiovascular Disease & Hypertension & Musculoskeletal Problem & Osteoarthritis or
Rheumatoid Arthritis
Cancer & Hypertension & Musculoskeletal Problem & Obesity
Cardiovascular Disease & Hypertension & Obesity & Osteoarthritis or Rheumatoid Arthritis
≥5
Cardiovascular Disease & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis
(n = 1,091)
or Rheumatoid Arthritis
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis
or Rheumatoid Arthritis
Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid Arthritis &
Osteoporosis
Anxiety or Depression & Cardiovascular Disease & Hypertension & Obesity & Osteoarthritis or
Rheumatoid Arthritis
Dementia & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or
Rheumatoid Arthritis
* Combinations listed in alphabetical order

Total Number
of Patients
76
69
63
54
49
31
26
21
19
19
17
14
11

% of Female Patients,
≥ 85 Years
2.0
1.8
1.6
1.4
1.3
0.8
0.7
0.5
0.5
0.5
0.4
0.4
0.3

11
9
8

0.3
0.2
0.2

7

0.2

6

0.2

6

0.2

5

0.1
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Most Frequently Occurring Combinations Among Male Patients
The most frequently occurring combinations were explored according to patient age and
total number of chronic diseases among male patients. These results include only those chronic
diseases that had at least one-day elapsing between the associated dates of diagnoses. Among
adult male patients of all ages (n = 30,478 patients), the most common combination of chronic
diseases was Musculoskeletal Problem and Obesity (1,073 patients). This meant that 1,073 male
patients were either diagnosed with Musculoskeletal Problem and then Obesity, or first with
Obesity and then Musculoskeletal Problem. This was followed by a combination of
Hypertension and Obesity (895 patients) and Anxiety or Depression and Musculoskeletal
Problem (882 patients). Among male patients with three chronic diseases, the most common
combination was Hypertension, Musculoskeletal Problem and Obesity (364 patients). For
patients with four chronic disease diagnoses, the most frequently occurring combination was
Hyperlipidemia, Hypertension, Musculoskeletal Problem and Obesity (153 patients). Lastly, for
male patients living with five or more chronic diseases, the most frequently occurring
combination was present in 66 patients and consisted of Diabetes, Hyperlipidemia, Hypertension,
Musculoskeletal Problem and Obesity. These results are presented in Table 5.20.
Among the youngest group of male patients aged 18 to 34 years (n = 2,624 patients), the
most commonly occurring combination was Anxiety or Depression and Musculoskeletal
Problem (313 patients), which was similar to the most common combination among female
patients aged 18 to 34 years. This was followed by a combination of Musculoskeletal Problem
and Obesity (219 patients). Among those patients with three chronic diseases, the most
frequently occurring combination was Anxiety or Depression, Musculoskeletal Problem and
Obesity among 69 patients (again, similar to the findings among females aged 18 to 34 years).
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For male patients with four chronic disease diagnoses, the most common combinations were
Anxiety or Depression, Chronic Obstructive Pulmonary Disease or Asthma, Musculoskeletal
Problem and Obesity, which was present among 8 patients. For male patients aged 18 to 34
years who were living with five or more chronic diseases, the combinations that were detected
were only present in fewer than five patients indicating increasingly unique clinical profiles in
these young, yet complex male patients. These results are presented in Table 5.21.
Among male patients aged 35 to 44 years (n = 3,583 patients), the most commonly
occurring combination was Musculoskeletal Problem and Obesity (299 patients). This was
followed by a combination of Anxiety or Depression and Musculoskeletal Problem (263
patients) and Anxiety or Depression and Obesity (175 patients). Among those male patients with
three chronic diseases, the most frequently occurring combinations were Anxiety or Depression,
Musculoskeletal Problem and Obesity (99 patients) and Cancer, Musculoskeletal Problem and
Obesity (50 patients). For patients with four chronic disease diagnoses, the most common
combination was Anxiety or Depression, Cancer, Musculoskeletal Problem and Obesity among
16 patients. Lastly, for male patients aged 35 to 44 years who were living with five or more
chronic diseases, the combinations that were detected were only present among fewer than five
patients, once again indicating unique clinical profiles among male patients aged 35 to 44 years
with five or more chronic diseases. These results are presented in Table 5.22.
For male patients aged 45 to 64 years (n = 12,372 patients), the most commonly
occurring combinations were Musculoskeletal Problem and Obesity (483 patients) and
Hypertension and Obesity (441 patients). Among those male patients with three chronic
diseases, the most frequently occurring combinations were Hypertension, Musculoskeletal
Problem and Obesity (201 patients) and Hyperlipidemia, Hypertension and Obesity (193
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patients). For patients with four chronic disease diagnoses, the most common combination was
Hyperlipidemia, Hypertension, Musculoskeletal Problem and Obesity, which was present among
100 patients. For male patients aged 45 to 64 years who were living with five or more chronic
diseases, the most common combination was a diagnosis of Diabetes, Hyperlipidemia,
Hypertension, Musculoskeletal Problem and Obesity (34 patients). These results are presented in
Table 5.23.
Among male patients aged 65 to 84 years (n = 9,652 patients), the most commonly
occurring combination was Hypertension and Obesity (280 patients). This was followed by the
combinations of Diabetes and Obesity (176 patients) and Hyperlipidemia and Hypertension (124
patients). Among those male patients with three chronic diseases, the most frequently occurring
combinations were Diabetes, Hypertension and Obesity (147 patients) and Hyperlipidemia,
Hypertension and Obesity (106 patients). For patients with four chronic disease diagnoses, the
most common combination was Diabetes, Hyperlipidemia, Hypertension and Obesity (52
patients). For male patients aged 65 to 84 years who were living with five or more chronic
diseases, the most common combination was a diagnosis of Diabetes, Hyperlipidemia,
Hypertension, Musculoskeletal Problem and Obesity, which was present among 28 patients.
These results are presented in Table 5.24.
Finally, among male patients aged 85 years and older (n = 2,247 patients), the most
commonly occurring combination was Cancer and Hypertension (42 patients). This was
followed by the combinations of Hypertension and Obesity (41 patients) and Cardiovascular
Disease and Hypertension (36 patients). Among those older male patients with three chronic
diseases, the most frequently occurring combinations were Diabetes, Hypertension and Obesity
(29 patients) and Cardiovascular Disease, Hypertension and Obesity (19 patients). For male
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patients with four chronic disease diagnoses, the most common combination was Hypertension,
Musculoskeletal Problem, Obesity and Osteoarthritis or Rheumatoid Arthritis (13 patients). For
male patients aged 85 years and older who were living with five or more chronic diseases, the
most common combinations were among less than five male patients, indicating an elderly and
uniquely complex set of patients. These results are presented in Table 5.25.
Once again, it is important to note that all unique combinations found among male
patients constituted mutually exclusive groups. For example, among all male patients, the 364
patients with Hypertension, Musculoskeletal Problem and Obesity (three chronic diseases) or the
Hyperlipidemia, Hypertension, Musculoskeletal Problem and Obesity (four chronic diseases) are
not subsets of the 1,073 patients with only Musculoskeletal Problem and Obesity (two chronic
diseases). This ensured that all clusters represented unique, unordered clinical profiles among
male patients with multimorbidity.
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Table 5.20 Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among
all eligible male patients with multimorbidity (n = 30,478)
Total Number of
Chronic Diseases
2
(n = 12,557)

Combinations*

Musculoskeletal Problem & Obesity
Hypertension & Obesity
Anxiety or Depression & Musculoskeletal Problem
Anxiety or Depression & Obesity
Diabetes & Obesity
3
Hypertension & Musculoskeletal Problem & Obesity
(n = 8,158)
Diabetes & Hypertension & Obesity
Anxiety or Depression & Musculoskeletal Problem & Obesity
Hyperlipidemia & Hypertension & Obesity
Hyperlipidemia & Musculoskeletal Problem & Obesity
4
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
(n = 4,190)
Diabetes & Hypertension & Musculoskeletal Problem & Obesity
Diabetes & Hyperlipidemia & Hypertension & Obesity
Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid Arthritis
Cancer & Hypertension & Musculoskeletal Problem & Obesity
≥5
Diabetes & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
(n = 4,853)
Anxiety or Depression & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
Diabetes & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid
Arthritis
Cancer & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or
Rheumatoid Arthritis
* Combinations listed in alphabetical order

Total Number
of Patients
1,073
895
882
622
467
364
343
340
326
238
153
120
101
92
91
66
41
39

% of Male Patients,
All Ages
3.5
2.9
2.9
2.0
1.5
1.2
1.1
1.1
1.1
0.8
0.5
0.4
0.3
0.3
0.3
0.2
0.1
0.1

39
38

0.1
0.1
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Table 5.21 Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among
eligible male patients aged 18 – 34 years with multimorbidity (n = 2,624)
Total Number of
Chronic Diseases
2
(n = 1,878)

3
(n = 573)

4
(n = 135)

Combinations*
Anxiety or Depression & Musculoskeletal Problem
Musculoskeletal Problem & Obesity
Anxiety or Depression & Obesity
Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal Problem
Cancer & Musculoskeletal Problem
Anxiety or Depression & Musculoskeletal Problem & Obesity
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal
Problem
Cancer & Musculoskeletal Problem & Obesity
Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal Problem & Obesity
Anxiety or Depression & Cancer & Musculoskeletal Problem
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal
Problem & Obesity
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity
Anxiety or Depression & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid
Arthritis
Anxiety or Depression & Colon Problem & Musculoskeletal Problem & Obesity
Cancer & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal Problem &
Obesity

Total Number
of Patients
313
219
189
88
80
69
35

% of Male Patients,
18 – 34 Years
11.9
8.3
7.2
3.4
3.0
2.6
1.3

31
26
22
8

1.2
1.0
0.8
0.3

6
5

0.2
0.2

5
5

0.2
0.2

≥5
(n = 38)
Results Supressed (<5 Patients)

* Combinations listed in alphabetical order
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Table 5.22 Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among
eligible male patients aged 35 – 44 years with multimorbidity (n = 3,583)
Total Number of
Chronic Diseases
2
(n = 2,139)

3
(n = 945)

4
(n = 352)

Combinations*
Musculoskeletal Problem & Obesity
Anxiety or Depression & Musculoskeletal Problem
Anxiety or Depression & Obesity
Hypertension & Obesity
Cancer & Musculoskeletal Problem
Anxiety or Depression & Musculoskeletal Problem & Obesity
Cancer & Musculoskeletal Problem & Obesity
Hypertension & Musculoskeletal Problem & Obesity
Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal Problem & Obesity
Anxiety or Depression & Hypertension & Obesity
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity
Anxiety or Depression & Hyperlipidemia & Musculoskeletal Problem & Obesity
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal
Problem & Obesity
Anxiety or Depression & Musculoskeletal Problem & Obesity & Stomach Problem

Total Number
of Patients
299
263
175
103
77
99
50
41
32
31
16
12
11
11

% of Male Patients,
35 – 44 Years
8.3
7.3
4.9
2.9
2.1
2.8
1.4
1.1
0.9
0.9
0.4
0.3
0.3
0.3

10

0.3

≥5
(n = 147)
Results Supressed (<5 Patients)

* Combinations listed in alphabetical order
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Table 5.23 Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among
eligible male patients aged 45 – 64 years with multimorbidity (n = 12,372)
Total Number of
Chronic Diseases
2
(n = 5,237)

Combinations*

Musculoskeletal Problem & Obesity
Hypertension & Obesity
Anxiety or Depression & Musculoskeletal Problem
Hyperlipidemia & Musculoskeletal Problem
Hypertension & Musculoskeletal Problem
3
Hypertension & Musculoskeletal Problem & Obesity
(n = 3,644)
Hyperlipidemia & Hypertension & Obesity
Hyperlipidemia & Musculoskeletal Problem & Obesity
Anxiety or Depression & Musculoskeletal Problem & Obesity
Diabetes & Hypertension & Obesity
4
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
(n = 1,992)
Diabetes & Hypertension & Musculoskeletal Problem & Obesity
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity
Cancer & Hypertension & Musculoskeletal Problem & Obesity
Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid Arthritis
≥5
Diabetes & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
(n = 1,499)
Anxiety or Depression & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or
Rheumatoid Arthritis
Cancer & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
Diabetes & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid
Arthritis
* Combinations listed in alphabetical order

Total Number
of Patients
483
441
268
247
243
201
193
173
154
147
100
65
51
40
39
34
24
16

% of Male Patients,
45 – 64 Years
3.9
3.6
2.2
2.0
2.0
1.6
1.6
1.4
1.2
1.2
0.8
0.5
0.4
0.3
0.3
0.3
0.2
0.1

14
13

0.1
0.1
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Table 5.24 Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among
eligible male patients aged 65 – 84 years with multimorbidity (n = 9,652)
Total Number of
Chronic Diseases
2
(n = 2,696)

Combinations*

Hypertension & Obesity
Diabetes & Obesity
Hyperlipidemia & Hypertension
Cancer & Hypertension
Diabetes & Hypertension
3
Diabetes & Hypertension & Obesity
(n = 2,460)
Hyperlipidemia & Hypertension & Obesity
Hypertension & Musculoskeletal Problem & Obesity
Cancer & Hypertension & Obesity
Hypertension & Obesity & Osteoarthritis or Rheumatoid Arthritis
4
Diabetes & Hyperlipidemia & Hypertension & Obesity
(n = 1,995)
Diabetes & Hypertension & Musculoskeletal Problem & Obesity
Cardiovascular Disease & Diabetes & Hypertension & Obesity
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid Arthritis
≥5
Diabetes & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
(n = 2,501)
Diabetes & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid
Arthritis
Cancer & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or
Rheumatoid Arthritis
Diabetes & Cardiovascular Disease & Hypertension & Musculoskeletal Problem & Obesity
* Combinations listed in alphabetical order

Total Number
of Patients
280
176
124
115
113
147
106
95
81
80
52
48
41
40
38
28
23

% of Male Patients,
65 – 84 Years
2.9
1.8
1.3
1.2
1.2
1.5
1.1
1.0
0.8
0.8
0.5
0.5
0.4
0.4
0.4
0.3
0.2

23
22

0.2
0.2

16

0.2
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Table 5.25 Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among
eligible male patients aged 85 years and older with multimorbidity (n = 2,247)
Total Number of
Chronic Diseases
2
(n = 607)

3
(n = 536)

4
(n = 436)

Combinations*
Cancer & Hypertension
Hypertension & Obesity
Cardiovascular Disease & Hypertension
Diabetes & Hypertension
Hypertension & Osteoarthritis or Rheumatoid Arthritis
Diabetes & Hypertension & Obesity
Cardiovascular Disease & Hypertension & Obesity
Hypertension & Musculoskeletal Problem & Obesity
Cancer & Hypertension & Obesity
Cancer & Cardiovascular Disease & Hypertension
Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid Arthritis
Cancer & Hypertension & Musculoskeletal Problem & Obesity
Cardiovascular Disease & Diabetes & Hypertension & Obesity
Cardiovascular Disease & Hypertension & Obesity & Osteoarthritis or Rheumatoid Arthritis
Cardiovascular Disease & Hypertension & Musculoskeletal Problem & Obesity

Total Number
of Patients
42
41
36
26
20
29
19
12
10
10
13
7
7
6
6

% of Male Patients,
≥ 85 Years
1.9
1.8
1.6
1.2
0.9
1.3
0.8
0.5
0.4
0.4
0.6
0.3
0.3
0.3
0.3

≥5
(n = 668)
Results Supressed (<5 Patients)

* Combinations listed in alphabetical order
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Most Frequent Permutations of Multimorbidity
Total Number of Permutations
The total numbers of permutations among patients with multimorbidity are presented in
Table 5.26. After stratifying the results by patient age, patient sex and total number of chronic
diseases, a large number of permutations were detected in each group. As described in Section
4.8.2, only those patients with at least one chronic disease and with at least one day elapsing
between chronic disease diagnoses were included in this analysis. A permutation is an ordered
cluster of multiple chronic diseases where the specific sequence in which the chronic disease
diagnoses occurred is assessed. These are not simply co-occurring chronic diseases, but instead
indicate a sequence of events over time. Overall, a total of 14,911 permutations were found
among female patients of all ages with multimorbidity (n = 47,381) and a total of 9,736
permutations were found among male patients of all ages with multimorbidity (n = 30,478).
While these results may indicate a mean of 3.2 female patients and 3.1 male patients who had the
same permutation of multiple chronic diseases, the spread of patients across permutation type
was not normally distributed.
Among patients aged 18 to 34 years, there were 1,288 permutations found among females
and approximately half the number (610) of permutations found among males. A more
comparative number of permutations were detected among females and males who were 35 to 44
years of age, with 1,917 and 1,026 permutations identified, respectively. For patients aged 45 to
64 years, there were 6,351 permutations found among females and 4,076 permutations found
among males. Similar to the total number of combinations, the largest number of permutations
were detected among patients aged 65 to 84 years; 7,019 permutations were found among
females and 5,149 permutations were found among males. For female and male patients aged 85
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years and older, a total of 2,532 permutations and 1,633 permutations were identified,
respectively. While the total number of permutations decreased among patients aged 85 years
and older, these permutations represented increasingly unique clusters.
As seen in Table 5.26, for both female and male patients, the total number of
permutations stratified by age category does not add up to the total number of permutations
among all ages. For example, male patients of all ages could be grouped into the same
permutation, which would reduce the amount of potential permutations occurring among males
of all patients. In contrast, more permutations were observed when stratified by patient age
category due to the categorization by patient age and permutation type. Therefore, there were a
total of only 14,911 permutations and 9,736 permutations detected among female and male
patients, respectively. Finally, to assess the differences that occurred when excluding cases in
which the time elapsing between diagnoses was zero days, the same computational analysis was
conducted for all patients and for all data points (that is, even when time elapsing between
chronic disease diagnoses was equal to zero). These results are included in Appendix W to
Appendix AH. While there were differences in the total number of permutations found among
the stratified groups, a large number of permutations (as well as similar patterns of permutation
types among females and males, stratified by patient age category) were detected among all
patients with multimorbidity.
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Table 5.26 Total number of permutations, stratified by patient age and patient sex, among
patients with multimorbidity
Patient Sex

Patient Age Category

n

Total Number of Permutations*

Females

All Ages

47,381

14,911

18 – 34 Years

5,565

1,288

35 – 44 Years

6,747

1,917

45 – 64 Years

18,426

6,351

65 – 84 Years

12,819

7,019

≥ 85 Years

3,824

2,532

All Ages

30,478

9,736

18 – 34 Years

2,624

610

35 – 44 Years

3,583

1,026

45 – 64 Years

12,372

4,076

65 – 84 Years

9,652

5,149

≥ 85 Years

2,247

1,633

Males

* The total number of permutations, stratified by age category among female and male patients, will not add to the
total number of permutations among female and male patients of all ages

Most Frequently Occurring Permutations Among Female Patients
The most frequently occurring permutations were explored according to patient age and
total number of chronic diseases among female patients. These results include only those
chronic diseases that had at least one day elapsing between the associated dates of diagnoses.
Among adult female patients of all ages (n = 47,381 patients), the most common permutation of
chronic diseases was Anxiety or Depression, and then Obesity (1,160 patients). This meant that
1,160 female patients were first diagnosed with Anxiety or Depression and then with Obesity.
This was followed by a permutation of Musculoskeletal Problem, and then Obesity (1,094
patients) and Anxiety or Depression, and then Musculoskeletal Problem (909 patients). Among
patients with three chronic diseases, the most common permutation was Anxiety or Depression,
then Obesity, and then Musculoskeletal Problem (177 patients). For patients with four chronic
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disease diagnoses, the most frequently occurring permutation was Hypertension, then Obesity,
then Musculoskeletal Problem, and then Anxiety or Depression (24 patients). Lastly, for female
patients living with five or more chronic diseases, the most frequently occurring permutations
were only present among fewer than five patients. These results are presented in Table 5.27.
Among the youngest group of female patients aged 18 to 34 years (n = 5,565 patients),
the most commonly occurring permutation was again Anxiety or Depression, and then Obesity
(388 patients). Likewise, the next two commonly occurring permutations were Anxiety or
Depression, and then Musculoskeletal Problem (249 patients) and Musculoskeletal Problem, and
then Obesity (245 patients). Among those female patients with three chronic diseases, the most
frequently occurring permutation was Musculoskeletal Problem, then Obesity, and then Anxiety
or Depression (41 patients). For female patients with four chronic disease diagnoses, the most
common permutation was the diagnoses of Thyroid Problem, then Anxiety or Depression, then
Obesity, and then Musculoskeletal Problem, which was present among 5 patients. For female
patients aged 18 to 34 years who were living with five or more chronic diseases, the
permutations that were detected were only present among fewer than five patients. These results
are presented in Table 5.28.
Among female patients aged 35 to 44 years (n = 6,747 patients), the most commonly
occurring permutation was again Anxiety or Depression, and then Obesity (327 patients). This
was followed by the permutations of Musculoskeletal Problem, and then Obesity (318 patients)
and Anxiety or Depression, and then Musculoskeletal Problem (256 patients). Among those
female patients with three chronic diseases, the most frequently occurring permutation was
Anxiety or Depression, then Musculoskeletal Problem, and then Obesity (57 patients). For
patients with four chronic disease diagnoses, the most common permutation was Anxiety or
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Depression, then Musculoskeletal Problem, then Obesity, and then Cancer, which was present in
10 patients. Lastly, for female patients aged 35 to 44 years who were living with five or more
chronic diseases, the most common permutations were once again present in fewer than five
patients. These results are presented in Table 5.29.
For female patients aged 45 to 64 years (n = 18,426 patients), the most commonly
occurring permutation was Musculoskeletal Problem, and then Obesity (456 patients). This was
followed by a permutation of Anxiety or Depression, and then Obesity (400 patients) and
Anxiety or Depression, and then Musculoskeletal Problem (365 patients). Among those female
patients with three chronic diseases, the most frequently occurring permutation was
Hypertension, then Obesity, and then Musculoskeletal Problem, which was present among 87
patients. For patients with four chronic disease diagnoses, the most common permutation was
Hypertension, then Obesity, then Musculoskeletal Problem, and then Anxiety or Depression (14
patients). Similar to the previous age groups, for female patients aged 45 to 64 years who were
living with five or more chronic diseases, the most frequent permutations were present among
less than five patients. These results are presented in Table 5.30.
Among female patients aged 65 to 84 years (n = 12,819 patients), the most commonly
occurring permutation was Hypertension, and then Obesity (322 patients). This was followed by
the permutation of Hypertension, and then Musculoskeletal Problem (102 patients) and
Hypertension, and then Hyperlipidemia (98 patients). Among those female patients with three
chronic diseases, the most frequently occurring permutations were Hypertension, then Obesity,
and then Hyperlipidemia (48 patients) and Hypertension, then Obesity, and then Musculoskeletal
Problem (46 patients). For patients with four chronic disease diagnoses, the most common
permutation was Hypertension, then Obesity, then Musculoskeletal Problem, and then
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Osteoarthritis or Rheumatoid Arthritis, which occurred in 9 patients. For female patients aged 65
to 84 years who were also living with five or more chronic diseases, the most frequent
permutations were present in fewer than five patients. These results are presented in Table 5.31.
Finally, among female patients aged 85 years and older (n = 3,824 patients), the most
commonly occurring permutation was Hypertension, and then Obesity (62 patients). This was
followed by the permutations of Hypertension, and then Dementia (53 patients) and
Hypertension, and then Cardiovascular Disease (44 patients). Among those older female patients
with three chronic diseases, the most frequently occurring permutations were Hypertension, then
Obesity, and then Osteoarthritis or Rheumatoid Arthritis (15 patients) and Hypertension, then
Obesity, and then Cancer (14 patients). For female patients aged 85 years and older who were
living with four and five or more chronic diseases, the most frequent permutations were present
among less than five female patients. These results are presented in Table 5.32.
All unique permutations found among female patients constituted mutually exclusive
groups as the results were stratified by the total number of chronic diseases. For example,
among all female patients, the 177 female patients who were diagnosed with Anxiety or
Depression, then Obesity, and then Musculoskeletal Problem (three chronic diseases) were not a
subset of the 1,160 female patients with only Anxiety or Depression, and then Obesity (two
chronic diseases) or the 1,094 female patients with only Musculoskeletal Problem, and then
Obesity (two chronic diseases). This ensured that all clusters represented unique, ordered
clinical profiles among female patients with multimorbidity. Likewise, patients diagnosed first
with Obesity, and then with Anxiety or Depression represent a distinct clinical profile from those
patients who were diagnosed first with Anxiety or Depression, and then with Obesity. This
ensured that all clusters were unique, ordered clinical profiles of multimorbidity.
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Table 5.27 Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among
all eligible female patients with multimorbidity (n = 47,381)
Total Number of
Chronic Diseases
2
(n = 19,168)

3
(n = 12,631)

4
(n = 7,494)

Permutations*
Anxiety or Depression >> Obesity
Musculoskeletal Problem >> Obesity
Anxiety or Depression >> Musculoskeletal Problem
Hypertension >> Obesity
Musculoskeletal Problem >> Anxiety or Depression
Anxiety or Depression >> Obesity >> Musculoskeletal Problem
Musculoskeletal Problem >> Obesity >> Anxiety or Depression
Anxiety or Depression >> Musculoskeletal Problem >> Obesity
Hypertension >> Obesity >> Musculoskeletal Problem
Musculoskeletal Problem >> Anxiety or Depression >> Obesity
Hypertension >> Obesity >> Musculoskeletal Problem >> Anxiety or Depression
Hypertension >> Obesity >> Musculoskeletal Problem >> Osteoarthritis or Rheumatoid Arthritis
Hypertension >> Obesity >> Musculoskeletal Problem >> Hyperlipidemia
Hypertension >> Obesity >> Hyperlipidemia >> Musculoskeletal Problem
Anxiety or Depression >> Musculoskeletal Problem >> Obesity >> Cancer

Total Number
of Patients
1,160
1,094
909
836
785
177
176
161
159
149
24
18
18
18
18

% of Female
Patients, All Ages
2.4
2.3
1.9
1.8
1.7
0.4
0.4
0.3
0.3
0.3
0.1
0.0
0.0
0.0
0.0

≥5
(n = 8,088)
Results Supressed (<5 Patients)

* Permutations listed in sequential order
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Table 5.28 Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among
eligible female patients aged 18 – 34 years with multimorbidity (n = 5,565)
Total Number of
Chronic Diseases
2
(n = 3,478)

3
(n = 1,387)

4
(n = 501)

Permutations*
Anxiety or Depression >> Obesity
Anxiety or Depression >> Musculoskeletal Problem
Musculoskeletal Problem >> Obesity
Musculoskeletal Problem >> Anxiety or Depression
Anxiety or Depression >> Cancer
Musculoskeletal Problem >> Obesity >> Anxiety or Depression
Anxiety or Depression >> Obesity >> Musculoskeletal Problem
Musculoskeletal Problem >> Anxiety or Depression >> Obesity
Anxiety or Depression >> Musculoskeletal Problem >> Obesity
Anxiety or Depression >> Obesity >> Cancer
Thyroid Problem >> Anxiety or Depression >> Obesity >> Musculoskeletal Problem

≥5
(n = 199)

Total Number
of Patients
388
249
245
194
131
41
41
37
35
22
5

% of Female Patients,
18 – 34 Years
7.0
4.5
4.4
3.5
2.4
0.7
0.7
0.7
0.6
0.4
0.1

Results Supressed (<5 Patients)

* Permutations listed in sequential order
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Table 5.29 Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among
eligible female patients aged 35 – 44 years with multimorbidity (n = 6,747)
Total Number of
Chronic Diseases
2
(n = 3,624)

3
(n = 1,859)

4
(n = 792)

Total Number
of Patients
327

% of Female Patients,
35 – 44 Years
4.8

Musculoskeletal Problem >> Obesity

318

4.7

Anxiety or Depression >> Musculoskeletal Problem

256

3.8

Musculoskeletal Problem >> Anxiety or Depression

241

3.6

Cancer >> Obesity

161

2.4

Anxiety or Depression >> Musculoskeletal Problem >> Obesity

57

0.8

Anxiety or Depression >> Obesity >> Musculoskeletal Problem

51

0.8

Musculoskeletal Problem >> Obesity >> Anxiety or Depression

48

0.7

Musculoskeletal Problem >> Anxiety or Depression >> Obesity

43

0.6

Anxiety or Depression >> Obesity >> Cancer

25

0.4

Anxiety or Depression >> Musculoskeletal Problem >> Obesity >> Cancer

10

0.1

Hypertension >> Obesity >> Musculoskeletal Problem >> Anxiety or Depression

6

0.1

Anxiety or Depression >> Obesity >> Musculoskeletal Problem >> Cancer

6

0.1

Anxiety or Depression >> Obesity >> Cancer >> Musculoskeletal Problem

6

0.1

Musculoskeletal Problem >> Obesity >> Anxiety or Depression >> Cancer

5

0.1

Permutations*
Anxiety or Depression >> Obesity

≥5
(n = 472)
Results Supressed (<5 Patients)

* Permutations listed in sequential order
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Table 5.30 Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among
eligible female patients aged 45 – 64 years with multimorbidity (n = 18,426)
Total Number of
Chronic Diseases
2
(n = 7,516)

3
(n = 5,171)

4
(n = 2,981)

Total Number
of Patients
456

% of Female Patients,
45 – 64 Years
2.5

Anxiety or Depression >> Obesity

400

2.2

Anxiety or Depression >> Musculoskeletal Problem

365

2.0

Hypertension >> Obesity

340

1.8

Musculoskeletal Problem >> Anxiety or Depression

309

1.7

Hypertension >> Obesity >> Musculoskeletal Problem

87

0.5

Anxiety or Depression >> Obesity >> Musculoskeletal Problem

80

0.4

Musculoskeletal Problem >> Obesity >> Anxiety or Depression

78

0.4

Anxiety or Depression >> Musculoskeletal Problem >> Obesity

65

0.4

Musculoskeletal Problem >> Anxiety or Depression >> Obesity

63

0.3

Hypertension >> Obesity >> Musculoskeletal Problem >> Anxiety or Depression

14

0.1

Hypertension >> Obesity >> Musculoskeletal Problem >> Hyperlipidemia

10

0.1

Hypertension >> Obesity >> Hyperlipidemia >> Musculoskeletal Problem

10

0.1

Musculoskeletal Problem >> Obesity >> Hypertension >> Anxiety or Depression

9

0.0

Musculoskeletal Problem >> Obesity >> Osteoarthritis or Rheumatoid Arthritis >> Anxiety or
Depression

9

0.0

Permutations*
Musculoskeletal Problem >> Obesity

≥5
(n = 2,758)
Results Supressed (<5 Patients)

* Permutations listed in sequential order
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Table 5.31 Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among
eligible female patients aged 65 – 84 years with multimorbidity (n = 12,819)
Total Number of
Chronic Diseases
2
(n = 3,467)

3
(n = 3,257)

4
(n = 2,527)

Total Number
of Patients
322

% of Female Patients,
65 – 84 Years
2.5

Hypertension >> Musculoskeletal Problem

102

0.8

Hypertension >> Hyperlipidemia

98

0.8

Hypertension >> Cancer

97

0.8

Diabetes >> Obesity

97

0.8

Hypertension >> Obesity >> Hyperlipidemia

48

0.4

Hypertension >> Obesity >> Musculoskeletal Problem

46

0.4

Diabetes >> Obesity >> Hypertension

42

0.3

Hypertension >> Obesity >> Cancer

38

0.3

Hypertension >> Obesity >> Osteoarthritis or Rheumatoid Arthritis

34

0.3

Hypertension >> Obesity >> Musculoskeletal Problem >> Osteoarthritis or Rheumatoid Arthritis

9

0.1

Hypertension >> Obesity >> Osteoarthritis or Rheumatoid Arthritis >> Musculoskeletal Problem

8

0.1

Hypertension >> Obesity >> Musculoskeletal Problem >> Hyperlipidemia

8

0.1

Hypertension >> Obesity >> Musculoskeletal Problem >> Cancer

7

0.1

Hypertension >> Obesity >> Hyperlipidemia >> Osteoarthritis or Rheumatoid Arthritis

7

0.1

Permutations*
Hypertension >> Obesity

≥5
(n = 3,568)
Results Supressed (<5 Patients)

* Permutations listed in sequential order
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Table 5.32 Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among
eligible female patients aged 85 years and older with multimorbidity (n = 3,824)
Total Number of
Chronic Diseases
2
(n = 1,083)

3
(n = 957)

Total Number
of Patients
62

% of Female
Patients, ≥ 85 Years
1.6

Hypertension >> Dementia

53

1.4

Hypertension >> Cardiovascular Disease

44

1.2

Hypertension >> Cancer

37

1.0

Hypertension >> Osteoarthritis or Rheumatoid Arthritis
Hypertension >> Obesity >> Osteoarthritis or Rheumatoid Arthritis
Hypertension >> Obesity >> Cancer
Hypertension >> Obesity >> Musculoskeletal Problem
Hypertension >> Osteoarthritis or Rheumatoid Arthritis >> Obesity
Hypertension >> Musculoskeletal Problem >> Osteoarthritis or Rheumatoid Arthritis

33
15
14
12
9
8

0.9
0.4
0.4
0.3
0.2
0.2

Permutations*
Hypertension >> Obesity

4
(n = 693)

≥5
(n = 1,091)

Results Supressed (<5 Patients)

* Permutations listed in sequential order
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Most Frequently Occurring Permutations Among Male Patients
The most frequently occurring permutations were explored according to patient age and
total number of chronic diseases among male patients. These results include only those chronic
diseases that had at least one day elapsing between the associated dates of diagnoses. Among
adult male patients of all ages (n = 30,478 patients), the most common permutation of chronic
diseases was Musculoskeletal Problem, and then Obesity (1,051 patients). This meant that 1,051
male patients were first diagnosed with Musculoskeletal Problem, and then Obesity and with that
specific sequence. This was followed by a permutation of Hypertension, and then Obesity (880
patients) and Anxiety or Depression, and then Obesity (618 patients). Among patients with three
chronic diseases, the most common permutation was Hypertension, then Obesity, and then
Hyperlipidemia (162 patients). For patients with four chronic disease diagnoses, the most
frequently occurring permutation was Hypertension, then Obesity, then Hyperlipidemia, and then
Musculoskeletal Problem (19 patients). Lastly, for male patients living with five or more chronic
diseases, the common permutations were present among less than five male patients. These
results are presented in Table 5.33.
Among the youngest group of male patients aged 18 to 34 years (n = 2,624 patients), the
most commonly occurring permutation was again Musculoskeletal Problem, and then Obesity,
which was present among 216 patients. The next two commonly occurring permutations were
Anxiety or Depression, and then Obesity (187 patients) and Anxiety or Depression, and then
Musculoskeletal Problem (161 patients). Among those male patients with three chronic diseases,
the most frequently occurring permutation was Anxiety or Depression, then Obesity, and then
Musculoskeletal Problem (22 patients). For male patients aged 18 to 34 years who were living
with four and five or more chronic diseases, the most common permutations were detected in
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fewer than five patients, indicating increasingly unique clinical profiles in these young, yet
complex male patients. These results are presented in Table 5.34.
Among male patients aged 35 to 44 years (n = 3,583 patients), the most commonly
occurring permutation was Musculoskeletal Problem, and then Obesity (291 patients). This was
followed by the permutation of Anxiety or Depression, and then Obesity (174 patients) and
Musculoskeletal Problem, and then Anxiety or Depression (135 patients). Among those male
patients with three chronic diseases, the most frequently occurring permutation was Anxiety or
Depression, then Obesity, and then Musculoskeletal Problem (31 patients). Lastly, for male
patients aged 35 to 44 years who were living with four and five or more chronic diseases, the
permutations that were detected were only present among less than five patients. These results
are presented in Table 5.35.
For male patients aged 45 to 64 years (n = 12,372 patients), the most commonly
occurring permutation was Musculoskeletal Problem, and then Obesity (473 patients). This was
followed by a permutation of Hypertension, and then Obesity (432 patients) and Anxiety or
Depression, and then Obesity (228 patients). Among those male patients with three chronic
diseases, the most frequently occurring permutation was Hypertension, then Obesity, and then
Hyperlipidemia, which occurred among 94 patients. For these middle-aged male patients with
four chronic disease diagnoses, the most common permutations were Hypertension, then
Obesity, then Hyperlipidemia, and then Musculoskeletal Problem (10 patients) and
Musculoskeletal Problem, then Obesity, then Hypertension, and then Hyperlipidemia (10
patients). For male patients aged 45 to 64 years who were living with five or more chronic
diseases, the most frequent permutations were detected in less than five patients and these results
were supressed. These results are presented in Table 5.36.
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Among male patients aged 65 to 84 years (n = 9,652 patients), the most commonly
occurring permutation was Hypertension, and then Obesity (278 patients). This was followed by
the permutation of Diabetes, and then Obesity (175 patients) and Hypertension, and then
Hyperlipidemia (79 patients). Among those male patients with three chronic diseases, the most
frequently occurring permutations were Diabetes, then Obesity, and then Hypertension (56
patients) and Hypertension, then Obesity, and then Musculoskeletal Problem (55 patients). For
patients with four chronic disease diagnoses, the most common permutations were Hypertension,
then Obesity, then Musculoskeletal Problem, and then Cancer, which occurred among 9 male
patients. For male patients aged 65 to 84 years who were living with five or more chronic
diseases, there were a number of permutations that were present among groups of fewer than five
male patients. These results are presented in Table 5.37.
Finally, among male patients aged 85 years and older (n = 2,247 patients), the most
commonly occurring permutation was Hypertension, and then Obesity (41 patients). This was
followed by the permutations of Hypertension, and then Cancer (30 patients) and Hypertension,
and then Cardiovascular Disease (22 patients). Among those older male patients with three
chronic diseases, the most frequently occurring permutations were Diabetes, then Obesity, and
then Hypertension (12 patients) and Hypertension, then Obesity, and then Musculoskeletal
Problem (9 patients). For male patients aged 85 years and older who were living with four and
five or more chronic diseases, the most common permutations occurred among fewer than five
patients. These results are presented in Table 5.38.
Similar to the combination analysis, all unique permutations found among male patients
constituted mutually exclusive groups as the results were stratified by the total number of chronic
diseases a patient had by the end of the observation period. For example, among male patients of
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all ages, the 162 patients who were diagnosed with Hypertension, then Obesity, and then
Hyperlipidemia (three chronic diseases) or the 132 patients who were diagnosed with
Hypertension, then Obesity, and then Musculoskeletal Problem (three chronic diseases) were not
a subset of the 880 patients who were diagnosed first with Hypertension, and then with Obesity.
Likewise, patients diagnosed first with Obesity, and then with Hypertension represent a distinct
clinical profile from those patients who were diagnosed first with Hypertension, and then with
Obesity. This ensured that all clusters represented unique, ordered clinical profiles among male
patients with multimorbidity.

165

Table 5.33 Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among
all eligible male patients with multimorbidity (n = 30,478)
Total Number of
Chronic Diseases
2
(n = 12,557)

3
(n = 8,158)

4
(n = 4,190)

Total Number
of Patients
1,051

% of Male
Patients, All Ages
3.4

Hypertension >> Obesity

880

2.9

Anxiety or Depression >> Obesity

618

2.0

Diabetes >> Obesity

458

1.5

Musculoskeletal Problem >> Anxiety or Depression

451

1.5

Hypertension >> Obesity >> Hyperlipidemia

162

0.5

Hypertension >> Obesity >> Musculoskeletal Problem

132

0.4

Diabetes >> Obesity >> Hypertension

110

0.4

Musculoskeletal Problem >> Obesity >> Hypertension

103

0.3

Hypertension >> Obesity >> Diabetes

97

0.3

Hypertension >> Obesity >> Hyperlipidemia >> Musculoskeletal Problem

19

0.1

Diabetes >> Obesity >> Musculoskeletal Problem >> Hypertension

15

0.0

Hypertension >> Obesity >> Musculoskeletal Problem >> Cancer

14

0.0

Hypertension >> Obesity >> Hyperlipidemia >> Diabetes

14

0.0

Hypertension >> Obesity >> Diabetes >> Musculoskeletal Problem

13

0.0

Permutations*
Musculoskeletal Problem >> Obesity

≥5
(n = 4,853)
Results Supressed (<5 Patients)

* Permutations listed in sequential order
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Table 5.34 Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among
eligible male patients aged 18 – 34 years with multimorbidity (n = 2,624)
Total Number of
Chronic Diseases
2
(n = 1,878)

3
(n = 573)

Total Number
of Patients
216

% of Male Patients,
18 – 34 Years
8.2

Anxiety or Depression >> Obesity

187

7.1

Anxiety or Depression >> Musculoskeletal Problem

161

6.1

Musculoskeletal Problem >> Anxiety or Depression

152

5.8

Chronic Obstructive Pulmonary Disease or Asthma >> Obesity

62

2.4

Anxiety or Depression >> Obesity >> Musculoskeletal Problem

22

0.8

Anxiety or Depression >> Musculoskeletal Problem >> Obesity

17

0.6

Musculoskeletal Problem >> Anxiety or Depression >> Obesity

16

0.6

Musculoskeletal Problem >> Obesity >> Anxiety or Depression

14

0.5

Chronic Obstructive Pulmonary Disease or Asthma >> Musculoskeletal Problem >> Anxiety or Depression

11

0.4

Permutations*
Musculoskeletal Problem >> Obesity

4
(n = 135)

≥5
(n = 38)

Results Supressed (<5 Patients)

* Permutations listed in sequential order
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Table 5.35 Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among
eligible male patients aged 35 – 44 years with multimorbidity (n = 3,583)
Total Number of
Chronic Diseases
2
(n = 2,139)

3
(n = 945)

Total Number
of Patients
291

% of Male Patients,
35 – 44 Years
8.1

Anxiety or Depression >> Obesity

174

4.9

Musculoskeletal Problem >> Anxiety or Depression

135

3.8

Anxiety or Depression >> Musculoskeletal Problem

128

3.6

Hypertension >> Obesity

99

2.8

Anxiety or Depression >> Obesity >> Musculoskeletal Problem

31

0.9

Musculoskeletal Problem >> Obesity >> Anxiety or Depression

27

0.8

Musculoskeletal Problem >> Anxiety or Depression >> Obesity

24

0.7

Musculoskeletal Problem >> Obesity >> Cancer

21

0.6

Musculoskeletal Problem >> Obesity >> Hypertension

17

0.5

Permutations*
Musculoskeletal Problem >> Obesity

4
(n = 352)

≥5
(n = 147)

Results Supressed (<5 Patients)

* Permutations listed in sequential order
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Table 5.36 Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among
eligible male patients aged 45 – 64 years with multimorbidity (n = 12,372)
Total Number of
Chronic Diseases
2
(n = 5,237)

3
(n = 3,644)

4
(n = 1,992)

Total Number
of Patients
473

% of Male Patients,
45 – 64 Years
3.8

Hypertension >> Obesity

432

3.5

Anxiety or Depression >> Obesity

228

1.8

Diabetes >> Obesity

201

1.6

Hyperlipidemia >> Obesity

184

1.5

Hypertension >> Obesity >> Hyperlipidemia

94

0.8

Musculoskeletal Problem >> Obesity >> Hyperlipidemia

69

0.6

Musculoskeletal Problem >> Obesity >> Hypertension

67

0.5

Hypertension >> Obesity >> Musculoskeletal Problem

58

0.5

Hypertension >> Obesity >> Diabetes

52

0.4

Hypertension >> Obesity >> Hyperlipidemia >> Musculoskeletal Problem

10

0.1

Musculoskeletal Problem >> Obesity >> Hypertension >> Hyperlipidemia

10

0.1

Hypertension >> Obesity >> Musculoskeletal Problem >> Hyperlipidemia

8

0.1

Hypertension >> Obesity >> Musculoskeletal Problem >> Diabetes

7

0.1

Hypertension >> Obesity >> Musculoskeletal Problem >> Anxiety or Depression

7

0.1

Permutations*
Musculoskeletal Problem >> Obesity

≥5
(n = 1,499)
Results Supressed (<5 Patients)

* Permutations listed in sequential order
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Table 5.37 Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among
eligible male patients aged 65 – 84 years with multimorbidity (n = 9,652)
Total Number of
Chronic Diseases
2
(n = 2,696)

3
(n = 2,460)

4
(n = 1,995)

Total Number
of Patients
278

% of Male Patients,
65 – 84 Years
2.9

Diabetes >> Obesity

175

1.8

Hypertension >> Hyperlipidemia

79

0.8

Hypertension >> Cancer

78

0.8

Cardiovascular Disease >> Obesity

67

0.7

Diabetes >> Obesity >> Hypertension

56

0.6

Hypertension >> Obesity >> Musculoskeletal Problem

55

0.6

Hypertension >> Obesity >> Hyperlipidemia

54

0.6

Hypertension >> Obesity >> Cancer

37

0.4

Hypertension >> Obesity >> Osteoarthritis or Rheumatoid Arthritis

36

0.4

Hypertension >> Obesity >> Musculoskeletal Problem >> Cancer

9

0.1

Hypertension >> Obesity >> Musculoskeletal Problem >> Osteoarthritis or Rheumatoid Arthritis

8

0.1

Hypertension >> Obesity >> Hyperlipidemia >> Urinary Problem

8

0.1

Hypertension >> Diabetes >> Hyperlipidemia >> Obesity

8

0.1

Diabetes >> Obesity >> Hypertension >> Musculoskeletal Problem

8

0.1

Permutations*
Hypertension >> Obesity

≥5
(n = 2,501)
Results Supressed (<5 Patients)

* Permutations listed in sequential order
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Table 5.38 Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among
eligible male patients aged 85 years and older with multimorbidity (n = 2,247)
Total Number of
Chronic Diseases
2
(n = 607)

3
(n = 536)

Hypertension >> Obesity

Total Number
of Patients
41

% of Male Patients,
≥ 85 Years
1.8

Hypertension >> Cancer

30

1.3

Hypertension >> Cardiovascular Disease

22

1.0

Diabetes >> Obesity

17

0.8

Hypertension >> Osteoarthritis or Rheumatoid Arthritis

14

0.6

Diabetes >> Obesity >> Hypertension

12

0.5

Hypertension >> Obesity >> Musculoskeletal Problem

9

0.4

Hypertension >> Obesity >> Cancer

8

0.4

Diabetes >> Hypertension >> Obesity

8

0.4

Hypertension >> Obesity >> Dementia

7

0.3

Permutations*

4
(n = 436)

≥5
(n = 668)

Results Supressed (<5 Patients)

* Permutations listed in sequential order
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5.2 Objective Two
The results for Objective Two describe the time elapsing between chronic disease
diagnoses among patients with at least one chronic disease. These results will describe the mean
time until subsequent chronic disease diagnosis, an assessment of whether this mean time
decreases as the number of chronic disease diagnoses increases, and whether other factors (e.g.,
patient age, patient sex, patient residential location, patient median household income, total
number of chronic diseases, provider age, provider sex, practice EMR type and practice location)
influence the mean time until subsequent chronic disease diagnosis.

5.2.1 Patient Sample Characteristics
The characteristics of patients with one or more chronic disease diagnoses (n = 286,998
patients) and two or more chronic disease diagnoses (n = 195,838 patients) are presented in
Table 5.39 to Table 5.41. For Research Question 1 and Research Question 3, the sample was
derived from all adult patients with at least one chronic disease diagnoses as of September 30,
2013. However, for Research Question 2, the sample was focused on those adult patients with at
least two chronic disease diagnoses. As described previously in the Methodology Chapter, all
analyses for Objective Two were conducted using those chronic diseases (or data points) that had
at least one day elapsing between diagnoses.
Overall, the patients with one or more chronic diseases were a mean age of 55.3 years
(SD: 17.8 years), with a range from 18 to 114 years. The majority of patients were female
(57.5%) and were between the ages of 45 and 64 years (39.2%). Slightly more than half of these
patients (51.4%) were living in an urban setting and the median of the median household income
was found to be $60,310 per year (Canadian dollars), ranging from as low as $22,457 to as much
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as $181,454 per year. Approximately one-third of patients did not have data recorded for their
residential postal code, and therefore their median household income could not be determined.
The mean number of chronic diseases these patients were living with was 2.6 (SD: 1.6) with a
range from those patients living with one chronic disease to fourteen chronic diseases. These
characteristics can be seen in Table 5.39.
The characteristics of patients with two or more chronic diseases were previously
presented for Objective One and are presented again in Table 5.39. These patients had a mean
age of 59.0 years (SD: 17.0 years), with a range between 18 and 114 years. The majority of
patients were female (57.8%) and were between 45 and 64 years of age (40.6%). Approximately
52% of these patients were living in an urban setting and the median of the median household
income was found to be $60,952 per year (Canadian dollars). Once again, approximately onethird of patients did not have data recorded for their residential postal code, and therefore their
median household income could not be determined. The mean number of chronic diseases these
patients were living with was 3.3 (SD: 1.5) with a range from those patients living with two
chronic diseases to fourteen chronic diseases.
The demographic characteristics of the PHC providers who were caring for these two
patient groups are presented in Table 5.40. For patients with one or more chronic diseases,
about one-quarter (25.3%) were being cared for by PHC providers who were aged 45 to 64 years.
These PHC providers had a mean age of 50.8 years (SD: 10.3 years). About 28.9% of patients
with one or more chronic diseases were being cared for by male PHC providers. For patients
with two or more chronic diseases, about 25.5% were being cared for by PHC providers who
were aged 45 to 64 years, these PHC providers had a mean age of 51.2 years (SD: 10.2 years)
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and about 29.8% of patients with two or more chronic diseases were being cared for by male
PHC providers.

Table 5.39 Patient-level characteristics of the two groups of adult patients (those with one
or more and two or more chronic diseases) for Objective Two
Patients with One or More

Patients with Two or More

Chronic Diseases

Chronic Diseases

(n = 286,998)

(n = 195,838)

55.3 Years (17.8 Years)

59.0 Years (17.0 Years)

18 Years – 114 Years

18 Years – 114 Years

18 – 34

41,980 (14.6%)

17,466 (8.9%)

35 – 44

43,450 (15.1%)

23,855 (12.2%)

45 – 64

112,354 (39.2%)

79,571 (40.6%)

65 – 84

71,808 (25.0%)

60,696 (31.0%)

≥ 85

17,406 (6.1%)

14,250 (7.3%)

Female

165,111 (57.5%)

113,209 (57.8%)

Male

121,870 (42.5%)

82,622 (42.2%)

Rural

44,741 (15.6%)

32,607 (16.7%)

Urban

147,501 (51.4%)

102,151 (52.2%)

Missing

94,756 (33.0%)

61,080 (31.2%)

Patient-Level Variable

Age (Years), n (%)
Mean (SD)
Range (Minimum – Maximum)

Sex, n (%)

Residential Location, n (%)

Median Household Income (Canadian Dollars)
Median (IQR)

$60,310 ($$12,497)

$60,952 ($12,497)

Range (Minimum – Maximum)

$22,457 – $181,454

$22,457 – $181,454

95,092 (33.1%)

61,263 (31.3%)

2.6 (1.6)

3.3 (1.5)

1 – 14

2 – 14

Missing (%)
Total Number of Chronic Diseases
Mean (SD)
Range (Minimum – Maximum)

* SD = Standard deviation, CI = Confidence interval, IQR = Interquartile range
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Table 5.40 Characteristics of PHC providers caring for the two groups of adult patients
(those with one or more and two or more chronic diseases) for Objective Two
Patients with One or More

Patients with Two or More

Chronic Diseases

Chronic Diseases

(n = 286,998)

(n = 195,838)

50.8 Years (10.3 Years)

51.2 Years (10.2 Years)

27 Years – 72 Years

27 Years – 72 Years

25 – 44

35,020 (12.2%)

22,402 (11.4%)

45 – 64

72,662 (25.3%)

49,871 (25.5%)

≥ 65

10,681 (3.7%)

7,730 (4.0%)

Missing

168,635 (58.8%)

115,835 (59.2%)

Female

61,082 (21.3%)

39,517 (20.2%)

Male

83,017 (28.9%)

58,364 (29.8%)

Missing

142,899 (49.8%)

97,957 (50.0%)

Provider-Level Variable

Age (Years), n (%)
Mean (SD)
Range (Minimum – Maximum)

Sex, n (%)

* SD = Standard deviation, CI = Confidence interval

The characteristics of the PHC practices where these two patient groups were cared for
are presented in Table 5.41. Among adult patients with one or more chronic diseases, 25.6%
came from PHC practices that were using the Nightingale EMR software. This was followed by
clinical data recorded using the Wolf (9.0%), Accuro (8.5%) and Bell (7.4%) EMR software
programs. The majority of these patients (57.2%) received care from urban PHC practices,
according to the first three letters of the practices’ postal code. The largest proportion of patients
belonged to Network 4 (21.4%) and Network 5 (24.4%), which were located in Central Ontario
and Eastern Ontario, respectively. While all adult PHC patients were allocated to one of the ten
CPCSSN Networks, approximately one-third of patients were missing data for both the EMR
software type and practice location variables.
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Table 5.41 Characteristics of PHC practices caring for the two groups of adult patients
(those with one or more and two or more chronic diseases) for Objective Two
Patients with One or More

Patients with Two or More

Chronic Diseases

Chronic Diseases

(n = 286,998)

(n = 195,838)

Accuro

24,324 (8.5%)

16,001 (8.2%)

Bell

21,247 (7.4%)

15,601 (8.0%)

DaVinci

824 (0.3%)

376 (0.2%)

Jonoke

16,399 (5.7%)

12,953 (6.6%)

Med Access

8,676 (3.0%)

6,437 (3.3%)

Nightingale

73,328 (25.6%)

50,998 (26.0%)

Oscar

11,177 (3.9%)

6,208 (3.2%)

Practice Solutions

14,111 (4.9%)

8,723 (4.5%)

Wolf

25,713 (9.0%)

18,732 (9.6%)

Xwave

680 (0.2%)

528 (0.3%)

Missing

90,519 (31.5%)

59,281 (30.3%)

Rural

26,450 (9.2%)

19,471 (9.9%)

Urban

164,048 (57.2%)

113,120 (57.8%)

Missing

96,500 (33.6%)

63,247 (32.3%)

1

30,128 (10.5%)

21,060 (10.8%)

2

15,344 (5.4%)

11,081 (5.7%)

3

5,897 (2.1%)

4,801 (2.5%)

4

61,403 (21.4%)

38,797 (19.8%)

5

70,098 (24.4%)

47,986 (24.5%)

6

1,900 (0.7%)

814 (0.4%)

7

25,883 (9.0%)

17,218 (8.8%)

8

27,278 (9.5%)

20,374 (10.4%)

9

40,003 (13.9%)

27,656 (14.1%)

10

9,064 (3.2%)

6,051 (3.1%)

Practice-Level Variable

EMR Type, n (%)

Practice Location, n (%)

CPCSSN Network, n (%)

* SD = Standard deviation, CI = Confidence interval
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5.2.2 Objective Two, Research Question 1 – Time Until Multimorbidity
To address Research Question 1, the median and mean time until the second chronic
disease diagnoses were explored for all adult patients with at least one chronic disease as of
September 30, 2013. As described previously in the Methodology Chapter, this included only
those chronic diseases in which at least one day elapsed between diagnoses. As such, the data
points that reported zero days elapsing between diagnoses were removed. A descriptive analysis
was conducted to determine the time elapsing (in days) between the first (X1) and second (X2)
chronic diseases. This time from morbidity to multimorbidity or “Time Until Multimorbidity” is
presented in Table 5.42 and has been stratified by patient age and patient sex.
These results indicate that the time elapsing until the onset of multimorbidity decreased
between the youngest and oldest age groups: a decrease of 200 days among female patients and a
decrease of 150 days among male patients. For example, among female patients aged 18 to 34
years, the median time elapsing between the first and second chronic disease diagnoses was
301.7 days, as compared to a median time of 97.4 days among female patients aged 85 years and
older. Similarly, among male patients aged 18 to 34 years, the median time until the onset of
multimorbidity was 249.0 days, while among male patients aged 85 years and older the median
time was only 93.0 days. For patients aged 35 to 44 years, the median time elapsing until the
second chronic disease diagnosis was 308.3 days among females and 244.0 days among males.
For patients aged 45 to 64 years, the median time elapsing between the first and second chronic
disease diagnoses was 224.3 days among females and 149.8 days among males. Finally, among
patients aged 65 to 84 years, the median time elapsing until the second chronic disease was 114.6
days among females and 83.0 days among males. Interestingly, the median time elapsing until
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multimorbidity was 10 days shorter among males aged 65 to 84 years, as compared to males
aged 85 years and older.
The “Time Until Multimorbidity” was also explored by the first or index chronic disease
type, and these results were stratified by patient age and patient sex. Table 5.43 presents the
index chronic disease types that led to the quickest and slowest accumulation of the next chronic
disease. For patients aged 18 to 34 years, both female and male patients progressed most quickly
to the second chronic disease when they were first diagnosed with Diabetes (median of 131.0
days and 30.8 days, respectively). In comparison, female patients aged 35 to 44 years progressed
most quickly to the next chronic disease when they were first diagnosed with Stroke or Transient
Ischemic Attack (median of 79.3 days) and male patients aged 35 to 44 years progressed quickly
when they first experienced Heart Failure (median of 69.6 days). Progression to the second
chronic disease occurred the quickest after first being diagnosed with Diabetes for female
patients aged 45 to 64 years (median of 50.1 days), 65 to 84 years (median of 39.5 days) and 85
years and older (median of 46.5 days). A similar quick progression was seen among male
patients aged 45 to 64 years and 65 to 84 years who were first diagnosed with Diabetes (median
of 44.4 days and 32.0 days, respectively). Finally, among male patients aged 85 years and older,
the quickest accumulation occurred for those patients who were first diagnosed with Stroke or
Transient Ischemic Attack (median of 18.5 days).
The index chronic disease types that led to the slowest accumulation of the second
chronic disease diagnosis was also explored in Table 5.43. For patients aged 18 to 34 years, the
longest median time until multimorbidity was observed among female patients who were first
diagnosed with Osteoporosis (median time of 921.4 days) and male patients who were first
diagnosed with Stroke or Transient Ischemic Attack (median of 1,993.1 days). For patients aged
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35 to 44 years, the slowest accumulation to the second chronic disease was seen among female
patients who were first diagnosed with Heart Failure (median time of 935.0 days) and male
patients who were first diagnosed with Liver Disease (median of 627.0 days). Among patients
aged 45 to 64 years, both female and male patients had the longest median time until
multimorbidity when they were first diagnosed with Dementia (median time of 603.3 days and
369.0 days, respectively). Progression to the second chronic disease occurred the slowest after
first being diagnosed with Kidney Disease or Failure for female patients aged 65 to 84 years and
85 years and older (median time of 680.4 days and 449.7 days, respectively). Male patients aged
65 to 74 years experienced the longest time until multimorbidity when they were first diagnosed
with Dementia (266.0 days). Male patients aged 85 years and older had the longest median time
(260.5 days) until the second chronic disease after first being diagnosed with Osteoporosis.
To assess the differences that occur when excluding data points in which the time
elapsing between diagnoses was zero days, the same analysis was conducted for all patients and
for all data points (that is, when time elapsing between chronic disease diagnoses was equal to
zero days). These results are included in Appendix AI. After including these data points, the
same patterns of time elapsing until multimorbidity were observed, while the median and mean
time elapsing between chronic disease diagnoses were notably lower as compared to the
estimates presented in Table 5.42. For example, within the sensitivity analysis, male patients
aged 18 to 34 years had a median time of only 87.0 days (mean of 424.1 days) until the second
chronic disease, as compared a median time of 249.0 days (mean of 534.1 days) in the original
analysis. A similar pattern was observed for all remaining patient categories, indicating the
impact of removing those data points where the time elapsing between diagnoses was equal to
zero days.
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Table 5.42 Time (in days) until subsequent chronic disease diagnosis, stratified by patient age category (years), patient sex and
total number of chronic diseases
Female

Male

18 – 34

35 – 44

45 – 64

65 – 84

≥ 85

18 – 34

35 – 44

45 – 64

65 – 84

≥ 85

T1  T2

301.7

308.3

224. 3

114.6

97.4

249.0

244.0

149.8

83.0

93.0

(n = 238,237)

537.1

569.7

521.6

407.2

366.4

534.1

525.2

473.5

387.9

363.4

(635.4)

(688.9)

(707.0)

(677.4)

(638.6)

(692.1)

(694.2)

(695.4)

(682.3)

(646.7)

T2  T3

377.9

396.0

342.0

238.5

202.4

364.8

365.0

321.0

239.0

211.0

(n = 141,684)

561.1

606.0

562.3

466.6

398.1

565.7

577.2

544.0

473.8

406.0

(598.8)

(667.1)

(667.1)

(617.6)

(519.3)

(667.3)

(680.7)

(661.3)

(649.3)

(542.0)

T3  T4

343.2

357.0

304.1

248.0

238.1

340.0

326.9

311.0

252.0

236.5

(n = 82,373)

488.8

522.4

473.0

408.6

398.9

524.2

508.2

484.3

421.8

389.0

(486.7)

(533.4)

(506.7)

(460.3)

(453.1)

(556.2)

(547.6)

(530.1)

(490.7)

(443.6)

T4  T5

292.0

360.0

294.0

260.0

245.9

349.2

301.4

320.0

278.0

251.4

(n = 44,255)

439.1

514.0

454.7

402.1

392.4

458.8

489.4

469.9

424.1

406.1

(462.6)

(516.2)

(485.3)

(435.4)

(427.2)

(430.0)

(529.1)

(487.3)

(466.2)

(462.6)

T5  T6

283.0

358.1

289.8

266.7

274.5

276.9

316.5

301.0

275.1

259.7

(n = 22,035)

395.5

496.7

433.9

398.6

417.5

441.4

461.2

451.8

417.2

398.4

(388.5)

(477.7)

(451.3)

(424.6)

(445.4)

(492.3)

(472.4)

(485.5)

(444.8)

(446.5)

* Each cell contains median time, mean time and standard deviation, all measured in days; longest time between diagnoses highlighted in green and shortest time
between diagnoses highlighted in red
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Table 5.43 Time (in days) until multimorbidity, stratified by patient age category (years), patient sex and index chronic disease
Female

Male

18 – 34

35 – 44

45 – 64

65 – 84

≥ 85

18 – 34

35 – 44

45 – 64

65 – 84

≥ 85

184.8

193.0

102.0

68.8

70.0

127.1

76.7

57.8

44.0

62.6

448.2

442.6

368.8

304.5

278.8

474.8

386.4

348.4

286.2

292.6

(591.1)

(583.2)

(616.2)

(582.9)

(551.4)

(709.8)

(635.0)

(607.8)

(582.9)

(581.7)

165.0

169.0

132.5

50.6

133.6

268.8

163.5

175.7

123.3

Results

280.4

383.9

370.8

274.8

184.3

571.6

437.7

410.2

182.2

Suppresse

(371.1)

(499.5)

(536.9)

(479.4)

(203.9)

(791.3)

(669.1)

(540.9)

(235.3)

d

131.0

196.5

50.1

39.5

46.5

30.8

75.0

44.4

32.0

59.1

437.8

488.4

321.3

316.8

327.8

284.6

362.9

319.6

258.6

306.5

(677.8)

(694.8)

(574.5)

(653.5)

(639.6)

(551.8)

(608.0)

(580.8)

(542.2)

(610.2)

Chronic Obstructive Pulmonary

216.5

286.0

219.9

153.2

91.7

154.7

218.1

193.5

130.1

109.3

Disease or Asthma  T2

433.1

526.5

496.5

410.6

415.4

390.0

474.6

500.0

475.7

309.2

(566.3)

(646.8)

(732.1)

(650.0)

(692.3)

(558.6)

(631.6)

(742.8)

(809.4)

(517.4)

238.6

209.6

178.6

103.1

47.3

126.1

150.0

99.0

62.6

88.0

580.6

483.6

459.3

344.0

254.8

372.5

414.0

404.7

325.6

280.9

(766.0)

(614.6)

(675.2)

(540.3)

(526.4)

(559.9)

(577.1)

(629.7)

(573.0)

(427.6)

Hypertension  T2

Obesity  T2

Diabetes  T2

Hyperlipidemia  T2

* Each cell contains median time, mean time and standard deviation, all measured in days; longest time between diagnoses highlighted in green and shortest time
between diagnoses highlighted in red for each patient category
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Table 5.43 Time (in days) until multimorbidity, stratified by patient age category (years), patient sex and index chronic
disease, Continued
Female

Male

18 – 34

35 – 44

45 – 64

65 – 84

≥ 85

18 – 34

35 – 44

45 – 64

65 – 84

≥ 85

321.5

350.8

311.9

168.6

107.0

217.5

238.0

183.4

100.5

103.7

525.5

601.8

579.5

484.3

389.9

509.6

528.0

496.9

446.6

423.9

(617.8)

(689.6)

(724.5)

(761.1)

(630.1)

(692.2)

(691.9)

(693.8)

(731.2)

(749.3)

429.5

336.5

354.6

175.0

139.7

275.7

398.0

239.5

111.9

83.5

613.3

635.9

642.2

492.3

449.0

579.6

546.9

591.8

492.4

391.7

(672.2)

(722.5)

(757.0)

(715.3)

(725.4)

(759.7)

(607.6)

(778.3)

(813.4)

(675.4)

201.5

935.0

259.0

65.0

152.0

141.9

69.6

116.6

189.0

87.6

298.1

820.7

581.0

391.0

372.6

561.3

140.5

524.8

433.9

332.1

(363.2)

(306.8)

(982.8)

(672.8)

(565.4)

(1,010.2)

(201.3)

(842.2)

(636.2)

(542.7)

278.4

281.3

240.0

174.3

118.9

237.7

244.0

167.6

134.1

207.7

534.6

548.8

540.7

476.7

446.2

518.4

533.5

481.0

507.0

520.7

(640.9)

(675.5)

(692.0)

(746.1)

(777.5)

(662.0)

(713.4)

(684.1)

(757.4)

(690.3)

Osteoarthritis or Rheumatoid

249.3

428.0

328.6

219.6

201.6

349.4

305.5

301.4

199.7

254.6

Arthritis  T2

523.3

618.5

640.4

555.9

569.0

667.6

616.4

634.7

600.7

571.6

(612.2)

(684.4)

(785.7)

(798.2)

(775.7)

(799.0)

(767.7)

(799.4)

(875.7)

(831.2)

Cancer  T2

Cardiovascular Disease  T2

Heart Failure  T2

Anxiety or Depression  T2

* Each cell contains median time, mean time and standard deviation, all measured in days; longest time between diagnoses highlighted in green and shortest time
between diagnoses highlighted in red for each patient category
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Table 5.43 Time (in days) until multimorbidity, stratified by patient age category (years), patient sex and index chronic
disease, Continued
Female
18 – 34
Stroke or Transient Ischemic
Attack  T2
Thyroid Problem  T2

Kidney Disease or Failure  T2

Osteoporosis  T2

Dementia  T2

Male

35 – 44

45 – 64

65 – 84

≥ 85

18 – 34

45 – 64

65 – 84

≥ 85

79.3

220.5

347.4

399.5

1,993.1

153.4

124.8

18.5

155.4

764.8

784.9

662.5

1,569.4

421.0

371.0

291.4

(219.4)

(949.8)

(931.4)

(842.5)

(1,406.2)

(555.5)

(544.5)

(689.2)

218.8

189.0

154.0

96.5

71.0

153.5

110.4

104.8

153.6

81.0

448.6

448.2

438.8

349.1

344.5

392.9

353.3

440.6

382.7

429.6

(580.3)

(611.6)

(644.3)

(604.2)

(671.5)

(636.7)

(616.7)

(701.5)

(524.4)

(739.6)

325.0

263.0

134.6

680.4

449.7

31.8

157.5

239.6

97.5

20.2

325.0

464.3

230.2

1,049.3

860.7

73.4

143.4

683.2

595.5

154.9

(321.5)

(552.0)

(243.1)

(1,182.4)

(1,039.57)

(106.9)

(95.7)

(893.1)

(934.2)

(308.1)

921.4

354.0

258.2

151.4

100.0

55.9

274.2

187.3

96.3

260.5

1,041.3

590.4

508.5

392.3

313.8

119.5

274.2

388.1

288.7

361.4

(901.2)

(660.6)

(641.3)

(524.2)

(495.5)

(165.3)

(383.6)

(502.2)

(404.9)

(364.2)

669.7

143.4

503.3

125.3

128.0

1,002.0

574.0

369.0

266.0

115.8

757.6

406.6

681.5

497.8

371.9

888.9

769.7

633.6

528.1

346.7

(454.0)

(777.2)

(835.6)

(806.4)

(585.5)

(683.0)

(650.4)

(734.7)

(675.8)

(579.0)

Results
Supressed

35 – 44
Results
Supressed

* Each cell contains median time, mean time and standard deviation, all measured in days; longest time between diagnoses highlighted in green and shortest time
between diagnoses highlighted in red for each patient category
** Results were supressed when < 5 patients were included in the category
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Table 5.43 Time (in days) until multimorbidity, stratified by patient age category (years), patient sex and index chronic
disease, Continued
Female
Musculoskeletal Problem  T2

Stomach Problem  T2

Colon Problem  T2

Liver Disease  T2

Urinary Problem  T2

Male

18 – 34

35 – 44

45 – 64

65 – 84

≥ 85

18 – 34

35 – 44

45 – 64

65 – 84

≥ 85

378.3

371.8

312.0

208.6

165.6

354.2

337.9

274.3

189.0

146.0

609.7

652.1

602.3

504.6

458.0

631.2

612.7

580.6

514.0

477.2

(676.0)

(739.6)

(748.8)

(724.3)

(680.9)

(753.2)

(736.5)

(755.8)

(752.6)

(735.9)

294.0

275.0

326.7

185.2

111.3

263.3

298.0

278.6

205.3

160.6

467.8

542.9

539.5

432.7

226.7

536.6

559.6

534.8

488.4

353.7

(497.0)

(690.5)

(655.4)

(629.5)

(319.2)

(656.6)

(700.7)

(694.1)

(749.2)

(529.5)

371.0

287.5

229.5

211.5

119.0

298.5

255.0

195.4

206.0

221.0

575.8

542.8

511.2

496.9

287.1

527.9

453.4

475.5

472.0

478.5

(629.3)

(708.3)

(657.9)

(712.7)

(450.8)

(636.1)

(537.0)

(667.5)

(649.2)

(633.9)

573.9

175.5

135.0

223.1

367.7

681.7

627.0

239.1

46.1

523.5

175.5

349.0

506.9

367.7

807.8

956.5

472.4

333.0

(423.5)

(73.8)

(531.2)

(646.1)

(519.4)

(600.1)

(966.8)

(620.2)

(550.0)

430.6

494.0

439.3

286.4

122.5

364.2

334.7

254.1

122.3

123.0

638.3

722.5

713.1

600.2

407.2

637.8

602.9

582.3

466.8

342.9

(657.5)

(772.7)

(814.6)

(834.5)

(680.4)

(750.6)

(751.2)

(754.3)

(746.8)

(633.0)

Results
Supressed

* Each cell contains median time, mean time and standard deviation, all measured in days; longest time between diagnoses highlighted in green and shortest time
between diagnoses highlighted in red for each patient category
** Results were supressed when < 5 patients were included in the category
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5.2.3 Objective Two, Research Question 2 – Time Until Advancing Multimorbidity
To address Research Question 2, the “Time Until Advancing Multimorbidity” was
assessed by determining the median and mean time until subsequent chronic disease diagnoses
after the second chronic disease (as seen in Table 5.42). This was conducted for adult patients
with at least two chronic diseases as of September 30, 2013 and only those chronic diseases with
at least one-day elapsing between diagnoses were included in the analysis. The results presented
in Table 5.42 were stratified by both patient age and patient sex. These results indicate that
generally, the time elapsing until advancing multimorbidity was indeed the slowest from the
second to third chronic disease diagnoses. For example, among patients aged 18 to 34 years, the
median time from the second to third chronic disease was 377.9 days for females and 364.8 days
for males. For female patients aged 35 to 44 years and 45 to 64 years, the median time until the
third chronic disease diagnoses was 396.0 days and 342.0 days, respectively. For male patients
aged 35 to 44 years and 45 to 64 years, the median time until the third chronic disease diagnoses
was 365.0 days and 321.0 days, respectively. Interestingly, for female and male patients aged 65
to 84 years and over 85 years, the longest time until the subsequent chronic disease was observed
from the fifth to sixth diagnoses. More specifically, for females, the median time until the sixth
chronic disease diagnoses was 266.7 days and 274.5 days among patients aged 65 to 84 years
and 85 years and older, respectively. For males, the median time until the sixth chronic disease
diagnoses was 279.1 days and 259.7 days among patients aged 65 to 84 years and 85 years and
older, respectively. These results demonstrate that the time until advancing multimorbidity is the
slowest from the second to third chronic disease among female and male patients aged 18 to 64
years, whereas the longest time was observed from the fifth to sixth chronic disease among
female and male patients aged 65 years and older.
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Similar to Research Question 1, in order to assess the differences that occurred when
excluding data points in which the time elapsing between diagnoses was zero days, the same
analysis was conducted for all patients and for all data points (that is, when time elapsing
between chronic disease diagnoses was equal to zero days). These results are included in
Appendix AI. While the same patterns were observed within this sensitivity analyses, the
median and mean time elapsing between chronic disease diagnoses was again notably lower as
compared to the estimates presented in Table 5.42. However, the data points that were equal to
zero days did not have as much of an impact on the median and mean time elapsing between
diagnoses when examining the time until advancing multimorbidity (that is, among patients with
more than two chronic diseases), as compared to the time elapsing until multimorbidity (that is,
among patients transitioning from the first to second chronic disease). Nonetheless, the time
elapsing between chronic diseases diagnoses still decreased within the sensitivity analysis. For
example, among male patients aged 18 to 34 years, the median time until the third chronic
disease was 340.7 days (mean of 577.1 days) when data points that were equal to zero days were
included in the analysis. This estimate was only slightly lower than the median time elapsing
until the third chronic disease in the original analysis, which was 364.8 days (mean of 565.7
days). As well, among female patients aged 85 years and older, the median time until the third
chronic disease diagnoses was only 5.2 days (mean of 224.4 days) when data points that were
equal to zero days were maintained in the analyses, as compared to a median time of 97.4 days
(mean of 366.4 days) when these data points were removed from the analysis.
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5.2.4 Objective Two, Research Question 3 – Examining Patient-, Provider- and PracticeLevel Predictors of Time Until Subsequent Chronic Disease
To address Research Question 3, univariate and bivariate analyses were first conducted
for both continuous and categorical predictors, and the results from these analyses are presented
in Table 5.44. This was conducted for adult PHC patients with at least one chronic disease as of
September 30, 2013 and only those chronic diseases with at least one-day elapsing between
diagnoses were included in the analysis. As described in the Methodology Chapter, a total of
nine predictors were included in the multilevel, recurrent event survival analysis. Among the
patient-level predictors, all five independent variables were statistically significantly related to
the dependent variable (p-value < 0.001). Similarly, among the provider- and practice-level
predictors, all four independent variables were statistically significantly related to the dependent
variable of time until subsequent chronic disease diagnosis (p-value < 0.001). Consequently, a
statistically significant correlation between each of the nine independent variables and the
continuous dependent variable (that is, time until subsequent chronic disease) was observed.
These graphs indicate that the majority of time elapsing until subsequent chronic disease was
under 5.5 years (or 2,000 days) for both female and male patient groups. This broad pattern was
observed among both female and male patients, regardless of patient age category. The
unadjusted Kaplan–Meier failure curves for female and male patients can also be seen in Figure
5.8 and Figure 5.9, and displays the event rate among those patients with one or more chronic
disease diagnoses and stratified by patient age category.
The results from the multilevel, recurrent event survival analysis are presented in Table
5.45 and demonstrate the relationship between each independent variable and dependent
variable, controlling for all other variables in the final model. This table also presents the
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variance contributed by clustering of events at the provider- and practice-level. After conducting
the bivariate analyses, each of the nine predictor variables were independently entered into the
basic survival analysis model. Following this initial assessment, all nine predictor variables were
included in the multilevel, recurrent event survival analysis among patients with at least one
chronic disease diagnosis. Among the patient-level variables, patient age, patient sex, median
household income and the total number of chronic diseases were all significantly related to time
until subsequent chronic disease, after controlling for all other variables in the model (p-value <
0.05). While patient sex and total number of chronic diseases demonstrated more notable effect
sizes, the effects of patient age, residential location and median household income were
negligible, despite being found statistically significant. From the hazard ratios reported in the
adjusted model, female patients experienced a 19% decrease in the rate until the next chronic
disease diagnosis, as compared to male patients and controlling for all other variables in the
model (p-value < 0.001). Similarly, as the number of chronic diseases increased by one unit, and
with all other variables held constant, there was a 33% increase in the rate until the next chronic
disease diagnosis (p-value < 0.001).
Among the provider-level variables, provider age and provider sex were both found to be
statistically significant (p-value < 0.05). While the increasing age of a PHC provider created
only a 2% decrease in the rate until the next chronic disease (p-value < 0.001), the patients who
received care from a female PHC provider experienced an 8% decrease in the rate until their next
chronic disease diagnosis (p-value < 0.05).
Finally, among the practice-level variables, both the EMR type and the location of the
PHC practice were found to have a statistically significant relationship with the outcome, holding
all other variables in the model constant. More specifically, adult patients who were receiving
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care from an urban-based PHC practices experienced a 26% decrease in the rate until their
subsequent chronic disease diagnosis (p-value < 0.001). Multiple EMR software types were also
significantly related to the outcome of interest, and as compared to the Accuro EMR software
(reference category). For example, those patients who were receiving care from a PHC practice
that utilized the Bell EMR software type had a 46% increase in rate until the subsequent chronic
disease, as compared to those patients receiving care from a PHC practice that utilized the
Accuro EMR software (p-value < 0.001). Likewise, those patients who were receiving care from
a PHC practice that used the Oscar EMR software had a 62% increase in the rate until
subsequent chronic disease diagnosis, as compared to the Accuro EMR software and holding all
other variables in the model constant (p-value < 0.001). Those patients who received care from a
PHC practice using the Practice Solutions and Wolf EMR software programs experienced a
decreased rate until their next chronic disease diagnosis. For example, those patients whose data
were recorded using the Practice Solutions EMR software had a 57% decrease in the rate until
their next chronic disease diagnosis (p-value < 0.001), whereas those patients whose data were
recorded using the Wolf EMR software had a 27% decrease in the rate until their next chronic
disease diagnosis (p-value < 0.001). Both of these hazard ratios were calculated as compared to
the Accuro EMR software and holding all other variables in the final model constant. As
highlighted further in the Discussion Chapter, these results could potentially be due to coding
artefacts within the EMR data based or due to true differences in the accumulation of multiple
chronic diseases among the patients within the sample.
When examining the potential for an interaction between patient age and patient sex, the
interaction term was found to be statistically significant (p-value < 0.001), but the hazard ratio
indicated a negligible effect size on the dependent variable and was not interpreted any further.
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The multilevel survival analysis also determined the variance contributed by clustering of events
at each level, that is within PHC providers and within PHC practices. In the results presented in
Table 5.45, almost 10.0% of variance was contributed by provider-level clustering. There was
no notable variance contributed by the practice-level clustering (0.18%). The associated
likelihood ratio test was statistically significant (p-value < 0.001) indicating the suitability of a
multilevel survival analysis. An exploration of the multilevel, single event survival analysis,
stratified by the total number of chronic diseases, was also conducted and the results are
presented in Appendix AJ. These additional analyses produced similar results when the
multilevel survival analyses was conducted for recurrent or single events.
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Table 5.44 Results of univariate and bivariate analyses between independent variables and
dependent variable (time until subsequent chronic disease diagnosis) among adult patients
with one or more chronic diseases (n = 238,237)
Independent Variable

Univariate Analysis

Bivariate Analysis (p-value)

Patient-Level
Age (Years)
Mean (SD)

54.5 Years (17.7 Years)

Median (IQR)

54.0 Years (26.0 Years)

Range (Minimum – Maximum)

<0.001

18 Years – 114 Years

Sex, n (%)
Female

137,587 (57.8%)

Male

100,650 (42.2%)

<0.001

Residential Location, n (%)
Rural

37,424 (15.7%)

Urban

112,072 (47.0%)

Missing

88,741 (37.3%)

<0.001

Median Household Income (Canadian Dollars)
Median (IQR)

$61,221 ($12,497)

Range (Minimum – Maximum)

$22,457 – $181,454

<0.001

Total Number of Chronic Diseases
Mean (SD)

2.5 (1.6)

Median (IQR)

2.0 (2.0)

Range (Minimum – Maximum)

<0.001

1 – 13

* SD = Standard deviation, IQR = Interquartile range
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Table 5.44 Results of univariate and bivariate analyses between independent variables and
dependent variable (time until subsequent chronic disease diagnosis) among adult patients
with one or more chronic diseases (n = 238,237), Continued
Independent Variable

Univariate Analysis

Bivariate Analysis (p-value)

Provider-Level
Age (Years)
Mean (SD)
Median
Range (Minimum – Maximum)

50.7 Years (10.3 Years)
50.0 Years

<0.001

27 Years – 72 Years

Sex, n (%)
Female

63,494 (26.7%)

Male

45,231 (19.0%)

Missing

129,512 (54.4%)

<0.001

Practice-Level Variable
EMR Type, n (%)
Accuro

20,318 (8.5%)

Bell

18,952 (8.0%)

DaVinci

678 (0.3%)

Jonoke

13,572 (5.7%)

Med Access

6,583 (2.8%)

Nightingale

53,319 (22.4%)

Oscar

9,624 (4.0%)

Practice Solutions

9,446 (4.0%)

Wolf

19,118 (8.0%)

Xwave

597 (0.3%)

Missing

86,030 (36.1%)

<0.001

Practice Location, n (%)
Rural

22,692 (9.5%)

Urban

124,682 (52.3%)

Missing

90,863 (38.1%)

<0.001

* SD = Standard deviation
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Figure 5.8 Kaplan-Meier curves indicating time (in days) until subsequent chronic disease
diagnosis (event) among female patients, stratified by patient age category
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Figure 5.9 Kaplan-Meier curves indicating time (in days) until subsequent chronic disease
diagnosis (event) among male patients, stratified by patient age category
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Table 5.45 Results of multilevel, recurrent event survival analyses for time until subsequent chronic disease diagnosis among
adult patients with one or more chronic diseases (n = 238,237)
Independent Variable
Hazard Ratio (95% CI) *
Patient-Level
1.002 (1.001 – 1.003)
Age
0.81 (0.78 – 0.85)
Sex (Female)
0.99 (0.97 – 1.01)
Residential Location (Urban)
1.000001
(1.00 – 1.000001)
Median Household Income
1.33 (1.33 – 1.34)
Total Number of Chronic Diseases
Provider-Level
0.98 (0.98 – 0.99)
Age
0.92 (0.85 – 0.99)
Sex (Female)
Practice-Level
EMR Type
Accuro
Reference
Bell
1.46 (1.23 – 1.72)
DaVinci
0.98 (0.90 – 1.08)
Jonoke
1.08 (0.96 – 1.14)
Med Access
0.87 (0.74 – 1.01)
Nightingale
0.95 (0.85 – 1.06)
Oscar
1.62 (1.40 – 1.88)
Practice Solutions
0.43 (0.37 – 0.50)
Wolf
0.73 (0.64 – 0.84)
Xwave
1.98 (0.82 – 4.73)
0.74 (0.67 – 0.83)
Practice Location (Urban)
Interaction Term
1.002 (1.001 – 1.002)
Patient Age & Patient Sex
% Variance (95% CI) Contributed by Each Level
Within Provider
9.51 (95% CI: 6.99 – 12.41)
Within Site
0.18 (95% CI: 0.00 – 0.20)
*CI = Confidence interval; Extra decimal places added where necessary

p-value
<0.001
<0.001
0.410
0.018
<0.001
<0.001
0.029

<0.001
0.067
0.093
0.083
0.332
<0.001
<0.001
<0.001
0.127
<0.001
<0.001
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Chapter 6
6 Discussion
This chapter will highlight the key results presented in the previous chapter with further
discussion and interpretation. This discussion will be supplemented by a highlight of this
research work’s strengths, limitations and implications within the broader clinical, policy and
research contexts.

6.1 Summary of Key Findings from Objective One
6.1.1 Prevalence and Characteristics of Patients with Multimorbidity
Overall, this research identified that about one in two adult PHC patients (or 53.3%)
within the CPCSSN database were living with two or more chronic diseases as of September 30,
2013. About one in three adult PHC patients (or 33.1%) within the CPCSSN database were
living with three or more chronic diseases as of September 30, 2013. These estimates were
compared to literature where a similar definition of multimorbidity was used, as well as those
studies that were conducted in a Canadian context and a PHC context.
Among those studies that were conducted in Canada, the prevalence of individuals with
two or more chronic diseases ranged from as low as 12.9% in a general adult population sample
(Roberts et al., 2015), to as high as 89.3% in an adult PHC patient sample (Fortin et al., 2005).
While the sample size of the study conducted by Roberts et al. (2015) was almost ten times
smaller than the sample size of the study conducted by Fortin et al. (2005), the prevalence of
multimorbidity was considerably lower as this was a health survey of the general adult
population in Canada and the measurement of multimorbidity only included nine, self-reported
diseases. In comparison, the study conducted by Fortin et al. (2005) collected data from
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consecutive visits of adult PHC patients and any diagnosed conditions were included in the
multimorbidity measurement. This study represented the collection of data from adults who
were seeking care from their health care provider and a full health record review was conducted
for each consenting patient. While this study provided the first Canadian prevalence estimate for
multimorbidity in the adult population, the prevalence of multimorbidity was found to be notably
higher than the prevalence estimate detected in the current study. Although both studies aimed
to capture the occurrence of multiple “chronic” health problems within a patient, the lists of
chronic diseases used in the two studies differed. A study conducted by Stewart et al. (2013)
took place in a Canadian setting and reported the most comparable prevalence estimate of
multimorbidity in the literature. This study included almost 3,000 adult PHC patients whose data
were collected in the Deliver Primary Health Care Information (DELPHI) database (also a
regional network of the CPCSSN database). Using a list of 98 chronic disease categories from
the International Classification of Primary Care (ICPC) system, this study found a prevalence of
34.0% adult PHC patients living with two or more chronic diseases. This prevalence estimate
was still approximately 20% lower than the estimate reported in the current study (53.3%), but
this may have been due to the variation in the definition of multimorbidity or the process of
identification of chronic disease diagnoses within the EMR data between the two studies.
The prevalence of individuals with three or more chronic diseases, within a Canadian
setting, ranged from as low as 3.9% among a general adult population (Roberts et al., 2015) to as
high as 75.6% among an adult PHC sample (Fortin et al., 2005). Once again, the study
conducted by Roberts et al. (2015) utilized self-reported data from just over 100,000 adults in the
Canadian Community Health Survey. This definition of multimorbidity included only nine
chronic diseases, and respondents were asked whether or not they had received a diagnosis for
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any of the diseases in the past. The study conducted by Fortin et al. (2005) found a high
prevalence of adult PHC patients diagnosed with any condition and who had three or more
chronic diseases, using a similar methodology to identifying patients with two or more chronic
disease diagnoses. The Canadian study conducted by Pefoyo et al. (2015) reported the most
comparable prevalence estimate of multimorbidity in the literature. This study utilized a large
population-based cohort and an administrative database from the province of Ontario. With a list
of sixteen chronic disease categories in the measurement of multimorbidity, this study reported a
prevalence estimate of 13.6% of residents who were living with three or more chronic diseases.
Again, this prevalence estimate was still approximately 20% lower than the estimate reported in
the current study (33.1%), but this may have been because the study by Pefoyo et al. (2015) used
a population-level approach, as compared to examining individuals specifically seeking care
from a PHC provider.
When compared to the international literature within the context of primary health care,
the prevalence estimate of adult patients living with two or more chronic diseases was most
comparable with three recently published studies: a sample of randomly selected PHC patients in
a retrospective cohort study in the United Kingdom, which reported a prevalence of 58.0%
among almost 100,000 adult patients over 182 PHC practices (Salisbury et al., 2011); a crosssectional sample of adult PHC patients in the United States, which reported a prevalence of
45.3% using a list of 24 chronic diseases within their definition of multimorbidity (Ornstein et
al., 2013); and a sample of randomly selected PHC patients within a prospective cohort study in
Australia, which reported a prevalence of 43.7% using health charts to capture multimorbidity
(Harrison et al., 2014). The prevalence of PHC adults with three or more chronic diseases was
most comparable with two recently published studies. As previously described, the study by
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Harrison et al. (2014) included a prospective sample of adult PHC patients and detected a
prevalence estimate of 27.4% of patients with three or more chronic diseases, which was
comparable to the prevalence estimate detected in the current study (33.1%). A retrospective
study by Prados-Torres et al. (2012) in Spain among more than 275,000 patients and including
chronic diseases with at least a 1% prevalence level in the population, reported that 20.2% of
their patients were living with three or more chronic diseases. Similar to the high prevalence
estimates detected by Fortin et al. (2005), a study conducted in Portugal by Prazeres et al. (2015)
detected a notably higher prevalence of adult PHC patients living with two or more and three or
more chronic diseases (72.7% and 57.2%, respectively). This study investigated a large list of
147 chronic health problems and included clinical data that were collected from three data
sources for each patient: provider knowledge of a patient’s history, patient self-reported
information and medical records. The high prevalence estimates detected by Fortin et al. (2005)
and Prazeres et al. (2015) may be due to the wide breadth of information that was collected for
each patient included in the sample. As a result, these studies may demonstrate the influence of
the data collection approach on the eventual estimates of multimorbidity.
Among our sample of patients with two or more chronic diseases, the mean age was 59.0
years (SD: 17.0) and 57.8% were female. Slightly more than half of these patients were living in
an urban setting (52.2%) and the median of the median household income was about $60,950 per
year (Canadian dollars). Similar characteristics were observed for patients with three or more
chronic diseases: the mean age of these patients was 62.7 years (SD: 15.9), the majority were
female (58.5%), the majority were living in an urban setting (53.4%) and the median of their
median of household incomes was $61,175 per year (Canadian dollars). The descriptive analysis
indicated that the mean age of patients increased as the number of chronic diseases diagnosed
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also increased. In fact, the mean age difference between those patients with no chronic disease
diagnoses and five or more chronic disease diagnoses was 26.6 years. The association between
multimorbidity and whether a patient is older or female has been consistently reported in the
existing literature (Harrison et al., 2013; Barnett et al., 2012; Salisbury et al., 2011; Britt et al.,
2008; Uijen et al., 2008; Fortin et al., 2005; van den Akker et al., 1998). However, while the
prevalence of multimorbidity increased as patient age increased, the largest proportion of
patients living with multimorbidity was between the ages of 45 to 64 years (about 25.0% of adult
PHC patients) and the majority of patients with multimorbidity were under the age of 65 years.
More specifically, 61.7% of patients with two or more chronic diseases were under the age of 65
years, while 53.4% of patients with three or more chronic diseases were under the age of 65
years. This finding is consistent with previous literature that has highlighted the growing burden
of multimorbidity among younger cohorts of individuals. Indeed, multimorbidity is no longer an
issue of the oldest patients and it must be appropriately managed among younger and younger
patients (Barnett et al., 2012; Taylor et al., 2010; Mercer et al., 2009).
The highest prevalence of multimorbidity was also explored amongst the most commonly
reported demographic characteristics: age and sex. This study found that the highest prevalence
of multimorbidity (defined as two or more chronic diseases) was among those patients aged 45 to
64 years (40.6%) and those patients who were female (57.8%). Much of the published
multimorbidity research conducted in the Canadian and international context has reported the
highest prevalence among those who are 65 years of age and older (Jovic et al., 2016; Pefoyo et
al., 2015; Pati et al., 2015; Prazeres et al., 2015; Roberts et al., 2015; Wang et al., 2015; Harrison
et al., 2014; Orueta et al., 2014; Rocca et al., 2014; Ornstein et al., 2013; Stewart et al., 2013;
Ward et al., 2013; Agborsangaya et al., 2012; Barnett et al., 2012; Prados-Torres et al., 2012;
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Rizza et al., 2012; van Oostrom et al., 2012; Salisbury et al., 2011; Fortin et al., 2005; van den
Akker et al., 1998). The published multimorbidity research is still demonstrating split findings
in whether the prevalence of multimorbidity is more notable among female or male individuals,
but the majority of studies seem to indicate a slightly higher prevalence among females (Roberts
et al., 2015; Wang et al., 2015; Pati et al., 2015; Orueta et al., 2014; Barnett et al., 2012; PradosTorres et al., 2012; van Oostrom et al., 2012; van den Akker et al., 1998). An exception was
observed in Portugal, in which the study conducted by Prazeres et al. (2015) found that male
patients had the highest prevalence of two or more chronic diseases (75.9%), as compared to
female patients.
Comparing the demographic characteristics with the literature that defined
multimorbidity as three or more chronic diseases is more difficult because these studies report
patient characteristics in less detail. While the current study found that the prevalence of three or
more chronic diseases was highest among those patients who were 45 to 64 years and who were
female (39.6% and 58.5%, respectively), the majority of the literature found the highest
prevalence of three or more chronic diseases among the oldest age group of patients (e.g., those
patients who are aged 65 and older or 85 years and older). The literature also showed mixed
findings in that some studies reported females with the higher prevalence of three or more
chronic diseases, ranging from 4.5% by Roberts et al. (2015) to 77.4% by Fortin et al. (2005).
However, two additional studies reported that males experienced the highest prevalence of three
or more chronic diseases, ranging from 7.6% by Rizza et al. (2012) to 61.6% by Prazeres et al.
(2015). These inconsistent findings indicate a need to further explore and understand the
characteristics of those patients who are living with advancing multimorbidity, as well as more
comprehensive reporting of research findings (Stewart et al., 2013).
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Overall, the estimates of multimorbidity detected within the current study fall on the
higher end of the prevalence spectrum (e.g., ranging from 0% to 100% prevalence), as compared
to the estimates that have been reported to date. The characteristics of those adult patients who
were living with multimorbidity (regardless of definition) were somewhat comparable with the
existing literature, but again, notable variation was observed in the distinct patterns of
characteristics. These differences may be a result of interrelated causes. For example, these
differences may indicate true and distinct differences between populations, in that perhaps the
burden of multimorbidity is higher in Portugal than in Canada. However, these differences also
may be due to methodological differences in data collection, sample recruitment and inclusion
criteria for disease within the multimorbidity definition. For example, the lack of comparable
findings between population-level surveys and clinical chart reviews may be an artefact of the
data collection approach. Or, these potential causes may be interrelated and more convoluted.
As such, comparisons between studies should be made cautiously as long as these differences in
research methodology continue to prevail.

6.1.2 Most Frequently Occurring Clusters of Multimorbidity
Before examining the discrete clusters of multiple chronic diseases, the prevalence of
individual chronic diseases, stratified by patient age and patient sex, were explored. This
analysis detected a changing distribution of individual chronic diseases as patient age increased.
For example, those patients who were between the ages of 18 and 34 years had the highest
prevalence of diagnoses for Obesity, Anxiety or Depression and Musculoskeletal Problem.
Among patients aged between 65 and 84 years, the most prevalent individual chronic diseases
were Hypertension and Obesity. Those patients who were 85 years of age and older had the
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highest prevalence of diagnoses for Hypertension, followed by diagnoses of Obesity, Diabetes
and Cardiovascular Disease. The changing prevalence of individual chronic diseases by patient
age group may be reflecting the changing characteristics of an aging patient. For example, PHC
providers may be more sensitive or attuned to the mental health challenges experienced by young
adults, creating a higher prevalence of diagnoses for Anxiety or Depression in this age group,
particularly due to increased media and policy attention for this important issue. Or perhaps
those young patients who are experiencing Anxiety or Depression or a Musculoskeletal Problem
require a diagnosis and a clinical note if work or school absences are required (e.g., missing an
examination due to chronic anxiety or requiring time off work due to chronic back pain). While
those patients who were aged 85 years and older were most likely to be diagnosed with
Hypertension and Obesity, the prevalence of the remaining chronic diseases was much more
evenly distributed. This pattern was observed for both female and male patients and may
indicate that older patients who are living with multiple chronic diseases are more likely to live
with a wide range of chronic diseases or those chronic diseases that have a less direct link with
mortality. As will be confirmed shortly, these older patients also represent increasingly complex
clinical profiles and are managing more unique clusters of multiple chronic disease diagnoses.
A high prevalence of obesity was found in a Canadian study using the Health Quality
Council of Alberta 2012 Patient Experience Survey that found an obesity prevalence of 28.1%
(Agborsangaya et al., 2013). However, a study conducted in the United States by Ornstein et al.
(2013) among 148 practices with more than 650,000 adult patients found a prevalence of obesity
of 11.9% using only ICD-9-CM codes. A study conducted in Sweden by Rizza et al. (2012)
using the ICPC-2 classification system found a very small prevalence of obesity, that of less than
3.0% among adult PHC patients. Likewise, a study conducted in Germany by Schafer et al.
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(2012) found a small prevalence of diagnosed obesity of 4.8% among adult PHC patients.
Hypertension is a consistently measured and highly prevalent chronic disease, particularly
among those with at least one chronic disease or older populations. Likewise, psychological
chronic diseases (including anxiety and depression) were prominent in many of the
multimorbidity studies. The study conducted by Prazeres et al. (2015) found a staggeringly high
prevalence of both hypertension and depressive disorder within their sample of patients. The
prevalence of hypertension among female and male patients with multimorbidity was about
94.0%, whereas the prevalence of depressive disorder among female patients with
multimorbidity was as high as 88.4% (Prazeres et al., 2015). In comparison, the study conducted
in Australia determined the prevalence of psychological or mental and behavioural disorders
ranged from 22.2% to 21.9% among adult PHC patients using the ICPC-2 and ICD-10
classification systems, respectively (Harrison et al., 2014). Although anxiety was not measured,
the studies conducted by Roberts et al. (2015) and Ornstein et al. (2013) reported a prevalence of
depression ranging from 11.2% among community-dwelling adults in Canada to almost 20.0%
among care-seeking adults in the United States. Finally, a high prevalence of chronic
musculoskeletal problems (e.g., chronic low back pain) were also reported in the multimorbidity
literature. A study conducted in Australia found a prevalence of 26.3% and 26.0% among adult
PHC patients, as measured using the ICPC-2 and ICD-10 classification systems, respectively
(Harrison et al., 2014). A higher prevalence was detected in sample of adult PHC patients in
Germany, in which at least 50.0% of the sample were living with chronic pain impacting
function (Schafer et al., 2012). Overall, the most prevalent individual chronic diseases were
Obesity, Hypertension, Musculoskeletal Problem and Anxiety or Depression, which
demonstrated consistency with the multimorbidity literature.
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The computational cluster analysis that was conducted using the Multimorbidity Cluster
Analysis Tool detected many unique combinations and permutations, and indicated that patients
with multimorbidity represent increasingly complex clinical profiles. A similar computational
cluster analysis has not been published in the multimorbidity literature to date. Instead, varying
techniques to identify co-occurring clusters of multiple chronic diseases have been reported,
including exploratory factor analysis, cluster analysis and latent class growth analysis (PradosTorres et al., 2014; Violán et al., 2014; Garin et al., 2014; Strauss et al., 2014; van Oostrom et
al., 2014; Ornstein et al., 2013; Prados-Torres et al., 2012; Newcomer et al., 2011; Schafer et al.,
2010; Cornell et al., 2007). In the current study, approximately 5,000 unique combinations were
detected for female and male patients living with multimorbidity, while almost 10,000 and
15,000 unique permutations were found for female and male patients living with multimorbidity,
respectively. Due to these large numbers of mutually exclusive clusters, this analysis indicates
that the top twenty most frequently occurring combinations and permutations among all female
and male patients represented only about 20.0% of adult patients with multimorbidity. This
means that even the most frequently occurring clusters represent a comparatively small
proportion of adult patients with multimorbidity.
Among female patients of all ages, the most frequently occurring combinations were
Anxiety or Depression and Musculoskeletal Problem (1,694 or 3.6% of all female patients);
Anxiety or Depression and Obesity (1,179 or 2.5% of all female patients); and Musculoskeletal
Problem and Obesity (1,132 or 2.4% of all female patients). These three commonly occurring
combinations remained the most common among female patients aged 18 to 34 years and 35 to
44 years. For female patients aged 45 to 64 years, the most common combination was Anxiety
or Depression and Musculoskeletal Problem (674 or 3.7% of female patients aged 45 to 64 years.
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The diagnosis of Hypertension was frequent in the top combinations among female patients aged
65 years and older and the most common combinations were Hypertension and Obesity (323 or
2.5% of female patients aged 65 to 84 years) and Dementia and Hypertension (76 or 2.0% of
female patients aged 85 years and older). Similar to the common combinations among female
patients of all ages, the most common permutations were Anxiety or Depression then Obesity
(1,160 or 2.4% of all female patients); Musculoskeletal Problem then Obesity (1,094 or 2.3% of
all female patients); and Anxiety or Depression then Musculoskeletal Problem (909 or 1.9% of
all female patients). These three commonly occurring permutations remained the most common
among female patients aged 18 to 34 years, 35 to 44 years and 45 to 64 years. A shift occurred
among female patients aged 65 years and older, in which the permutation of Hypertension then
Obesity became the most commonly occurring permutation among patients aged 65 to 84 years
(322 or 2.5% of female patients aged 65 to 84 years) and 85 years and older (62 or 1.6% of
female patients aged 85 years and older).
Among male patients of all ages, the most frequently occurring combinations were
Hypertension and Obesity (3,866 or 4.7% of all male patients); Musculoskeletal Problem and
Obesity (3,580 or 4.3% of all male patients); and Anxiety or Depression and Obesity (2,431 or
2.9% of all male patients). These three commonly occurring combinations were persistent
among male patients aged 18 to 34 years, 35 to 44 years and 45 to 64 years. For male patients
aged 65 years and older, the diagnosis of Obesity was present in the most common combinations
and the most frequent combination was Hypertension and Obesity (1,092 or 4.0% of male
patients aged 65 to 84 years). Similar to the common combinations among all male patients, the
most common permutations were Obesity then Hypertension (2,201 or 2.7% of all male
patients); Obesity then Musculoskeletal Problem (2,138 or 2.6% of all male patients); and
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Hypertension then Obesity (1,665 or 2.0% of all male patients). For all age groups of male
patients, Obesity was involved in the most frequent permutations. Among male patients aged 18
to 34 years, the most common permutation was Obesity then Anxiety or Depression (437 or
7.3% of male patients aged 18 to 34 years); for male patients aged 35 to 44 years, the most
common permutation was Obesity then Musculoskeletal Problem (532 or 5.8% of male patients
aged 35 to 44 years); and for patients aged 45 years and older, the most common permutation
was Obesity then Hypertension (1,167 or 3.3% of male patients aged 45 to 64 years; 584 or 2.1%
of male patients aged 65 to 84 years; and 68 or 1.3% of male patients aged 85 years and older.
While to our knowledge, no published literature to date has examined the sequence of
multiple chronic disease diagnoses, a recent systematic review of the clusters or patterns of
multimorbidity identified three most prevalent patterns: cardiovascular and metabolic disorders,
mental health problems and musculoskeletal disorders (Prados-Torres et al., 2014). The
cardiovascular and metabolic disorder pattern described by Prados-Torres et al. (2014) was
composed of diseases that are consistent with what is commonly known as the metabolic
syndrome, such as hyperlipidemia, hypertension, heart disease, diabetes and obesity. The second
group of patterns included at least one mental health problem, such as depression and anxiety,
which co-occurred with thyroid disease, pain, asthma and obesity. The third group of patterns
included at least one musculoskeletal problem, such as back or neck pain (Prados-Torres et al.,
2014). Another systematic review of patterns of multimorbidity in primary health care found
similar commonly occurring patterns in that cardiovascular and metabolic disorders, mental
health disorders and musculoskeletal pain were the most frequent patterns among females and
males (Newcomer et al., 2011). Finally, a systematic review conducted by Sinnige et al. (2015)
found that among older adult populations, depression was the disease that most commonly
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clustered with other disease diagnoses and was specifically paired with eight other diseases
(hypertension, arthritis, diabetes mellitus, asthma or chronic obstructive pulmonary disease,
stroke, cancer, heart failure and heart disease).
The patterns found in the above systematic reviews were also detected in the current
study of adult PHC patients. While the three chronic disease categories of Obesity,
Musculoskeletal Problem and Anxiety or Depression were the most prevalent individual chronic
diseases in our sample of adult patients, these diagnoses indicated an interesting clustering with
less prevalent chronic diseases (e.g., Dementia, Cancer). Distinct patterns were also seen based
on whether these chronic disease categories occurred in a combination (no specific sequence) or
a permutation (specific sequence). For example, for female patients who were 85 years and
older, one of the most commonly occurring combination was that of Dementia and Hypertension
(76 or 2.0% of female patients aged 85 years and older). However, if the specific sequence of
chronic disease diagnoses mattered, the more commonly occurring combination was actually
Hypertension then Obesity (62 or 1.6% of female patients aged 85 years and older).
Importantly, the aim of this computational cluster analysis was not to determine a causal
link between disease diagnoses. While the temporality of diagnoses was accounted for in the
permutation or ordered cluster analysis, this does not necessarily indicate a pathophysiological
link between one chronic disease diagnosis and the following chronic disease diagnoses. Indeed,
a robust life course approach would be necessary to determine substantial causal links between
multiple chronic disease occurrence (Wister et al., 2016; Pavela and Latham, 2015; van den
Akker et al., 2015; Vos et al., 2015; Strauss et al., 2014). This approach, combined with the
information provided from objective cluster analysis, could be used to inform single-disease,
basic science research to investigate the biology of co-occurring diseases and potentially
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exploring pathophysiological pathways to these clustered diseases. For example, a study
conducted by Lappenschaar et al. (2013) determined that among individuals with both
hyperlipidemia and hypertension at baseline, the probability of having coexisting ischemic heart
disease and heart failure was greater than the product of their individual rates. The conclusion
that hyperlipidemia and hypertension interact synergistically to effect risk of ischemic heart
disease and heart failure is important for guiding combined prevention efforts, such as population
interventions to reduce fast-food intake (Prados-Torres et al., 2014).
From the current study, the synergistic relationship between Hypertension and Obesity,
as well as the potentially synergistic effects of lifestyle behaviours between Musculoskeletal
Problem and Obesity, could be explored in more detail. Even further, these relationships could
be explored among less concordant diseases, such as the co-occurrence of Hypertension and
Cancer or the specific sequence of patients who were first diagnosed with Anxiety or Depression
and then a Musculoskeletal Problem. While these clusters demonstrate less obvious
pathophysiological pathways, clinical insight might help to inform why these patterns co-exist.
Moving beyond these investigations to more broad implications, the results from the cluster
analysis could be used to suggest new (physiological, clinical or behavioural) interaction
hypotheses that could be used in the design and implementation of more pragmatic and
personalized intervention or prevention programs for patient with multimorbidity. Making these
interventions more personalized to the unique clusters of patients with multimorbidity will also
make them more actionable.
However, these findings should be used cautiously to inform clinical care or intervention
programs. While this information may be used to inform more creative approaches to clinical
care and pragmatic interventions, these quantitative results importantly lack the voice and
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perspective of the individuals who are living with multimorbidity. Using a large populationbased database, this research provides empirical evidence of the increasingly unique clinical
profiles among adult PHC patients with multimorbidity. While the patients could be grouped
into the same clusters (based on sequence of diagnosis or not), these clusters do not completely
capture or depict the same experience among all patients. Instead, it is crucial to recognize the
individuality of each patient who has been diagnosed with and is now managing multimorbidity,
as well as their changing needs over time (Gill et al., 2014; Noël et al., 2007; Fortin et al., 2007;
Noël et al., 2005).
Ultimately, this research further supports the need for a patient-centered approach to
delivering comprehensive and effective care for this important patient population. Although
several models of patient-centeredness have been suggested, essential components of a patientcentered consultation for patients with multimorbidity was presented by Stewart and Fortin in the
“ABC of Multimorbidity” textbook (Mercer et al., 2014). These four components are
interrelated and are meant to be guides for the patient-provider relationship. Over time, the
provider will weave back and forth between the four components: exploring diseases and illness
experience; understanding the whole person; finding common ground; and enhancing the patientprovider relationship. Stewart and Fortin state that the main justification for a patient-centered
approach, particularly for those with multimorbidity, is that this is the “moral imperative” or the
“right approach to take”. Moreover, this approach can alleviate common pitfalls encountered
with complex patients and enable the PHC provider to deliver more comprehensive, effective,
continuous and responsive health care to their patients over time.
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6.2 Summary of Key Findings from Objective Two
6.2.1 Time Until Multimorbidity
In exploring the “Time Until Multimorbidity”, that is the accumulation of a second
chronic disease diagnosis, patterns of the shortest and longest amount of time elapsing between
diagnoses were stratified by patient age and patient sex. Among all male patients, the quickest
accumulation of a subsequent chronic disease occurred between the first and second chronic
disease, regardless of age group. For example, the median time until the second chronic disease
ranged from 249.0 days among male patients aged 18 to 34 years to only 93.0 days among male
patients aged 85 years and older. In fact, the fastest median time until the second chronic disease
diagnosis occurred among male patients aged 65 to 84 years. In comparison, all female patients
who were 35 years and older and living with at least one chronic disease received their second
chronic disease the quickest, as compared to diagnoses that occurred after the second chronic
disease. The median time until the second chronic disease ranged from 308.3 days among
female patients aged 35 to 44 years to only 97.4 days among female patients aged 85 years and
older. The exception to this pattern was female patients aged 18 to 34 years, who experienced
the quickest median time (283.0 days) until the subsequent chronic disease diagnosis between the
fifth and sixth chronic disease.
The “Time Until Multimorbidity” was also explored when stratified by patient age,
patient sex and index chronic disease type. This descriptive analysis indicated that among
female and male patients, the quickest accumulation until the second chronic disease occurred
most often when the index chronic disease type was Diabetes. For example, the median time
elapsing between the diagnosis of Diabetes until the second chronic disease for female patients
aged 18 to 34 years was 131.0 days. Those female patients aged 65 to 84 years who were first
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diagnosed with Diabetes received their second chronic disease diagnosis in a median time of
46.5 days. Likewise, among male patients aged 18 to 34 years who were first diagnosed with
Diabetes, the second chronic disease diagnosis was made in only 30.8 days. Among male
patients aged 65 to 84 years, those patients who were first diagnosed with Diabetes were
diagnosed with their second chronic disease in a median time of 32.0 days. Further exploration
of the data (to potentially describe the very short time elapsing after a diagnosis of Diabetes)
showed that the large majority of patients (regardless of patient age and patient sex) who were
first diagnosed with Diabetes were subsequently diagnosed with either Hypertension or Obesity
following their Diabetes diagnosis. This may indicate the pathophysiological link between
diagnoses, but again, the causal associations between chronic diseases were not explored in this
current research.
The longest median time until second chronic disease diagnosis did not demonstrate a
clear pattern. For example, among patients aged 18 to 34 years, the longest median time until the
second chronic disease elapsed when female patients were first diagnosed with Osteoporosis
(921.4 days) and when male patients were first diagnosed with Stroke or Transient Ischemic
Attack (1,993.1 days). Those female and male patients aged 45 to 64 years who were first
diagnosed with Dementia experienced the longest time until their second chronic disease with a
median time of 503.3 days and 369.0 days, respectively. Finally, among female and male
patients who were 85 years and older, the longest median time until their second chronic disease
occurred when these patients were first diagnosed with Kidney Disease or Failure (449.7 days)
and Osteoporosis (260.5 days), respectively. Further exploration of the data also did not show
consistent patterns in subsequent chronic disease type for these index chronic disease diagnoses.
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6.2.2 Time Until Advancing Multimorbidity
The “Time Until Advancing Multimorbidity” exploration, that is the accumulation of
more than two chronic diseases, indicated two distinct patterns. First, among both female and
male patients who were younger than 65 years of age, the longest median time elapsed between
their second and third diagnoses (as compared to all other diagnoses and regardless of disease
type). Second, among both female and male patients who were 65 years of age and older, the
longest median time elapsed between their fifth and sixth diagnoses (as compared to all other
diagnoses and regardless of disease type). It could be hypothesized that patients accumulate
subsequent chronic diseases quicker as the number of chronic disease diagnoses increases, due to
an increased exposure to health care services (and therefore higher potential to receive a new
diagnosis) and an increased potential susceptibility to further pathology (Fabbri et al., 2015; Hsu,
2015; Vos et al., 2015; Strauss et al., 2014; van den Akker et al., 2006). This in fact was not
observed in our sample of adult patients with multimorbidity. Two studies that examined the
trajectory of multimorbidity determined specific groups of low risk of multimorbidity, specific
risk of a cluster and risk of multiple clusters of chronic diseases (Hsu, 2015; Strauss et al., 2014).
More specifically, Strauss et al. (2014) detected five groups of individuals who
represented different trajectories: those who had no recorded chronic diseases (40.0% of
sample); those who developed their first chronic disease in a 3-year observation period (10.0% of
sample); those who progressed into multimorbidity (37.0% of sample); those with advancing
multimorbidity (12.0% of sample); and those patients who started with multimorbidity and
further developed more chronic diseases during the observation period (1.0% of sample). A
study conducted by Hsu (2015) used a group-based trajectories approach to identify four
trajectory groups of multimorbidity: low risk (55.5% of sample); cardiovascular disease risk only
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(15.6% of sample); gastrointestinal disease and lung disease risk (20.2% of sample); and
multiple risks (8.7% of sample). These two studies indicate a differentiation between the onset
of multimorbidity and the progression of multimorbidity, which was was also detected in the
current study. More specifically, the potential or risk for a subsequent chronic disease diagnosis
(after existing morbidity) changes over time. However, this study explored risk using the
measurement of time (that is, the time-to-event risk that will be presented in the next section). In
fact, comparing methodologies in this broad life course approach to multimorbidity, based on
risk profiles and time-to-event risk, would be a very interesting next step for the complex field of
longitudinal multimorbidity research.
To date, extensive research has been conducted to examine and delineate the life course
epidemiology of individual chronic diseases (Bijker et al., 2016; Oliveira et al., 2016; BenShlomo et al., 2016; Pavela and Latham, 2015; Viner et al., 2015; Duijts et al., 2014; Kelishadi et
al., 2014; Power et al., 2013; Godfrey et al., 2010; White et al., 2009; Batty et al., 2007; Lynch
and Smith, 2005; Barker, 2004). However, further research is required to move beyond the focus
on individual chronic disease epidemiology across the life course. This will help to determine
how and why individuals accumulate multiple diseases over a lifetime, using both social and
biological pathways (Ben-Shlomo et al., 2016). This information can encourage PHC providers
to proactively offset the risk of their patients developing multimorbidity based on their
influential role in society (Mercer et al., 2014; McWhinney and Freeman, 2009; Starfield et al.,
2005). Ideally, this information will also support the need for more comprehensive health
promotion across the life course. These resources must be made available to individuals
regardless of life circumstances, such as early childhood disease or socioeconomic disadvantage.
Finally, this information will enable the collaborative work of primary health care and public
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health systems in the prevention of individual chronic diseases and multiple chronic diseases as
populations continue to age over time.

6.2.3 Predicting Time Until Subsequent Chronic Disease
In the multilevel, recurrent event survival analysis, the relevant patient-level predictors of
time until subsequent chronic disease included patient age, patient sex, patient residential
location, median household income and the total number of chronic diseases diagnosed. The
provider- and practice-level predictors of time until subsequent chronic disease were provider
age, patient sex, EMR software type and practice location. Among the patient-level independent
variables, patient sex and total number of chronic diseases were found to be significantly related
to the time until subsequent chronic disease diagnosis, controlling for all other variables in the
final model. Female patients were found to experience a 19% decrease in the rate until the next
chronic disease diagnosis, as compared to male patients and controlling for all other variables in
the model. Similarly, as the number of chronic diseases increased by one unit, and with all other
variables held constant, there was a 33% increase in the rate until the next chronic disease
diagnosis. Hsu (2015) and Strauss et al. (2014) also found that patient age and patient sex were
factors in the trajectory of multimorbidity over time among patients who were 50 years of age
and older. More generally, the association between multimorbidity, patient age and patient sex
has been demonstrated in more descriptive findings (Barnett et al., 2012; Salisbury et al., 2011;
Harrison et al., 2013; Britt et al., 2008; Uijen et al., 2008; Fortin et al., 2005).
Among the provider-level independent variables, provider age and provider sex were
both found to be significantly related to the time until subsequent chronic disease diagnosis,
controlling for all other variables in the final model. More specifically, while the increasing age
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of a PHC provider demonstrated only a 2% decrease in the rate until the next chronic disease
diagnosis, the patients who received care from a female PHC provider experienced an 8%
decrease in the rate until their next chronic disease diagnosis. For practice-level independent
variables, adult patients who were receiving care from urban-based PHC practices experienced a
26% decrease in the rate until their subsequent chronic disease diagnosis. Multiple EMR
software types were also significantly related to the time until subsequent chronic disease
diagnosis, as compared to the Accuro EMR software (reference category).
As described in the Methodology Chapter, provider-level characteristics (including
provider age and provider sex) may influence diagnostic behaviours and whether a provider
prefers to use an interventionist or “wait and see” approach (Hajjaj et al., 2010; Forrest et al.,
2006; Tracy et al., 2005; Franks and Bertakis, 2003; Bertakis et al., 2003; McKinlay et al., 2002).
Likewise, practice-level influences can include characteristics of the practice organization, such
as geographic location of the practice and availability of health resources (Iverson et al., 2005;
McKinlay et al., 1996). Consequently, the patient-, provider- and practice-level domains were
relevant layers to capture and explore in this time-to-event analysis.
Finally, within this multilevel survival analysis, the variation in the time until subsequent
chronic disease diagnosis was assessed at both the level of the PHC provider and the PHC
practice. The amount of variation in the outcome contributed at the provider-level was 10.0%
(95% CI: 8.4 – 11.9), while the amount of variation contributed at the site-level was less than
1.0% (that is, 0.18%, 95% CI: 0.0 – 2.0). Although it was important to examine the effect of
clustering of events (or diagnoses) within PHC practices and within PHC providers, this analysis
indicated reasonably minimal impact (< 10%) of these clusters.
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6.3 Strengths and Limitations
6.3.1 Strengths of Research
There are three notable strengths of this research. Firstly, the findings of this work
provide necessary insight into the prevalence, patterns and progression of multimorbidity among
adult patients in the Canadian PHC context. While the multimorbidity literature continues to
become much more mature and robust, national estimates of multimorbidity in Canada are still
missing. While this research represents a small piece of the “multimorbidity puzzle”, it may help
to guide future multimorbidity research and it will contribute to the international evidence base.
Secondly, the CPCSSN EMR database represents an important and unique resource for
researchers who are interested in the combined fields of PHC and multimorbidity. The
longitudinal nature of the CPCSSN EMR data allowed for estimates of multimorbidity
prevalence among adult PHC patients and the examination of the progression of multimorbidity
over time. This longitudinal analysis included information that spanned many years (in some
cases, ten or more years) for a large cohort of patients. As such, this rich source of longitudinal,
clinical data provides a PHC-specific picture of how patients progress from living with one
chronic disease to multiple chronic diseases. Building on these findings, health care providers
and health care policy makers could utilize longitudinal data to inform prevention and
management practices for patients who are most at-risk of developing a subsequent chronic
disease. Ideally, these interventions would aim to prevent patient progression into complex
clinical profiles, and to help a patient maintain or improve upon their current health status.
Thirdly, the methodology used in this research provided a solution to addressing a
number of challenges in the EMR database and the study of the complex issue of multimorbidity.
The challenges encountered in using the EMR database included detecting singular chronic
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disease diagnoses, as well as clusters of chronic disease diagnoses. Another challenge was the
appropriate analyses of the complex longitudinal data. While the approaches utilized for the
current research must be compared and contrasted with other approaches, the methodology
outlined in the work may help to inform future research in similar areas or facing similar
methodological or data-related challenges. Finally, this methodology has been published and has
been made accessible to external researchers to encourage its replication and comparison of the
eventual findings (Nicholson et al., 2015).

6.3.2 Limitations of Research
This research has three important limitations to consider. Firstly, this research used a
simplified approach to operationalize the definition of multimorbidity by strictly counting
chronic disease diagnoses and incident ICD-9 codes within the EMR database. This approach
allowed for the identification of the first occurrence of ICD-9 diagnoses throughout the patient’s
longitudinal electronic record. However, this approach does not account for the severity of
disease or symptom burden on the patient, which may be very valuable information when
examining progression into more complex clinical profiles. While examining the occurrence of
combinations and permutations of multiple chronic diseases created an understanding of the
multidimensional characteristics of multimorbidity, another potentially important dimension
would be the severity of chronic disease. For example, although this research was able to detect
that specific combinations and permutations were most frequent in the sample of adult PHC
patients, these findings were not stratified by disease severity. In a similar sense, the
identification of combinations and permutations did not indicate a causal relationship between
diseases. Indeed, this would be an area for extensive further study.
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Secondly, the use of EMR data may have introduced the potential for misclassification of
chronic disease occurrence and, therefore, a biased estimate of multimorbidity prevalence. This
potential for misclassification is not only specific to EMRs, but to medical records in general.
For example, if a patient was truly living with one of the twenty chronic diseases included in the
measurement of multimorbidity, this patient may not have been detected in the EMR database
because: 1) the patient did not present pathophysiological indications for the PHC provider to
examine further through laboratory tests or examinations that would confirm a diagnosis; 2) the
patient did present pathophysiological indications that were diagnosed as one of the twenty
chronic diseases by the PHC provider, but this diagnosis was not recorded within the patient’s
EMR; or 3) the patient did present pathophysiological indications that were diagnosed as one of
the twenty chronic diseases by the PHC provider, but this diagnosis was not recorded in an area
of the patient’s EMR that was extracted into the CPCSSN EMR database. Each of these factors
may have resulted in a patient being misclassified as not living with a chronic disease, when in
fact this patient was living with one or more chronic diseases. Alternatively, patient diagnoses
may have been entered incorrectly into the EMR or with an incorrect date of diagnoses. A
related limitation of the EMR data is that potentially modifiable risk factors that were not
available in the CPCSSN EMR database (e.g., socioeconomic status, lifestyle behaviours or
levels of self-efficacy to improving lifestyle behaviours) would be meaningful to explore in
terms of their potential impact on the occurrence or progression of multimorbidity among adult
PHC patients. The impact of socioeconomic status on multimorbidity has been identified in
previous literature (Roberts et al., 2015; Payne et al., 2013; Agborsangaya et al., 2012; Mercer et
al., 2012; Barnett et al., 2012), and indicates an important area of improvement within the
CPCSSN EMR database.
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Finally, the time elapsing between chronic diseases (explored in Objective Two) was
potentially impacted by the recording behaviours of the providers within an electronic medical
record. For example, providers are expected to record the diagnostic codes when a diagnosis
follows patient visit and presentation of related symptoms. To adequately examine the time
elapsing between diagnoses, providers are also expected to record the diagnostic codes at first
detection or confirmation of a disease within a patient. While the original intent of Objective
Two was to report and describe the natural history of multimorbidity over time, the measure of
“time” could not differentiate between the recording behaviours of the PHC provider and the true
progression of multimorbidity over time. For example, the observation that approximately 20%
of patients received multiple chronic disease diagnoses at the same encounter may have indicated
an artefact of the EMR data. However, this is not completely clear as a patient may have been
truly diagnosed with multiple chronic diseases at a single encounter because: 1) the PHC
provider may have received awaited results from multiple laboratory tests and/or examinations;
2) the patient may have been a new patient to the PHC provider and already living with multiple
chronic diseases, which would then be recorded at a single encounter; or 3) the PHC provider
may have entered the diagnostic information or associated dates incorrectly.

6.4 Implications
6.4.1 Clinical and Policy Implications
The findings from this research could be used in the clinical context to inform training for
future health care providers, as well as in the policy context to guide intervention efforts. For
example, the cluster information could be used to create “multimorbidity-based patient
vignettes” of either the most common or most uncommon clusters of chronic diseases occurring
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within subsets of patients. These could be used for educational purposes by introducing and
orienting future health care professionals with the realities and complexities of multimorbidity.
In fact, these vignettes can prime current medical students and health care providers with
commonly co-occurring issues among PHC patients in Canada. This information could be used
to tailor educational modules programs around questions like: “When is the patient most
susceptible to acquire another chronic disease?” or “How can this progression into a subsequent
chronic disease be avoided, based on the patient’s preferences and goals?” These are complex,
clinical questions to answer in any context. However, it may be important to start asking these
questions now within our educational programs. This approach could be nested within the
enhanced training environments in which multidisciplinary health care professionals can be
trained together to provide more integrated and patient-centered health care.
The implications for the purposes of health policy should be somewhat conservative, due
to the observed complex nature of this patient group. However, the time elapsing between
multiple chronic disease diagnoses information that was derived from Objective Two could be
used strategically in the design and implementation of chronic disease prevention and
management programs. The point of transition from living with one chronic disease to living
with multimorbidity (defined as two or more chronic diseases) indicates a period of time in
which the health care team must deliver its most effective care. This is particularly important to
avoid a negative evolution into poorer and poorer health by the patient, especially as the patient
continues to age. While the exact trajectory of an individual patient cannot be completely
predicted, the longitudinal data collected over time from millions of adult PHC patients could be
used to inform more proactive delivery of care. As stated previously, the time to event findings
could be carefully used to identify at-risk patients for specific and pragmatic interventions within
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a PHC setting. These more adaptive and proactive interventions could be a new focus for health
policy makers who are looking to alleviate the growing burden of multimorbidity.

6.4.2 Research Implications
The completion of this work indicates three main areas in which future multimorbidity
research will be particularly important. Firstly, measures and definitions of multimorbidity that
are used in research should be more systematically compared and contrasted between study
settings. This would include the replication of the definition and operationalization of
multimorbidity from the current study in other populations in Canada and abroad. A more
consistent methodological approach would allow the international research community to
establish a more robust understanding of the true burden of multimorbidity among community
and clinical populations. Secondly, future research should more clearly define what factors
make a patient most susceptible to developing multiple chronic diseases. In other words, the
sociodemographic and socioeconomic risk factors to becoming a patient with complex chronic
disease profile should be explored further. While our research accounted for a number of
patient-, provider- and practice-level factors that may influence the time until another chronic
disease diagnosis is received, more substantial and potentially modifiable risk factors (e.g.,
family history, lifestyle habits or patient resiliency) should be examined. Finally, future research
should work to understand the impact of these patients with multimorbidity on the health care
system, and more importantly, where additional resources and supports are needed for both
patients and their caregivers to improve health-related outcomes. More specifically, research
should continue to identify and focus on the most successful approaches to delivering
individualized, adaptive and patient-centered care for this significant and growing population of
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patients. Indeed, this research will be one of the keys to ensuring that those patients living with
multimorbidity are receiving the highest quality of care from their multidisciplinary health care
team.

6.5 Future Directions
Overall, the results from this doctoral research indicate that the burden of multimorbidity
among adult PHC in Canada is substantial as approximately 50% of adult PHC patients in our
sample were living with multimorbidity, defined as two or more chronic diseases. Moreover, the
complexity of these patients with multimorbidity was detected. These results indicate that even
among a large cohort of adult PHC patients in Canada, patients with multimorbidity were living
with increasingly unique and increasing complex clinical profiles, indicating the importance of
an individualized and patient-centered approach to delivering effective and responsive care. The
time elapsing between chronic disease diagnoses indicated that there were certain patient profiles
that resulted in a much quicker accumulation of another chronic disease diagnoses, as well as
relevant patient-, provider- and practice-level factors influencing this progression. These
findings should be carefully assessed in further research in order to confirm whether these
patterns exist in other patient populations, beyond the pan-Canadian CPCSSN EMR database.
The results of this research, however, provide empirical evidence that there will not be a singular
solution to the challenge of multimorbidity. As such, the international research community must
continue to work collaboratively together to put the elusive “multimorbidity puzzle” together.
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Chapter 7
7 Conclusion
Broadly, this thesis provided insight into the prevalence, patterns and natural progression
of multimorbidity among adult PHC patients in Canada. The prevalence of multimorbidity,
defined either as “two or more chronic diseases” or “three or more chronic diseases” was found
to be 53.3% or 33.1% among adult PHC patients in the CPCSSN EMR database, respectively.
While common combinations and permutations of multiple chronic diseases were explored by
both patient age and patient sex, the findings from the computational cluster analysis suggested
that patients with multimorbidity represent increasingly unique clinical profiles. This has been
somewhat supported in the growing “associative multimorbidity” literature, but this research is
distinct as it provides empirical evidence that multimorbidity patients are indeed unique and
cannot be easily clumped together. The longitudinal CPCSSN database allowed for the
exploration of the natural progression of multimorbidity over time. From this analysis,
independent predictors of progressing multimorbidity were detected, particularly at the patientlevel. This requires further exploration, and further delineation of relevant and modifiable risk
factors. Most importantly, however, is the voice and perspective of the patients and caregivers
who are living with these “unique and complex clinical profiles” of multimorbidity. The
multidimensional and far-reaching impact that multimorbidity has on patient’s life cannot be
underestimated or underexplored. As such, the conduct of both large-scale, quantitative
analyses, as presented here in this thesis, and small-scale, qualitative analyses should be
encouraged and facilitated into the future. This multidisciplinary combination of research will
provide the complete picture and understanding of multimorbidity – something for which we are
continuing to strive towards.
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Appendices
Appendix A. Multilevel structure of the CPCSSN data and relevant CPCSSN data elements

Group Data Element

Detailed Data Elements

Network_ID

NetworkName

Practice_ID

LocationType, LocationFSA, Province, EMRName, StartDate

Provider_ID

BirthYear, Sex
BirthYear, Sex, OptedOut, PatientStatus_orig, PatientStatus_calc, Occupation,

Patient_ID

HighestEducation, HousingStatus, Language, Ethnicity, DeceasedYear, ResidenceFSA,
DateCreated
EncounterDate, Reason_orig, Reason_calc, EncounterType, DiagnosisText_orig,

Encounter_ID

DiagnosisText_calc, DiagnosisCodeType_orig, DiagnosisCodeType_calc,
DiagnosisCode_orig, DiagnosisCode_calc, DateCreated
ServiceDate, ServiceCode, DiagnosisText_orig, DiagnosisText_calc,

Billing_ID

DiagnosisCodeType_orig, DiagnosisCodeType_calc, DiagnosisCode_orig,
DiagnosisCode_calc, DateCreated
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Appendix B. CPCSSN Letter of Permission for secondary data source access
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Appendix C. Ethics approval notice from research ethics board (#104705)
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Appendix D. Data dictionary of original and created CPCSSN data elements
Data Element
Cycle_ID
Network_ID
NetworkName
Site_ID
Site_LocationType
Site_LocationFSA
Site_Province
Site_EMRName
Site_EMRStartDate
Provider_ID
Provider_BirthYear
Provider_Sex
Patient_ID
Patient_BirthYear
Patient_Sex
Patient_OptedOut
PatientStatus_orig
PatientStatus_calc
Patient_Occupation
Patient_HighestEducation
Patient_HousingStatus
Patient_Language
Patient_Ethnicity
Patient_DeceasedYear
Patient_ResidenceFSA
Patient_DateCreated
Encounter_ID
EncounterDate
EncounterReason_orig
EncounterReason_calc
EncounterType
DiagnosisText_orig
EncounterDiagnosisText_calc
EncounterDiagnosisCodeType_orig
EncounterDiagnosisCodeType_calc
EncounterDiagnosisCode_orig
EncounterDiagnosisCode_calc
Encouner_DateCreated
Billing_ID
ServiceDate
Billing_ServiceCode
BillingDiagnosisText_orig

Description
Name of the cycle
Unique identifier for each network
Name of CPCSSN network
Unique identifier for each site
Type of site practice
First three digits of the postal code of the site location
Unique two-character province name of the site location
Name of the EMR used by the participating site
Date the site implemented the EMR
Unique identifier for each provider in the database
Birth year of provider
Sex of provider
Unique identifier for each patient in the database
Birth year of patient
Sex of patient
If the patient has opted out in any extraction
Status of patient (original)
CPCSSN re-coding of patient status into consistent text (data cleaning)
Occupation of patient
Highest education achieved by patient
Housing status of patient
Primary language of patient
Ethnicity of patient
Deceased year of patient
First three digits of the patient residential postal code
EMR date stamp of when the original record was created
Unique identifier for each encounter
Date the encounter occurred
Reason for the encounter exactly as it appears in the EMR (original)
CPCSSN re-coding of the reason for the encounter as it appears in the EMR (data
cleaning)
How or where the encounter occurred
Diagnosis text exactly as it appears in the EMR (original)
CPCSSN re-coding of the diagnosis text into consistent text (data cleaning)
Diagnosis code type associated with the encounter exactly as it appears in the EMR
(original)
CPCSSN re-coding of diagnosis code type into consistent text (data cleaning)
Diagnosis code associated with the encounter exactly as it appears in the EMR
(original)
CPCSSN re-coding diagnosis code into consistent text (data cleaning)
EMR date stamp of when the original record was created
Unique identifier for each billing entry
Date the billing was performed/submitted
Service code associated with the billing
Diagnosis text exactly as it appears in the EMR (original)
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BillingDiagnosisText_calc
BillingDiagnosisCodeType_orig
BillingDiagnosisCodeType_calc
BillingDiagnosisCode_orig
BillingDiagnosisCode_calc
Billing_DateCreated
Patient_Age
Residential_Location
Provider_Age
Practice_Location
Chronic_Disease
Time_BetweenDisease
Total_ChronicDisease

CPCSSN re-coding of diagnosis into consistent text (data cleaning)
Diagnosis code type associated with the billing exactly as it appears in the EMR
(original)
CPCSSN re-coding of diagnosis code type into consistent text (data cleaning)
Diagnosis code associated with the billing exactly as it appears in the EMR (original)
CPCSSN re-coding of diagnosis code into consistent text (data cleaning)
EMR date stamp of when the original record was created
Calculated as of September 30, 2013 with the recorded Patient_BirthYear
Re-coding based on the second character of Patient_ResidenceFSA
Calculated as of September 30, 2013 with the recorded Provider_BirthYear
Re-coding based on the second character of Site_LocationFSA
Identified in the EMR using list of twenty chronic disease categories and associated
ICD-9 disease codes
Time elapsing (in days) between chronic disease diagnoses
Total number of “first occurrence” chronic disease diagnoses recorded in the EMR
using list of twenty chronic disease categories and associated ICD-9 disease codes
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Appendix E. Example data entries of patient-level socioeconomic characteristics
Occupation Data Entry Examples
admin manager

engineering

machinist (self-employed)

RETAIL MANAGER

Airport attendant

Family Caregiver

manufacturing manager

Retired

assistant to disabled

financial management

multiple jobs

Revenue Canada

bank teller

FREELANCE WRITER

nanny

Roofer, full time

bookkeeper

Government analyst

Nurse

sales coordinator

Cake decorator

hairdresser

nutritionist

secretarial

Cashier

Home Care Worker

Office Work

self employed mechanic

Client Service Officer

homemaker

Owner/Operator

Social work

consulting business

HOUSECLEANER

Part-time in sales

technician

delivery driver

interior designer

Project Co-ordinator

Director of Marketing

Lawyer

Public Health Nurse

Employed

LIBRARY ASSISTANT

Realtor

truck driver
Work, Full-time Bookkeeper
works as chef

Highest Education Data Entry Examples
CEGEP

Professional Degree

Technical College

Unfinished studies

College

Secondary

Trade School

University

Common-law spouse

Lives alone

Separated

Widow(er)

Common-law - x 8 years

Married

Single

With spouse

Divorced

New spouse - 1 year

Single - lives with mother

With spouse - since 2001

ABORIGINAL

CAMBODIAN

ENGLISH/SCOTTISH

JEWISH

AFRICAN

CANADIAN

ETHIOPIAN

KOREAN

ASIAN

CANTONESE

FILIPINO

MEXICAN

AUSTRALIAN

CAUCASIAN

FIRST NATIONS

NATIVE

BHUTAN

CHINESE

FRANCOPHONE

PAKISTAN

BLACK/CAUCASIAN
BLACK/NATIVE/SPANIS
H/CAUCASIAN
BRAZILIAN

CHINESE/ CAUCASIAN

FRENCH CANADIAN

PHILIPPINO

COLUMBIAN

GERMAN

PORTUGUESE

CZECH

IRISH

SRI LANKAN

BURMESE

EAST INDIAN

ITALIAN

UKRANIAN

Belgian

EL SALVADOR

JAPANESE

Undetermined

Italian
Other language not
specified

Portuguese

Undetermined

High School
Housing Status Data Entry Examples

Ethnicity Data Entry Examples

Language Data Entry Examples
English
French

Some English
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Appendix F. First character of forward sortation area and corresponding province, territory
or major region
Alphabetic Character

Province, Territory or Region

A

Newfoundland and Labrador

B

Nova Scotia

C

Prince Edward Island

E

New Brunswick

G

Québec East

H

Montréal

J

Québec West

K

Eastern Ontario

L

Central Ontario

M

Toronto

N

Southwestern Ontario

P

Northern Ontario

R

Manitoba

S

Saskatchewan

T

Alberta

V

British Columbia

X

Northwest Territories and Nunavut

Y

Yukon Territory
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Appendix G. Complete list of chronic disease categories and corresponding International
Classification of Disease, 9th Revision (ICD-9) disease codes, for the identification of adult
primary health care patients with multimorbidity*
ICD-9
ICD-9 Description
Code
1. Hypertension
401-405
Hypertensive disease
401
Essential hypertension
401
Malignant essential hypertension
401.1
Benign essential hypertension
401.9
Unspecified essential hypertension
405
Secondary hypertension
405
Malignant secondary hypertension
405.01
Malignant renovascular hypertension
405.09
Other malignant secondary hypertension
405.1
Benign secondary hypertension
405.11
Benign renovascular hypertension
405.19
Other benign secondary hypertension
405.9
Unspecified secondary hypertension
405.91
Unspecified renovascular hypertension
405.99
Other unspecified secondary hypertension
2. Obesity
278
278
278.01
≥30

Overweight and obesity
Obesity, unspecified
Morbid obesity
Body mass index

3. Diabetes – 51 ICD-9 Codes
250
Diabetes mellitus
250
Diabetes mellitus without mention of complication
250
Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled
250.01
Diabetes mellitus without mention of complication, type I [juvenile type], not stated as uncontrolled
250.02
Diabetes mellitus without mention of complication, type II or unspecified type, uncontrolled
250.03
Diabetes mellitus without mention of complication, type I [juvenile type], uncontrolled
250.1
Diabetes with ketoacidosis
250.1
Diabetes with ketoacidosis, type II or unspecified type, not stated as uncontrolled
250.11
Diabetes with ketoacidosis, type I [juvenile type], not stated as uncontrolled
250.12
Diabetes with ketoacidosis, type II or unspecified type, uncontrolled
250.13
Diabetes with ketoacidosis, type I [juvenile type], uncontrolled
250.2
Diabetes with hyperosmolarity
250.2
Diabetes with hyperosmolarity, type II or unspecified type, not stated as uncontrolled
250.21
Diabetes with hyperosmolarity, type I [juvenile type], not stated as uncontrolled
250.22
Diabetes with hyperosmolarity, type II or unspecified type, uncontrolled
250.23
Diabetes with hyperosmolarity, type I [juvenile type], uncontrolled
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250.3
250.3
250.31
250.32
250.33
250.4
250.4
250.41
250.42
250.43
250.5
250.5
250.51
250.52
250.53
250.6
250.6
250.61
250.62
250.63
250.7
250.7
250.71
250.72
250.73
250.8
250.8
250.81
250.82
250.83
250.9
250.9
250.91
250.92
250.93

Diabetes with other coma
Diabetes with other coma, type II or unspecified type, not stated as uncontrolled
Diabetes with other coma, type I [juvenile type], not stated as uncontrolled
Diabetes with other coma, type II or unspecified type, uncontrolled
Diabetes with other coma, type I [juvenile type], uncontrolled
Diabetes with renal manifestations
Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled
Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled
Diabetes with renal manifestations, type II or unspecified type, uncontrolled
Diabetes with renal manifestations, type I [juvenile type], uncontrolled
Diabetes with ophthalmic manifestations
Diabetes with ophthalmic manifestations, type II or unspecified type, not stated as uncontrolled
Diabetes with ophthalmic manifestations, type I [juvenile type], not stated as uncontrolled
Diabetes with ophthalmic manifestations, type II or unspecified type, uncontrolled
Diabetes with ophthalmic manifestations, type I [juvenile type], uncontrolled
Diabetes with neurological manifestations
Diabetes with neurological manifestations, type II or unspecified type, not stated as uncontrolled
Diabetes with neurological manifestations, type I [juvenile type], not stated as uncontrolled
Diabetes with neurological manifestations, type II or unspecified type, uncontrolled
Diabetes with neurological manifestations, type I [juvenile type], uncontrolled
Diabetes with peripheral circulatory disorders
Diabetes with peripheral circulatory disorders, type II or unspecified type, not stated as uncontrolled
Diabetes with peripheral circulatory disorders, type I [juvenile type], not stated as uncontrolled
Diabetes with peripheral circulatory disorders, type II or unspecified type, uncontrolled
Diabetes with peripheral circulatory disorders, type I [juvenile type], uncontrolled
Diabetes with other specified manifestations
Diabetes with other specified manifestations, type II or unspecified type, not stated as uncontrolled
Diabetes with other specified manifestations, type I [juvenile type], not stated as uncontrolled
Diabetes with other specified manifestations, type II or unspecified type, uncontrolled
Diabetes with other specified manifestations, type I [juvenile type], uncontrolled
Diabetes with unspecified complication
Diabetes with unspecified complication, type II or unspecified type, not stated as uncontrolled
Diabetes with unspecified complication, type I [juvenile type], not stated as uncontrolled
Diabetes with unspecified complication, type II or unspecified type, uncontrolled
Diabetes with unspecified complication, type I [juvenile type], uncontrolled

4. Chronic Obstructive Pulmonary Disease or Asthma
491
Chronic bronchitis
491
Simple chronic bronchitis
491.1
Mucopurulent chronic bronchitis
491.2
Obstructive chronic bronchitis
491.2
Obstructive chronic bronchitis without exacerbation
491.21
Obstructive chronic bronchitis with (acute) exacerbation
491.22
Obstructive chronic bronchitis with acute bronchitis
491.8
Other chronic bronchitis
491.9
Unspecified chronic bronchitis
492
Emphysema
492
Emphysematous bleb
492.8
Other emphysema
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493
493
493
493.01
493.02
493.1
493.1
493.11
493.12
493.2
493.2
493.21
493.22
493.8
493.81
493.82
493.9
493.9
493.91
493.92
496

Asthma
Extrinsic asthma
Extrinsic asthma, unspecified
Extrinsic asthma with status asthmaticus
Extrinsic asthma with (acute) exacerbation
Intrinsic asthma
Intrinsic asthma, unspecified
Intrinsic asthma with status asthmaticus
Intrinsic asthma with (acute) exacerbation
Chronic obstructive asthma
Chronic obstructive asthma, unspecified
Chronic obstructive asthma with status asthmaticus
Chronic obstructive asthma with (acute) exacerbation
Other forms of asthma
Exercise induced bronchospasm
Cough variant asthma
Asthma unspecified
Asthma, unspecified type, unspecified
Asthma, unspecified type, with status asthmaticus
Asthma, unspecified type, with (acute) exacerbation
Chronic airway obstruction, not elsewhere classified

5. Hyperlipidemia
272
Disorders of lipoid metabolism
272
Pure hypercholesterolemia
272.1
Pure hyperglyceridemia
272.2
Mixed hyperlipidemia
272.3
Hyperchylomicronemia
272.4
Other and unspecified hyperlipidemia
6. Cancer
140-239
140-149
150-159
160-165
170-176
179-189
190-199
200-209

Neoplasms
Malignant Neoplasm Of Lip, Oral Cavity and Pharynx
Malignant Neoplasm Of Digestive Organs And Peritoneum
Malignant Neoplasm Of Respiratory And Intrathoracic Organs
Malignant Neoplasm Of Bone, Connective Tissue, Skin and Breast
Malignant Neoplasm Of Genitourinary Organs
Malignant Neoplasm Of Other And Unspecified Sites
Malignant Neoplasm Of Lymphatic And Hematopoietic Tissue

7. Cardiovascular Disease
412
Old myocardial infarction
413
Angina pectoris
413
Angina decubitus
413.1
Prinzmetal angina
413.2
Other and unspecified angina pectoris
440-449
Diseases Of Arteries, Arterioles and Capillaries
427
Cardiac dysrhythmias
427.3
Atrial fibrillation and flutter
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427.31
417.32

Atrial fibrillation
Atrial flutter

8. Heart Failure
428
Heart failure
394
Diseases of mitral valve
394
Mitral stenosis
394.1
Rheumatic mitral insufficiency
394.2
Mitral stenosis with insufficiency
395
Diseases of aortic valve
395.1
Rheumatic aortic insufficiency
395.2
Rheumatic aortic stenosis with insufficiency
395.9
Other and unspecified rheumatic aortic diseases
9. Anxiety or Depression
296
Episodic mood disorders
296.2
Major depressive disorder single episode
296.2
Major depressive affective disorder, single episode, unspecified
296.21
Major depressive affective disorder, single episode, mild
296.22
Major depressive affective disorder, single episode, moderate
296.23
Major depressive affective disorder, single episode, severe, without mention of psychotic behavior
296.24
Major depressive affective disorder, single episode, severe, specified as with psychotic behavior
296.25
Major depressive affective disorder, single episode, in partial or unspecified remission
296.26
Major depressive affective disorder, single episode, in full remission
296.3
Major depressive disorder recurrent episode
296.3
Major depressive affective disorder, recurrent episode, unspecified
296.31
Major depressive affective disorder, recurrent episode, mild
296.32
Major depressive affective disorder, recurrent episode, moderate
296.33
Major depressive affective disorder, recurrent episode, severe, without mention of psychotic behavior
296.34
Major depressive affective disorder, recurrent episode, severe, specified as with psychotic behavior
296.35
Major depressive affective disorder, recurrent episode, in partial or unspecified remission
296.36
Major depressive affective disorder, recurrent episode, in full remission
300
Anxiety, dissociative and somatoform disorders
300
Anxiety states
300
Anxiety state, unspecified
300.01
Panic disorder without agoraphobia
300.02
Generalized anxiety disorder
300.09
Other anxiety states
10. Osteoarthritis or Rheumatoid Arthritis
714
Rheumatoid arthritis and other inflammatory polyarthropathies
714
Rheumatoid arthritis
714.1
Felty's syndrome
714.2
Other rheumatoid arthritis with visceral or systemic involvement
714.3
Juvenile chronic polyarthritis
715
Osteoarthrosis and allied disorders
715
Osteoarthrosis generalized
715.1
Osteoarthrosis localized primary
715.2
Osteoarthrosis localized secondary
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715.3
715.8
715.9

Osteoarthrosis localized not specified whether primary or secondary
Osteoarthrosis involving or with mention of more than one site but not specified as generalized
Osteoarthrosis unspecified whether generalized or localized

11. Stroke or Transient Ischemic Attack
434
Occlusion of cerebral arteries
434
Cerebral thrombosis
434
Cerebral thrombosis without mention of cerebral infarction
434.01
Cerebral thrombosis with cerebral infarction
434.1
Cerebral embolism
434.1
Cerebral embolism without mention of cerebral infarction
434.11
Cerebral embolism with cerebral infarction
433.9
Cerebral artery occlusion unspecified
434.9
Cerebral artery occlusion, unspecified without mention of cerebral infarction
434.91
Cerebral artery occlusion, unspecified with cerebral infarction
435
Transient cerebral ischemia
435
Basilar artery syndrome
435.1
Vertebral artery syndrome
435.2
Subclavian steal syndrome
435.3
Vertebrobasilar artery syndrome
435.8
Other specified transient cerebral ischemias
435.9
Unspecified transient cerebral ischemia
12. Thyroid Problem
240-246
Disorders Of Thyroid Gland
240
Goiter, simple not otherwise specified
241
Nontoxic nodular goiter
242
Thyrotoxicosis
243
Congenital hypothyroidism
244
Acquired hypothyroidism
245
Thyroiditis
246
Other disorders of the thyroid
13. Kidney Disease or Failure
585
Chronic kidney disease
585.1
Chronic kidney disease, Stage I
585.2
Chronic kidney disease, Stage II (mild)
585.3
Chronic kidney disease, Stage III (moderate)
585.4
Chronic kidney disease, Stage IV (severe)
585.5
Chronic kidney disease, Stage V
585.6
End stage renal disease
585.9
Chronic kidney disease, unspecified
14. Osteoporosis
733
Osteoporosis
733
Osteoporosis, unspecified
733.01
Senile osteoporosis
733.02
Idiopathic osteoporosis
733.03
Disuse osteoporosis
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733.09

Other osteoporosis

15. Dementia
290
Dementias
290
Senile dementia, uncomplicated
290.1
Presenile dementia
290.1
Presenile dementia, uncomplicated
290.11
Presenile dementia with delirium
290.12
Presenile dementia with delusional features
290.13
Presenile dementia with depressive features
290.2
Senile dementia with delusional or depressive features
290.2
Senile dementia with delusional features
290.21
Senile dementia with depressive features
290.3
Senile dementia with delirium
290.4
Vascular dementia
294
Persistent mental disorders due to conditions classified elsewhere
294.1
Dementia in conditions classified elsewhere
294.2
Dementia, unspecified
16. Musculoskeletal Problem
723
Other disorders of cervical region
723.1
Cervicalgia
724
Other and unspecified disorders of back
724.1
Pain in thoracic spine
724.2
Lumbago
724.3
Sciatica
724.4
Thoracic or lumbosacral neuritis or radiculitis, unspecified
724.5
Backache, unspecified
725
Polymyalgia rheumatica
726
Peripheral enthesopathies and allied syndromes
726
Adhesive capsulitis of shoulder
726.1
Rotator cuff syndrome of shoulder and allied disorders
726.2
Other affections of shoulder region, not elsewhere classified
726.3
Enthesopathy of elbow region
726.3
Enthesopathy of elbow, unspecified
726.31
Medial epicondylitis
726.32
Lateral epicondylitis
726.33
Olecranon bursitis
726.39
Other enthesopathy of elbow region
726.4
Enthesopathy of wrist and carpus
726.5
Enthesopathy of hip region
726.6
Enthesopathy of knee
726.6
Enthesopathy of knee, unspecified
726.61
Pes anserinus tendinitis or bursitis
726.62
Tibial collateral ligament bursitis
726.63
Fibular collateral ligament bursitis
726.64
Patellar tendinitis
726.65
Prepatellar bursitis
726.69
Other enthesopathy of knee
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726.7
726.7
726.71
726.72
726.73
726.79
726.9
726.9
726.91
727
727
727
727.01
727.03
727.04
727.05
727.06
727.09
727.2
727.3
729
729
729.1
729.2
729.4
729.5

Enthesopathy of ankle and tarsus
Enthesopathy of ankle and tarsus, unspecified
Achilles bursitis or tendinitis
Tibialis tendinitis
Calcaneal spur
Other enthesopathy of ankle and tarsus
Unspecified enthesopathy
Enthesopathy of unspecified site
Exostosis of unspecified site
Other disorders of synovium tendon and bursa
Synovitis and tenosynovitis
Synovitis and tenosynovitis, unspecified
Synovitis and tenosynovitis in diseases classified elsewhere
Trigger finger (acquired)
Radial styloid tenosynovitis
Other tenosynovitis of hand and wrist
Tenosynovitis of foot and ankle
Other synovitis and tenosynovitis
Specific bursitides often of occupational origin
Other bursitis
Other disorders of soft tissues
Rheumatism, unspecified and fibrositis
Myalgia and myositis, unspecified
Neuralgia, neuritis and radiculitis, unspecified
Fasciitis, unspecified
Pain in limb

17. Stomach Problem
530
Diseases of esophagus
530.81
Esophageal reflux
531
Gastric ulcer
531.4
Chronic or unspecified gastric ulcer with hemorrhage
531.4
Chronic or unspecified gastric ulcer with hemorrhage, without mention of obstruction
531.41
Chronic or unspecified gastric ulcer with hemorrhage, with obstruction
531.5
Chronic or unspecified gastric ulcer with perforation
531.5
Chronic or unspecified gastric ulcer with perforation, without mention of obstruction
531.51
Chronic or unspecified gastric ulcer with perforation, with obstruction
531.6
Chronic or unspecified gastric ulcer with hemorrhage and perforation
531.6
Chronic or unspecified gastric ulcer with hemorrhage and perforation, without mention of obstruction
531.61
Chronic or unspecified gastric ulcer with hemorrhage and perforation, with obstruction
531.7
Chronic gastric ulcer without mention of hemorrhage or perforation
531.7
Chronic gastric ulcer without mention of hemorrhage or perforation, without mention of obstruction
531.71
Chronic gastric ulcer without mention of hemorrhage or perforation, with obstruction
531.9
Gastric ulcer unspecified as acute or chronic without mention of hemorrhage or perforation
Gastric ulcer, unspecified as acute or chronic, without mention of hemorrhage or perforation, without
531.9
mention of obstruction
Gastric ulcer, unspecified as acute or chronic, without mention of hemorrhage or perforation, with
531.91
obstruction
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18. Colon Problem
555
Regional enteritis
555.1
Regional enteritis of large intestine
555.2
Regional enteritis of small intestine with large intestine
555.9
Regional enteritis of unspecified site
556
Ulcerative enterocolitis
556
Ulcerative (chronic) enterocolitis
556.4
Pseudopolyposis of colon
556.5
Left-sided ulcerative (chronic) colitis
556.6
Universal ulcerative (chronic) colitis
556.8
Other ulcerative colitis
556.9
Ulcerative colitis, unspecified
564
Functional digestive disorders not elsewhere classified
564.1
Irritable bowel syndrome
19. Liver Disease
571
Chronic liver disease and cirrhosis
571
Alcoholic fatty liver
571.1
Acute alcoholic hepatitis
571.2
Alcoholic cirrhosis of liver
571.3
Alcoholic liver damage, unspecified
571.4
Chronic hepatitis
571.4
Chronic hepatitis, unspecified
571.41
Chronic persistent hepatitis
571.42
Autoimmune hepatitis
571.49
Other chronic hepatitis
571.5
Cirrhosis of liver without mention of alcohol
571.6
Biliary cirrhosis
571.8
Other chronic nonalcoholic liver disease
571.9
Unspecified chronic liver disease without mention of alcohol
20. Urinary Problem
593
Other disorders of kidney and ureter
593.3
Stricture or kinking of ureter
593.4
Other ureteric obstruction
593.5
Hydroureter
593.7
Vesicoureteral reflux
593.7
Vesicoureteral reflux unspecified or without reflux nephropathy
593.71
Vesicoureteral reflux with reflux nephropathy, unilateral
593.72
Vesicoureteral reflux with reflux nephropathy, bilateral
593.73
Other vesicoureteral reflux with reflux nephropathy NOS
593.8
Other specified disorders of kidney and ureter
593.82
Ureteral fistula
593.89
Other specified disorders of kidney and ureter
593.9
Unspecified disorder of kidney and ureter
595
Cystitis
595.1
Chronic interstitial cystitis
595.2
Other chronic cystitis
595.9
Cystitis, unspecified
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597
Urethritis not sexually transmitted and urethral syndrome
597.8
Urethritis, unspecified
597.81
Urethral syndrome NOS
597.82
Other urethritis
600
Hyperplasia of prostate
601
Inflammatory diseases of prostate
601.1
Chronic prostatitis
601.3
Prostatocystitis
601.8
Other specified inflammatory diseases of prostate
601.9
Prostatitis, unspecified
602
Other disorders of prostate
602
Calculus of prostate
602.1
Congestion or hemorrhage of prostate
602.2
Atrophy of prostate
602.3
Dysplasia of prostate
602.8
Other specified disorders of prostate
602.9
Unspecified disorder of prostate
* Reproduced with permission from co-Principal Investigator of PACE in MM CBPHC Team (Dr. Martin Fortin)

270

Appendix H. Multimorbidity Cluster Analysis Toolkit

Multimorbidity Cluster Analysis Toolkit
Background
In examining the burden of multimorbidity, which is the co-occurrence of multiple health issues
within an individual, previous literature has focused on the descriptive counting of singular
diseases and the link between non-random clusters of diseases (Garin et al., 2014; Prados-Torres
et al., 2012). When examining clusters of diseases, the majority of research has been limited in
reporting pairs or triplets of chronic disease occurrences. However, the analysis of cumulative
interactions and the complete clustering that is occurring within a cohort will help lead to a more
nuanced understanding of the complexity and uniqueness of individuals living with
multimorbidity.

A computational cluster analysis can be used to explore and detect the distinct clinical profiles
that exist within a sample of participants or patients in a research project. While the
operationalization of multimorbidity can vary in research projects due to the lack of a gold
standard measure, research has indicated that at least 12 chronic diseases should be included to
capture the burden of multimorbidity (Fortin et al., 2012). As such, detecting all possible
combinations (that is, unordered clusters) and permutations (that is, ordered clusters) in a dataset
can become exponentially difficult. However, there is a need to identify these diverse patients
and to understand how health outcomes might be impacted based on cluster type.

The Multimorbidity Cluster Analysis Tool (herein referred to as: Tool) and the accompanying
Multimorbidity Cluster Analysis Toolkit (herein referred to as: Toolkit) have been created to
allow researchers to identify distinct clusters or clinical profiles that exist within a sample of
participants or patients living with multimorbidity. This computational program can be adapted
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for research projects that utilize varying data sources, diagnostic or disease-reporting systems,
multimorbidity measurements, sample sizes and research settings. Its intent is to facilitate a
consistent approach to identifying subgroups of participants or patients who are living with
multimorbidity, based on cluster type and cluster sequence. This information is driven by the
data and the corresponding results should be assessed carefully. While this information can be a
helpful resource for research, clinical care and health policy decisions, the results should be
interpreted within the appropriate context. Interpretation of these should incorporate both
clinical and patient-centered insight.

Development Of This Tool & Toolkit
The Tool and Toolkit was developed by a research team at Western University from the
Department of Epidemiology & Biostatistics and the Department of Computer Science. The
computational program was developed and prototyped using the electronic medical record
(EMR) data from the Canadian Primary Care Sentinel Surveillance Network (CPCSSN)
database. This database is based at Queen’s University and is funded by the Public Health
Agency of Canada under a contribution agreement with the College of Family Physicians of
Canada. The views expressed herein do not necessarily represent the views of the Public Health
Agency of Canada or the College of Family Physicians of Canada.

The Tool and Toolkit is available for use by any academic researchers who are interested in
exploring the nuanced characteristics of participants or patients living with multimorbidity.
When used in research projects, the authors request that appropriate acknowledgement (below) is
made in any publications or presentations.

Bauer M & Nicholson K. Multimorbidity Cluster Analysis Tool & Toolkit. 2016.

Who Should Use This Tool & Toolkit?
Once again, the Tool and Toolkit is available for use by any academic researchers who are
interested in exploring the nuanced characteristics of participants or patients living with
multimorbidity. As noted, the computational program can be adapted to the methodological
elements of the research project. These variations include: 1) type of data (e.g., large secondary
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datasets of electronic information; small primary datasets of self-reported information); 2) type
of chronic disease information (e.g., ICD-10 Codes; ICD-9 Codes; ICPC-2 Codes; SNOMED CT
Codes; Read Codes; self-reported diagnoses); 3) multimorbidity measurements (e.g.,
operationalization using 12, 20 or 100 chronic disease diagnoses or chronic disease categories);
4) sample sizes (e.g., from 2 to approximately 150,000 individual records from participants or
patients); and 5) research settings (e.g., primary health care; administrative; communitydwelling).

The computational program will identify all existing, and mutually exclusive, combinations and
permutations within the dataset. A description of each concept is included below.

An example of an unordered cluster or combination of multiple chronic diseases would be those
individuals (participants or patients) who have been diagnosed or have self-reported the same
three chronic diseases (e.g., obesity, hypertension, cancer), but these diseases did not occur in the
same sequence between the individuals. For example, some individuals may have been
diagnosed with hypertension, then cancer and then obesity. In comparison, other individuals
may have been diagnosed with cancer, then obesity and then hypertension. These individuals
would still be clustered within the same combination.

An example of an ordered cluster or permutation of multiple chronic diseases would be those
individuals (participants or patients) who have been diagnosed or have self-reported the same
three chronic diseases (e.g., obesity, hypertension, cancer), and these diseases did occur in the
same sequence between the individuals. For example, all individuals who may have been
diagnosed with hypertension, then cancer and then obesity would be clustered within the same
permutation. In comparison, those individuals who were diagnosed with cancer, then obesity
and then hypertension would be clustered within the same permutation.

This computational program will conduct an individual-level categorization to determine the
frequency and type of mutually exclusive clusters of diseases (that is, combinations and
permutations) among a sample of individuals with multimorbidity. This analysis could also be
tailored to exploring the burden of multimorbidity among a specific subset of participants or
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patients, such as among a cohort of individuals who are all living with diabetes or depression. In
these analyses, the data input file will include only those individuals with the main chronic
disease of interest, and as such, these results will create output that is more in accordance with
the concept of co-morbidity. The concept of multimorbidity ensures that no one chronic disease
diagnoses takes precedence or focus over any other co-occurring disease within an individual.
As such, each chronic disease is of equal importance in the conceptualization and analysis of the
data. Importantly, however, the results that are created by the computational program do not
indicate any causal link between the diseases.

What Does This Tool & Toolkit Contain?
As a companion to the Multimorbidity Cluster Analysis Tool, this Toolkit contains the following
items: 1) summary of the background, development and use of the Tool; 2) summary of the
process of creating both the input and output files for the Tool; and 3) frequently asked
questions. The Multimorbidity Cluster Analysis Tool (which consists of JAVA code and an
executable file) has been developed and tested to support up to 150,000 individual records and
up to 100 disease diagnoses or disease categories. The basic setup of the input data file was
designed to allow for reasonable adaptability to methodological differences between research
projects. The time that elapses between occurrences of another chronic disease can also be
explored using this Tool, if the data are available within the research project.

How Should This Tool & Toolkit Be Used?
The process of using this Tool is outlined below in two multi-part steps. Step One describes how
to create the required structure of the input data file and Step Two describes how to run the
computational program that will create the output data files. Finally, although the purpose of the
Multimorbidity Cluster Analysis Tool was developed (and will be explained) with a focus on
multiple chronic diseases, the same approach could be applied using multiple disease symptoms
or multiple acute diseases.
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Step One
1. Unique Participant/Patient Identifier
o

A unique identifier should be created for each participant or patient within the input data
file (herein referred to as: ID). This ID can be maintained from the original study
database (e.g., 12345, 12346) or can be created as a new unique identifier in the input
file (e.g., 1, 2, 3).

o

The unique ID for each participant or patient should begin each new line. This will be
followed by the individual’s corresponding chronic disease and the time elapsing
between each occurrence (if applicable). Only one unique ID should be included on
each line, and the diagnoses and time variables should be included on the same line and
correspond directly to each ID.

o

This structure forms the basis of the input data file. This file can be created in a data
management program (e.g., SAS, Stata, Excel) and it must then be saved as or exported
as a “.txt (comma separated values)” file.

o

After the input data file has been saved, it is encouraged that the file is then opened and
inspected to ensure for appropriate structure and layout (displayed in Figure 1).

Figure 1: Example Input Data File

2. Chronic Disease Diagnosis/ Disease Category
o

The chronic disease diagnoses or chronic disease category (herein referred to as:
Disease) that is included in the definition of multimorbidity should be created and
finalized prior to creating the input data file. All relevant ICD-10 codes, Read codes or
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self-reported diseases should be identified to identify those individuals living with
multimorbidity. For example, the list of codes or self-reported diseases that constitute
an occurrence of “diabetes” or “anxiety” should be applied to the dataset.
o

The name of the diagnosis or category can be maintained from the original study, but
only up to a maximum of ten characters (e.g., anxiety, cancer, Hypertensi). As such, the
research team can decide to pre-emptively shorten the name of the diagnosis or category
before running the computational program. It is important that the identification and
naming of each chronic disease is maintained throughout the input data file to ensure
appropriate interpretation of the output data files, where the same names will be used.

3. Time Between Chronic Diseases
o

If available within the original database, the time elapsing between each date of chronic
disease (herein referred to as: Time) should be calculated (e.g., in whole days, in whole
years) and included in the input data file. The accuracy of these dates should be
assessed, and biases should be acknowledged if necessary.

o

Typically, the first date of chronic disease occurrence should be used in the calculation
(to capture the incident chronic disease occurrence) and the resulting time value must be
rounded to the nearest whole number.

o

The time elapsing between individual chronic disease diagnoses can be calculated in the
original database by the following equation: [Date of Diagnosis 2] – [Date of Diagnosis
1]. The same calculation should be used to determine the time elapsing between each
chronic disease occurrence.

o

It is important to structure the input data file as follows:
ID, Disease 1, Time 1, Disease 2, Time 2, Disease 3, Time 3, …
Where Time 1 = Time (whole number) elapsing between Disease 2 and Disease 1
Time 2 = Time (whole number) elapsing between Disease 3 and Disease 2
Time 3 = Time (whole number) elapsing between Disease 4 and Disease 3

Step One Summary
o The input data file should consist of the following information (separated by commas):
ID, Disease 1, Time 1, Disease 2, Time 2, Disease 3, Time 3, …
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o The input data can be prepared in a data management program (e.g., SAS, Stata, Excel)
and should be saved as or exported as a “.txt (comma separated values)” file for use in the
computational program.
o This file should be named to be easily identifiable for use in the Multimorbidity Cluster
Analysis Tool (e.g., mmpatients.txt).
o Finally, a new folder should be created to hold both the .txt input data file and the
Multimorbidity Cluster Analysis Tool computational program (which will be accessed
from the internet in Step Two).

Step Two
1. Running Computational Program
o
Once the final input data file has been prepared and saved as a .txt file, the
Multimorbidity Cluster Analysis Tool can now be utilized. Both the Tool and Toolkit
are accessible from www.csd.uwo.ca/faculty/bauer/ under the link called
“Multimorbidity Toolkit” (located to the left on the webpage).
o

To download the program, click on “mm cluster tool”. When asked to save the
program, select “Yes”. The program will download onto the computer system and is
labelled as “mm cluster tool.jar”. This .jar program should be saved and moved into the
same folder as the final input data file that was previously created and saved.

➢

A JAVA runtime environment is required on the system. If the “mm cluster tool.jar”
does not run, a JAVA runtime environment is needed. A JAVA runtime environment
can be downloaded online. To download, select the version that is required for the
system (e.g., Windows x86) and install this JAVA runtime environment.

o

To run the Multimorbidity Cluster Analysis Tool, double click on the saved “mm cluster
tool.jar” file. The program will first prompt for the input data file using an “Open” box.
Select the appropriate input data file and select “Open”.

o

The program will produce a sequence of display messages, which will inform the user
of completed steps (e.g., Reading from file; Number of records processed; Number of
permutations/combinations found; Writing permutations to file; Completed writing
permutations; Writing combinations to file; Completed writing combinations;
Processing completed). Select “OK” for each step, as program waits for user response.
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o

Each output data file name indicates if it holds the permutations (mmperms.txt) or
combinations (mmcombs.txt) and whether it holds detailed results (mmpermsDetails.txt
or mmcombsDetails.txt). Each output file name also contains the date and time of file
creation, which will be displayed below. This means that consecutive runs of the
program will produce uniquely named files and previous files will not be overwritten.

2. Output Data Files
o
After running through all completed steps, the program will automatically save the
output data files (as .txt files) in the same folder as the .jar program and input data file.
o

A total of four output files will be created and each are described further below.
Example output data files are also included below.
1)

The “mmpermsDATETIME.txt” output data file contains all permutations
(ordered clusters) of diagnoses or categories. The output is a sort list of
permutations, which is presented in order from most frequent to least frequent for
each group of participants or patients with the same number of diseases (e.g., 2
diseases, 3 diseases, 4 diseases). These permutations are represented using the
“>>” character, which indicates an additional disease (in that specific sequence).
The format of this output file is: Disease Permutation Type, Number of
Occurrences (Number of Participants/Patients), Total Time (Cumulative from
First to Last Disease in Days), Mean Time (Days), Standard Deviation Time
(Days). This is displayed in Figure 2.

Figure 2: Output Data File of Permutations
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2)

The “mmcombsDATETIME.txt” output data file contains all combinations
(unordered clusters) of diagnoses or categories. The output is a sort list of
combinations, which is presented in order from most frequent to least frequent for
each group of participants or patients with the same number of diseases (e.g., 2
diseases, 3 diseases, 4 diseases). These combinations are represented using the
“&” character, which indicates an additional disease (regardless of specific
sequence). The format of this output file is: Disease Combination Type, Number
of Occurrences (Number of Participants/Patients), Total Time (Cumulative from
First to Last Disease in Days), Mean Time (Days), Standard Deviation Time
(Days). This is displayed in Figure 3.

Figure 3: Output Data File of Combinations

3)

The “mmpermsDetailsDATETIME.txt” output data file contains the same
permutations as the “mmpermsDATETIME.txt” output data file. This includes
the Disease Permutation Type, Number of Occurrences (Number of
Participants/Patients), Total Time (Cumulative from First to Last Disease in
Days), Mean Time (Days), Standard Deviation Time (Days). To build from this
information, the output data file contains further details for each permutation.
More specifically, the Mean Time (Days) and Standard Deviation Time (Days) is
presented for each sequence of diseases within a permutation. The IDs of
individuals contained within these mutually exclusive clusters are also included in
this output data file. This is displayed in Figure 4.
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Figure 4: Output Data File of Permutation Details

4)

The “mmcombsDetailsDATETIME.txt” output data file contains the same
combinations as the “mmcombsDATETIME.txt” output data file. This includes
the Disease Combination Type, Number of Occurrences (Number of
Participants/Patients), Total Time (Cumulative from First to Last Disease in
Days), Mean Time (Days), Standard Deviation Time (Days). To build from this
information, the output data file contains further details for each combination.
More specifically, the Mean Time (Days) and Standard Deviation Time (Days) is
presented for each sequence of diseases within a combination. The IDs of
individuals contained within these mutually exclusive clusters are also included in
this output data file. This is displayed in Figure 5.

Figure 5: Output Data File of Permutation Details
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Step Two Summary
o The Multimorbidity Cluster Analysis Tool and Toolkit can be accessed from
www.csd.uwo.ca/faculty/bauer/ under the link called “Multimorbidity Toolkit”. To run
the computational program, the “mm cluster tool.jar” and a JAVA runtime environment
must be downloaded onto the computer.
o After running through the complete computational program, a total of four output data
files are created and automatically saved as .txt files within the same folder as the Tool
and the input data file. If the program does not run properly, the process of addressing
any issues in the input data file is outlined in Frequently Asked Questions.
o These files are named using unique titles based on the date and time of data analysis,
which means that consecutive runs of the program will produce uniquely named files and
previous files will not be overwritten.
o Finally, these four output data files capture both the general and specific information of
the combinations (that is, unordered clusters) and the permutations (that is, ordered
clusters) that exist among the participants or patients within the input data file. These
output files can be then be imported into data management programs (e.g., Excel) for
further processing.

Frequently Asked Questions
Question:

Do I have to abbreviate the chronic disease diagnosis/chronic disease category
names myself?

Answer:

You may choose to shorten the condition/disease category names yourself or the
program will automatically shorten the category names to ten characters.

Question:

I cannot find the “mm cluster tool.jar” file on my computer after accessing and
downloading the Tool online. Where is it located on my computer?

Answer:

After accessing the Tool online and downloading the file to your computer, the
file may automatically be placed in the “Downloads” folder or the “Desktop”.
You can also “Search” for the file on your computer. Once the file has been
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located, the file should then be relocated into the same folder that holds the input
data file.

Question:

The data that I will be using to create my input data file does not contain
information on the date of diagnoses, so I cannot calculate the time between
diagnoses. Can I still use this Tool to determine the most frequently occurring
clusters?

Answer:

Yes, researchers who do not have data on the time between diagnoses can still use
this Tool. In order for the computational program to run properly, however, it is
important to maintain a column for the time variable between each diagnoses
(space holder = 0). For example, it is important to structure the input data file as
follows:
ID, Disease 1, Time 1, Disease 2, Time 2, Disease 3, Time 3, …
Where Time 1, Time 2 and Time 3 = 0

Question:

I have prepared the input data file as outlined in this Toolkit and have saved it as a
common separated text file (.txt file). After ensuring that the input data file is
saved in the same folder as the “mm cluster tool.jar” file on my computer and
selecting this data file for the computational program, I am still receiving an error
message that the program cannot run. Why isn’t the program working?

Answer:

There may be a few reasons why the Multimorbidity Cluster Analysis Tool is not
working properly. Typically, this is resolved by carefully reviewing your data
file after exporting the data from the data management program. Firstly, it is
important to ensure that you have the correct data structure in your file:
Participant/Patient ID, Disease Diagnosis/Disease Category, Time Between
Diseases. Secondly, it is important to ensure that the Time Between Diseases is
rounded to the nearest whole number (no decimal points or values below zero).
Finally, it is important to ensure that there are no extra commas (,) or blank data
lines in the input data file. Each of these steps should alleviate errors previously
encountered, after careful review of the input data file.
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Question:

If I have a follow-up question or comment about the Multimorbidity Cluster
Analysis Tool and/or Toolkit, where can these be submitted?

Answer:

Further questions or comments about the Multimorbidity Cluster Analysis Tool
and/or Toolkit can be directed to: mmclusteranalysis@gmail.com.
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Appendix I. Identifying “First Occurrence” Chronic Disease Diagnoses
For each eligible adult patient, the first occurrence of a chronic disease diagnoses (from
the list of twenty chronic disease categories in Table 4.2) was identified. This approach
captured the patient’s first recorded diagnosis for a chronic disease, as well as the corresponding
diagnosis date. This represented the first time a patient received documentation of a diagnoses
within their EMR. Importantly, the term “incident” was not selected for these chronic disease
diagnoses, as one cannot definitively state that the diagnostic codes that appear in the patient’s
EMR are true incident cases of the disease. For example, a patient may be experiencing
symptoms of Anxiety or Depression, without receiving a diagnostic code within their EMR. In
these cases, while the diagnostic code was not recorded in the patient’s EMR, the patient is very
much living with this chronic disease. Alternatively, a patient may have already received a
diagnosis for Anxiety or Depression from a PHC provider who is not participating in the
CPCSSN database. In these cases, the diagnosis for Anxiety or Depression may eventually
appear within the patient’s EMR, but does not represent the true incidence of this disease (which
was detected first by the non-participating PHC provider). Instead, the diagnosis recorded by the
participating provider would constitute the “first occurrence” of this chronic disease in the
CPCSSN database. To detect each patient’s first occurrence of a chronic disease diagnosis,
patient data were sorted by Patient ID and Encounter Date or Service Date variables (for
Encounter Diagnosis codes and Billing Diagnosis codes, respectively) and the first
chronologically diagnosed chronic disease (again, from the list of twenty) was identified.
The corresponding date on which these chronic disease diagnoses were made was another
important consideration for Objective Two and its time-to-event analysis. Within the Billing
Diagnosis and Encounter Diagnosis tables, date information could be found within two variables:
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Encounter Date (which represented the actual date of the encounter) and Date Created (which
represented the date the code was input into the EMR). A systematic approach was used to
assign the most appropriate date to each chronic disease diagnosis. To begin, the Encounter Date
was selected if available; if this date was missing, the Date Created was used as the alternate date
source. Consistency between dates was checked for diagnoses that had both an Encounter Date
and Date Created. Consistency between dates was reasonable and did not represent a large
discrepancy (e.g., the majority of Date Created entries were within one week of the Encounter
Date), indicating that this was a feasible approach to obtaining the approximate date of each
chronic disease diagnosis.
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Appendix J: Comparative prevalence estimates for selected self-reported chronic disease diagnoses from the 2013 Canadian
Community Health Survey (CCHS) and the chronic disease categories from the Canadian Primary Care Sentinel Surveillance
Network (CPCSSN) electronic medical record (EMR) data
Prevalence (95% CI)
Data Source
Disease Category

CCHS

CPCSSN

CCHS

High Blood

Hypertension

Overweight or

Pressure

Category

Obese

CPCSSN

CCHS

CPCSSN

Obesity Category

Diabetes

Diabetes Category

Females (Age Category, Years)
18 – 34

1.9 (1.6 – 2.1)

1.0 (1.0 – 1.2)

33.0 (32.2 – 33.8)

19.7 (19.3 – 20.0)

1.1 (0.9 – 1.3)

0.8 (0.7 – 0.8)

35 – 44

5.9 (5.4 – 6.5)

2.9 (2.8 – 3.1)

44.9 (43.9 – 46.0)

25.3 (24.9 – 25.8)

3.3 (2.9 – 3.7)

1.2 (1.1 – 1.3)

45 – 64

24.9 (24.3 – 25.4)

9.4 (9.2 – 9.6)

53.4 (52.8 – 54.1)

26.3 (26.0 – 26.6)

8.8 (8.4 – 9.1)

2.7 (2.6 – 2.8)

65 – 79

48.3 (47.6 – 49.1)

21.0 (20.6 – 21.4)

55.8 (55.0 – 56.7)

23.4 (23.0 – 23.8)

15.8 (15.2 – 16.4)

6.1 (5.9 – 6.4)

≥ 80 **

56.4 (55.1 – 57.6)

28.9 (28.3 – 29.6)

41.0 (39.7 – 42.2)

13.1 (12.7 – 13.6)

15.2 (14.3 – 16.1)

6.9 (6.6 – 7.3)

Males (Age Category, Years)
18 – 34

2.8 (2.5 – 3.1)

1.6 (1.5 – 1.7)

46.4 (45.4 – 47.3)

18.8 (18.4 – 19.3)

0.9 (0.7 – 1.1)

0.8 (0.7 – 1.0)

35 – 44

9.2 (8.6 – 9.9)

4.5 (4.2 – 4.7)

66.7 (65.6 – 67.8)

27.6 (27.0 – 28.1)

3.1 (2.6 – 3.5)

1.8 (1.7 – 2.0)

45 – 64

28.9 (28.3 – 29.6)

11.6 (11.3 – 11.8)

69.1 (68.4 – 69.7)

31.8 (31.4 – 32.1)

11.2 (10.7 – 11.6)

4.5 (4.4 – 4.7)

65 – 79

46.3 (45.5 – 47.2)

19.4 (19.0 – 19.9)

65.4 (64.6 – 66.2)

28.2 (27.7 – 28.8)

21.6 (20.9 – 22.4)

9.3 (9.0 – 9.7)

≥ 80 **

46.9 (45.2 – 48.6)

23.0 (22.3 – 23.7)

44.8 (43.2 – 46.5)

18.5 (17.8 – 19.1)

18.4 (17.2 – 19.7)

9.5 (9.0 – 10.0)

Note: All prevalence estimates and 95% CIs calculated by author
* CI = Confidence interval
** The oldest age category in the 2013 CCHS was 80 years and older
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Appendix J: Comparative prevalence estimates for selected self-reported chronic disease diagnoses from the 2013 Canadian
Community Health Survey (CCHS) and the chronic disease categories from the Canadian Primary Care Sentinel Surveillance
Network (CPCSSN) electronic medical record (EMR) data, Continued
Prevalence (95% CI)
Data Source

Disease Category

CCHS

CCHS

CPCSSN

CCHS

CPCSSN

Cancer

Cancer Category

Chronic Obstructive

Chronic Obstructive

Asthma

Pulmonary Disease

Pulmonary Disease or
Asthma Category

Females (Age Category, Years)
18 – 34

Not Reported

10.4 (9.9 – 11.0)

3.9 (3.8 – 4.1)

0.3 (0.2 – 0.4)

4.9 (4.7 – 5.1)

35 – 44

1.6 (1.3 – 1.9)

10.0 (9.4 – 10.7)

3.9 (3.7 – 4.1)

0.8 (0.6 – 1.0)

5.7 (5.5 – 6.0)

45 – 64

5.0 (4.8 – 5.3)

9.6 (9.2 – 10.0)

3.2 (3.1 – 3.3)

2.5 (2.4 – 2.8)

5.9 (5.8 – 6.1)

65 – 79

8.5 (8.1 – 9.0)

9.2 (8.8 – 9.7)

2.5 (2.3 – 2.6)

4.8 (4.5 – 5.2)

5.2 (5.0 – 5.4)

≥ 80 **

8.0 (7.4 – 8.7)

6.8 (6.2 – 7.4)

2.0 (1.8 – 2.2)

5.4 (4.9 – 6.0)

4.8 (4.5 – 5.1)

18 – 34

Not Reported

8.5 (8.0 – 9.0)

4.5 (4.3 – 4.8)

0.2 (0.1 – 0.3)

3.2 (3.0 – 3.4)

35 – 44

1.3 (1.0 – 1.6)

7.0 (6.5 – 7.7)

3.7 (3.5 – 4.0)

0.3 (0.2 – 0.4)

3.2 (3.0 – 3.4)

45 – 64

4.6 (4.3 – 4.9)

6.3 (5.9 – 6.6)

2.5 (2.4 – 2.6)

2.4 (2.2 – 2.6)

3.4 (3.2 – 3.5)

65 – 79

7.3 (6.8 – 7.7)

6.0 (5.6 – 6.4)

1.9 (1.8 – 2.1)

6.1 (5.7 – 6.5)

4.9 (4.7 – 5.2)

≥ 80 **

9.1 (8.1 – 10.1)

6.5 (5.7 – 7.4)

2.1 (1.8 – 2.3)

9.6 (8.6 – 10.6)

7.0 (6.6 – 7.4)

Males (Age Category, Years)

Note: All prevalence estimates and 95% CIs calculated by author
* CI = Confidence interval
** The oldest age category in the 2013 CCHS was 80 years and older
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Appendix J: Comparative prevalence estimates for selected self-reported chronic disease diagnoses from the 2013 Canadian
Community Health Survey (CCHS) and the chronic disease categories from the Canadian Primary Care Sentinel Surveillance
Network (CPCSSN) electronic medical record (EMR) data, Continued
Prevalence (95% CI)
Data Source

CCHS

Disease Category

Heart Disease

CPCSSN
Cardiovascular Disease
Category

CCHS

CCHS

Anxiety

Depression

CPCSSN
Anxiety or Depression
Category

Females (Age Category, Years)
18 – 34

0.8 (0.7 – 1.0)

0.6 (0.5 – 0.7)

11.5 (11.0 – 12.1)

33.0 (32.2 – 33.8)

12.1 (11.8 – 12.4)

35 – 44

1.0 (0.8 – 1.3)

0.7 (0.6 – 0.8)

9.7 (9.1 – 10.4)

32.2 (31.2 – 33.2)

12.1 (11.8 – 12.4)

45 – 64

4.1 (3.8 – 4.3)

1.0 (0.9 – 1.1)

9.7 (9.3 – 10.1)

33.9 (33.3 – 34.5)

9.6 (9.4 – 9.8)

65 – 79

11.8 (11.3 – 12.3)

2.1 (1.9 – 2.2)

6.6 (6.2 – 7.0)

33.3 (32.6 – 34.0)

5.2 (5.0 – 5.5)

≥ 80 **

23.1 (22.0 – 24.1)

5.5 (5.2 – 5.9)

4.1 (3.7 – 4.7)

31.7 (30.5 – 32.9)

3.6 (3.4 – 3.9)

18 – 34

0.8 (0.6 – 0.9)

0.6 (0.5 – 0.7)

6.6 (6.1 – 7.1)

31.9 (31.0 – 32.7)

10.7 (10.3 – 11.0)

35 – 44

1.6 (1.3 – 1.9)

0.6 (0.5 – 0.7)

6.2 (5.7 – 6.8)

32.4 (31.3 – 33.5)

8.9 (8.5 – 9.2)

45 – 64

7.7 (7.3 – 8.1)

1.7 (1.6 – 1.8)

5.9 (5.6 – 6.2)

33.3 (32.6 – 33.9)

5.8 (5.6 – 6.0)

65 – 79

19.1 (18.4 – 19.8)

4.8 (4.5 – 5.0)

3.7 (3.4 – 4.0)

34.0 (33.2 – 34.9)

3.0 (2.8 – 3.2)

≥ 80 **

26.0 (24.5 – 27.5)

8.3 (7.9 – 8.8)

2.6 (2.1 – 3.2)

29.9 (28.4 – 31.4)

2.1 (1.9 – 2.4)

Males (Age Category, Years)

Note: All prevalence estimates and 95% CIs calculated by author
* CI = Confidence interval
** The oldest age category in the 2013 CCHS was 80 years and older
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Appendix J: Comparative prevalence estimates for selected self-reported chronic disease diagnoses from the 2013 Canadian
Community Health Survey (CCHS) and the chronic disease categories from the Canadian Primary Care Sentinel Surveillance
Network (CPCSSN) electronic medical record (EMR) data, Continued
Prevalence (95% CI)
Data Source

CCHS

CPCSSN

CCHS

Osteoarthritis or
Disease Category

Arthritis

Rheumatoid Arthritis

CPCSSN

CCHS

Stroke or Transient
Stroke

Category

Ischemic Attack

Back Problems

Category

CPCSSN
Musculoskeletal
Problem Category

Females (Age Category, Years)
18 – 34

3.1 (2.8 – 3.4)

0.4 (0.4 – 0.5)

2.0 (1.8 – 2.3)

0.01 (0.0 – 0.02)

14.1 (13.5 – 14.7)

7.1 (6.8 – 7.3)

35 – 44

8.7 (8.1 – 9.3)

0.8 (0.7 – 0.9)

2.2 (1.9 – 2.5)

0.02 (0.01 – 0.05)

18.2 (17.4 – 19.1)

9.5 (9.2 – 9.8)

45 – 64

30.4 (29.8 – 31.0)

2.7 (2.6 – 2.8)

3.5 (3.3 – 3.8)

0.05 (0.04 – 0.07)

25.4 (24.8 – 26.0)

10.7 (10.5 – 11.0)

65 – 79

50.0 (48.9 – 50.5)

4.9 (4.7 – 5.1)

3.6 (3.4 – 3.9)

0.2 (0.1 – 0.2)

26.6 (25.9 – 27.3)

6.5 (6.2 – 6.7)

≥ 80 **

57.2 (55.9 – 58.4)

5.7 (5.4 – 6.0)

3.6 (3.2 – 4.1)

0.5 (0.4 – 0.6)

28.3 (27.2 – 29.5)

5.2 (4.9 – 5.5)

Males (Age Category, Years)
18 – 34

2.4 (2.1 – 2.7)

0.5 (0.4 – 0.6)

1.7 (1.5 – 2.0)

0.01 (0.01 – 0.04)

10.5 (9.9 – 11.1)

9.9 (9.6 – 10.3)

35 – 44

7.1 (6.5 – 7.7)

0.9 (0.8 – 1.0)

2.2 (1.9 – 2.5)

0.01 (0.00 – 0.03)

19.0 (18.1 – 20.0)

12.5 (12.1 – 12.9)

45 – 64

21.1 (20.5 – 21.7(

2.2 (2.1 – 2.3)

2.9 (2.6 – 3.2)

0.1 (0.1 – 0.2)

25.8 (25.2 – 26.4)

10.8 (10.6 – 11.1)

65 – 79

34.1 (33.2 – 34.9)

3.5 (3.2 – 3.7)

2.9 (2.6 – 3.2)

0.1 (0.1 – 0.2)

25.6 (24.8 – 26.4)

5.6 (5.3 – 5.8)

≥ 80 **

42.1 (40.4 – 43.7)

4.1 (3.8 – 4.4)

3.2 (2.6 – 3.8)

0.5 (0.4 – 0.7)

24.3 (22.9 – 25.8)

4.5 (4.1 – 4.9)

Note: All prevalence estimates and 95% CIs calculated by author
* CI = Confidence interval
** The oldest age category in the 2013 CCHS was 80 years and older

289

Appendix J: Comparative prevalence estimates for selected self-reported chronic disease diagnoses from the 2013 Canadian
Community Health Survey (CCHS) and the chronic disease categories from the Canadian Primary Care Sentinel Surveillance
Network (CPCSSN) electronic medical record (EMR) data, Continued
Prevalence (95% CI)
Data Source

CCHS

CPCSSN

CCHS

CPCSSN

Disease Category

Stomach Problems

Stomach Problem Category

Bowel Problems

Colon Problem Category

18 – 34

1.1 (0.9 – 1.3)

0.7 (0.6 – 0.8)

0.2 (0.1 – 0.3)

1.8 (1.7 – 1.9)

35 – 44

3.0 (2.7 – 3.4)

0.7 (0.7 – 0.8)

0.4 (0.2 – 0.5)

1.3 (1.2 – 1.5)

45 – 64

9.0 (8.7 – 9.4)

0.8 (0.8 – 0.9)

1.3 (1.1 – 1.4)

1.1 (1.0 – 1.2)

65 – 79

16.4 (15.8 – 17.0)

0.9 (0.8 – 1.0)

2.5 (2.3 – 2.8)

0.8 (0.7 – 0.9)

≥ 80 **

20.6 (19.6 – 21.7)

0.7 (0.6 – 0.8)

5.2 (4.7 – 5.8)

0.6 (0.5 – 0.7)

18 – 34

0.5 (0.4 – 0.7)

1.1 (1.0 – 1.2)

0.1 (0.1 – 0.2)

1.1 (1.0 – 1.3)

35 – 44

1.2 (1.0 – 1.5)

1.2 (1.1 – 1.4)

0.4 (0.3 – 0.6)

1.0 (0.9 – 1.1)

45 – 64

4.9 (4.6 – 5.2)

1.0 (0.9 – 1.1)

1.5 (1.3 – 1.7)

0.7 (0.6 – 0.8)

65 – 79

15.3 (14.7 – 16.0)

0.8 (0.7 – 0.9)

4.0 (3.6 – 4.3)

0.6 (0.5 – 0.7)

≥ 80 **

22.0 (20.6 – 23.5)

0.6 (0.5 – 0.8)

6.1 (5.4 – 7.0)

0.7 (0.6 – 0.9)

Females (Age Category, Years)

Males (Age Category, Years)

Note: All prevalence estimates and 95% CIs calculated by author
* CI = Confidence interval
** The oldest age category in the 2013 CCHS was 80 years and older
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Appendix K: Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases,
among female patients of all ages with multimorbidity (n = 113,209)
Total Number of
Chronic Diseases
2
(n = 41,890)

Combinations*

Anxiety or Depression & Obesity
Musculoskeletal Problem & Obesity
Hypertension & Obesity
Cancer & Obesity
Anxiety or Depression & Musculoskeletal Problem
3
Anxiety or Depression & Musculoskeletal Problem & Obesity
(n = 29,597)
Hypertension & Musculoskeletal Problem & Obesity
Diabetes & Hypertension & Obesity
Anxiety or Depression & Cancer & Obesity
Anxiety or Depression & Hypertension & Obesity
4
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity
(n = 19,043)
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid Arthritis
Diabetes & Hyperlipidemia & Hypertension & Obesity
≥5
Anxiety or Depression & Cancer & Hypertension & Musculoskeletal Problem & Obesity
(n = 22,679)
Diabetes & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or
Rheumatoid Arthritis
Anxiety or Depression & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or
Rheumatoid Arthritis
* Combinations listed in alphabetical order

Total Number
of Patients
3,991
3,837
3,491
2,791
2,291
1,621
1,019
869
854
816
454
428
346
329
308
155
149
138

% of Female
Patients, All Ages
3.5
3.4
3.1
2.5
2.0
1.4
0.9
0.8
0.8
0.7
0.4
0.4
0.3
0.3
0.3
0.1
0.1
0.1

138
115

0.1
0.1
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Appendix L: Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among
female patients aged 18 – 34 years with multimorbidity (n = 11,507)
Total Number of
Chronic Diseases
2
(n = 7,143)

Combinations*

Anxiety or Depression & Obesity
Musculoskeletal Problem & Obesity
Anxiety or Depression & Musculoskeletal Problem
Cancer & Obesity
Anxiety or Depression & Cancer
3
Anxiety or Depression & Musculoskeletal Problem & Obesity
(n = 2,914)
Anxiety or Depression & Cancer & Obesity
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Obesity
Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal Problem & Obesity
Cancer & Musculoskeletal Problem & Obesity
4
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity
(n = 1,026)
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal
Problem & Obesity
Anxiety or Depression & Musculoskeletal Problem & Obesity & Urinary Problem
Anxiety or Depression & Musculoskeletal Problem & Obesity & Thyroid Problem
Anxiety or Depression & Colon Problem & Musculoskeletal Problem & Obesity
≥5
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity & Thyroid Problem
(n = 424)
Anxiety or Depression & Cancer & Chronic Obstructive Pulmonary Disease or Asthma &
Musculoskeletal Problem & Obesity
Anxiety or Depression & Cancer & Colon Problem & Musculoskeletal Problem & Obesity
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity & Urinary Problem
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Colon Problem &
Musculoskeletal Problem & Obesity
* Combinations listed in alphabetical order

Total Number
of Patients
1,197
817
608
581
332
373
205
131
104
100
68
58

% of Female Patients,
18 – 34 Years
10.4
7.1
5.3
5.0
2.9
3.2
1.8
1.1
0.9
0.9
0.6
0.5

37
28
28
10
10

0.3
0.2
0.2
0.1
0.1

9
9
8

0.1
0.1
0.1
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Appendix M: Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases,
among female patients aged 35 – 44 years with multimorbidity (n = 14,756)
Total Number of
Chronic Diseases
2
(n = 7,696)

Combinations*

Anxiety or Depression & Obesity
Musculoskeletal Problem & Obesity
Cancer & Obesity
Anxiety or Depression & Musculoskeletal Problem
Hypertension & Obesity
3
Anxiety or Depression & Musculoskeletal Problem & Obesity
(n = 4,145)
Anxiety or Depression & Cancer & Obesity
Cancer & Musculoskeletal Problem & Obesity
Anxiety or Depression & Cancer & Musculoskeletal Problem
Anxiety or Depression & Obesity & Thyroid Problem
4
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity
(n = 1,834)
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal
Problem & Obesity
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity
Anxiety or Depression & Musculoskeletal Problem & Obesity & Thyroid Problem
Anxiety or Depression & Musculoskeletal Problem & Obesity & Urinary Problem
≥5
Anxiety or Depression & Cancer & Hypertension & Musculoskeletal Problem & Obesity
(n = 1,081)
Anxiety or Depression & Cancer & Chronic Obstructive Pulmonary Disease or Asthma &
Musculoskeletal Problem & Obesity
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Hypertension &
Musculoskeletal Problem & Obesity
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity & Thyroid Problem
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal
Problem & Obesity & Thyroid Problem
* Combinations listed in alphabetical order

Total Number
of Patients
1,140
1,034
654
634
338
483
234
170
156
130
110
86

% of Female Patients,
35 – 44 Years
7.7
7.0
4.4
4.3
2.3
3.3
1.6
1.2
1.1
0.9
0.7
0.6

76
56
54
24
24

0.5
0.4
0.4
0.2
0.2

22

0.1

22
13

0.1
0.1
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Appendix N: Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among
female patients aged 45 – 64 years with multimorbidity (n = 44,712)
Total Number of
Chronic Diseases
2
(n = 17,048)

Combinations*

Musculoskeletal Problem & Obesity
Hypertension & Obesity
Anxiety or Depression & Obesity
Cancer & Obesity
Anxiety or Depression & Musculoskeletal Problem
3
Anxiety or Depression & Musculoskeletal Problem & Obesity
(n = 12,480)
Hypertension & Musculoskeletal Problem & Obesity
Cancer & Musculoskeletal Problem & Obesity
Anxiety or Depression & Hypertension & Obesity
Hyperlipidemia & Hypertension & Obesity
4
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity
(n = 7,693)
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
Anxiety or Depression & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid
Arthritis
Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid Arthritis
≥5
Anxiety or Depression & Cancer & Hypertension & Musculoskeletal Problem & Obesity
(n = 7,491)
Anxiety or Depression & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
Diabetes & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or
Rheumatoid Arthritis
Anxiety or Depression & Diabetes & Hypertension & Musculoskeletal Problem & Obesity
* Combinations listed in alphabetical order

Total Number
of Patients
1,693
1,595
1,439
1,181
935
680
551
426
425
360
238
222
187
139

% of Female Patients,
45 – 64 Years
3.8
3.6
3.2
2.6
2.1
1.5
1.2
1.0
1.0
0.8
0.5
0.5
0.4
0.3

130
86
81
76
64

0.3
0.2
0.2
0.2
0.1

58

0.1
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Appendix O: Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases,
among female patients aged 65 – 84 years with multimorbidity (n = 33,264)
Total Number of
Chronic Diseases
2
(n = 7,820)

Combinations*

Hypertension & Obesity
Diabetes & Obesity
Cancer & Obesity
Hyperlipidemia & Hypertension
Musculoskeletal Problem & Obesity
3
Diabetes & Hypertension & Obesity
(n = 8,016)
Hyperlipidemia & Hypertension & Obesity
Hypertension & Musculoskeletal Problem & Obesity
Hypertension & Obesity & Osteoarthritis or Rheumatoid Arthritis
Cancer & Hypertension & Obesity
4
Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid Arthritis
(n = 6,811)
Diabetes & Hyperlipidemia & Hypertension & Obesity
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
Diabetes & Hypertension & Musculoskeletal Problem & Obesity
Diabetes & Hypertension & Obesity & Osteoarthritis or Rheumatoid Arthritis
≥5
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or
(n = 10,617)
Rheumatoid Arthritis
Diabetes & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
Diabetes & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid
Arthritis
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity & Thyroid Problem
Cancer & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid
Arthritis
* Combinations listed in alphabetical order

Total Number
of Patients
1,181
446
343
323
275
427
386
292
269
252
158
153
141
131
110
69

% of Female Patients,
65 – 84 Years
3.6
1.3
1.0
1.0
0.8
1.3
1.2
0.9
0.8
0.8
0.5
0.5
0.4
0.4
0.3
0.2

66
63

0.2
0.2

56
50

0.2
0.2
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Appendix P: Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among
female patients aged 85 years and older with multimorbidity (n = 8,970)
Total Number of
Chronic Diseases
2
(n = 2,183)

Combinations*

Hypertension & Obesity
Dementia & Hypertension
Cardiovascular Disease & Hypertension
Diabetes & Hypertension
Cancer & Hypertension
3
Diabetes & Hypertension & Obesity
(n = 2,042)
Hypertension & Obesity & Osteoarthritis or Rheumatoid Arthritis
Cancer & Hypertension & Obesity
Hypertension & Musculoskeletal Problem & Obesity
Cardiovascular Disease & Hypertension & Obesity
4
Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid Arthritis
(n = 1,679)
Cardiovascular Disease & Hypertension & Musculoskeletal Problem & Osteoarthritis or
Rheumatoid Arthritis
Anxiety or Depression & Hypertension & Obesity & Osteoarthritis or Rheumatoid Arthritis
Cardiovascular Disease & Diabetes & Hypertension & Obesity
Diabetes & Hypertension & Obesity & Osteoarthritis or Rheumatoid Arthritis
≥5
Cardiovascular Disease & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or
(n = 3,066)
Rheumatoid Arthritis
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or
Rheumatoid Arthritis
Cancer & Cardiovascular Disease & Hypertension & Obesity & Osteoarthritis or Rheumatoid
Arthritis
Dementia & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid
Arthritis
Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid Arthritis &
Thyroid Problem
* Combinations listed in alphabetical order

Total Number
of Patients
212
151
126
99
98
59
54
53
46
46
33
21

% of Female Patients,
≥ 85 Years
2.4
1.7
1.4
1.1
1.1
0.7
0.6
0.6
0.5
0.5
0.4
0.2

20
17
16
14

0.2
0.2
0.2
0.2

14

0.2

12

0.1

11

0.1

10

0.1
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Appendix Q: Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases,
among male patients of all ages with multimorbidity (n = 82,622)
Total Number of
Chronic Diseases
2
(n = 32,080)

Combinations*

Hypertension & Obesity
Musculoskeletal Problem & Obesity
Anxiety or Depression & Obesity
Hyperlipidemia & Obesity
Diabetes & Obesity
3
Hyperlipidemia & Hypertension & Obesity
(n = 22,010)
Diabetes & Hypertension & Obesity
Hypertension & Musculoskeletal Problem & Obesity
Anxiety or Depression & Musculoskeletal Problem & Obesity
Hyperlipidemia & Musculoskeletal Problem & Obesity
4
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
(n = 13,823)
Diabetes & Hyperlipidemia & Hypertension & Obesity
Diabetes & Hypertension & Musculoskeletal Problem & Obesity
Cancer & Hyperlipidemia & Hypertension & Obesity
Cancer & Hypertension & Musculoskeletal Problem & Obesity
≥5
Diabetes & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
(n = 14,709)
Cancer & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
Anxiety or Depression & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or
Rheumatoid Arthritis
Cancer & Diabetes & Hyperlipidemia & Hypertension & Obesity
* Combinations listed in alphabetical order

Total Number
of Patients
3,866
3,580
2,431
2,109
1,966
1,389
1,226
1,061
823
755
551
539
376
283
244
254
138
127
97

% of Male
Patients, All Ages
4.7
4.3
2.9
2.6
2.4
1.7
1.5
1.3
1.0
0.9
0.7
0.7
0.5
0.3
0.3
0.3
0.2
0.2
0.1

93

0.1
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Appendix R: Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among
male patients aged 18 – 34 years with multimorbidity (n = 5,959)
Total Number of
Chronic Diseases
2
(n = 4,204)

3
(n = 1,331)

4
(n = 327)

Combinations*
Anxiety or Depression & Obesity
Musculoskeletal Problem & Obesity
Anxiety or Depression & Musculoskeletal Problem
Chronic Obstructive Pulmonary Disease or Asthma & Obesity
Cancer & Obesity
Anxiety or Depression & Musculoskeletal Problem & Obesity
Cancer & Musculoskeletal Problem & Obesity
Anxiety or Depression & Cancer & Obesity
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal
Problem
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Obesity
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal
Problem & Obesity
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity
Diabetes & Hyperlipidemia & Hypertension & Obesity
Anxiety or Depression & Colon Problem & Musculoskeletal Problem & Obesity

Total Number
of Patients
713
648
422
260
227
171
67
60
53

% of Male Patients,
18 – 34 Years
12.0
10.9
7.1
4.4
3.8
2.9
1.1
1.0
0.9

52
18
18

0.9
0.3
0.3

13
10
10

0.2
0.2
0.2

≥5
(n = 97)
Results Supressed (<5 Patients)

* Combinations listed in alphabetical order

298

Appendix S: Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among
male patients aged 35 – 44 years with multimorbidity (n = 9,098)
Total Number of
Chronic Diseases
2
(n = 5,439)

Combinations*

Musculoskeletal Problem & Obesity
Anxiety or Depression & Obesity
Hypertension & Obesity
Anxiety or Depression & Musculoskeletal Problem
Hyperlipidemia & Obesity
3
Anxiety or Depression & Musculoskeletal Problem & Obesity
(n = 2,357)
Hypertension & Musculoskeletal Problem & Obesity
Cancer & Musculoskeletal Problem & Obesity
Hyperlipidemia & Hypertension & Obesity
Hyperlipidemia & Musculoskeletal Problem & Obesity
4
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
(n = 873)
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity
Diabetes & Hyperlipidemia & Hypertension & Obesity
Chronic Obstructive Pulmonary Disease or Asthma & Hypertension & Musculoskeletal Problem &
Obesity
≥5
Anxiety or Depression & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
(n = 429)
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Hypertension &
Musculoskeletal Problem & Obesity
Chronic Obstructive Pulmonary Disease or Asthma & Diabetes & Hypertension & Musculoskeletal
Problem & Obesity
Anxiety or Depression & Diabetes & Hypertension & Musculoskeletal Problem & Obesity
Diabetes & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
* Combinations listed in alphabetical order

Total Number
of Patients
932
653
479
369
340
241
127
122
104
99
31
30
28
24
22

% of Male Patients,
35 – 44 Years
10.2
7.2
5.3
4.1
3.7
2.6
1.4
1.3
1.1
1.1
0.3
0.3
0.3
0.3
0.2

13
10

0.1
0.1

7

0.1

7
6

0.1
0.1
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Appendix T: Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among
male patients aged 45 – 64 years with multimorbidity (n = 34,856)
Total Number of
Chronic Diseases
2
(n = 14,268)

Combinations*

Hypertension & Obesity
Musculoskeletal Problem & Obesity
Hyperlipidemia & Obesity
Diabetes & Obesity
Anxiety or Depression & Obesity
3
Hyperlipidemia & Hypertension & Obesity
(n = 10,148)
Hypertension & Musculoskeletal Problem & Obesity
Diabetes & Hypertension & Obesity
Hyperlipidemia & Musculoskeletal Problem & Obesity
Anxiety or Depression & Musculoskeletal Problem & Obesity
4
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
(n = 5,834)
Diabetes & Hyperlipidemia & Hypertension & Obesity
Diabetes & Hypertension & Musculoskeletal Problem & Obesity
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity
Anxiety or Depression & Hyperlipidemia & Hypertension & Obesity
≥5
Diabetes & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
(n = 4,606)
Anxiety or Depression & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
Cancer & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
Cardiovascular Disease & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
Anxiety or Depression & Diabetes & Hyperlipidemia & Hypertension & Obesity
* Combinations listed in alphabetical order

Total Number
of Patients
1,999
1,725
1,310
937
919
785
605
559
532
378
347
277
188
145
137
148
75
62
45
44

% of Male Patients,
45 – 64 Years
5.7
4.9
3.8
2.7
2.6
2.3
1.7
1.6
1.5
1.1
1.0
0.8
0.5
0.4
0.4
0.4
0.2
0.2
0.1
0.1
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Appendix U: Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among
male patients aged 65 – 84 years with multimorbidity (n = 27,430)
Total Number of
Chronic Diseases
2
(n = 6,914)

Combinations*

Hypertension & Obesity
Diabetes & Obesity
Cancer & Obesity
Hyperlipidemia & Obesity
Cardiovascular Disease & Obesity
3
Diabetes & Hypertension & Obesity
(n = 6,981)
Hyperlipidemia & Hypertension & Obesity
Cancer & Hypertension & Obesity
Hypertension & Musculoskeletal Problem & Obesity
Cardiovascular Disease & Hypertension & Obesity
4
Diabetes & Hyperlipidemia & Hypertension & Obesity
(n = 5,768)
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
Diabetes & Hypertension & Musculoskeletal Problem & Obesity
Cancer & Hyperlipidemia & Hypertension & Obesity
Cardiovascular Disease & Diabetes & Hypertension & Obesity
≥5
Diabetes & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
(n = 7,767)
Cancer & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or
Rheumatoid Arthritis
Cancer & Diabetes & Hyperlipidemia & Hypertension & Obesity
Diabetes & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid
Arthritis
* Combinations listed in alphabetical order

Total Number
of Patients
1,092
678
377
361
267
536
468
262
258
237
221
159
158
146
143
95
68
61

% of Male Patients,
65 – 84 Years
4.0
2.5
1.4
1.3
1.0
2.0
1.7
1.0
0.9
0.9
0.8
0.6
0.6
0.5
0.5
0.3
0.2
0.2

54
53

0.2
0.2
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Appendix V: Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among
male patients aged 85 years and older with multimorbidity (n = 5,279)
Total Number of
Chronic Diseases
2
(n = 1,255)

Combinations*

Hypertension & Obesity
Cancer & Hypertension
Cardiovascular Disease & Hypertension
Diabetes & Obesity
Diabetes & Hypertension
3
Diabetes & Hypertension & Obesity
(n = 1,193)
Cardiovascular Disease & Hypertension & Obesity
Cancer & Hypertension & Obesity
Hypertension & Musculoskeletal Problem & Obesity
Cancer & Cardiovascular Disease & Hypertension
4
Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid Arthritis
(n = 1,021)
Cancer & Cardiovascular Disease & Hypertension & Obesity
Cardiovascular Disease & Diabetes & Hypertension & Obesity
Cancer & Diabetes & Hypertension & Obesity
Cancer & Hypertension & Musculoskeletal Problem & Obesity
≥5
Cancer & Cardiovascular Disease & Hypertension & Musculoskeletal Problem & Obesity
(n = 1,810)
Cancer & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid
Arthritis
Cancer & Hypertension & Musculoskeletal Problem & Osteoarthritis or Rheumatoid Arthritis &
Urinary Problem
Cancer & Hypertension & Obesity & Osteoarthritis or Rheumatoid Arthritis & Urinary Problem
Cardiovascular Disease & Dementia & Hypertension & Obesity & Osteoarthritis or Rheumatoid
Arthritis
* Combinations listed in alphabetical order

Total Number
of Patients
124
71
63
62
58
53
38
29
28
25
23
23
18
17
12
8
7

% of Male Patients,
≥ 85 Years
2.3
1.3
1.2
1.2
1.1
1.0
0.7
0.5
0.5
0.5
0.4
0.4
0.3
0.3
0.2
0.2
0.1

7

0.1

7
6

0.1
0.1
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Appendix W: Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases,
among female patients of all ages with multimorbidity (n = 113,209)
Total Number of
Chronic Diseases
2
(n = 41,890)

Permutations*

Obesity >> Musculoskeletal Problem
Obesity >> Anxiety or Depression
Obesity >> Cancer
Obesity >> Hypertension
Anxiety or Depression >> Obesity
3
Obesity >> Anxiety or Depression >> Musculoskeletal Problem
(n = 29,597)
Obesity >> Musculoskeletal Problem >> Anxiety or Depression
Hypertension >> Obesity >> Musculoskeletal Problem
Anxiety or Depression >> Obesity >> Musculoskeletal Problem
Obesity >> Hypertension >> Musculoskeletal Problem
4
Obesity >> Hypertension >> Anxiety or Depression >> Musculoskeletal Problem
(n = 19,043)
Obesity >> Anxiety or Depression >> Cancer >> Musculoskeletal Problem
Hypertension >> Obesity >> Hyperlipidemia >> Musculoskeletal Problem
Obesity >> Hypertension >> Musculoskeletal Problem >> Osteoarthritis or Rheumatoid Arthritis
Hypertension >> Obesity >> Musculoskeletal Problem >> Hyperlipidemia
≥5
Obesity >> Hypertension >> Hyperlipidemia >> Musculoskeletal Problem >> Anxiety or
(n = 22,679)
Depression
Hypertension >> Obesity >> Hyperlipidemia >> Musculoskeletal Problem >> Osteoarthritis or
Rheumatoid Arthritis
Hypertension >> Diabetes >> Obesity >> Hyperlipidemia >> Cancer
Obesity >> Hypertension >> Hyperlipidemia >> Cancer >> Musculoskeletal Problem
Hypertension >> Obesity >> Diabetes >> Musculoskeletal Problem >> Cancer
* Permutations listed in sequential order

Total Number
of Patients
2,455
2,286
1,942
1,869
1,705
389
311
275
274
252
39
37
36
36
35
7

% of Female
Patients, All Ages
2.2
2.0
1.7
1.7
1.5
0.3
0.3
0.2
0.2
0.2
0.0
0.0
0.0
0.0
0.0
0.0

6

0.0

6
6
5

0.0
0.0
0.0
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Appendix X: Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among
female patients aged 18 – 34 years with multimorbidity (n = 11,507)
Total Number of
Chronic Diseases
2
(n = 7,143)

3
(n = 2,914)

4
(n = 1,026)

Permutations*
Obesity >> Anxiety or Depression
Anxiety or Depression >> Obesity
Obesity >> Musculoskeletal Problem
Obesity >> Cancer
Anxiety or Depression >> Musculoskeletal Problem
Obesity >> Musculoskeletal Problem >> Anxiety or Depression
Obesity >> Anxiety or Depression >> Musculoskeletal Problem
Anxiety or Depression >> Obesity >> Musculoskeletal Problem
Obesity >> Cancer >> Anxiety or Depression
Obesity >> Anxiety or Depression >> Cancer
Obesity >> Anxiety or Depression >> Cancer >> Musculoskeletal Problem
Obesity >> Cancer >> Anxiety or Depression >> Musculoskeletal Problem
Chronic Obstructive Pulmonary Disease or Asthma >> Obesity >> Anxiety or Depression >>
Musculoskeletal Problem
Thyroid Problem >> Anxiety or Depression >> Obesity >> Musculoskeletal Problem
Obesity >> Chronic Obstructive Pulmonary Disease or Asthma >> Musculoskeletal Problem >>
Anxiety or Depression

Total Number
of Patients
667
530
507
400
351
92
76
57
54
53
8
7
7

% of Female Patients,
18 – 34 Years
5.8
4.6
4.4
3.5
3.1
0.8
0.7
0.5
0.5
0.5
0.1
0.1
0.1

6
6

0.1
0.1

≥5
(n = 424)
Results Supressed (<5 Patients)

* Permutations listed in sequential order
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Appendix Y: Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among
female patients aged 35 – 44 years with multimorbidity (n = 14,756)
Total Number of
Chronic Diseases
2
(n = 7,696)

3
(n = 4,145)

4
(n = 1,834)

Total Number
of Patients
665

% of Female Patients,
35 – 44 Years
4.5

Obesity >> Musculoskeletal Problem

653

4.4

Anxiety or Depression >> Obesity

475

3.2

Obesity >> Cancer

429

2.9

Musculoskeletal Problem >> Obesity

381

2.6

Obesity >> Anxiety or Depression >> Musculoskeletal Problem

132

0.9

Obesity >> Musculoskeletal Problem >> Anxiety or Depression

88

0.6

Anxiety or Depression >> Obesity >> Musculoskeletal Problem

75

0.5

Obesity >> Anxiety or Depression >> Cancer

72

0.5

Anxiety or Depression >> Musculoskeletal Problem >> Obesity

69

0.5

Anxiety or Depression >> Musculoskeletal Problem >> Obesity >> Cancer

11

0.1

Obesity >> Anxiety or Depression >> Cancer >> Musculoskeletal Problem

10

0.1

Anxiety or Depression >> Obesity >> Musculoskeletal Problem >> Cancer

10

0.1

Obesity >> Chronic Obstructive Pulmonary Disease or Asthma >> Anxiety or Depression >>
Musculoskeletal Problem
Hypertension >> Obesity >> Musculoskeletal Problem >> Anxiety or Depression

9

0.1

8

0.1

Permutations*
Obesity >> Anxiety or Depression

≥5
(n = 1,081)
Results Supressed (<5 Patients)

* Permutations listed in sequential order
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Appendix Z: Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among
female patients aged 45 – 64 years with multimorbidity (n = 44,712)
Total Number of
Chronic Diseases
2
(n = 17,048)

3
(n = 12,480)

4
(n = 7,693)

≥5
(n = 7,491)

Permutations*
Obesity >> Musculoskeletal Problem
Obesity >> Hypertension
Obesity >> Cancer
Obesity >> Anxiety or Depression
Hypertension >> Obesity
Obesity >> Anxiety or Depression >> Musculoskeletal Problem
Hypertension >> Obesity >> Musculoskeletal Problem
Obesity >> Hypertension >> Musculoskeletal Problem
Anxiety or Depression >> Obesity >> Musculoskeletal Problem
Hypertension >> Obesity >> Hyperlipidemia
Hypertension >> Obesity >> Musculoskeletal Problem >> Hyperlipidemia
Hypertension >> Obesity >> Musculoskeletal Problem >> Anxiety or Depression
Obesity >> Hypertension >> Anxiety or Depression >> Musculoskeletal Problem
Hypertension >> Obesity >> Hyperlipidemia >> Musculoskeletal Problem
Obesity >> Hypertension >> Hyperlipidemia >> Musculoskeletal Problem
Obesity >> Hypertension >> Hyperlipidemia >> Musculoskeletal Problem >> Anxiety or
Depression

Total Number
of Patients
1,096
905
844
819
690
156
151
137
125
114
20
20
20
18
17
5

% of Female Patients,
45 – 64 Years
2.5
2.0
1.9
1.8
1.5
0.3
0.3
0.3
0.3
0.3
0.0
0.0
0.0
0.0
0.0
0.0

Results Supressed (<5 Patients)

* Permutations listed in sequential order
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Appendix AA: Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases,
among female patients aged 65 – 84 years with multimorbidity (n = 33,264)
Total Number of
Chronic Diseases
2
(n = 7,820)

3
(n = 8,016)

4
(n = 6,811)

≥5
(n = 10,617)

Hypertension >> Obesity

Total Number
of Patients
604

% of Female Patients,
65 – 84 Years
1.8

Obesity >> Hypertension

577

1.7

Obesity >> Diabetes

257

0.8

Obesity >> Cancer

249

0.7

Hypertension >> Hyperlipidemia

224

0.7

Hypertension >> Obesity >> Hyperlipidemia

110

0.3

Obesity >> Hypertension >> Hyperlipidemia

94

0.3

Obesity >> Diabetes >> Hypertension

91

0.3

Diabetes >> Obesity >> Hypertension

90

0.3

Hypertension >> Obesity >> Musculoskeletal Problem

86

0.3

Obesity >> Hypertension >> Musculoskeletal Problem >> Osteoarthritis or Rheumatoid Arthritis

18

0.1

Hypertension >> Obesity >> Hyperlipidemia >> Musculoskeletal Problem

17

0.1

Obesity >> Hypertension >> Cancer >> Musculoskeletal Problem

16

0.0

Hypertension >> Obesity >> Musculoskeletal Problem >> Hyperlipidemia

15

0.0

Hypertension >> Diabetes >> Obesity >> Osteoarthritis or Rheumatoid Arthritis

15

0.0

Obesity >> Hypertension >> Thyroid Problem >> Musculoskeletal Problem >> Hyperlipidemia

5

0.0

Permutations*

Results Supressed (<5 Patients)

* Permutations listed in sequential order
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Appendix AB: Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases,
among female patients aged 85 years and older with multimorbidity (n = 8,970)
Total Number of
Chronic Diseases
2
(n = 2,183)

3
(n = 2,042)

4
(n = 1,679)

Permutations*
Hypertension >> Obesity
Hypertension >> Dementia
Obesity >> Hypertension
Hypertension >> Cardiovascular Disease
Hypertension >> Cancer
Hypertension >> Obesity >> Cancer
Hypertension >> Obesity >> Osteoarthritis or Rheumatoid Arthritis
Obesity >> Hypertension >> Cancer
Hypertension >> Obesity >> Dementia
Hypertension >> Obesity >> Musculoskeletal Problem
Hypertension >> Obesity >> Musculoskeletal Problem >> Osteoarthritis or Rheumatoid Arthritis
Hypertension >> Obesity >> Musculoskeletal Problem >> Osteoporosis

≥5
(n = 3,066)

Total Number
of Patients
119
108
93
74
72
22
20
16
15
15
6
5

% of Female
Patients, ≥ 85
Years
1.3
1.2
1.0
0.8
0.8
0.2
0.2
0.2
0.2
0.2
0.1
0.1

Results Supressed (<5 Patients)

* Permutations listed in sequential order
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Appendix AC: Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases,
among male patients of all ages with multimorbidity (n = 82,622)
Total Number of
Chronic Diseases
2
(n = 32,080)

3
(n = 22,010)

4
(n = 13,823)

≥5
(n = 14,709)

Total Number
of Patients
2,201

% of Male
Patients, All Ages
2.7

Obesity >> Musculoskeletal Problem

2,138

2.6

Hypertension >> Obesity

1,665

2.0

Obesity >> Hyperlipidemia

1,530

1.9

Obesity >> Anxiety or Depression

1,467

1.8

Obesity >> Hypertension >> Hyperlipidemia

382

0.5

Hypertension >> Obesity >> Hyperlipidemia

336

0.4

Obesity >> Hypertension >> Musculoskeletal Problem

286

0.3

Obesity >> Hyperlipidemia >> Hypertension

271

0.3

Obesity >> Hyperlipidemia >> Musculoskeletal Problem

237

0.3

Obesity >> Hypertension >> Hyperlipidemia >> Musculoskeletal Problem

64

0.1

Hypertension >> Obesity >> Hyperlipidemia >> Musculoskeletal Problem

51

0.1

Obesity >> Hyperlipidemia >> Hypertension >> Musculoskeletal Problem

42

0.1

Obesity >> Hypertension >> Diabetes >> Hyperlipidemia

36

0.0

Obesity >> Diabetes >> Hypertension >> Musculoskeletal Problem

35

0.0

Obesity >> Diabetes >> Hyperlipidemia >> Hypertension >> Musculoskeletal Problem

8

0.0

Diabetes >> Hypertension >> Hyperlipidemia >> Musculoskeletal Problem >> Obesity

8

0.0

Hypertension >> Obesity >> Hyperlipidemia >> Musculoskeletal Problem >> Diabetes

6

0.0

Hypertension >> Hyperlipidemia >> Cancer >> Obesity >> Musculoskeletal Problem

6

0.0

Musculoskeletal Problem >> Hypertension >> Hyperlipidemia >> Obesity >> Urinary Problem

6

0.0

Permutations*
Obesity >> Hypertension

* Permutations listed in sequential order
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Appendix AD: Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases,
among male patients aged 18 – 34 years with multimorbidity (n = 5,959)
Total Number of
Chronic Diseases
2
(n = 4,204)

3
(n = 1,331)

Permutations*
Obesity >> Anxiety or Depression
Obesity >> Musculoskeletal Problem
Musculoskeletal Problem >> Obesity
Anxiety or Depression >> Obesity
Musculoskeletal Problem >> Anxiety or Depression
Obesity >> Anxiety or Depression >> Musculoskeletal Problem
Anxiety or Depression >> Obesity >> Musculoskeletal Problem
Musculoskeletal Problem >> Anxiety or Depression >> Obesity
Obesity >> Anxiety or Depression >> Cancer
Musculoskeletal Problem >> Obesity >> Anxiety or Depression

Total Number
of Patients
437
356
292
276
213
54
34
24
23
20

% of Male Patients,
18 – 34 Years
7.3
6.0
4.9
4.6
3.6
0.9
0.6
0.4
0.4
0.3

4
(n = 327)

≥5
(n = 97)

Results Supressed (<5 Patients)

* Permutations listed in sequential order
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Appendix AE: Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases,
among male patients aged 35 – 44 years with multimorbidity (n = 9,098)
Total Number of
Chronic Diseases
2
(n = 5,439)

3
(n = 2,357)

4
(n = 873)

Permutations*
Obesity >> Musculoskeletal Problem
Musculoskeletal Problem >> Obesity
Obesity >> Anxiety or Depression
Obesity >> Hypertension
Anxiety or Depression >> Obesity
Obesity >> Anxiety or Depression >> Musculoskeletal Problem
Obesity >> Musculoskeletal Problem >> Anxiety or Depression
Anxiety or Depression >> Obesity >> Musculoskeletal Problem
Musculoskeletal Problem >> Obesity >> Anxiety or Depression
Musculoskeletal Problem >> Anxiety or Depression >> Obesity
Obesity >> Hypertension >> Hyperlipidemia >> Musculoskeletal Problem

≥5
(n = 429)

Total Number
of Patients
532
400
379
288
274
55
47
41
37
36
5

% of Male Patients,
35 – 44 Years
5.8
4.4
4.2
3.2
3.0
0.6
0.5
0.5
0.4
0.4
0.1

Results Supressed (<5 Patients)

* Permutations listed in sequential order
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Appendix AF: Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases,
among male patients aged 45 – 64 years with multimorbidity (n = 34,856)
Total Number of
Chronic Diseases
2
(n = 14,268)

3
(n = 10,148)

4
(n = 5,834)

≥5
(n = 4,606)

Total Number
of Patients
1,167

% of Male Patients,
45 – 64 Years
3.3

1,066

3.1

Obesity >> Hyperlipidemia

963

2.8

Hypertension >> Obesity

832

2.4

Musculoskeletal Problem >> Obesity

659

1.9

Obesity >> Hypertension >> Hyperlipidemia

214

0.6

Hypertension >> Obesity >> Hyperlipidemia

185

0.5

Obesity >> Hypertension >> Musculoskeletal Problem

174

0.5

Obesity >> Hyperlipidemia >> Musculoskeletal Problem

172

0.5

Obesity >> Hyperlipidemia >> Hypertension

156

0.4

Obesity >> Hypertension >> Hyperlipidemia >> Musculoskeletal Problem

33

0.1

Hypertension >> Obesity >> Hyperlipidemia >> Musculoskeletal Problem

27

0.1

Obesity >> Hypertension >> Musculoskeletal Problem >> Hyperlipidemia

25

0.1

Obesity >> Hyperlipidemia >> Hypertension >> Musculoskeletal Problem

23

0.1

Obesity >> Diabetes >> Hyperlipidemia >> Hypertension

22

0.1

Obesity >> Diabetes >> Hyperlipidemia >> Hypertension >> Musculoskeletal Problem

5

0.0

Obesity >> Hyperlipidemia >> Diabetes >> Hypertension >> Musculoskeletal Problem

5

0.0

Permutations*
Obesity >> Hypertension
Obesity >> Musculoskeletal Problem

Results Supressed (<5 Patients)
* Permutations listed in sequential order
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Appendix AG: Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases,
among male patients aged 65 – 84 years with multimorbidity (n = 27,430)
Total Number of
Chronic Diseases
2
(n = 6,914)

3
(n = 6,981)

4
(n = 5,768)

Permutations*
Obesity >> Hypertension
Hypertension >> Obesity
Obesity >> Diabetes
Diabetes >> Obesity
Obesity >> Cancer
Obesity >> Hypertension >> Hyperlipidemia
Hypertension >> Obesity >> Hyperlipidemia
Obesity >> Diabetes >> Hypertension
Diabetes >> Hypertension >> Obesity
Diabetes >> Obesity >> Hypertension
Obesity >> Hypertension >> Hyperlipidemia >> Musculoskeletal Problem
Hypertension >> Obesity >> Hyperlipidemia >> Musculoskeletal Problem
Obesity >> Hypertension >> Cancer >> Musculoskeletal Problem
Obesity >> Diabetes >> Hypertension >> Musculoskeletal Problem
Obesity >> Hypertension >> Hyperlipidemia >> Cancer

Total Number
of Patients
584
508
364
314
288
134
118
113
96
95
24
19
19
19
18

% of Male Patients,
65 – 84 Years
2.1
1.9
1.3
1.1
1.0
0.5
0.4
0.4
0.3
0.3
0.1
0.1
0.1
0.1
0.1

≥5
(n = 7,767)
Results Supressed (<5 Patients)

* Permutations listed in sequential order
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Appendix AH: Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases,
among male patients aged 85 years and older with multimorbidity (n = 5,279)
Total Number of
Chronic Diseases
2
(n = 1,255)

3
(n = 1,193)

Permutations*
Hypertension >> Obesity
Obesity >> Hypertension
Hypertension >> Cancer
Hypertension >> Cardiovascular Disease
Obesity >> Diabetes
Diabetes >> Obesity >> Hypertension
Hypertension >> Obesity >> Musculoskeletal Problem
Hypertension >> Obesity >> Dementia
Hypertension >> Obesity >> Cancer
Hypertension >> Diabetes >> Obesity

Total Number
of Patients
68
56
52
41
38
14
13
11
11
11

% of Male Patients,
≥ 85 Years
1.3
1.1
1.0
0.8
0.7
0.3
0.2
0.2
0.2
0.2

4
(n = 1,021)

≥5
(n = 1,810)

Results Supressed (<5 Patients)

* Permutations listed in sequential order
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Appendix AI: Time (in days) until subsequent chronic disease diagnosis (including zero days elapsing between diagnoses),
stratified by patient age category (years), patient sex and total number of chronic diseases
Female

Male

18 – 34

35 – 44

45 – 64

65 – 84

≥ 85

18 – 34

35 – 44

45 – 64

65 – 84

≥ 85

T1  T2

178.0

158.0

63.0

10.6

5.2

87.0

63.0

21.7

5.5

7.5

(n = 286,998)

442.6

453.5

383.5

266.5

224.4

424.1

403.9

345.3

256.1

232.8

(612.2)

(654.8)

(646.6)

(577.5)

(527.7)

(654.9)

(647.8)

(630.9)

(581.0)

(540.2)

T2  T3

372.5

374.0

297.6

192.7

168.0

340.7

327.1

268.0

194.2

173.0

(n = 195,838)

587.5

616.9

554.9

464.1

406.2

577.1

583.2

542.2

468.6

396.1

(756.1)

(802.6)

(804.8)

(838.6)

(763.5)

(792.2)

(821.6)

(819.7)

(842.4)

(723.6)

T3  T4

337.6

348.0

283.7

219.8

203.9

334.0

304.2

285.0

224.0

208.0

(n = 121,864)

488.1

517.4

466.9

398.4

378.6

517.1

498.5

476.6

416.4

373.0

(507.3)

(579.2)

(560.8)

(532.6)

(485.2)

(567.8)

(599.3)

(587.4)

(586.1)

(490.3)

T4  T5

282.4

346.0

285.2

243.9

224.0

290.1

295.6

300.1

264.0

239.0

(n = 70,256)

427.3

501.5

449.9

395.9

386.5

426.4

483.1

461.7

420.0

385.0

(465.2)

(532.6)

(503.6)

(455.3)

(475.0)

(454.5)

(535.6)

(512.4)

(484.5)

(445.2)

T5  T6

332.0

280.0

259.7

252.0

276.8

276.8

291.9

301.0

269.0

242.2

(n = 37,390)

482.4

424.9

402.2

402.3

431.0

431.0

446.0

455.6

416.4

389.6

(496.7)

(462.3)

(445.1)

(446.2)

(505.0)

(505.0)

(469.4)

(494.3)

(453.8)

(444.8)

* Each cell contains median time, mean time and standard deviation, all measured in days; longest time between diagnoses highlighted in green and shortest time
between diagnoses highlighted in red
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Appendix AI: Time (in days) until subsequent chronic disease diagnosis (including zero days elapsing between diagnoses),
stratified by patient age category (years), patient sex and total number of chronic diseases, Continued
Female

Male

18 – 34

35 – 44

45 – 64

65 – 84

≥ 85

18 – 34

35 – 44

45 – 64

65 – 84

≥ 85

67.8

40.5

3.0

1.2

1.0

8.2

1.1

1.0

1.0

3.2

343.3

313.6

242.1

191.0

171.9

328.3

273.0

234.0

181.8

192.5

(549.9)

(527.3)

(527.0)

(482.0)

(462.7)

(624.9)

(567.0)

(523.0)

(479.3)

(484.5)

27.2

5.7

1.0

1.0

4.0

1.0

1.0

1.0

1.0

1.0

203.0

235.9

209.6

161.9

92.2

311.8

259.2

249.9

113.9

109.3

(346.4)

(429.7)

(436.0)

(382.8)

(165.9)

(648.1)

(545.5)

(524.0)

(253.8)

(188.5)

6.6

25.7

2.0

1.0

1.0

1.0

2.0

1.0

1.0

2.0

301.8

342.9

204.7

187.6

166.2

181.4

235.1

201.1

153.0

184.7

(595.5)

(640.4)

(482.8)

(520.0)

(472.8)

(455.3)

(515.3)

(493.4)

(429.4)

(487.7)

Chronic Obstructive Pulmonary

70.0

109.4

45.6

19.9

21.0

8.4

22.0

14.5

20.0

6.6

Disease or Asthma  T2

322.3

391.2

358.4

277.0

279.9

275.9

344.0

348.4

324.8

191.2

(523.3)

(600.6)

(663.2)

(580.0)

(594.7)

(502.0)

(579.4)

(669.0)

(705.7)

(428.0)

194.3

109.6

69.5

21.0

1.0

47.0

38.4

31.2

13.5

4.5

486.9

414.9

363.3

228.9

145.0

297.6

312.4

307.9

229.0

162.4

(727.9)

(587.1)

(626.8)

(464.1)

(398.1)

(517.6)

(529.8)

(572.3)

(495.9)

(341.5)

Hypertension  T2

Obesity  T2

Diabetes  T2

Hyperlipidemia  T2

* Each cell contains median time, mean time and standard deviation, all measured in days; longest time between diagnoses highlighted in green and shortest time
between diagnoses highlighted in red for each patient category
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Appendix AI: Time (in days) until subsequent chronic disease diagnosis (including zero days elapsing between diagnoses),
stratified by patient age category (years), patient sex and total number of chronic diseases, Continued
Female

Male

18 – 34

35 – 44

45 – 64

65 – 84

≥ 85

18 – 34

35 – 44

45 – 64

65 – 84

≥ 85

237.5

231.8

139.1

35.0

7.3

99.8

80.3

58.4

15.4

19.2

460.9

504.8

456.0

341.7

243.0

439.3

431.7

400.0

319.6

283.7

(603.0)

(669.2)

(684.2)

(669.8)

(525.4)

(664.9)

(656.9)

(650.3)

(652.4)

(637.5)

307.9

225.0

114.0

17.4

12.2

65.0

62.0

29.6

10.5

4.2

528.3

513.8

470.2

323.7

265.4

461.2

391.3

420.9

323.7

233.9

(655.8)

(692.7)

(709.4)

(618.2)

(593.8)

(714.2)

(564.9)

(711.4)

(693.9)

(548.3)

14.0

28.0

176.6

9.1

29.0

141.9

60.3

17.0

16.6

21.7

165.6

381.6

440.1

248.4

240.9

561.3

117.1

372.0

273.1

209.2

(301.1)

(467.2)

(872.5)

(562.9)

(481.1)

(1,010.2)

(189.0)

(725.2)

(534.9)

(456.5)

149.8

132.3

68.0

26.5

19.4

80.2

56.6

24.5

10.6

49.7

435.7

430.7

392.2

319.1

288.8

413.4

407.9

341.3

344.7

329.9

(614.8)

(638.1)

(634.5)

(644.7)

(648.0)

(634.6)

(663.8)

(614.7)

(679.3)

(596.7)

Osteoarthritis or Rheumatoid

140.0

216.3

136.5

39.9

31.5

137.8

94.0

70.5

29.7

17.4

Arthritis  T2

428.8

495.2

494.7

388.4

358.9

523.9

489.1

477.7

418.6

368.9

(587.2)

(658.5)

(738.7)

(710.2)

(667.9)

(755.7)

(725.5)

(744.4)

(784.2)

(734.5)

Cancer  T2

Cardiovascular Disease  T2

Heart Failure  T2

Anxiety or Depression  T2

* Each cell contains median time, mean time and standard deviation, all measured in days; longest time between diagnoses highlighted in green and shortest time
between diagnoses highlighted in red for each patient category
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Appendix AI: Time (in days) until subsequent chronic disease diagnosis (including zero days elapsing between diagnoses),
stratified by patient age category (years), patient sex and total number of chronic diseases, Continued
Female
18 – 34
Stroke or Transient Ischemic
Attack  T2
Thyroid Problem  T2

Kidney Disease or Failure  T2

Osteoporosis  T2

Dementia  T2

Male

35 – 44

45 – 64

65 – 84

≥ 85

18 – 34

45 – 64

65 – 84

≥ 85

1.00

74.0

46.9

7.6

996.5

7.0

8.4

3.0

103.6

595.8

507.6

392.5

1,177.0

289.5

235.8

199.7

(190.0)

(868.9)

(829.9)

(711.2)

(1,390.7)

(498.9)

(456.2)

(575.0)

91.9

63.0

31.6

7.6

10.1

39.0

29.6

10.5

4.0

8.6

364.9

349.4

319.0

232.8

215.9

286.1

263.7

303.4

241.6

274.4

(554.8)

(569.2)

(577.2)

(525.5)

(536.9)

(575.1)

(552.6)

(608.3)

(476.8)

(610.0)

48.8

124.5

26.7

183.3

95.7

7.6

52.8

124.8

50.0

1.0

162.5

361.1

139.8

712.9

566.5

58.7

89.6

547.8

466.4

92.9

(263.9)

(520.1)

(217.5)

(1,052.0)

(910.8)

(98.2)

(103.6)

(830.8)

(867.5)

(248.2)

199.0

110.5

71.3

14.5

1.0

28.0

3.0

92.3

25.3

64.0

650.8

383.7

369.1

247.9

168.6

95.6

182.8

326.5

197.0

269.6

(859.7)

(599.2)

(604.4)

(455.0)

(378.4)

(152.8)

(314.1)

(474.9)

(346.3)

(354.5)

451.0

130.2

166.3

6.6

5.3

555.7

554.7

188.0

25.2

6.0

505.1

355.7

500.7

297.0

216.2

666.6

705.6

507.4

326.3

202.4

(526.0)

(733.7)

(773.9)

(661.2)

(476.4)

(707.7)

(658.8)

(700.4)

(590.0)

(475.3)

Results
Supressed

35 – 44
Results
Supressed

* Each cell contains median time, mean time and standard deviation, all measured in days; longest time between diagnoses highlighted in green and shortest time
between diagnoses highlighted in red for each patient category
** Results were supressed when < 5 patients were included in the category
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Appendix AI: Time (in days) until subsequent chronic disease diagnosis (including zero days elapsing between diagnoses),
stratified by patient age category (years), patient sex and total number of chronic diseases, Continued
Female
Musculoskeletal Problem  T2

Stomach Problem  T2

Colon Problem  T2

Liver Disease  T2

Urinary Problem  T2

Male

18 – 34

35 – 44

45 – 64

65 – 84

≥ 85

18 – 34

35 – 44

45 – 64

65 – 84

≥ 85

245.4

257.6

159.6

61.1

52.0

191.0

196.0

113.3

38.6

62.5

524.7

553.1

483.4

360.8

311.4

528.2

508.6

471.0

368.0

330.3

(664.9)

(718.5)

(711.0)

(651.2)

(591.4)

(726.9)

(710.8)

(720.2)

(670.3)

(638.0)

197.4

137.4

118.8

75.8

54.3

141.1

132.0

99.0

56.5

39.2

385.2

444.4

397.9

296.2

178.0

451.1

438.8

416.1

343.3

243.0

(485.4)

(653.0)

(614.1)

(548.0)

(294.8)

(639.2)

(656.6)

(673.3)

(651.7)

(454.7)

252.0

137.9

98.0

60.0

67.0

161.0

36.9

53.0

81.7

85.6

477.5

421.9

390.6

359.8

224.5

432.3

332.1

368.3

346.7

324.4

(609.3)

(658.8)

(610.8)

(668.1)

(402.9)

(610.8)

(499.0)

(610.5)

(585.7)

(557.7)

320.6

0.0

34.0

0.0

367.7

643.5

564.6

101.8

34.0

0.00

437.6

70.2

248.0

262.2

367.7

734.4

731.4

384.1

321.1

9.8

(414.0)

(102.9)

(473.5)

(524.5)

(519.4)

(619.2)

(935.9)

(581.4)

(663.4)

(17.1)

342.4

385.4

276.2

154.0

46.2

268.6

185.5

130.0

26.5

35.5

569.5

647.3

589.2

471.4

287.8

565.7

513.2

480.7

338.4

264.9

(650.8)

(763.4)

(784.9)

(774.4)

(591.4)

(734.1)

(724.6)

(725.0)

(665.3)

(565.9)

* Each cell contains median time, mean time and standard deviation, all measured in days; longest time between diagnoses highlighted in green and shortest time
between diagnoses highlighted in red for each patient category
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Appendix AJ: Results of multilevel, single event survival analyses among adult patients with one or more chronic diseases

Independent Variable

≥ 1 Chronic Diseases
(n = 238,237)

Patient-Level
1.00 (1.00 – 1.00) ***
Age
0.81 (0.78 – 0.85) ***
Sex (Female)
0.99 (0.97 – 1.01)
Residential Location (Urban)
1.00 (1.00 – 1.00) **
Median Household Income
1.33 (1.33 – 1.34) ***
Total Number of Chronic
Diseases
Provider-Level
0.98 (0.98 – 0.99) ***
Age
0.92 (0.85 – 0.99) **
Female
Practice-Level
EMR Type
Accuro
Reference
Bell
1.43 (1.21 – 1.69) ***
DaVinci
0.85 (0.72 – 1.03)
Jonoke
0.91 (0.80 – 1.10)
Med Access
0.87 (0.74 – 1.01)
Nightingale
0.95 (0.85 – 1.05)
Oscar
1.56 (1.35 – 1.80) ***
Practice Solutions
0.43 (0.37 – 0.50) ***
Wolf
0.73 (0.64 – 0.84) ***
Xwave
1.91 (0.82 – 4.46)
0.74 (0.67 – 0.83) ***
Practice Location (Urban)
Interaction Term
1.00 (1.00 – 1.00)
Patient Age & Patient Sex
% Variance (95% CI) Contributed by Each Level
Within Provider
9.10 (6.82 – 12.14)
Within Site
0.18 (0.00 – 2.13)
* CI = Confidence interval; ** p-value < 0.05; *** p-value < 0.001

≥ 2 Chronic Diseases
(n = 159,365)

Hazard Ratio (95% CI)
≥ 3 Chronic Diseases
(n = 96,945)

≥ 4 Chronic Diseases
(n = 54,753)

≥ 5 Chronic Diseases
(n = 28,675)

1.00 (1.00 – 1.00) ***
0.83 (0.78 – 0.87) ***
0.98 (0.96 – 1.01)
1.00 (1.00 – 1.00) **
1.29 (1.29 – 1.30) ***

1.00 (1.00 – 1.00) **
0.78 (0.72 – 0.85) ***
0.98 (0.95 – 1.01)
1.00 (1.00 – 1.00)
1.23 (1.22 – 1.24) ***

1.00 (1.00 – 1.00)
0.74 (0.66 – 0.83) ***
0.96 (0.92 – 1.00)
1.00 (1.00 – 1.00)
1.19 (1.17 – 1.20) ***

1.00 (1.00 – 1.00)
0.80 (0.66 – 0.95) **
0.95 (0.89 – 1.02)
1.00 (1.00 – 1.00)
1.16 (1.14 – 1.18) ***

0.99 (0.98 – 0.99) ***
0.97 (0.88 – 1.05)

0.99 (0.98 – 0.99) ***
0.97 (0.88 – 1.08)

0.98 (0.98 – 0.99) ***
0.95 (0.84 – 1.06)

0.98 (0.98 – 0.99) ***
0.94 (0.83 – 1.06)

Reference
1.27 (1.04 – 1.55) **
0.77 (0.71 – 1.04)
0.82 (0.73 – 1.01)
0.80 (0.67 – 0.96) **
0.86 (0.77 – 0.97) **
1.47 (1.24 – 1.74) ***
0.41 (0.35 – 0.49) ***
0.68 (0.58 – 0.80) ***
1.79 (0.62 – 5.16)
0.75 (0.66 – 0.85) ***

Reference
1.15 (0.90 – 1.48)
0.72 (0.61 – 1.05)
0.82 (0.77 – 1.02)
0.76 (0.62 – 0.93) **
0.84 (0.73 – 0.96) **
1.34 (1.10 – 1.63) **
0.43 (0.36 – 0.53) ***
0.63 (0.53 – 0.75) ***
1.56 (0.40 – 6.12)
0.71 (0.61 – 0.82) ***

Reference
1.04 (0.76 – 1.43)
0.67 (0.54 – 1.01)
0.74 (0.63 – 1.05)
0.70 (0.56 – 0.88) **
0.79 (0.68 – 0.91) **
1.29 (1.01 – 1.63) **
0.44 (0.36 – 0.55) ***
0.59 (0.48 – 0.72) ***
0.66 (0.08 – 5.60)
0.69 (0.58 – 0.82) ***

Reference
0.99 (0.68 – 1.44)
0.72 (0.58 – 1.04)
0.79 (0.67 – 1.02)
0.74 (0.58 – 0.94) **
0.81 (0.69 – 0.95) **
1.35 (1.00 – 1.82) **
0.51 (0.40 – 0.63) ***
0.62 (0.50 – 0.76) ***
0.67 (0.08 – 5.65)
0.72 (0.60 – 0.88) **

1.00 (1.00 – 1.00)

1.00 (1.00 – 1.00)

1.00 (1.00 – 1.01)

1.00 (1.00 – 1.00)

11.66 (8.45 – 16.08)
0.20 (0.00 – 3.63)

14.48 (12.00 – 17.47)
0.00 (0.00 – 0.00)

16.98 (13.84 – 20.84)
0.00 (0.00 – 0.00)

16.41 (13.01 – 20.69)
0.00 (0.00 – 0.00)
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